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Abstract  
This research explored the optimisation of three novel antimalarial series based on the MMV 
compound leads shown below. (1)  
 
 
 
 
 
 
 
Extensive research began to optimise these potent hits through exploration of multiple 
functional group substitutions on two or more sites of the core structure (shown above).  
The highest activity tetrahydro-β-carboline analogue discovered during this research was 
LVT30 (IC50=1µM) which possesses an absent C
3 interaction and a p-trifluoromethyl R2 
substitution. Meanwhile, of the spirocyclic subset of derivatives, a high nanomolar activity 
compound was generated LVT86 (IC50=960 nM), possessing a butyl R
1 chain and a m-
trifluoromethyl R2 group and future work will include optimisation of this analogues 
pharmacokinetic properties.  
The most fruitful subseries of this project was a catalogue of 2-iminobenzimidazole 
compounds. In an attempt to optimise activity and increase potency, exploration involved 
variation of all three R positions and as a result, generated the most potent derivative over 
all three series. Compound LVTa95 possesses an inhibitory concentration of 33.4 nM and 
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exhibits: a pentane R1 group, 2,4-dichloro R2 substitution and a hydroxy R3 group. As this 
compound existed as enantiomers, they were subsequently separated, and it was found both 
stereoisomers had similar activity.  
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Chapter 1: Malaria: An Introduction  
1:1 The malaria parasite  
1:1:1 Plasmodium pathogenesis  
Malaria is a parasite transmitted by the genus, Anopheles, of which there are five common 
species that can infect humans: Plasmodium falciparum, Plasmodium vivax, Plasmodium 
ovale, Plasmodium knowlesi and Plasmodium malariae. (2) There are approximately 3,500 
species across the world, of these, around 40 are capable of transmitting malaria to humans. 
The female Anopheles act as a vector for the parasite, and subsequently transmit the parasite 
to humans, upon taking human blood (see Figure 1). 
 
 
 
 
 
 
 
  
 
 
Figure 1: Plasmodium lifecycle (1) 
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Approximately 30 minutes post infection the asexual parasite form travels to the liver, where 
a dormancy stage is reached which can cause reinfection months or even years later. During 
the next 48 hours, active merozoites circulate within host red blood cells and transform into 
schizonts, which give rise to the clinical features of a malaria infection. The schizont form 
(see Table 1 for definitions) multiplies producing more merozoites, until the red blood cell 
finally bursts and releases more parasite into the bloodstream, thus proliferates the life cycle. 
Whilst in the red blood cells, gametocytes form 10 days later, which is known as ‘the sexual 
stage’ of the lifecycle. Upon the female taking a second blood meal from the host, the 
parasite is transported inside the mosquito vector and results in ‘the mosquito stage’. The 
parasite situates itself in the midgut of the insect and over a period of two weeks reproduces 
sexually to create schizonts, which travel to the salivary glands of the insect where the life 
cycle restarts and waits for blood feeding to commence (see Table 1 for definitions).  
Parasite Stage Definition 
Schizont Seen in both blood and liver stages of the parasite, 
this is a development stage which contains many 
merozoites.  
Merozoite Formed by asexual development. Schizonts 
contain many merozoites and once the schizont is 
mature within the RBCs – both the cell and 
schizonts erupt, releasing the merozoites ready to 
infect further RBCs 
Trophozoite Another development form during the blood stage 
of the malaria parasite.  Once the merozoites have 
invaded RBCs, they develop into trophozoites. 
This stage known as ‘rings’ develop into schizonts  
Gametocyte Sexual stage of the parasite, typically crescent 
shaped. Microgametocyte (male) and 
macrogametocytes (female) are within RBCs in 
circulation. If ingested by Anopheles, they 
undergo sexual reproduction, which restarts the 
parasite life cycle.  
Table 1: Parasite lifecycle definitions 
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1:1:2 Clinical features  
Once infection occurs the patient symptoms are categorised as, ‘uncomplicated’ or 
‘complicated’ malaria – the latter being more severe. An ‘incubation period’ occurs 7–30 
days post infection, which results in most patients being asymptomatic. P. falciparum 
infected patients display symptoms sooner, due to the severity of this species. The most 
critical cases are caused by ‘cerebral malaria’, which is due to infected erythrocytes adhering 
to the vascular endothelium of venual blood vessel walls within the brain and as a result, 
higher mortality rates are seen for P. falciparum infections. On the other hand, due to the 
delayed onset of symptoms, in some cases, malaria can be misdiagnosed or missed altogether 
– often mistaken for common cold or infection. Therefore, visual blood tests under 
microscopy are required to make a formal diagnosis.  
Uncomplicated malaria patients experience common symptoms such as; fever, chills, 
sweats, headache, nausea and general body ache. However, if uncomplicated symptoms are 
left untreated they can progress and manifest themselves as: high temperature, enlarged 
spleen, mild jaundice, enlarged liver and increased heart rate. In addition, if a patient has 
organ, blood or metabolism abnormalities, complicated malaria symptoms arise which 
include: cerebral malaria, severe anaemia (destruction of red blood cells), inflammation of 
the lungs, blood clotting problems, kidney failure, low blood pressure, hyperparasitemia, 
acidity in the blood and tissues and hypoglycaemia. (2) 
The most vulnerable group to infection are children under 5 years and pregnant women, who 
consequently suffer from complications due to their compromised immune systems. The 
widespread problem of gestational malaria results in: low birth weight, severe anaemia and 
haemorrhage at childbirth, which leads to increased infant fatalities. (3) Furthermore, 
pregnant women are most at risk from P. falciparum infections, which also leads to 
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premature labour and stillbirth. Congenital malaria also occurs in 5% of cases but clears 
spontaneously in 62% of cases. (3)  
 
1:1:3 IPP synthesis   
The mevalonate pathway is an essential metabolic process that takes place in eukaryote cells, 
within an organelle known as the apicoplast. (4) The apicoplast possesses its own genome 
and expresses a small number of genes, it is a nonphotosynthetic plastid and has functions 
such as: fatty acid synthesis, isoprenoid, and haem synthesis, which are vital for parasite 
survival. (5)  
The primary function of this pathway is to biosynthesise key building blocks: isopentenyl 
pyrophosphate (IPP) and dimethylallyl pyrophosphate (DMAPP). These two crucial 
precursors are used to generate isoprenoids, which are central to the synthesis of compounds 
that play key roles within development and sustaining life for example: cholesterol, fatty 
acids, coenzymes, steroidal hormones, and haem. However, malaria uses an alternate 
pathway absent in humans known as the non-mevalonate pathway, which generates the vital 
precursors IPP and DMAPP via 1-deoxy-D-xylulose 5-phosphate (DOXP) (see Scheme 1). 
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Scheme 1: Non-mevalonate pathway 
During the second step of the pathway DOXP reductase also known as IspC, is the enzyme 
which converts DOXP into a methylerythrose intermediate (MEP). DOXP reductase is a 
homodimer with three constituent domains: a N-terminal cofactor binding domain, a central 
domain consisting of the many active site residues, a flexible segment acting as a gate for 
the catalytic centre and a C-terminal alpha helical domain. (6) The mechanism starts with the 
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cofactor binding first followed by the substrate DOXP. Two mechanisms have been 
suggested for initial isomerisation that converts DOXP to a methylerythrose intermediate, 
an α-ketol rearrangement or a retro aldol/aldol reaction. The intermediate is then reduced by 
the hydride source NADPH.  
During research carried out on IPP inhibitors that target the non-mevalonate pathway it has 
been shown by supplementing apicoplast absent parasites with IPP, it can reverse the effects 
of apicoplast removal. IPP reversal assays can therefore be used to screen drugs thought to 
target this pathway by firstly dosing the parasite with the test drug and then supplementing 
the parasite with IPP and measuring subsequent parasitic growth.  
DOXP reductase has been targeted for P. falciparum chemotherapies and a more recent 
study testing the antibiotic fosmidomycin (FOS, 1). FOS resulted in growth inhibition of P. 
falciparum and has cured malaria infected mice. (7)  
 
 
 
 
FOS contains a hydroxamate moiety and has been found to inhibit the enzyme through 
coordination of the metal ion Mn2+ to mimic the DOXP substrate (see Figure 2). (6) 
Furthermore, the phosphate group provides a tether to the enzyme at the catalytic centre, 
which subsequently targets metabolism within the apicoplast. However, due to high parasite 
reoccurrence levels, FOS has been trialled as a combination therapy with another antibiotic 
clindamycin (2), which is a slow acting antibiotic. As this pathway is absent in humans it is 
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an ideal target for anti-malarials as none of the enzymes used for human IPP and DMAPP 
production would be affected.  
 
 
 
 
 
 
Genetic analysis has shown this reductoisomerase is required for intraerythrocytic 
development of the P. falciparum parasite. Therefore, to exploit this pathway for a potential 
chemotherapy the drug candidate would need to reach the enzyme target by passing into the 
parasite and then crossing the apicoplast membrane, thus keeping Lipinski’s rules in mind 
when designing such chemotherapy. (6) For example, Table 2 shows the comparison in the 
Lipinski values for both FOS and DOXP. Both compounds adhere to all four parameters but 
most importantly, the logP values show they are highly polar molecules. This high polarity 
will allow them to cross the cell membrane within the apicoplast thus, any potential 
candidate would need to have similar polarity to access the same target within the apicoplast.  
Lipinski parameter FOS DOXP 
HBA (<10) 6 6 
HBD (<5) 3 4 
logP (<5) − 0.32 − 1.09 
Molecular weight/gmol−1(<500) 138.10 198.11 
                  Table 2: Comparison of Lipinski’s rule 
 
Figure 2: FOS-DOXP structural comparison and FOS docking within DOXP reductase (7) 
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1:2 Overview of malaria progress  
1:2:1 Prevention, treatment and elimination 
Despite an increase in malaria intervention over the past two decades, malaria still causes 
the most fatalities and is the most prevalent parasitic disease facing humans to date. The 
disease is transmitted across poverty afflicted countries inhabited by an estimated 3 billion 
people and is still considered to be endemic in 91 of those 108 countries at the beginning of 
2016. (8) However, it is estimated that 663 million clinical cases of malaria were averted 
between 2000 and 2015. Many of the improvements were from: bed nets 68%, artemisinin 
combination therapies (ACT) 22% and indoor residual sprays 10%. (9) 
However, complacency should not prevail and action is being taken to generate a healthy 
bank of new antimalarials and insecticides. This project is driven by product development 
partnerships coordinated by the Medicine for Malaria Venture (MMV), who update their 
portfolio every three months and the Innovation Vector Control Consortium. The long-term 
goal is vaccine development, which would ultimately reduce parasite transmission and 
progress endemic countries to malaria eradication.  
Alongside annual MMV reports, an ‘Open Access Malaria Box’ (MB) has been compiled 
for malaria with the hope of provoking interest in malaria drug research. (10) Through use of 
a high throughput screening (HTS) programme they have highlighted over 400 diverse new 
compound leads with promising activity against malaria. The compounds compiled have 
confirmed activities against the asexual intraerythrocytic stages of P. falciparum and have 
low cytotoxicities, but the mechanisms of action are still unknown for the majority. From 
this, the lead compounds can be exploited as a foundation for research groups, to help the 
development of new drugs with novel mechanisms of action against this deadly disease. 
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Furthermore, the target candidate profiles for treatment and prophylaxis have a stringent set 
of biological traits to filter through new clinical candidates. The candidates are compared to 
current gold standards for each type of chemotherapy and are as follows: fast parasite 
clearance Artemisinin 3; long duration 4-aminoquinolines 4; relapse prevention and chemo 
prophylaxis atovaquone 5/proguanil 6/mefloquine 7. (11) This new framework provides open 
access information to create a new strategy for malaria drug development and sustained 
investment into these programmes is essential to assist the long-term goal of malaria 
eradication.  
 
 
 
 
 
 
 
 
In line with the World Health Organisation (WHO) recommendations, Table 3 highlights the 
target product profiles of drug clinical candidates for both treatment and prophylaxis 
chemotherapies. The most important feature of a new clinical candidate is to target the 
parasite via an alternative mechanism of action to current drugs, which will help combat the 
biggest issue in current chemotherapies, parasitic resistance.  
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Table 3: Attributes desired to target parasite elimination (11) 
A specific report was published by MMV for P. falciparum, as this severe strain results in 
90% of fatalities and highlighted desirable attributes for potential chemotherapies targeting 
this species (see Table 4).  
Desired feature Resolution 
Combination therapies  Decrease the resistance opportunities  
Maximum of 3-day dosing  Once/twice daily helps keep costs low and 
patient compliance  
Development of fixed combination doses  Avoids misuse compared to monotherapies  
New mechanism of action  To tackle resistant strains  
Effective as a paediatric and adult 
chemotherapy  
Infants and children under 5 years have 
highest mortality rates  
Table 4: Summary of P. falciparum drug attributes (12) 
The majority of current chemotherapies target the early blood stage of the malaria lifecycle, 
due to the symptomatic display from the patient. However, parasite targets fall into several 
categories to target both host and vector stages such as; blood stage, growth/replication 
Treatment Prevention 
- Single exposure  
- Radical cure of all five species 
infecting humans  
- Clinical transmission blocking 
- Affordable  
- Single exposure/affordable  
- Suitable for mass administration at 
infrequent intervals (one per 
month) 
- Chemo-protection against all five 
species infecting humans  
- Fast parasitic clearance  
- Long duration/post treatment  
- All lifecycle stages 
- High barrier to resistance  
- Different mechanism of action  
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within infected erythrocytes, sexual stage, liver stage and insect stage. (1) An ideal drug 
candidate would possess activity against several stages of the parasite life cycle.  
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1:2:2 Medicine for Malaria Venture reports (2014–2016)  
In 2013, 198 million cases of malaria occurred globally of which, 82% arose in African 
WHO regions, 12% in South East Asia WHO regions and 5% in East Mediterranean WHO 
regions (see Table 5).  Of those cases, 584 000 deaths resulted, with 90% of mortalities 
occurring in the WHO African regions and 78% of those occurred in children aged 5 and 
under.  
Table 5: Summary of malaria cases over 3 years 
Figure 3: Global malaria cases in 2013 (13) 
Furthermore, 128 million people were infected with P. falciparum in sub-Saharan Africa at 
any one time, with 37 million infectious cases in Nigeria and 14 million infectious cases in 
Democratic Republic of the Congo (see Figure 3). (13) 
Funding for control and elimination totalled US$ 2.7 billion in 2013 and the report details 
future plans to decrease malaria cases. Substantial funding was proposed for preventative 
 WHO region percentage of cases/% 
Year N° of cases/million African South East Asian East Mediterranean 
2013 198 82 12 5 
2015 214 88 10 2 
2016 212 90 7 2 
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strategies including: increased distribution of insecticide-treated nets (ITNs) for pregnant 
women and children 5 and under specifically, long lasting insecticidal nets (LLIN), indoor 
residual sprays and wider distribution of diagnostic tests. Also, treatment strategies prioritise 
the expansion of access to artemisin combination therapies (ACTs). Shortfalls in access to 
prevention/diagnostic testing and post-infection chemotherapies were due to low levels of 
education and poverty, with a high proportion of malaria sufferers not seeking care or 
receiving treatment that was available. (13)  
In 2015, there were 214 million cases of malaria infection and considering population 
growth, this results in a decrease of cases by 37% from the year 2000. Furthermore, of these 
214 million cases: 88% of cases occurred in the WHO African regions, 10% in South East 
Asia WHO regions and 2% in East Mediterranean WHO regions (see Table 5). The country 
persistent with highest mortality was the African WHO region, of which 438 000 deaths 
occurred. The mortality rate for children under 5 decreased from 723 000 in 2000 to 306 000 
in 2015, but despite these improvements malaria remains a prevalent killer of children – 
particularly in sub-Saharan Africa, taking the life of a child every 2 minutes (see Figure 4). 
(14) 
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Figure 4: Estimated P. falciparum infectious cases amongst children aged 2–10 years (14) 
Proposed strategies still consist of those set in the 2014 report, but despite progress there is 
a slow decline of cases in high-burden countries and access to essential prevention services 
and post-infection chemotherapies are still primary issues.  
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Highlighted in the 2016 report is an urgent movement to relieve the malaria burden and the 
WHO have strategized an accelerated programme titled ‘Action and Investment to defeat 
malaria 2016–2030’. (8) The programme details the importance of open access to 
interventions for malaria prevention, diagnosis and treatment, and this will allow advanced 
progress in the elimination of the malaria burden.  
 
Figure 5:  Countries remaining endemic for malaria in 2016 (10) 
 
Figure 5 displays the countries which remain endemic for malaria in 2016 and the projections 
for 2030 aim to: reduce malaria cases and malaria mortalities by ≥90%, eliminate malaria 
from at least 35 of the infected countries and, prevent re-establishment of malaria in all 
countries that are malaria free. (8)  
To summarise, over the past three years each report has highlighted the overall improvement 
in malaria prevention and treatment since the year 2000, reducing deaths by 50%. However, 
in more recent years the milestones are not as advanced and indicate a need for new 
chemotherapies with novel mechanisms of action to target the growing issue of resistance. 
Meanwhile, a continued effort to widen the access to ITNs, other prevention strategies and 
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diagnostic testing for poverty-stricken countries is necessary upkeep. Furthermore, the 
information gathered from individual research groups needs to be shared on an open 
network, to increase the awareness of new parasite targets, to subsequently generate novel 
antimalarials.   
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1:3 Antimalarial chemotherapies 
1:3:1 Quinine and Chloroquine 
1:3:1:1 Historical Malaria Chemotherapy  
In 1820 two French chemists, Pierre Joseph Pelletier and Joseph Caventou isolated quinine 
8 from the South American native cinchona tree bark. The use of its medicinal tree bark has 
been dated back to the 17th century and became a treatment of reference for intermittent fever 
throughout the world. (15) Furthermore, since the 1940’s this antipyretic drug has been used 
as an antimalarial treatment and despite the widespread discovery of quinine resistant 
parasite, it remains an important and effective treatment for severe malaria cases. Quinine is 
an alkaloid which consists of an aromatic quinoline ring system connected to a tertiary amine 
via a hydroxymethine moiety.  
 
 
 
The antimalarial mechanism of action is still unknown however, it is documented to act on 
the blood schizont stage and interferes with the parasites ability to digest haemoglobin, 
which results in a toxic accumulation of haem, causing parasite death. (15) Additionally, it 
has shown gametocidal activity in P. vivax and P. malariae, but not in P. falciparum. Quinine 
is a weak base, and therefore concentrates itself in the acidic pH food vacuole of P. 
falciparum and has a rapid onset of action, reaching peak concentration 1–3 hours after 
dosing. Furthermore, quinine readily crosses the placental barrier and has also been 
ascertained in cerebral fluid, which is an important feature for severe cerebral malaria 
treatment. (15)  
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Meanwhile, a more efficacious and less toxic antimalarial is a derivative of 8, chloroquine 
9, which was developed by German scientists in 1934.  
 
 
 
      
From 1947 the use of chloroquine was extensive, and it was subsequently listed as a World 
Health Organisation essential medicine for antimalarial eradication. (15) As a result, over the 
next 50 years chloroquine resistant P. falciparum was discovered: in 1957 in four separate 
locations along the Thai-Cambodian border; in 1960 in Venezuela and parts of Columbia; in 
the mid 1970’s in Papua New Guinea and; in 1978 in Kenya and Tanzania, spreading to 
Sudan, Uganda, Zambia and Malawi in 1983. (15,16) This lead to the resurge of quinine use in 
cases where the infected patient did not respond to chloroquine. To date, chloroquine is used 
as the ‘gold standard’ in biological assay testing as the positive control.  
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1:3:1:2 Derivatives  
Since the discovery of quinine 8 and subsequently chloroquine 9, the natural product scaffold 
has been retained to synthesise a variety of synthetic antimalarial derivatives. To obtain 
quinine, an extraction process of the natural tree bark was necessary, but this was lengthy 
and consequently did not fulfil demand. This propelled the optimisation of the quinine 
structure shown below are a variety of derivatives that have been synthesised since the 
1920’s.  
Prior to the discovery of compound 9, quinacrine 10 was developed by Bayer and approved 
in 1930 to treat malaria, and even though it provided no stronger efficacy or physiochemical 
advantages over compound 8, the compound could be synthetically generated to meet 
demand. (17) Not only does quinacrine have antimalarial potency, but it also displays 
anticancer potential. The compound has been shown to act on breast and colon cancer by 
interfering with the S phase of the cell cycle (DNA replication stage), resulting in cancer cell 
death. (17)  
On the other hand, in 2014 primaquine 11 was shown to inhibit pyridoxal kinase (allows 
conversion of ATP to ADP through phosphorus transfer), which effects interaction of the 
parasite mitochondria, resulting in the energy supply of the cell being cut off, causing 
parasite death. (17) This derivative is primarily useful in the hepatic stages of P. vivax and P. 
ovale infections, as it prevents a relapse infection occurring. To date, it is the only marketed 
antimalarial with the key feature of hypnozoite activity, however tafenoquine 12 is now in 
phase III clinical trials for P. vivax hypnozoite treatment. (16)  
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Due to high antimalarial demand, in the 1980’s mefloquine 13 was used to treat infected 
patients before phase III clinical trials had been completed and has questionable side effects 
concerning the nervous system and gastro intestines, which now appear on the packaging as 
a warning. (16) Marketed at Lariam, compound 13 can cause serious neuropsychiatric side 
effects that can persist after treatment withdrawal.  The type of neurological symptoms 
which can occur include: dizziness, tinnitus and loss of balance. Also, psychiatric symptoms 
experienced by some patients include: suicidal thoughts, depression, anxiety and vivid 
dreams therefore, mefloquine is not recommended in the use of patients who have a history 
of psychiatric problems. Lariam is more effective than both quinine and chloroquine and like 
quinine, results in the accumulation of toxic haem. This analogue also interacts with 
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phosphatidylinositol, which blocks the membrane transport system through inhibition of this 
particular group of lipids from regulating intracellular signalling. (17)  
Further structural derivatives arose in the early 1990’s from investigating shortening of the 
alkyl chain (AQ13, 14) and the addition of an aromatic component (naphthoquine, 15), with 
the former being active against chloroquine resistant malaria.   
 
 
 
 
The partner compound 15 can be found within a fixed-dose Artemisinin combination therapy 
and is recommended as a single-dose treatment for malaria and is marketed in Papua New 
Guinea among other tropical countries. (18) 
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1:3:1:3 Synthesis 
Since publication of the ‘total synthesis of quinine’ in 1945 by Woodward and Doering, 
consistent discussion has been carried out as to whether the collaboration synthesised the 
chiral 4-aminoquinoline. The total synthesis of quinine attributed to the Nobel Prize given 
to R. B. Woodward in 1965, for his outstanding achievements in organic synthesis. Both 
himself and Doering state ‘they had succeeded, where generations of great scientists had 
failed’. However, a review of the quinine synthetic journey concluded what they actually 
obtained was d,l-homomeroquinene 16 and isolated d-quinotoxine 17. (19)  
 
 
 
Also, previous research conducted in 1943 by Proštenik and Prelog obtained non-racemic 
homomeroquinene from degradation of the natural product cinchonine. They performed a 
Claisen condensation reaction and generated a β-keto ester protected intermediate 18. This 
was then combined with 4-quinoline carboxylate 19 in another condensation reaction to give 
17 (see Scheme 2). Their contribution is highlighted in the review and they state the synthesis 
of quinine should be referred to as the Woodward-Doering/Proštenik-Prelog/Rabe-Kindler 
total synthesis of quinine.  
 
Scheme 2: Proštenik-Prelog synthesis 
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In 1918 fellow chemists Rabe and Kindler performed a 3-step conversion of 17 into 8 and 
were ‘the first’ to synthesise this illusive compound. They based their confirmation on the 
physical properties of quinine i.e. melting point and optical rotation measurements (see 
Scheme 3). (19)  
Scheme 3: Rabe and Kindler conversion of d-quintoxine 17 into quinine 8 (20) 
The first step involves bromination of d-quintoxine with sodium hypobromate to generate 
proposed intermediate V but, intermediate W was also highlighted. Rabe and Kindler 
proposed that based on their primary observations intermediate V did not react with methyl 
iodide therefore, it was unlikely W had been formed. The next step in the synthesis takes V 
and reacts it with sodium ethoxide in ethanol to generate quininone X and its less soluble 
epimer quinidinone Y. Treatment with sodium ethoxide in ethanol has two effects: to cause 
cyclisation to X and Y and, to establish an equilibrating mixture of these two ketones. They 
did not fully understand in 1918 that both X and Y are formed and interconverted under 
basic conditions. This observed interconversion is critical for the next step which involves 
reduction with aluminium powder alongside sodium ethoxide in ethanol. It is unknown if 
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Rabe and Kindler used a pure source of compound Y or a mixture of X and Y but, it is not 
important as the presence of sodium ethoxide and ethanol ensure conversion between X and 
Y. Issues surrounding this procedure outlined by Rabe and Kindler arose due to no 
experimental detail being published in the original paper and could therefore not be 
replicated. When Doering was questioned about the replicability of Rabe’s work he said, ‘it 
is almost never possible to reproduce published details. They assume an indefinable amount 
of experience and cannot be written for the first time cook who has never mastered the 
elementary techniques.’  
It wasn’t until 2001 when Stork et al published the first stereoselective synthesis of quinine, 
generating 22% of the desired product over 15 steps. (21) Due to the multistep synthetic route 
used to generate quinine, it would not be viable to scale up to bulk production and would not 
produce high enough overall yield to be worthwhile. To date, the most effective way to 
obtain quinine for antimalarial purposes is through extraction from its natural source, 
cinchona tree bark.  
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1:3:2 Artemisinin   
1:3:2:1 Antimalarial history  
A common herb used by Chinese herbalists for thousands of years, Artemisinin was first 
isolated in the early 1970’s by Chinese scientists from the Artemisia annua plant, also known 
as sweet woodworm (see Figure 6). The promising compound was found to be efficacious 
as an antimalarial and possessed comparable activity to quinine and chloroquine. 
Artemisinin quickly became a first-line of defence malaria treatment, particularly in South-
East Asia.  
 
 
 
 
 
 
                                                      
 
Artemisinin 20 is a fast acting antimalarial and useful in the treatment of severe cases of 
malaria, but it is also eliminated rapidly following administration to the patient. Even though 
the mechanism of action is unproven, reports have highlighted that the endoperoxide moiety 
present is necessary for antimalarial activity. (22) It is noted this moiety is a source of a 
reactive oxygen species (ROS), which generate free radicals. ROS can consist of radical and 
non-radical oxygen containing species for example, a hydroxyl radical or hydrogen peroxide. 
They are produced endogenously within mitochondria but can also arise from exogenous 
sources such as, xenobiotic compounds. Furthermore, high levels of ROS within the body 
Figure 6: Sweet woodworm 
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can result in oxidative stress which leads to ROS-mediated damage of: nucleic acids, 
proteins, lipids and has been implicated in neurodegeneration, diabetes and aging. (23) 
The parasite is rich in haem-iron and this subsequently activates artemisinin, through 
catalytic activation (see Figure 7). This results in the artemisinin derived free radicals 
damaging intracellular components within the parasite (it is hypothesised via alkylation). 
There are multiple proposals of action involving the artemisinin-derived free radicals for 
example, artemisinin forms covalent bonds with haem and prevents the digestion of 
haemoglobin and protein alkylation. (22) Not only do these endoperoxides have activity 
against erythrocytic stages of the parasite, particularly the ring stage, but also against 
gametocytes which helps prevention of transmission.  
 
 
 
 
 
                                        
 
Since the eruption of its use against malaria, cases of artemisinin resistant malaria have been 
commonly reported since 2009. To tackle the primary issue of resistance artemisinin-
combination therapies (ACTs) replaced first-line of defence drug treatments in 79 countries. 
(9) This decision has played a key role in the overall motion of malaria eradication. Resistance 
initially grew along the Cambodia-Thailand border, which has resulted in higher rates of 
failure to ACTs. It has been reported in some parts, that the malaria strain observed is 
Figure 7: Artemisinin and free radical formation 
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resistant to four different ACTs (see Figure 8). (8) Decreased parasite clearance rates have 
been seen in patients and more recently, resistance is wide spread across South-East Asia. 
(24) The role of ACTs is to provide a paired mechanism of action approach, which helps to 
reduce the cases of resistance. The artemisinin component reduces the biomass of the 
parasite and combined with a relatively slow acting drug, can reduce parasite burden and 
proves an effective chemotherapy.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: Migration of ACT resistance (9) 
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1:3:2:2 Derivatives and ACTs  
The endoperoxide class of antimalarials are the most widely used compounds as both 
monotherapies and combination therapies in chloroquine resistant malaria. The primary 
derivatives are; artesunate 21, arteether 22 dihydroartemisinin 23 and artemether (ART, 24), 
with the latter semisynthetic compound being significantly more effective than the other 
derivatives. The derivative 24 has demonstrated haemoglobin consumption within the 
parasites digestive vacuole, which generates ROS via oxidative stress and ultimately causes 
death of the parasite. Furthermore, ART has been found to inhibit the calcium ion transport 
protein PfaTP6, resulting in calcium ion homeostasis disruption within P. falciparum. (17)  
 
 
 
 
Derivative 21 is the most frequently prescribed derivative and intravenous artesunate is most 
popular for cerebral malaria, as the free carboxylate moiety enhances water solubility. (16) In 
combination with a drug partner possessing a longer half-life, several therapies exist which 
combine these endoperoxides with alkaloid derivatives such as: Coartem (artemether-
lumefantrine 25), artesunate-amodiaquine 26, artesunate-mefloquine 27 and artesunate-
sulfadoxine-pyrimethamine, in the hope of reducing resistance cases. 
 29 
 
 
 
 
 
 
 
 
Figure 9 displays a future hybrid antimalarial, which has been designed to combine fast 
acting artemisinin and chloroquine derivative, primaquine. This futuristic compound has 
been found to target both blood and liver stage parasitaemia and is currently under 
investigation in early in vivo studies. (16)  
 
 
 
 
 
 
 
 
 
 
 
Figure 9: Future multistage antimalarial 
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1:3:2:3 Synthesis 
Like quinine, the only viable means of sourcing artemisinin is through extraction of the 
active component from its natural plant source, which leads to high extraction costs to meet 
desired demand. In 1983 Schmid and Hofheinz synthesised artemisinin from (−)-Isopulegol 
and over a 13-step synthesis they generated the natural product in a 5% yield (see Scheme 
4). (25)  
 
Scheme 4: Artemisinin synthesis 
Scheme 5: Peroxide formation 
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Scheme 5 shows one possible mechanistic pathway to generate Artemesinin. Step 2 
highlights the key peroxide bond formation followed by an SN1 reaction eliminating 
methanol. Step 6 shows a second SN1 reaction that generates the final carbonyl electrophile 
which is attacked in step 7 to create a new 6 membered ring seen in step 8.     
Significant efforts have been made to investigate synthetic and semi-synthetic artemisinin 
analogues. For example, OZ277 28 was the first synthetic ozonide to be evaluated clinically 
and is now in phase III clinical trials as a combination therapy with piperaquine phosphate. 
(26) However, it displays reduced plasma exposure as well as a short half-life in vivo. From 
this, an optimisation compound OZ439 29 was generated and shows improved 
pharmacokinetic properties as well as proving to be a very successful clinical candidate (IC50 
of 3.4 nM against P. falciparum, see Scheme 6).  
 
 
Furthermore, enzymes present in A. annua, which take part in the bioproduction of the 
artemisinin precursor, artemisinic acid, have been cloned into bacteria. This biological 
approach alongside a fermentation process has allowed partial biosynthetic artemisinin to be 
synthesised. (16) Despite these advances in synthetic progress, the sheer demand for a 
successful chemotherapy requires the drug to be cheap and easily prepared.  
Scheme 6: Synthetic route to 29 
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1:3:3 Upcoming clinical candidates 
1:3:3:1 NITD609 
The most promising candidate in 20 years, NITD609 (also known as Cipargamin, 30), 
possess a novel mechanism of action and within the last year has completed a phase IIa 
clinical trial study. This highly potent compound has an IC50 of 1 nM against P. falciparum 
and has shown rapid suppression of protein synthesis in the parasite, in fact, it has 
demonstrated protein synthesis blocking within 1 hour of exposure. (27,28)  Not only have 
extensive studies highlighted NITD609 to possess high potency against symptomatic asexual 
stages of the parasite but also, shown to be as efficacious against early and late stage 
gametocyte development. (29) Therefore, the hit compound inhibits several stages of the 
parasite lifecycle and prevents transmission of the parasite through prevention of fertilisation 
within the mosquito midgut.  
  
 
 
 
 
Yeung et al investigated the structure-activity relationship of this spirotetrahydro-β-
carboline and highlighted the important features which are important for antimalarial 
activity. (30) Firstly, the 1R, 3S configuration is essential for activity, as they tested several 
derivatives with a 1S, 3R stereocentre and for the majority resulted in a complete loss of 
activity. Meanwhile, the chlorophenyl moiety contributed a balance between potency, 
favourable pharmacokinetics and synthetic accessibility. Also, analogues with varying 
central carbon ring sizes were tested for example, they increased the ring size to 7 and 8 
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carbon rings, this small change resulted in compound inactivity. Finally, the single methyl 
group enhances potency 5-fold, whereas alternate n-propyl and gem-dimethyl bulky groups 
decreased antimalarial potency (see Figure 10). (30)  
 
 
 
 
 
Further details and discussion on the structural and biological evaluation of NITD609 can 
be found in Chapter 3.  
 
 
 
 
 
 
 
 
 
 
Figure 10: Investigation of the SAR 
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1:3:3:2 DDD498 
In a collaboration with the University of Dundee Drug Discovery unit, a highly potent 
quinoline multistage chemotherapy was uncovered, DDD498 (also known as, MMV121). 
(31)  This potent antimalarial shown in Figure 11 has shown activity against: resistant parasite 
strains, possess a long half-life and inhibits gametocyte formation, as well as liver stage and 
blood stage parasites. This unique multi-stage compound was discovered via a screening of 
over 4700 antimalarial active compounds.  
 
 
 
 
 
Figure 11: Lead compound DDD498 
However, the initial hit required further medicinal chemistry optimisation as it was too 
lipophilic and metabolically unstable. Firstly, swapping bromine for fluorine reduced ClogP 
and subsequently replacing pyridine with an alkyl chain and tertiary amine increased 
solubility and metabolic stability. Finally, the addition of a morpholine group dramatically: 
increased in vivo potency, further reduced logP, increased metabolic stability and increased 
solubility (see Figure 12). (32) 
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Although not fully understood, the mechanism of action is thought to target translation 
elongation factor 2, which coordinates tRNA and mRNA moving through the ribosome 
(disrupts protein synthesis). This theory is supported by the compounds ability to target 
multiple stages of the parasite life cycle. (32) Hit compound DDD498 has now been approved 
by Merck for progress as a clinical candidate and the compound is predicted to undergo 
human studies in 2017, after toxicology and pharmacokinetic in vitro and in vivo studies 
have been performed to establish safe dosage quantities.  
 
 
 
 
 
Figure 12: Synthetic route to DDD498 
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1:3:3:3 MMV390048 
In 2014 a highly potent compound entered phase I clinical trials, with the hope of 
MMV390048 becoming a single dose cure for malaria. The first African-led team at the 
University of Cape Town Drug Discovery and Development Centre (H3D) synthesised and 
screened over 350 compounds. (33) Of the library generated, 8 aminopyridine hits were 
highlighted with varying aryl group at positions 3 and 5 of the aminopyridine core and 
displayed >80% parasite inhibition at the screening dose 1.82 μM (see Figure 13). (34) 
 
Figure 13: HTS hits 
Compounds possessing a methylsulfonyl phenyl substitution at position 5 of the 
aminopyridine core displayed the best potencies. Therefore, optimisation studies took place 
using the original hit, compound X which possesses an IC50 of 49 nM. 
(34) 
The first stage of optimisation removed the ‘metabolic hot spot’ present on compound X 
which resulted in the addition of a methoxylpyridyl moiety seen in compound Y. Not only 
did this change increase metabolic stability but also, when tested in vivo cured mice with a 
50 mg/kg dose after 4-day treatment. Further optimisation replaced the methoxy group with 
a trifluoromethyl group which increased potency (DDD498, see Figure 14). The MMV 
compound cured mice of P. berghei following a single dose of either 30 or 100 mg/kg which 
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is significant as chloroquine, mefloquine and artemisinin do not achieve a single dose oral 
dose cure in the same P. berghei in vivo model. From the study DDD498 showed the best 
activity alongside: good metabolic stability, low potential for CYP450 inhibition, negative 
Ames test and moderate hERG activity. (34) 
 
 
 
 
 
Figure 14: Route to MMV390048 
The compound showed promising activity in vitro against Plasmodium falciparum KI, 
NF54, 3D7 and Dd2 strains. The mechanism of action is shown to competitively inhibit the 
binding of a single protein, P14 kinase, which plays a role in phosphorylation of proteins 
within the cell and in turn affects cell signalling and inhibits the parasites ability to function. 
Also, it has shown activity against several stages of the parasite lifecycle as well as resistant 
strains, therefore DDD498 plays a promising role in the future of malaria control, 
transmission and eradication.  
Firstly, to synthesise this lead compound 4-bromobenzenethiol underwent methylation using 
triethylamine and methyl iodide. The research group also tested the reaction with potassium 
carbonate and DIPEA as the base however, both resulted in side products (not included) and 
low yield of the desired product (35%). 
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Scheme 7: Synthetic route to DDD498 
Then, intermediate B underwent sulfur oxidation and the resultant sulfone was collected in 
75% yield. The oxidised product C was kept to undergo Suzuki cross-coupling later on in 
the synthesis. Next, a boronate ester intermediate was generated over a three-step synthesis 
and started with iodination of 5-bromopyridin-2-amine D. Then, a Suzuki-Miyaura coupling 
took place with (6-(trifluoromethyl)pyridin-3-yl)boronic acid and intermediate E. A 
catalytic borylation takes place with intermediate F and bis(pinacolato)diboron to generate 
the desired boronate ester in 50% yield. The two intermediates C and G were combined 
through Suzuki coupling and the hit 32 was collected in 90% yield. (35) 
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Chapter 2: Tetrahydro-β-carbolines  
2:1 Indole alkaloids  
An indole core moiety can be found at the structural centre of a variety of biologically active 
compounds and the majority are found within their natural plant source, for example indole 
31 and β-carboline 32. The diversity surrounding these structures has given rise to 
compounds possessing activity against numerous biological processes. These compounds 
have been utilised for decades within the pharmaceutical industry as: antiparasitics, 
antimicrobials, anticonvulsants, antivirals, and antipsychotics.  
 
 
 
 
For example, the planar β-carboline structure consists of an aromatic pyridine ring fused to 
the indole moiety and compounds containing this core have been shown to: intercalate DNA, 
interact with serotonin/benzodiazepine receptors, and inhibit topoisomerases and 
monoamine oxidases. (36) Also, on reduction of the pyridine ring a tetrahydro-β-carboline 
moiety is revealed and an example such as, tryptoline has shown to act as a reuptake inhibitor 
of serotonin (note the structural similarities between tryptoline, 33 and serotonin, 34). (37) 
 
 
 
A type of fungi called Ergot produces a wide variety of these alkaloidal compounds. For 
example, the biological activity of ergoline 35 has been exploited in the treatment of 
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migraines via vasoconstriction and, it has also been investigated in the treatment for 
Parkinson’s disease. Due to the interest in their biological activity to target disease, several 
derivatives of ergoline have been synthesised. The most common ergoline derivate is 
lysergic acid, more commonly known as LSD 36 and is an illegal psychedelic compound 
which has been used recreationally for decades. (38)  
 
 
 
 
During the 1930’s, an alkaloid known as ajmaline 37 was discovered in East Asia and is 
obtained through extraction of the flowering shrub, snakeroot. This biologically active 
compound has been utilised in the pharmaceutical industry for its antiarrhythmic properties 
and works by blocking the sodium channels within a patient who is experiencing an 
abnormal heart rhythm. It has been suggested that the hemiaminal moiety present in ajmaline 
is responsible for its activity towards cardiovascular abnormalities. (39)  
 
 
 
 
More recently, alkaloids found within the seeds of Peganum harmala known as harmala 
alkaloids, have been tested for their fungicidal activity. Their normal biological function is 
to reversibly inhibit monoamine oxidases, which has resulted in these compounds being used 
37 
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to treat depression. (36) They have also been investigated for their antifungal activity and 
alkaloids such as harmine 38 and harmaline 39 exhibit good activity against 14 different 
varieties of fungus. (40)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
38 39 
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2:2 MMV008138  
2:2:1 Initial leads  
In 2012 two groups of researchers at Keele university were working on indole alkaloids. The 
Bailey group were attempting a complete synthesis of ajmaline and the Allin group were 
investigating the alkaloid scaffold of indoloisoquinolines, which was prompted by historical 
compounds with structural similarity to the natural product dihydrousambarensine 40. (41) 
The potential lead 41 was further optimised by investigating three points of variation on 
template 42: indole N-substituent (R), hydroxmethyl-O-substituent (R1) and alkenic 
substitution around the lactam ring (R2). (42) 
 
 
Recognising the intermediates made in the route to ajmaline showed structural resemblance 
to the indoloisoquinolines, the compounds were tested for their antimalarial activity. Of the 
compounds made, the most active were several tetrahydro-β-carboline compounds which 
had been synthesised during an investigation of the Pictet-Spengler reaction used to form the 
tetrahydro-β-carboline ring. (41,43) Consequently, the discovery of compound mc72a was 
made and displayed an IC50 of 1.3 μM, thus stimulating an interest in a potential new series 
of antimalarial compounds yet to be investigated. (44) Two key features of this novel 
40 41 42 
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compound are an allyl ester moiety and electron withdrawing nitro group present on the C1 
aromatic ring. Therefore, a strategy to try and optimise this structure developed with two 
points of variation: ester linkages (R1) and C1 aromatic ring substituents (R2) (see Figure 15). 
Our initial testing indicated the L trans derivative (1R, 3S) was more active than the L cis 
(1R, 3R) however, we recognised that a fuller exploration of the stereochemistry of the two 
chiral positions using both L and D tryptophan would be of interest.  
 
 
 
 
Figure 15: mc72a (left) and compound optimisation strategy (right) 
As mentioned earlier, the Open Access Malaria Box (MB) was published in 2013 and over 
5,000 compounds were sourced from: GlaxoSmithKline (GSK), Novartis and St. Jude 
Children’s Research Hospital (St Jude). The compound library endured a rigorous filtering 
process to generate highly potent antimalarial compounds that could be further optimised by 
external research groups, to generate a catalogue of novel antimalarial compounds. The bank 
of compounds includes 200 ‘drug-like’ and 200 ‘probe-like’ hits that have: inhibitory 
concentrations ranging from 30 nM to 4 μM against blood-stage resistant P. falciparum 
strains; have passed cytotoxic tests against HEK-293 cell lines and hand-picked by a group 
of experienced medicinal chemists considering Lipinski’s rules and; already possess 
structural similarities to aminoquinolines and endoperoxide antimalarials. (45) 
To gather more information regarding the mechanism of action of these 400 compounds, in 
2014 Bowman et al, highlighted a key compound during the investigation of the previously 
discussed apicoplast organelle. The loss of the apicoplast can be supplemented in vitro with 
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200 μM of IPP within experimental growth medium. Therefore, phenotypic screening can 
be utilised to narrow down the mechanism of action for compounds within the MB by 
measuring the growth recoveries before and after supplementation. Fosmidomycin (FOS, 1) 
is utilised as a control for this experiment because more is known about its mechanism of 
action towards the apicoplast.  (43)  
 
 
A compound which was brought to light by these studies is MMV008138.  Phenotypic 
screening carried out by Bowman showed this compound to have an antiapicoplast 
mechanism of action. Not only has the compound shown in Figure 16 been identified to 
target the apicoplast but has also shown to have a different target within the apicoplast. FOS 
targets DOXP reductase within the non-mevalonate pathway and MMV008138 has shown 
to act in a similar way by having a direct effect on the metabolism of the apicoplast. Current 
drugs which target this pathway such as, doxycycline and clindamycin still result in the 
parasite producing daughter merozoites, however it is the daughter cells which fail to 
replicate. 
                                     
 
 
           
 
Figure 16: Compounds targeting the apicoplast 
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Therefore, both FOS and MMV008138 have a direct effect on the metabolism of the 
apicoplast and no daughter merozoites can be produced, leading to cell death and eventually 
parasitic death. (46)  
The IPP recovery data for MMV008138 demonstrated that greater than 85% recovery of 
growth inhibition occurs in the presence of 200 μM IPP after a 72 hour incubation period 
with the compound. Furthermore, the inhibitory concentration was found to be 350 nM 
although, no data was yet available about the stereochemical compositions of the compound 
supplied. They state the important structural features are the pipecolic acid moiety and 
tetrahydro-β-carboline core seen in compound 30. In addition, the group propose the (1R, 
3R) stereoisomer best simulates the structural form of the previously discussed antimalarial 
hit NITD609, which targets the plasma membrane sodium efflux pump. (46) 
 
 
                                  
The similarity of structure between MMV008138 and our own lead molecule mc72a 
affirmed our interest in the tetrahydro-β-carbolines as potential antimalarial compounds and 
further analogues were designed to investigate the chemical space around the two 
compounds.  
Whilst our investigation was underway a number of other research groups have focused on 
the investigation into the biological target responsible for the mechanism of action. In 2014 
Herrera et al were the first group to discover the importance of the 1R, 3S configuration as 
it was discovered to be significantly more potent than the other diastereoisomers (see Table 
6). As a result, they created (1R, 3S) MMV008138-resistant P. falciparum strains and each 
strain contained an important mutation correlating to the IspD enzyme, which takes part in 
30 
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the non-mevalonate pathway generating IPP therefore, they propose MMV008138 targets 
the IspD enzyme. (47) 
 
 
 
                      Table 6: Individual diastereoisomer activity results 
Furthermore, an additional research group in America demonstrated (1R, 3S)-MMV008138 
to competitively inhibit the substrate CTP, which normally reacts with MEP via the IspD 
enzyme to generate a CDP-ME substrate (see Figure 17). They carried out a specific IspD 
inhibitory concentration assay and (1R, 3S)-MMV008138 was found to have an IC50 of 47 
nM against wild type PfIspD. Also, they include a docking proposal of (1R, 3S)-
MMV008138 within the active site of IspD and believe this will generate future structure-
based drug design efforts (see Figure 18). (48)  Figure 18 highlights the important amino acids 
present within the active site of IspD and includes hydrogen bond interactions with arginine, 
lysine and threonine.  
 
  
 
 
 
 
Stereoisomer IC50/μM 
1S, 3S >25 
1R, 3S 0.0071 
1R, 3R 0.17 
1S, 3R 2.5 
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Figure 17: CTP to CDP-ME conversion via IspD  
 
 
 
 
 
 
 
Figure 18: Docking of the (1R, 3S) stereoisomer of MMV008138 within IspD (46) 
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2:2:2 Background work   
The first round of analogues focused on the chemical space between our lead molecules and 
the MMV hit to explore what functional group contributed to activity. Table 7 displays the 
primary data collected from initial analogues synthesised and from these, compounds which 
possessed an inhibitory concentration of less than 20 µM were taken forward for further 
optimisation. 
 
 
 
 
                              
 
 
 
 
 
Table 7: Initial data July 2013 
A benzyl ester link was proposed as this would highlight a need, if any, for hydrophobic 
interactions or π stacking within the unknown target. Also, exchanging the oxygen hydrogen 
bond acceptor for benzyl amide derivatives would test whether a hydrogen bond donor or 
acceptor made any significant difference to inhibitory concentration. Furthermore, a benzyl 
moiety would allow further optimisation for substitution around this phenyl ring to 
Stereochemistry R1 R2 IC50/µM 
L cis 
 
 
H 19 
L cis 
 
17 
L cis 
 
3-OMe 36 
L trans 20 
L cis 4-OMe 39 
L trans 34 
L cis 3-Cl 27 
L trans 32 
L cis 4-Cl 22 
L trans 18 
L cis 4-NO2 25 
L trans 21 
L cis 3-NO2 12 
L trans 1 
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investigate whether adding for example, an electron withdrawing group, would have any 
effect on potency. 
Firstly, to bridge the gap with MMV data and the research group data both carboxylic acid 
and methyl ester derivatives of four analogues were generated during a summer research 
project in 2013. The methyl ester was chosen over the allyl ester moiety for ease of synthesis 
and Figure 19 displays the proposed primary structures to explore the MMV008138 structure 
activity relationship (SAR). Early SAR investigated the acid moiety alongside a new methyl 
ester group to see the effects a small hydrophobic interaction has on biological activity and 
whether the acidic proton donor was required for potency.  
 
 
 
 
 
 
 
 
Figure 19: Early analogues (R=H/Me) 
The MMV C1 phenyl 2,4-dichloro substitution was synthesised and used as a standard 
comparison for alternative substitution patterns. A m-nitro moiety was retained, as this was 
a feature of mc72a - the lowest IC50 compound generated previously by the research group. 
Therefore, by combining a m-nitro group with both acid and methyl ester moieties it gave 
the research group further information regarding which moieties were necessary for potent 
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activity and began to explore the importance of functional group position on the C1 phenyl 
ring.   
 
 
R1 
 
R2 
IC50/µM 
L cis L trans D cis D trans 
Me  2,4-Cl2 26.5 11.3 23.0 25.8 
H 
(MMV008138) 
12.0 0.36 1.31 8.16 
Me  m-NO2 64.8 17.7 8.30 45.5 
H > 50 > 50 > 50 > 50 
Me 3-CF3 31.2 25.7 5.10 23.3 
Me 4-CF3 23.5 25.4 10.6 23.8 
Table 8: 2013 results 
Table 8 displays a comparison of the four diastereoisomers for both MMV008138 and the 
methyl ester derivative. The data shows the superior antimalarial activity of the L trans form 
of MMV008138 (360 nM). From this data, it was thought the ester linkage provided vast 
potential scope for further substrate analogues therefore, it was concluded at the time to keep 
the methyl ester link, even though the acid MMV008138 displayed higher potency.  
Also, Table 8 highlights a preference for the m-NO2 and methyl ester combination therefore, 
gives further evidence to retain ester functionality. In contrast to the MMV008138 data, the 
methyl ester m-nitro derivatives have the lowest IC50 for the D cis configuration (BB6-A), 
therefore both L and D tryptophan should be explored in future analogues.  
Further exploration proposed to see what effect increasing electrophilicity on the C1 phenyl 
ring had on biological activity and naturally a trifluoromethyl moiety was explored in both 
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meta and para positions to see what effect each substitution pattern has on biological 
activity. However, the summer project student struggled to isolate the acid analogues and 
the compounds that were generated displayed poor activity.  
In correlation with the m-nitro derivative, both the meta and para trifluoromethyl analogues 
displayed favoured activity for the D cis configuration (BB10-A) and resulted in the lowest 
inhibitory concentration 5.10 μM (see Table 8). Although, the 2,4-dichloro derivatives retain 
superior activity as neither trifluoromethyl analogue possessed lower activity than 
MMV008138. Both L trans and D cis configurations have shown to be of importance for 
activity and they both possess the phenyl group in the 1R position. Therefore, predicted low 
IC50 analogues would correlate with previous discussion involving the antimalarial 
NITD609, which requires a stereochemistry of 1R,3R (D cis) for biological activity.  
A primary focus for the beginning of this PhD project was to generate the derivatives 
outlined in Figure 20 to investigate alternate ester linkages and compared their activity to 
the allyl ester lead compound mc72a. As our previous results had demonstrated a methyl 
ester group was inferior to the allyl ester, but the allyl group does not possess good medicinal 
chemistry properties for example, it is a target for oxidation during metabolism. So, the focus 
was shifted onto benzyl ester and amide analogues which showed promising initial data. Due 
to previous evidence suggesting an electron withdrawing group is highly favourable, 
pyridine groups were proposed to strengthen the evidence for this (see Figure 20).  
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Figure 20: Latest analogue proposals 
Figure 21 highlights two compounds derived from tryptamine and α-methyl tryptamine. The 
purpose of these analogues is to explore the 3D space where the carboxylic acid group is 
present on the MMV analogue.  
 
 
 
 
Figure 21: Further compound proposals 
To summarise, at the early stage of this PhD project it was forecast that by combining either 
a benzyl ester or benzyl amide moiety with a m-nitro or p-chloro substituted C1 ring it would 
lead to a more active compound in comparison to the allyl ester derivative which possessed 
an unsubstituted C1 ring and poor activity.  
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2:3 The Pictet-Spengler reaction  
2:3:1 Background  
The Pictet-Spengler (PS) reaction is an essential step in accessing the scaffold of 
pharmaceutically active isoquinolines and indole alkaloids such as MMV008138. In 1911 
Pictet and Spengler came across their eponymous condensation reaction by reacting β-
phenylethylamine and formaldehyde dimethylacetal under acidic reaction conditions (see 
Scheme 8). (49) The one step cyclisation quickly became a standard synthesis for the 
preparation of tetrahydroisoquinolines (THIQs). The reaction is thought to occur naturally 
within plants to biologically synthesise important alkaloidal compounds via condensation of 
β-arylethylamines and a variety of carbonyl compounds.  
 
 
 
Scheme 8: Mechanism of original tetrahydroisoquinoline formation 
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Furthermore, in 1928 Tatsui came across the use of the PS reaction for the formation of 
indole scaffolds, during the preparation of 1-methyl-1,2,3,4-tetrahydro-β-carboline (THBC) 
under traditional acid catalysed, aprotic conditions (see Scheme 9). (50) 
 
 
 
Scheme 9: Straight forward indole formation  
Not only does the PS reaction allow for the formation of structurally simple alkaloids, but it 
can also be utilised in the construction of more complex alkaloids that have been well 
documented for their uses in traditional medicine. Complex examples include: (−)-
Mitragynine 43, a strong analgesic and opium substitute used in native medicines; 
Koumidine 44, a natural indole alkaloid tested for its use treating neuralgia and obtained 
from the poisonous Gelsemium plant and Fumitremergin B 45, a mycotoxic compound used 
by many fungi to destroy crops. (51-53) 
  
 
 
 
Firstly, the condensation reaction begins with the formation of an iminium ion followed by 
nucleophilic attack but, the iminium ion can add directly at position C2 or at C3 to form a 
spiro intermediate (Scheme 10). The spiro route (C3) uses the delocalisation of the nitrogen 
lone pair and avoids disruption of the benzene aromaticity. (54) 
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Scheme 10: Pictet-Spengler intermediates  
 
Consequently, analysis of the transition state took place to examine interactions between the 
indole moiety and aldehyde substituent, prior to cyclisation. Figure 22 highlights the steric 
and electronic consequences for both cis and trans isomers during the imine transitions state. 
 
 
 
 
 
 
 
 
 
 
Figure 22: Steric and electronic transition state interactions 
Part A displays the transition state interactions between the indole and would be C1 phenyl 
group, which are more repulsive for the cis isomer (top) due to the two bulky rings whereas, 
the trans isomer only has a hydrogen-indole interaction (bottom). Furthermore, as the imine 
begins to approach sp3 hybridisation, disfavoured electronic interactions between the 
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aldehyde substituent and methyl ester moiety occur for the cis isomer, in comparison to the 
trans isomer which possess a single hydrogen atom interacting with the ester group shown 
in part B. Cook states in a review of this particular observation; trans selectivity is 
thermodynamically controlled, as a consequence of combined stereoelectronic and 
conformational interaction influences i.e. trans is more stable. (55) 
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2:3:2 Reaction scope   
Research carried out by Yoneda in 1965 discovered the PS reaction can be carried out in 
nonacidic conditions, as opposed to the classical acidic conditions in an aqueous medium. 
These findings from non-conventional synthesis led to exploration of reaction scope and 
understanding the factors which underlie stereochemical control of this condensation 
reaction. Initial research carried out to generate a desired benzyl amine intermediate led to 
the start of a surprising investigation into aprotic PS conditions (see Scheme 11). (56,57) 
 
Scheme 11: Non-acidic Pictet-Spengler conditions 
 
In 1979 Cook et al heated the reactants in benzene at reflux with Dean-Stark apparatus fitted 
to remove the water formed as the reaction proceeds, and to the groups surprise, they saw 
two diastereoisomer products as opposed to the imine they previously made when stirred at 
25 ºC in benzene. As a result, the investigation revealed this unusual method could be utilised 
with the condensation of acid-labile aldehydes and produce better yields for general 
aldehydes in this aprotic reaction. For example, the reaction of an N-benzyl protected 
tryptophan methyl ester with diethoxyacetaldehyde produced superior yields in aprotic 
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conditions (see Scheme 12). They extended the library of aldehydes with different 
functionalities to include: acetals, esters, amides and acetonitriles. (56,58) 
 
 
 
Scheme 12: Acid-labile aldehydes 
Cook and co-workers investgiated the aprotic approach to study the electrophilic nature of 
the imine intermediate double bond. Previous protonation of the nitrogen atom in protic 
conditions complicated the analysis of the imine and it is this property which is the driving 
force of the cyclisation. The investigation began by comparing tryptophan methyl ester and 
tryptamine intermediates, which resulted in only the Schiff base being formed for the latter, 
compared to a yield of 90% for the methyl ester cyclised product. Analysis of the pKa for 
the iminium showed the tryptophan methyl ester intermediate being more electrophilic, 
when compared with the tryptamine iminium which fails to cyclise (see Scheme 13). (58) 
 
 
 
 
 
Scheme 13: Imine study under aprotic conditions 
 59 
 
To solidify findings, mesomeric effects were studied by reacting an aldehyde possessing an 
electron donating group with tryptophan methyl ester. Under traditional acidic conditions 
the reaction overall yield was 3.5% of a cis/trans diastereoisomer mix, however under 
aprotic conditions only imine was detected. In fact, the imine was so unreactive the 
intermediate was reacted with p-toluenesulfonic acid and heated at reflux for 2 days and 
resulted in the fully aromatic product under these harsh conditions (see Scheme 14). (56) 
 
 
 
 
 
 
 
Scheme 14: Effects of electron donating groups on imine reactivity 
Also, Scheme 14 shows how the phenolic oxygen electron donation leaves the imine double 
bond less electrophilic in comparison to the tryptophan methyl ester substrate which results 
in un-cyclised imine. On the other hand, if acetylation of the phenolic oxygen takes place, 
this new functionality retards the electron donation from the oxygen and allows cyclisation 
to occur and results in a yield of 40% cyclised cis/trans mix of diastereoisomers.  
Alternatively, if the indole substrate is Nβ-benzylated, the resultant imine intermediate 
readily undergoes cyclisation. This approach is useful for unreactive intermediates and can 
simply be removed later through traditional catalytic hydrogenation. Cook et al, found the 
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temporary benzylation increased the speed of cyclisation and improved overall yield of the 
reaction. For example, Scheme 15 shows the previously reluctant salicylaldehyde 
undergoing cyclisation and with this approach now results in a yield of 97% product. 
However, it is detailed some aldehydes can distil through Dean-Stark apparatus, which 
contributes to poor yield and is therefore essential to ensure the boiling point of the chosen 
aldehyde is higher than that of the solvent. (55) 
 
 
 
 
 
Scheme 15: Nβ-benzylation to increase imine reactivity 
Proposed analogues for this project involve electron withdrawing groups substituted on the 
C1 phenyl ring therefore, the activity of the imine intermediate formed should not create any 
problems as there is no electron donation into the phenyl ring. Also, traditional protic 
conditions have been selected to generate this set of tetrahydro-β-carbolines to eliminate any 
unforeseen problems during imine formation as well as ease of synthesis.  
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2:3:3 Thermodynamic control: trans selectivity 
During the condensation of salicylaldehyde with Nβ-benzylated tryptophan methyl ester, it 
was noted that only a single diastereoisomer was obtained (see Scheme 16). Cook proposed 
this observation was due to the phenolic hydrogen causing hydrogen bonding interactions, 
which favoured trans selectivity. However, on repeating the Pictet-Spengler reaction with 
cyclohexanecarboxaldehyde under aprotic conditions, a trans cyclised product was obtained 
in 87% yield thus, ruling out hydrogen bonding as a cause for stereocontrol. A further 
reaction was carried out with unprotected tryptophan methyl ester, which resulted in a 
mixture of cis/trans cyclised products. (56) 
Scheme 16: Primary investigations into trans selectivity  
Also, if a percentage of the N-benzyl cis diastereoisomer is formed it can be converted to the 
more thermodynamically favoured trans diastereoisomer via epimerisation under acidic 
conditions. If this method was employed to generate derivatives for this project, a terminal 
N-benzyl deprotection step would have to be carried out to achieve the tetrahydro-β-
carboline core we desire. However, this project requires both cis and trans diastereoisomers 
for biological testing. As a result, a trans selective approach would only become of use if a 
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synthesised novel trans compound proves highly active and larger quantities of the 
compound is required.  
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2:3:4 Kinetic control: cis selectivity 
Bailey et al, comprised a set of reaction conditions which involves preformation of the imine 
intermediate before adding an excess of acid at low temperature to form the final cyclised 
product (see Scheme 17).  
 
 
Scheme 17: General Bailey Pictet-Spengler conditions 
A disadvantage of thermodynamic conditions is the possibility of product racemisation, 
which would be unfortunate for the synthesis of natural products containing multiple chiral 
centres. Furthermore, most natural products possess a 1,3-substituted cis relationship, such 
as the previously mentioned natural product, Koumidine, so a cis relationship is highly 
desired.  
Investigations into kinetic control followed the observations of Cook et al, looking into the 
conformations of imine transition states of Nβ-benzyl tryptophan methyl esters previously 
discussed in chapter 2:3:1. Bailey states 1,3-disubstituted tryptophan methyl ester would 
prefer to be equatorial, reducing 1,3-diaxial interactions, and therefore results in cis 
selectivity in the absence of Nβ-benzylation. To support this, Pictet-Spengler reactions were 
carried out at low temperatures to demonstrate this hypothesis of cis selectivity to be the 
case. Additionally, they report the high temperature conditions do not reduce the kinetic 
selectivity, but more so the fact that the reaction conditions proposed by Cook are reversible.  
This statement is supported by experimental evidence, through subjecting pure cis cyclised 
product to Cook conditions and the observed outcome resulted in 1:2 cis/trans selectivity 
(see Scheme 18). From the tryptophan methyl ester derivatives generated, Bailey et al found 
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a general 4:1 cis/trans selectivity for a reaction carried out at room temperature and all 
products obtained retain their optical integrity, therefore no racemisation took place utilising 
these conditions. (59) 
 
 
 
Scheme 18: Cis selectivity in tryptophan methyl esters 
Later, Bailey reported further scope for the cis selective Pictet-Spengler reaction conditions, 
whilst conducting research into the total synthesis of ajmaline. The group discovered a 
certain combination of ester and aldehyde which, under kinetic conditions, produced 
virtually 100% cis cyclised tetrahydro-β-carboline (see Scheme 19).  
 
 
 
 
 
 
Scheme 19: Ajmaline (above) and surprising cis selectivity (below) 
Bailey summarised over 10 years after his initial research was conducted that only allyl 
esters display 100% cis selectivity, as replacing allyl with a propyl ester generated 4:1 
cis/trans selectivity. Also, only aryl aldehydes produced >95 cis selectivity, as alkyl 
aldehydes such as butanal produced 78:22 cis/trans selectivity. (43) Furthermore, this method 
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uses milder reaction conditions which tolerate aryl aldehyde substrates with a variety of 
electron donating/withdrawing groups in ortho, meta or para positions. For example, p-
methoxybenzaldehyde generates >95:5 cis/trans, and identically 4-chlorobenzaldehyde 
generates >95:5 cis/trans. (43) 
Moreover, in 2009 Bailey et al identified good selectivity in tryptophan substrates which 
possessed a C3 carbonyl π bond alongside an aldehyde substrate with an appropriate π 
moiety, to achieve high cis selectivity. The tryptophan allyl ester substrate repeatedly 
produced the highest cis selectivity when compared to other substrates tested (Scheme 20). 
(41) 
 
 
 
 
 
Scheme 20: Variety of substrate scope 
Compared to Cook’s trans selective synthesis the Bailey method offers the generation of 
both diastereoisomers (general 4:1 selectivity at room temperature), which this project 
desires. Furthermore, if a novel compound with a cis relationship is found to be highly active 
then this synthetic strategy could be tailored i.e. reaction temperature decrease to generate 
more of the desired cis compound under these kinetic conditions.  
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2:3:5 Lewis acid catalysis  
In the last 15 years various Pictet-Spengler catalysts have been investigated to improve: 
reaction times, yields and broaden substrate scope. Lewis acids have been probed alongside 
microwave irradiation, to shorten reaction times further. Ganesan et al investigated multiple 
Lewis acids and categorised into poor, moderate and high activity PS catalysts. Examples 
include: AgOTf – poor activity, Cu(OTf)2 – moderate activity and Sc(OTf)3 – high activity. 
(60) The Lewis acids possessing the less nucleophilic triflate counterparts were superior 
compared to metal chlorides such as TiCl4, for which a competing imine hydrolysis reaction 
was found to take place. (60) 
Yb(OTf)3 gave the best yields when reacted with the intermediate imine and it was shown 
to only require 5 mol% of catalyst and 30 minutes in a microwave reactor to achieve high 
imine conversion, with both aromatic and aliphatic imines. In comparison, a one-pot 
synthesis could also be applied by generating the imine in situ with excess aldehyde, which 
resulted in higher yields and cleaner product mixtures.  For example, Scheme 21 shows the 
reaction of L-tryptophan methyl ester with benzaldehyde, generating a crude product of 1:1.6 
cis/trans selectivity with an overall 85% yield. (60)  
 
 
 
Scheme 21: Lewis acid one-pot microwave reaction 
The reaction can also be carried out in a conventional oil bath heated to 120 ºC for 50 
minutes, which was found to give comparable yields to using microwave irradiation.  
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The Lewis acid approach can also be applied to both electron donating and electron 
withdrawing aldehydes, the former previously discussed for causing frequent problems for 
Pictet-Spengler cyclisation due to the low reactivity of imine intermediate. However, with 
this method aldehydes such as, 3,4,5-(trimethoxy)phenyl aldehyde, can be reacted with L-
tryptophan methyl ester to give 1:1.4 cis/trans selectivity and 93% yield. Furthermore, 
tryptamine can be reacted with the same electron donating aldehyde, and combined with the 
poor tryptamine imine, surprisingly still produces 89% yield (as a mixture of enantiomers, 
see Figure 23). (60) 
 
 
 
    
 
Figure 23: Surprising Pictet-Spengler product 
For this medicinal chemistry project, a Lewis acid approach would generate more even 
quantities of both cis and trans diastereoisomers. Therefore given: the shorter reaction times, 
increased product yield and more even cis/trans formation, this method would greatly benefit 
analogue generation.  
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2:4 Biological results and discussion 
2:4:1 Tryptamine derivatives 
During the investigation, the key interaction was removed to see the effects this had on 
biological activity. Figure 24 displays the analogue generated and possess a p-
trifluoromethyl group chosen to retain the important electron withdrawing functionality. 
 
 
 
 
Figure 24: Tryptamine analogue (left) and MMV008138 (right) 
This derivative was synthesised via traditional aqueous, acid catalysed conditions, 
discovered by Tatsui. Firstly, p-trifluoromethyl benzaldehyde was pre-stirred in water 
containing 5 drops of sulfuric acid for 30 minutes. Then, tryptamine was added into the 
solution and stirred overnight at reflux. Some viscous insoluble solid forms within the 
reaction mixture and is thought to contribute to low overall yield. However, the product was 
purified using column chromatography and easily separated from its constituents, to yield a 
white solid.  
 
 
                                    
 
       Scheme 22: Tryptamine analogue synthesis 
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Biological results showed this tryptamine analogue to have an IC50 of 1 µM, which is the 
lowest inhibitory concentration discovered for this tetrahydro-β-carboline series. 
Furthermore, in direct comparison to the methyl ester analogue possessing the same phenyl 
substituent the tryptamine analogue has superior activity (see Figure 25). In 2012 research 
carried out by Gellis and co-workers highlighted a similar compound possessing an electron 
donating group which possessed lower activity than the tryptamine compound synthesised 
in this project. (61) Early assumptions highlighted the carbonyl link as essential for 
antimalarial activity particularly for MMV008138, in combination with orientation.  
                        
 
 
 
 
 
Figure 25: Tryptamine and tryptophan methyl ester comparison 
However, these two compounds indicate the primary predictions may be inaccurate but, it is 
still unknown if this result is due to general toxicity of the compound, as opposed to a 
targeted mechanism of action. Therefore, more biological tests need to be carried out before 
making any deductions. More tryptamine derivatives should be synthesised to probe this 
interesting find.  
Following these findings two α-methyl tryptamine derivatives were synthesised to explore 
the interaction of a short hydrophobic R1 alkyl substitution. Hence, Scheme 23 shows the 
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route taken to first synthesise the desired α-methyl tryptamine starting material, via a 
nitroalkene intermediate.  
                                     
 
 
 
 
 
Scheme 23: Preparation of α-methyl tryptamine 
Tatsui Pictet-Spengler conditions were then used to generate the desired cyclised product, 
as previously shown in the case of tryptamine and the diastereomeric pairs were separated 
via column chromatography. Biological data gathered, gave inhibitory concentrations as 
follows; 4.5 µM for LVT33-1 and 1.4 µM for LVT33-2 (see Figure 26).  
 
 
 
 
                                        
Figure 26: α-methyl tryptamine analogues 
Consequently, these analogues indicate that the carboxylic acid interaction is not vital for 
activity but, more derivatives with a short methyl interaction should be generated to 
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strengthen this observation. Also, the p-trifluoromethyl C1 phenyl substitution seems to be 
important as low activity compounds are observed and should therefore be retained in future 
derivatives.  
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2:4:2 Tryptophan methyl ester derivatives  
This set of synthetic targets retained the methyl ester and looked at varying the nature of the 
electron withdrawing aromatic substituent at C1. For example, compounds A and B have a 
nitrogen atom within the phenyl ring and therefore, offer alternative electronic interactions. 
Compound C explores the effects of two strong electron withdrawing groups in a 2,4-
substitution pattern to mimic the original MMV compound. Finally, compound D possesses 
an ortho EWG group thus, offering a complete look at the effects an EWG has at all positions 
on the phenyl ring.  
 
Structure Stereochemistry Bailey 
d.r. 
cis:trans 
Yb(OTf)3 
d.r. 
cis:trans 
A L trans 1.7:1 1.2:1 
L cis 
D trans 2:1 1.3:1 
D cis 
B L trans 2.2:1 1.2:1 
L cis 
D trans 1.6:1 1.2:1 
D cis 
C L trans 2.3:1 1.1:1 
L cis 
D trans 1.6:1 1.1:1 
D cis 
D L trans 3:1 1.3:1 
L cis 
D trans 1.6:1 1.2:1 
D cis 
Table 9: Synthetic route d.r. comparison 
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This subset of analogues were generated by both the Bailey method (TFA, rt, 4 h) and the 
Lewis acid microwave conditions (Yb(OTf)3, 100 ºC, 0.5 h). Table 9 highlights the 
comparison of diastereomeric ratio observed for both methods. 
The Bailey method shows a range of 1.6–3:1 d.r. on the other hand, the Pictet-Spengler 
reaction carried out via Lewis acid catalysis displays lower selectivity with a d.r. range of 
1.1–1.3:1 selectivity. The Lewis acid method overall gives better yielding products and the 
crude reaction mixture does not contain any unreacted imine, which makes separation of the 
diastereoisomers simpler (see Table 10). 
 
 
 
 
 
 
 
 
Table 10: Yield comparisons 
 
Structure Stereochemistry Bailey  
Yield/% 
Yb(OTf)3  
Yield/% 
A L trans 31 31 
L cis 29 32 
D trans 8 31 
D cis 15 29 
B L trans 17 40 
L cis 35 35 
D trans 16 33 
D cis 18 29 
C L trans 8 40 
L cis 42 37 
D trans 19 36 
D cis 21 37 
D L trans 10 38 
L cis 18 37 
D trans 6 37 
D cis 4 31 
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For example, the entries highlighted in Table 10 show very poor yield for the trans 
diastereoisomer generated by the Bailey method. This can be explained by the favoured 
generation of the cis diastereoisomer in combination with tricky purification i.e. unreactive 
imine with similar retention factors and solubility issues.  
The overall lowest yield is seen for the D cis diastereoisomer of compound D and an 
explanation for this comes from the compound itself being very insoluble. As a result, only 
a small amount of the diastereoisomer mix could be dissolved and subsequently purified to 
obtain each diastereoisomer for biological testing.  
Additionally, the Bailey method involves preformation of the imine before acid catalysed 
cyclisation, so requires an 18 hour stir before allowing 4 hours for cyclisation. It was 
observed that this method leads to unreacted imine within the crude mixture after monitoring 
the reaction by TLC over 4 hours which contributes to lower yields, as seen in Table 10. 
This issue can be overcome by adding more than 2 equivalents of TFA, but leaving the 
reaction longer was not found to increase cyclised product. Higher quantities of TFA could 
also risk racemisation of the chiral centre. The imine intermediates have similar retention 
factors to the desired cyclised product, it makes purification more complex and results in 
isolated yields not being consistent. In comparison, the Lewis acid methodology only 
requires a reaction time of 30 minute in a one-pot microwave irradiation reaction, which can 
be purified straight away after an aqueous work up. Overall, the Pictet-Spengler reaction 
carried out utilising Yb(OTf)3 should be employed for future analogue generation due to 
both, cleaner and faster reactions.  
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2:4:2:1 Tryptophan methyl ester biological data  
Following synthesis of the proposed methyl ester derivatives, the inhibitory concentrations 
were obtained for Plasmodium falciparum and are displayed in Table 11.  
 
 
 
 
 
 
 
Table 11: Methyl ester derivatives 
 
The pyridine moiety did not produce compounds with high activity in either, D or L 
conformation nor, 3-pyridinyl or 4-pyridinyl positions about the phenyl ring. The lowest 
inhibitory concentration achieved, as highlighted in Table 11 is 16.7 µM. The alternate 
electronic properties offered by the addition of a nitrogen atom within the aromatic ring does 
not warrant further investigation.  
Structure  Stereochemistry IC50/μM  
Dd2 strain 
A L trans 24.5 
L cis 30.0 
D trans > 50 
D cis 25.6 
B L trans 16.7 
L cis >50 
D trans 31.0 
D cis 39.5 
C L trans 5.40 
L cis 8.90 
D L trans 10.5 
L cis 22.3 
D trans 5.20 
D cis 3.30 
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On the other hand, attempts to optimise the structure activity relationship of MMV008138 
resulted in the replacement of the original 2,4-dichloro moiety with a more electron 
withdrawing functional group i.e. trifluoromethyl group. Further to this, a 2,4-disubstitution 
relationship was retained as it is thought to be of importance for antimalarial activity, even 
though a previously discussed methyl ester analogue possessed a 3-trifluoromethyl 
substitution and has an IC50 of 4.9 μM. Overall, the L diastereoisomers of compound C 
possess good activity for example; the L trans conformation has lower activity (IC50 of 5.4 
μM) compared to L cis (IC50 8.9 μM), which supports previous evidence suggesting a 1R, 3S 
relationship is required for better activity.  
Furthermore, o-trifluoromethyl substitution was investigated (compound D) to ensure all 
substitution positions on the phenyl ring had been explored thus, allowing a full set of 
biological data to be gathered. Surprisingly, the D cis diastereoisomer of compound D (IC50 
3.3 μM) has even better activity than the L trans diastereoisomer of compound C, therefore 
this observation provides insight that functional group position may not be as crucial as first 
thought and it is more the conformation of the diastereoisomer, in combination with the 
functional group present.  
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2:4:2:2 Methyl ester NITD609 derivative  
As previously highlighted, recent clinical candidate NITD609 possesses a spiro core and a 
trans configured chlorine-amide relationship. Therefore, attempts to mimic this active 
structure was explored through synthesis of a 2,5-disubstituted compound, which includes a 
chlorine and acetamide moiety. The structural comparison can be seen in Figure 27 however, 
biological results indicate only good activity for example; the L trans diastereoisomer has an 
IC50 of 5 μM, which is not significant, but nevertheless reinforces the significance of a (1R, 
3S) conformation (see Table 12).  
 
 
 
Figure 27: NITD609 structure comparison 
Stereochemistry Bailey  
d.r. 
cis:trans 
Yb(OTf)3 
d.r. 
cis:trans 
Bailey 
Yield/% 
Yb(OTf)3 
Yield/% 
IC50/μM 
L trans 1.7:1 1.1:1 20 22 5.00 
L cis 11 24 8.80 
Table 12: NITD609 mimic results 
The protected aldehyde was first prepared before carrying out the Pictet-Spengler 
cyclisation. The starting material 2-amino-5-chlorobenzaldehyde was stirred in acetic 
anhydride and pyridine at room temperature overnight and once purified, leaves a yellow 
solid in good yield (see Scheme 24).   
 
 
Scheme 24: Aldehyde synthesis 
 78 
 
2:4:3 Tryptophan benzyl ester derivatives  
To explore the importance of carboxylate functionality, a series of benzyl ester derivatives 
were synthesised. As previously highlighted the lead benzyl ester analogue possessed an 
unsubstituted C1 phenyl ring and the tested L cis diastereoisomer had an IC50 of 19 µM. 
Therefore, the purpose of this series was to attempt to improve the activity observed and to 
probe the effects a large hydrophobic interaction has on biological activity in comparison to 
previous methyl ester derivatives and the original MMV acid proton donor. A benzyl group 
offers π-stacking interactions as well as, the potential for further substitution on a second 
ring structure within the molecule. Therefore, this sub-set has the potential for a wide range 
of potential candidates.  
To access the desired benzylated tryptophan starting material a benzylation was carried out 
with the relevant Boc-protected tryptophan i.e. D or L-Trp, obtaining moderate yield, without 
epimerisation at the α-centre (see Scheme 25).    
 
 
 
 
Scheme 25: Tryptophan benzyl ester formation i. MeOH, H2O, Cs2CO3, ii. DMF, BnBr, rt. 
Once benzylated, a required deprotection step takes place to remove N-Boc protection using 
trifluoroacetic acid in methanol/dichloromethane and produces a yellow oil in good yield 
that solidifies on standing (see Scheme 26). The reaction is followed easily by TLC due to 
the unprotected product being considerably more polar than the starting material, thus 
allowing simple purification by column chromatography.   
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Scheme 26: N-Boc deprotection  
Alongside this methodology, more direct synthetic approaches were carried out to achieve 
the desired starting material whilst avoiding racemisation of the resultant product. However, 
all alternate attempts resulted in a racemic mixture, which was confirmed through optical 
rotation measurements (see Scheme 27).  
 
 
 
 
Scheme 27: Alternate strategies 
i. K2CO3, CH3CN, BnBr, Δ; ii. NaHCO3, CH3CN, BnBr, Δ; iii. Cs2CO3, CH3CN, BnBr, rt 
 
The traditional Bailey method was initially employed to synthesis all benzyl ester 
derivatives, but the Lewis acid approach was subsequently carried out to allow comparison 
of diastereomeric ratios and yields - to see if the latter produces consistent results for 
alternate functional groups present during the cyclisation step.  
 
 
 
R Stereochemistry 
Bailey 
d.r. 
cis:trans 
Bailey 
Yield/% 
Yb(OTf)3 
d.r. 
cis:trans 
Yb(OTf)3 
Yield/% 
m-NO2 
L trans 
3:1 
25 
1.2:1 
36 
L cis 29 40 
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Table 13: Method comparison 
A comparison for diastereomeric ratios can be seen in Table 13 and, as previously seen in 
all methyl ester derivatives, the Lewis acid method provides moderately equal quantities of 
both cis and trans cyclised product (average selectivity 1.1:1 cis/trans). Furthermore, yields 
are higher for the Lewis acid approach, when compared to the Bailey method. For example, 
the Lewis acid approach for 2,4-dichloro substituted analogues produced nearly twice the 
amount of product compared to the Bailey method (highlighted in Table 13). Also, 
purification was more straightforward compared to methyl ester derivatives, as the margin 
of separation on thin layer chromatography is larger.  
 
 
 
 
 
 
 
p-CF3 
L trans 
3:1 
29 
1.1:1 
36 
L cis 32 41 
m-CF3 
L trans 
3.3:1 
23 
1.2:1 
36 
L cis 26 35 
D trans 
3:1 
24 
1.1:1 
24 
D cis 26 27 
2,4-Cl2 
L trans 
3:1 
15 
1.1:1 
32 
L cis 20 30 
D trans 3.1:1 
 
13 1.1:1 
 
31 
D cis 12 35 
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2:4:3:1 Tryptophan substituted benzyl ester derivatives 
In addition, successive analogues were synthesised to explore the contribution of an electron 
withdrawing group located on the benzyl ester ring for example, para trifluoromethyl and a 
para fluoro group. The substitution allows comparison of activity with the original MMV 
compound, by retaining a 2,4-dichloro moiety, and seeing the effects this change has on 
biological activity. A small fluorine group provides a strong electronegative interaction with 
hydrogen bond acceptor capabilities therefore, if this type of interaction is favourable then 
the inhibitory concentration should decrease. Also, a trifluoromethyl group was tested to see 
the effects a significantly more electronegative moiety had on biological activity.  
To access this follow-on set of benzyl derivatives, the relevant substituted benzyl bromide 
was interchanged in the synthesis of the tryptophan ester to synthesise the desired starting 
material, which was then taken through to N-Boc deprotection and then Pictet-Spengler 
cyclisation (Scheme 28).  
 
Scheme 28: Substituted benzyl ester synthesis 
i. MeOH, H2O, Cs2CO3, ii. DMF, X-PhCH2Br, rt., iii. MeOH/CH2Cl2, TFA, rt., 18 h. 
 
The comparable diastereomeric ratios are highlighted in Table 14 as well as yields, for the 
traditional Bailey method and Lewis acid method.  On average the selectivity is ~3:1 for the 
Bailey method, and 1.1:1 for the Lewis acid method, therefore consistent with previous 
subsets.  Also, product yields for both methods are similar with two exceptions highlighted 
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in Table 14, although unforeseen purification issues are the likely to be the cause of this 
discrepancy.  
 
 
 
      
 
 
 
 
Table 14: Substituted benzyl esters 
 
 
 
 
 
 
 
 
 
R Stereochemistry Bailey 
d.r. 
cis:trans 
Bailey 
Yield/% 
Yb(OTf)3  
d.r. 
cis:trans 
Yb(OTf)3 
Yield/% 
F L cis 3:1 27 1.1:1 24 
L trans 36 30 
D trans 3.1:1 18 1.1:1 33 
D cis 32 36 
CF3 D trans 3:1 27 1.2:1 24 
D cis 36 25 
L trans  3:1 28 1.3:1 27 
L cis 14 29 
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2:4:3:2 Tryptophan benzyl ester biological data  
Table 15 displays the inhibitory concentrations obtained for the synthesised benzyl ester 
derivatives and those which possess an IC50 of less than 6 μM have been highlighted.  
 
 
 
 
 
           
   Table 15: Benzyl ester inhibitory concentration data 
Both diastereoisomers of compound A possess activity ten times lower than the primary lead 
compound mc72a of which, the only difference is the ester linker, i.e. benzyl versus allyl 
ester. Therefore, as no improvement in activity was observed and the disfavoured medicinal 
chemistry properties of a nitro group, it was decided not to pursue nitro functionality any 
further.  
Meanwhile, a benzyl ester derivative displaying good activity is the L trans diastereoisomer 
of compound B (IC50 3.6 μM) and the L cis conformation shows poor activity (LVT15-2 
Structure Stereochemistry IC50/μM  
Dd2 strain 
A L trans 15.2  
L cis 13.7 
B L trans 3.6 
L cis 13.7 
C L trans 5.3 
L cis 3.1 
D L trans 2.3 
L cis 4.4 
D trans 5.4 
D cis 3.2 
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IC50 13.7 μM) thus supporting the favoured 1R position of the phenyl ring. Furthermore, 
compound C L trans (5.3 μM) and L cis (3.1 μM) have moderate inhibitory concentrations. 
On the contrary to conformation trend the L cis compound displays lower activity, therefore 
the activity prediction cannot always follow through to observation. Overall, compounds 
which have a benzyl ester link in combination with a trifluoromethyl group show moderate 
activity and should be considered when making future compounds.  
To compare a benzyl ester link to the original carboxylic acid moiety present for 
MMV008138, the 2,4-dichloro moiety was retained so a comparison could be made on 
inhibitory concentration. All four diastereoisomers of compound D in particular, the L trans 
and D cis conformations display marginally better activity than their partners, therefore 
complying with the prediction that the C1 phenyl group is required to be in the 1R 
configuration for good activity. Although, the lowest activity of 2.3 μM (L trans) is still not 
superior to both, (1R, 3S)-MMV008138 and mc72a. The activity is not dissimilar from the 
trifluoromethyl benzyl ester derivatives, nevertheless, there is potential for further 
functionalisation on the benzyl ester ring, so more derivatives were synthesised to explore 
this novelty in the compound.  
A subset of substituted benzyl ester derivatives were synthesised however, biological data 
was only obtained for the L trans and D cis stereoisomers. Interestingly, the D cis 
diastereoisomer of compound F (6.57 μM) is preferred over L trans diastereoisomer (48.1 
μM). Whereas, the L trans conformation (4.35 μM) of compound E displayed higher activity 
compared to the D cis (32.3 μM) diastereoisomer (see Figure 28). This could suggest for a 
(1R, 3S) configuration a larger electronegative interaction is favoured for this specific 
orientation, whereas a (1R, 3R) configuration desires a small electronegative interaction 
which provides the possibility of a hydrogen bond interaction. 
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Figure 28: Substituted benzyl ester derivatives 
As only two electron withdrawing moieties have been tested and produced unpredictable 
results in biological activity, further derivatives with alternate functionality such as, electron 
donating should be generated to probe these findings further before any conclusions can be 
made.  
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2:4:3:3 IPP reversal experiment results  
To investigate the mechanism of action for this set of benzyl derivatives another biological 
experiment was conducted by the biology department known as an IPP reversal assay. The 
derivatives chosen to undergo this investigation represent a range of inhibitory activity 
observed across the compound screening as well as, reflecting the favoured L trans and D 
cis conformations. Table 16 shows the inhibitory concentrations for the nine compounds 
chosen and it is to be proven whether a low inhibitory concentration correlates to an increase 
in fold-change during the IPP assay. A large fold-change indicates the derivative is targetting 
the IspD enzyme and those that do not possess a fold-change are likely to act on an unknown 
target yet to be deciphered.  
 
 
 
Reference Stereochemistry R  IC50/ µM 
942 L trans 
 
48.1 
962 D cis 6.57 
971 L trans 
 
4.35 
952 D cis 32.3 
1281 L trans -OH 0.34 
1282 L cis 16.9 
1291 D trans 8.08 
Table 16: Inhibitory concentration results 
The assay was carried out on the trophozoite parasites due to the expression of a luciferase 
reporter protein at this stage which allows the experimenter to monitor parasite viability 
following exposure to an IC50 dose. Alongside dosing the parasite with an IC50 amount, one 
group is subject to IPP supplementation and the other group is not. Therefore, between the 
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two data groups the fold-change in parasite viability is calculated (i.e. luciferase counts) and 
Figure 29 displays the outcome of this experiment.  
 
 
 
 
 
 
 
 
Figure 29: IPP fold-change results 
As a result of the IPP reversal assay it is clear that supplementing the benzyl ester derivatives 
has minimal or no effect in reversing the initial inhibitory effect of the derivatives. On the 
other hand, IPP supplementation of the original MMV008138 stereoisomers shows the 
opposite and a significant fold-change is seen for these three compounds (Figure 29, far 
right). Also, each compound was dosed with an individual IC50 amount and since the IPP 
reversal effect is observed to be similar for these three acid compounds it suggests they all 
target the IspD enzyme regardless of their individual potencies. Further statistical analysis 
was carried out and it was concluded that there is no likely correlation between the inhibitory 
concentration potency and the ability to reverse the inhibition by IPP supplementation. 
However, to strengthen these findings the IPP reversal assay would need to be carried out 
on numerous derivatives. (62) 
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2:4:4 Tryptophan benzyl amide derivatives  
Initial testing for the original benzyl amide lead possessed an unsubstituted C1 phenyl ring 
and had an IC50 of 17 µM. As a result, the benzyl amide link was explored to see if activity 
could be improved and to probe the effects a proton donor next to the carbonyl carbon has 
on biological activity. Scheme 29 shows the first step in this synthetic strategy towards this 
small subset of analogues, which involves a primary amide coupling reaction.   
 
 
 
 
Scheme 29: Amide coupling i. 1,4-dioxane, CDI, 45 ºC, 3h., ii. 0 ºC, BnNH2, 18 h. 
CDI was used to generate the benzyl amide link desired via the mixed anhydride for which 
the mechanism is shown in Scheme 30. 
Scheme 30: CDI coupling mechanism 
A simple N-Boc deprotection step was then carried out using methanol and 4M HCl under 
standard atmospheric conditions (see Scheme 31). The reaction time for this step was trialled 
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at 6 hours however, high amounts of starting material resided therefore, the reaction was left 
for 18 hours and the final product collected in good yield.  
 
 
 
Scheme 31: Benzyl amide N-Boc deprotection  
Table 17 displays a method comparison of diastereomeric ratios and yield for both, the 
Bailey method and Lewis acid approach. As previously seen the Bailey method produces 
much higher selectivity 2.5–3:1, whereas the Lewis acid method generates almost equal 
quantities of cyclised product. Also, purification of this subset of diastereoisomers proved 
less straightforward and a combination of this and high cis selectivity seen for the Bailey 
method resulted in particularly low yields for A and B.  
 
 
 
 
 
Table 17: Method comparison 
 
 
Structure Stereochemistry  Bailey 
d.r. 
cis:trans 
Bailey 
Yield/% 
Yb(OTf)3  
d.r. 
cis:trans 
Yb(OTf)3 
Yield/% 
A L trans 2.5:1 9 1.1:1 21 
L cis 53 21 
B L trans 3:1 8 1.1:1 24 
L cis 15 23 
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2:4:4:1 Tryptophan benzyl amide biological data  
Highlighted in Table 18 are the biological results obtained for this subset of benzyl amide 
analogues. The data obtained shows both the L trans for a p-CF3 group and the L cis 
diastereoisomer for a m-CF3 group is favoured. For example, the L trans diastereoisomer for 
compound F has the lowest inhibitory concentration (IC50 of 3.6 μM), whereas the L cis 
diastereoisomer of compound E has the lower IC50 of 2.3 μM compared to the L trans 
diastereoisomer (13.4 μM). To gather further insight into this observed pattern more benzyl 
amide derivatives would need to be synthesised to investigate.  
 
 
 
 
 
 
 
 
 
 
Table 18: Benzyl amide and benzyl ester comparison 
The inhibitory concentrations collected for the analogues possessing a benzyl amide link can 
now be compared to those obtained for compounds with a benzyl ester link. This will allow 
a primary comparison if any, between a proton donor and acceptor. Table 18 shows the 
comparison of the values obtained thus far and certain deductions can be extracted. There is 
no preference in stereochemistry overall and the differences in activity are negligible. 
Furthermore, no improvement in biological activity has been observed over the original 
R Stereochemistry IC50/μM 
E 
IC50/μM 
F 
p-CF3 L trans 3.5 3.6 
L cis 18.3 13.7 
m-CF3 L trans 13.4 5.3 
L cis 2.3 3.1 
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MMV hit. Although, novel compounds showing better activity than the original benzyl 
amide lead (17 µM) and benzyl ester lead (19 µM) have been discovered.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 92 
 
 
2:4:4:2 Methyl amide derivatives  
The investigation of a small hydrophobic interaction is important, as a comparison with 
previously synthesised methyl ester analogues can then be made. The most active methyl 
ester derivative possessed a phenyl m-CF3 substitution and an IC50 of 5.10 µM. The 
comparison will allow conclusions to be made regarding the importance of a proton donor 
in place of the proton acceptor next to the carbonyl group at C3 (see Figure 30). Also, it gives 
insight into what environment the compound is interacting with, i.e. a tight hydrophobic 
pocket displacing fewer interacting water molecules, compared to a benzyl group which 
interacts with a bigger surface area and offers π-stacking, as well as large hydrophobic 
interactions. Furthermore, R substitutions retained electron withdrawing properties and 
consisted of varying halogen patterns.  
 
 
 
 
 
Initial screening was carried out on the 7 derivatives synthesised as part of another PhD 
project and the results highlighted an overall loss of potency. However, two of the more 
active compounds were taken and tested for their inhibitory concentration. Table 19 shows 
the biological activity of both methyl amide derivatives tested for their inhibitory 
concentration. Both methyl amide compounds tested display a large decrease in activity from 
the original MMV hit as well as, a loss of potency compared to the best methyl ester analogue 
(5.10 µM).  
Figure 30: Methyl amide derivative 
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Table 19: Methyl amide biological data 
Unfortunately, only one diastereoisomer was isolated from the reaction mixture so, cis and 
trans stereochemistry could not be assigned as both carbon NMR spectra are required to do 
this. As a result, a methyl amide moiety in place of a methyl ester group has provided no 
benefit for antimalarial activity. However, only seven analogues have been screened 
therefore no definite conclusions can be drawn.  
 
 
 
 
 
 
 
 
 
 
R IC50/ µM 
p-CF3 > 100 
m-CF3 > 100 
2,4-Cl2 8.79 
p-F > 100 
p-Cl 172 
m-Cl > 100 
2,4-CF3 > 100 
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2:5 Enantiomeric resolution of tryptamine derivative 
Meanwhile, as LVT30 provided the best activity tetrahydro-β-carboline thus far, it was 
proposed the enantiomeric mixture should be separated into (R) and (S) configurations and 
tested separately for inhibitory concentration. A chiral moiety was incorporated via amide 
coupling as shown in Scheme 32, which generates diastereoisomers. Subsequently, 
separating the diastereoisomers and the temporary chiral group removed, to allow testing of 
(R)-LVT30 and (S)-LVT30.  
 
 
 
 
Scheme 32: Generation of LVT30 diastereoisomers 
An alternative chiral Moshers acid chloride was also coupled to LVT30 to generate the 
diastereoisomers but more material was produced for the menthyl compound and was 
therefore used for enantiomer resolution. Firstly, thin layer chromatography was employed 
to attempt diastereoisomer separation with different mobile phases on SiO2 but no separation 
was observed. As a result, other methods of separation had to be considered. Eventually, 
HPLC separation was carried out to obtain the separated enantiomers with the hope of then 
cleaving the amide bond created from menthyl chloroformate.  
The only literature preparation found for cleavage of this particular menthyl amide bond is 
outlined in Scheme 33. Compound LVT30a and sodium methoxide were subjected to 
anhydrous conditions inside a round bottom flask and flushed with nitrogen. Then, dry 
methanol was added via syringe and the resultant solution left at room temperature to stir for 
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30 minutes. (63) After 30 minutes, a TLC was taken of the reaction mixture and showed only 
starting material therefore the reaction was left overnight. Unfortunately, only starting 
material was shown on TLC after 18 hours so this method was abandoned.  
 
 
 
 
Scheme 33: Sodium methoxide amide cleavage 
Due to very limited methodologies focusing on menthyl amide hydrolysis, a straightforward 
sodium hydroxide hydrolysis was investigated. Consequently, a 2M NaOH solution was 
stirred in a round bottom flask, along with an equal volume of tetrahydrofuran (THF) and 
LVT30a was added (see Scheme 34). The mixture was stirred at reflux for 18 hours and thin 
layer chromatography revealed solitary starting material. 
 
 
 
 
Scheme 34: Sodium hydroxide hydrolysis 
Therefore, higher concentrations of 4M and 6M NaOH were also tested, to see if a higher 
concentration was required to perform the hydrolysis. Unfortunately, neither concentration 
of NaOH successfully hydrolysed the menthyl amide group. To understand if reaction phase 
was the issue, tetrabutylammonium bromide (TBAB, 1.2 eq.) was added as a carrier, to aid 
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transfer of starting material between the aqueous and organic phase however, this 
methodology was ineffective.  
Scheme 35 displays an alternate method using hydrogen bromide.  A TLC could not be taken 
on reaction completion as the reaction mixture was too acidic and the product would be 
protonated so is unlikely to move on TLC. Therefore, toluene (4 mL) and water (4 mL) were 
subsequently added and left to stir for 5 minutes. The organics were extracted and TLC sadly 
revealed simply starting material.  
 
 
 
 
                                           Scheme 35: Hydrogen bromide method  
The final method employed lithium aluminium hydride to attempt cleavage of this stubborn 
menthyl amide bond (see Scheme 36). Unfortunately, this hopeful methodology was not 
successful and the aim to hydrolyse this menthyl amide was retired until future investigations 
take over.  
 
 
 
 
                                    Scheme 36: Lithium aluminium hydride method 
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2:6 Future work  
The central tetrahydro-β-carboline moiety offers great potential for additional optimisation, 
as only two sites of functionality have been investigated thus far and no improvement in 
activity has been found compared to the MMV hit.  
Figure 31 highlights prospective sites surrounding this core, which are yet to be explored for 
antimalarial potential, or still have potential for further optimisation.  
 
 
 
 
Figure 31: Sites for further optimisation 
Even though the R1 group has been the focus of this series of analogues, there are still 
suggestions of alternate functionality to be researched. For example, a small interaction is 
required at the R1 position for this IPP mechanism of action; an isopropyl ester could explore 
a small branch interaction. Furthermore, it would be interesting to observe a primary amine 
linked to the carbonyl carbon, to permit a comparison with the original MMV008138 
carboxylic acid. Finally, a carboxylic acid alternative such as, a tetrazole functional group 
could provide insight into the size of moiety required at the R1 position, while retaining an 
acidic environment.  
However, priority should be given to further tryptamine and α-methyl tryptamine derivatives 
as these proved the most active. Developing the α-methyl subset further could include: α-
ethyl, α-isopropyl, α-acetyl and a digeminal methyl group – to observe what functionality 
gives the lowest inhibitory concentration. Figure 32 displays potential future structures, 
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which should be synthesised to allow conclusions to be drawn regarding an absent C3 
carbonyl group interaction.  
 
 
 
 
 
Compound A retains a 2,4-dichloro moiety, which will allow direct comparison to 
MMV008138 and therefore provide a stronger insight as to whether the carboxylic acid 
moiety is required for activity targeting IPP inhibition. On the other hand, compound B and 
C explore the structure activity relationship further, as both compounds simulate NITD609 
functionality therefore, allowing comparisons to be made to another superior antimalarial 
hit.  
By generating more α-methyl tryptamine derivatives alongside varying functionalities at R3 
it would give way to further insight into the important features required for high activity and 
probe this solitary short hydrophobic interaction over the original carboxylic acid moiety 
(see Figure 33).  
 
 
 
 
 
Figure 32: Tryptamine proposals 
Figure 33: α-methyl tryptamine proposals  
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A 2,4-dichloro moiety (D) would allow direct comparison to MMV008138, as well as 
observing activity with a new fluorine analogue (E) that offers a small electronic interaction, 
with the potential for hydrogen bond accepting. The proposed compound F mimics NITD609 
thus allows direct comparison and offers potential for further optimisation on the central 
indole moiety.  
Future compounds in the methyl ester subset should not include pyridine substitutes as they 
do not show good activity. Also, this set of compounds has indicated the position of the 
electron withdrawing group is not necessarily as important as first thought. The key feature 
is the moiety attached to the carbonyl carbon, which, in combination with an electron 
withdrawing group – gives good compound activity. However, in this subset no arrangement 
synthesised so far has come close to the superior activity of (1R, 1S)-MMV008138. Figure 
34 displays future compound suggestions which includes a 2,4-difluoro moiety, and an 
analogue which retains the features of previously discussed compound simulating NITD609 
with the addition of further R5 substitutions.  
 
 
A 2,4-difluoro substitution offers two, small, highly electronic interactions, as well as the 
ability to offer hydrogen bond interactions – which is yet to be investigated. Simulating 
NITD609 offers an interesting comparison, therefore by synthesising a (1R, 3S) version of a 
tetrahydro-β-carboline alternative, comparisons of the biological activities can be made.  
 
  
 
Figure 34: Future analogues and NITD609  
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Alternatively, biological data obtained from the benzyl ester series has provided insight into 
what features should not be retained for future analogues for example, the nitro group Also, 
inhibitory concentrations obtained for trifluoromethyl derivatives were comparable to 
compounds possessing a 2,4-dichloro moiety, therefore negligible differences would inspire 
future analogues to retain a 2,4-dichloro substitution as this provides lower molecular 
weight. However, substituted benzyl ester derivatives provide a wider scope for future 
generation of compounds, as shown in Figure 35.  
 
 
 
 
 
Figure 35: Benzyl ester analogue proposals 
Through retention of a 2,4-dichloro moiety alongside novel benzyl ester substitutions it will 
allow the investigation into the effects of: importance of substitute position, an electron 
withdrawing group and hydrogen bond acceptor/donor. Also, as previously discussed for 
methyl ester compounds, further substitution on the tetrahydro-β-carboline ring system 
should be investigated. 
Furthermore, at this stage of optimisation all four diastereoisomers still need to be generated 
as there is no guarantee both, D cis and L trans conformations possess the best activity. The 
subsequent wider set of derivatives will give insight into what moieties are important for low 
activity and positional significance, with the projection of generating compounds with 
significantly lower inhibitory concentrations. 
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The same statement can be applied to the benzyl amide derivatives, as shown in Figure 36 
to explore the contribution of the benzyl amide link. Future analogue suggestions include 
further benzyl amide substitution to investigate interactions surrounding the novel phenyl 
ring.  
 
 
 
 
 
Figure 36: Benzyl amide proposals 
At this stage there is no discrepancy between benzyl ester and benzyl amide analogues and 
neither subset produced a compound with better activity than the original MMV hit or our 
lead mc72a. Overall it can be concluded that future analogues possessing either benzyl link 
would not display superior antimalarial activity compared to the original hit. Both benzyl 
links have comparative stability in drug compounds and can be cleaved either by esterase or 
peptidase enzymes, so one does not offer advantages over the other. 
 
 
 
 
 
 102 
 
On the other hand, changes to R4 offers limited potential for multiple variation however, 
should not be overlooked as there is great difference between a hydrogen bond interaction 
and a methyl/ethyl hydrophobic interaction. Meanwhile, R2 substitution provides a wider 
scope of functionality through N-substitution for example inserting an; acetyl group, alkyl 
chain or an amide/ester link, thus derivatives of this nature should be generated to see the 
effects they have on biological activity.                   
Finally, R5 has yet to be explored, as seen in compound NITD609 a chlorine and fluorine 
moiety are situated in similar positions and are required for potent activity. Therefore, as 
previously discussed in detail, it would be essential to explore activity of different 
functionalities on the indole core, to see if positive effects are observed in biological activity.  
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2:7 Summary  
Over 50 novel compounds have been generated to investigate the optimisation of (1R, 3S)-
MMV008138, of which, each subset highlighted essential insight into which structural 
features are required for good activity. Figure 37 shows the relatively flat structure-activity 
relationship and summarises all analogue features generated which all resulted in overall 
decreased in activity compared to the original MMV008138 hit.  
 
 
 
 
 
 
Figure 37: Tetrahydro-β-carboline summary 
Meanwhile, biological assay data has provided evidence that the mechanism of action is 
different for the analogues generated during this project, in comparison to MMV008138 as 
they are not reversed by IPP supplementation. To conclude, although this smaller project 
still has potential to generate further derivatives, it seems unlikely that any new derivative 
generated by this project are likely to offer a compound with superior inhibitory 
concentration over (1R, 3S)-MMV008138. 
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Chapter 3: Spiroindolines  
3:1 Spirocycles in drug discovery 
Natural and synthetic compounds containing two rings fused by a solitary shared atom are 
known as spirocyclic and are abundant in natural products. Figure 38 displays the general 
spiro format and some examples.   
 
 
 
Figure 38: Two ring spiro formula 
For example, Griseofulvin 46 was discovered in 1939 within Penicillium mould and is now 
present on the World Health Organisation (WHO) list of essential medicines. It is an oral 
antifungal treatment for nail and skin infections after primary antifungal cream failure and 
does not work as a topical formula. Griseofulvin binds to tubulin and on disrupting 
microtuble function, results in mitosis inhibition. (64)  
 
 
                        
 
 
Over the past two decades this spirocyclic feature has risen in popularity for its 3-
dimentiality to generate novel drug candidates. The most common ring systems are five or 
six membered rings, which provide molecular complexity in a drug molecule and may offer 
greater benefit over flat ring systems. (65) However, these types of structures have been 
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labelled as difficult to synthesise due to the presence of a stereogenic quaternary carbon 
fusing the two rings. As a result, recent progress has produced new synthetic routes to 
generate these spiro building blocks which have allowed incorporation of this desired 
scaffold into synthetic bioactive molecules. (65) 
Although, introducing spirocyclic fusion tends to impose rigidity if this feature is 
incorporated within the core of the molecule but if present within the periphery of a 
compound this conformational impact is reduced. It has been suggested that compounds with 
too many flat rings have disfavoured physical properties and are less likely to become 
developed drugs. Therefore, adding a peripheral spirocyclic moiety allows modulation of 
physical properties such as: water solubility, logP and metabolic stability. Additionally, 
opposed to flat aromatic systems, a spiro group introduces structural novelty – which allows 
access to novel patent space. (65) Consequently, spiro compounds have become a popular area 
of development within the pharmaceutical industry to exploit bioactive molecules.  
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3:2 Spirocyclic synthetic strategies 
3:2:1 Asymmetric catalysis   
As previously discussed the antimalarial candidate NITD609 requires a 1R, 3S configuration 
to generate the highest potency form (0.9 nM). This specificity results in expensive 
separation techniques on a chiral column to obtain the desired form. Therefore, Feng et al 
suggested using asymmetric catalysis to generate optically active spirocyclic oxindoles to 
combat some of the issues surrounding this type of synthesis such as: diastereo and 
enantioselectivity, the spirocyclic fused core and the tertiary carbon centre (see Scheme 37). 
(66) 
 
 
 
 
Scheme 37: Enantioselective Nickel(II)-mediated asymmetric synthesis with chiral ligand  
They state by reacting 3-vinylindoles with ketimines in a aza-Diels-Alder cycloaddition it 
can generate a high regio, diastereo and enantioselective synthesis. Two Boc groups are used 
with the notion that the catalyst would activate the aza-dienophile (ketimine) by binding to 
the two carbonyl groups in a bidentate form. The C2 of the indole bonds to the electron poor 
carbon-nitrogen double bond however, after 48 hours only 13% of the product 3a had been 
generated in 68:32 e.r.. Therefore, the reaction conditions were optimised and as a result the 
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reaction was carried out at −10 ºC using an alternate L-RaPr3 catalyst constituent, which 
produced 78% of 3a with 97.5:2.5 e.r. (66) Since the reaction conditions were optimised, the 
research group turned their attention to reaction substrate scope.  
Firstly, ketimine variation was explored and it was found to tolerate electron donating groups 
such as a nitro group as well as electron withdrawing groups such as halogens which are 
important in the case of NITD609 (30, see Figure 39).  
Figure 39: Ketimine reaction scope 
During the investigation into substituted 3-vinylindole starting materials, they decreased the 
reaction temperature to −30 ºC to give good enantioselectivity. The primary derivatives 
explored both single and double halogen group substitutions at position 5/6 but, in the case 
of NITD609, a 5,6-dihalo substitution is required and was achieved in similar compound 
(S)-3v (see Figure 40). Furthermore, an E/Z mixture of 3-propen-yl-indole gave intermediate 
4y in 63% yield, 99:1 d.r. and an e.r. of 99.5:0.5 (see Figure 40). They found the E-
configuration of the vinylindole only participated under the optimised reaction conditions, 
which produced high diastereoselectivity. (66) 
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Figure 40: 3-Vinylindole variation 
To incorporate both variation points detailed above, they generated NITD609 on a one gram 
scale through a 3-step, efficient, straightforward asymmetric catalytic synthesis with high 
selectivity (see Scheme 38). (66) 
Scheme 38: Asymmetric catalysis to generate 30 (66) 
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3:2:2 Convergent metal-free approach 
Balamurugan et al proposed a racemic one pot, four component, domino reaction involving: 
phenylhydrazine A, 3-amino-crotononitrile B, cyclic 1,3-diketones C and substituted isatins 
D in an aqueous medium to generate a spirocyclic centre (see Scheme 49). The original route 
carried out involved 1 equivalence of p-toluenesulfonic acid (p-TsOH) under reflux for 10 
hours however, this afforded 80% yield of compound 10a (see Scheme 39). During reaction 
condition optimisation they utilised 0.5 equivalents of (±)-camphor-10-sulfonicacid (CSA) 
which produced 10a in 92% yield in 2 hours. Therefore, they concluded using CSA in a 
water medium produced the best reaction conditions for generating the spirocyclic product 
in high yields. (67)   
 
 
 
 
 
 
 
           Scheme 39: One-pot, four component syntheses (X=C=O, R=H, Cl, NO2) 
(80)  
As optimal conditions were achieved they explored substrate scope and found this synthesis 
can tolerate a range of starting materials. For example, the spiro heterocycle can include two 
conjoined aromatic rings and the cyclic 1,3-diketone can possess a sulfur component as well 
as an alternate dimethyl substituent (see Figure 41).  
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Figure 41: Substrate scope 
A proposed mechanism for this reaction involves a phenylpyrazole intermediate E which is 
thought to be responsible for activating the domino sequence of reactions. This intermediate 
is created from the acid-catalysed reaction of phenylhydrazine and 3-aminocrotononitrile 
and generates E in 98% yield. Then, E goes on to react with isatin D which generates a 
second intermediate compound F and has been isolated as the sole product in some of the 
optimisation reactions. Subsequently, F undergoes a reaction with the cyclic 1,3-diketone 
under acidic conditions. Finally G carries out annulation then, a dehydration step occurs to 
produce 10a (see Scheme 40).  
 
Scheme 40: Proposed reaction mechanism (X=C=O and R=H) 
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Overall, Balamurugan et al state to have created a convergent, short reaction time, excellent 
yielding, easy operation, broad scope and an environmentally friendly synthetic route to 
incorporate a spirocyclic moiety.  
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3:3 Spirocyclic antimalarials  
3:3:1 NITD609   
In 2010 Yeung et al reported novel compound 47 to display potent antimalarial activity and 
was highlighted during high-throughput screening. Compound 47 possesses an inhibitory 
concentration of 90 nM against wild type malaria (NF54) and 80 nM against a chloroquine-
resistant strain (KI) (see Figure 42). After further biological probing, 47 was found to be 
active against P. berghei in mouse models and a single 100 mg/kg dose resulted in a 96% 
reduction in parasitic activity. (68) Therefore, optimisation of this promising compound was 
undertaken to increase potency and in vivo activity.  
 
 
 
 
Figure 42: Original hit 
Firstly, the research group intended to synthesise this novel compound as it existed as a 
racemic mixture. Therefore, Scheme 41 displays the synthetic route to generate 47. The 
novel compound can exist as (1S, 3S) and (1R, 3R) or (1R, 3S) and (1S, 3R) stereoisomers 
and, the favoured pair were found to be (1R, 3S) and (1S, 3R) in ~9:1 diastereomeric excess 
after chiral separation and confirmatory X-ray structure determination. (68) 
The individual diastereoisomers were tested in vivo and were found to possess significantly 
different potencies. For example, the most potent stereoisomer (1R, 3S) was found to be over 
250 times more potent than its sister (1S, 3R) stereoisomer (see Scheme 41). 
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Scheme 41: Hit synthesis and diastereoisomer activity comparison 
To explore the effect of ring size variation (highlighted above) on activity six, seven and 
eight membered ring derivatives were generated from 5-chloroisatin via the synthetic route 
shown in Scheme 42.  
 
 
 
 
 
Scheme 42: Ring size variation 
Alternatively, a second synthetic route was employed to generate the majority of analogues 
during the optimisation stage (see Scheme 43). This strategy employed indole as the starting 
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reagent and the desired product formed via a Vilsmeier-Haack intermediate with a high 
degree of diastereoselectivity. (68) 
 
Scheme 43: Alternate synthetic route R1, R2, R4=F/Cl and R3=H/CH3/(CH3)2 
Furthermore, (1R, 3S) and (1S, 3R) enantiomers were resolved by chiral chromatography 
and differentiated by their optical rotation measurements. The minor pair of diastereoisomers 
were not always isolated from the reaction mixture, except in a few cases. Analogue 9x 
demonstrates the vast difference in antimalarial activity of each stereoisomer pair, with the 
most active (1R, 3S) stereoisomer possessing an IC50 of 9 nM (9a) which is superior to the 
original hit compound (racemate, 20 nM) against NF54. Also, compound 9x possessed the 
overall lowest inhibitory concentration (27 nM) during exploration of ring size and C3 
substitution (see Figure 43). A digeminal methyl substitution was tested at C3 but resulted 
in a decrease in potency (857 nM) and an increase of the ring size to 8 carbons resulted in 
an inhibitory concentration of >5000 nM. (68) Therefore, the optimum combination taken 
forward for further optimisation was a 6-membered ring with a single methyl substitution at 
C3.  
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Figure 43: Optimum analogue 9x 
This observed trend in diastereoisomer activity was consistent across all analogues 
synthesised therefore, the research group concluded that the (1R, 3S) configuration was an 
essential feature in Plasmodium falciparum activity. (68) This led to primary testing of the 
racemic mixtures and if the inhibitory concentration displayed high potency it was assumed 
on chiral separation, potency would be further improved on isolation of the (1R, 1S) 
stereoisomer. To obtain a higher degree of diastereoselectivity, enantiopure 5-α-methyl 
indoleamines were used to form the desired single pair of stereoisomers instead of relying 
on expensive chiral separation. For example, the active stereoisomer 9a was generated from 
the corresponding S-α-methyl indoleamine (see Scheme 44). 
 
Scheme 44: Higher selectivity pathway a) i. CbzCl, Na2CO3, rt, ii) TsCl, Et3N, rt, b) H2, Pd(OH)2, 
rt, c) p-TsOH•H2O (cat.), 110 ºC 
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Further derivatives were synthesised to investigate the structure-activity relationship on the 
indole aromatic ring. Two highly potent compounds (1R, 3S)-17a (3 nM) and (1R, 3S)-18a 
(4 nM) were discovered during this exploration and possessed a C6-fluoro moiety and C7-
chloro moiety respectively. As a result, the two substitutions were combined and generated 
30 (NITD609). The group stated positions C6 and C7 were prone to oxidation during 
metabolism and resulted in high clearance of the derivatives during testing. Therefore, this 
dihalogen substitution blocks oxidation at those positions and counteracts the high clearance 
issue. (68) 
 
                                             
 
 
 
Also, the group found the less active (1S, 3R) configuration to show: greater metabolic 
stability lower in vivo clearance and fewer drug-drug interactions (CYP450 liabilities). 
Whereas, the most potent form displayed the complete opposite pharmacokinetic properties 
and was even found to inhibit CYP2C9, an enzyme important for the metabolism of: 
warfarin, angiotensin II receptor blockers, antidiabetics and non-steroidal anti-inflammatory 
drugs. Therefore, future work needs to include increasing metabolic stability and reducing 
CYP2C9 binding. Overall, the derivatives did not show any signs of cytotoxicity across the 
several human lines tested and low hERG activity was observed, as well as being negative 
for the Ames test. (68) 
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Figure 44: Summary of findings 
In conclusion, the research group denoted key features which they found essential for high 
activity and state should be retained in future optimisation programmes (see Figure 44). 
Surprisingly, the research group discovered an even better compound displaying an 
inhibitory concentration of 0.2 nM and Yeung et al predict the data obtained for compound 
20a shows the potential analogue to become a single dose or low dose cure for malaria. 
Compound 20a possesses: low hepatic clearance in human and mouse models and low 
CYP2C9 binding, thus solving the problems seen for 30. (68) However, analogue 30 has only 
been seen to be taken forward into clinical studies, as seen in the current published literature 
resources and the rest of the series is still undergoing preclinical evaluation. 
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3:3:2 Mechanism of action   
In late 2010 research was carried out by Rottman et al looking at spiroindolones as an 
antimalarial treatment. The screening carried out identified 275 primary hits with 
submicromolar activity against P. falciparum. Of these, the compounds not retaining activity 
against multidrug resistant parasites and displaying cytotoxic properties against mammalian 
cells were eliminated. The hits still present were analysed for their pharmacokinetic and 
physical properties and from these, 17 compounds resulted. They state, spiroindolone 
compound NITD609 stood out as a basis for further medicinal chemistry optimisation and 
displayed good drug-like attributes as well as, physiochemical properties consistent with 
conventional tablet format. (69) 
Initial hypotheses suggested the mechanism of action involved disruption of a P-type cation 
transporter ATPase4 (PfATP4), which regulates sodium ion homeostasis. Firstly, an in vitro 
experiment was carried out to determine which stage(s) of the parasite was most affected by 
NITD609. The experiment involved 3 stages of the parasite lifecycle which includes: rings, 
trophozoites and schizonts. The three forms were treated separately with NITD609 and left 
for different lengths of time: 1, 6, 12 and 24 hours, before removing the dosed drug and 
allowing culture continuation for a further 24 hours. They found at high concentrations of 
the drug (100 × IC50 value) all stages of the parasite were similarly sensitive. Whereas, at 
low concentration (1 or 10 × IC50 value) schizonts were the most susceptible form therefore, 
they concluded the drug target to be present in all 3 stages tested but schizonts are 
particularly vulnerable. It was also found NITD609 did not inhibit growth as quickly as 
artemether, as >90% inhibition was seen at 1.6 nM after 24 hours whereas, artemether 
inhibits the same amount at 8 nM after 6 hours. (69) 
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To investigate further a second experiment was conducted which involved 35S radiolabelled 
methionine and cysteine, two components important in protein synthesis. An incorporation 
assay involved uptake of the radiolabelled amino acids within the parasite and the amount 
of each amino acid was measured at different intervals after dosing with the chosen drug. 
They revealed NITD609 to block protein synthesis in P. falciparum within 1 hour compared 
to artemesinin and mefloquine which showed < 25% decrease in [35S] met/cys within 1 hour. 
They state this rapid suppression of protein synthesis suggests a different mode of action to 
both traditional antimalarial agents. (69) 
To strengthen their hypothesis a resistance experiment was conducted which created a 
NITD609-resistant strain of parasite. They created the resistant strain by repeated exposure 
of NITD609 to the parasite at increasing concentrations over a period of 3-4 months. 
Amongst the resistant strain 27 genetic differences were observed and of these, 7 mapped to 
a single gene for PfATP4 – strongly suggesting this spiroindoline specifically selects for a 
mutation of PfATP4.  This mutated form was taken and the PfATP4 gene sequenced and 
showed changes noted as 11 mutations. Therefore, these highlighted mutations were inserted 
into wild-type or resistant lines of malaria which displayed an increase in inhibitory 
concentration towards NITD609 whereas, artemisinin and mefloquine showed retained 
potency. (69) Thus, resistance was specific to the spiroindoline however; it is difficult to 
distinguish the exact process of PfATP4 action as little is known about the molecular 
function of PfATP4.  
Meanwhile, in 2012 Pelt-Koops et al explored NITD609 gametocyte activity and concluded 
the compound to show a dose-dependent effect on all stages of gametocyte development in 
vitro. Not only does the compound show activity against the asexual stage of the parasite but 
also, demonstrates significant activity for gametocyte reduction at the lowest tested 
concentration of 5 nM. Furthermore, the compound was found to completely block 
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transmission of the parasite at 500 nM. They state the potent drug can be used to treat 
asymptomatic carriers of the parasite who possess a reservoir of mature gametocytes in areas 
of high parasite transmission. Finally, they predict NITD609 could be part of a novel 
combination therapy with transmission blocking activity. (70) 
In 2014, Bowman et al conducted an antiapicoplast and gametocytocidal screen of the 
Medicine for Malaria Venture (MMV) box. They refer to (1R, 3S)-NITD609 and state it 
targets PfATPase4, a plasma membrane sodium ion efflux pump. (71) 
 
 3:3:3 NITD609 in 2017    
Currently NITD609 (known as Cipargamin) has completed first phase IIa clinical trials as a 
short-duration monotherapy and is now being prepared for dose escalation studies in infected 
patients. This antimalarial is the first validated new molecule target in 20 years and has very 
rapid onset for killing the parasite with the potential to become a transmission blocking 
agent.   
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3:4 MMV spiroindoline lead 
3:4:1 Discovery 
In 2014 Spangenberg et al explored the MMV box and screened the library of compounds 
for their blood-stage P. falciparum activity. During the compound selection process, they 
applied a strict ‘rule of 5’ filter however; they highlight several compounds which would not 
have been retrieved under this type of selection. For example, compound 16x shown in 
Figure 45 has a molecular mass of 414.54 gmol−1 and a logP of 5.3. Compound 16x contains 
an attractive spiro[indoline-3,4-piperidine] fragment with a potency of 990 nM against the 
3D7 parasite strain. (72) This initial hit displayed 3 points of variation therefore: the original 
cyano moiety was replaced with a chlorine atom, the allyl group substituted with a benzyl 
group and finally, the methyl moiety on the indole centre was removed to simplify the 
structures core (MMV668732, see Figure 45). 
  
The novel derivative MMV668732 possesses a higher molecular weight than the parent hit 
and an undesirable logP but, the structure is less complex and allows investigation of the 
structure activity relationship at the two positions highlighted in Figure 45. Furthermore, due 
to the high level of interest in the potent antimalarial NITD609, a spiroindoline feature in 
drug molecules has grown in popularity. As a result, in July 2015, MMV668732 provided a 
Figure 45: Spiroindoline hit with point of variation (left) and simplified sister compound 
(17) 
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novel starting point for further optimisation and work was undertaken by a Keele 
undergraduate student to generate potential antimalarial hits.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 123 
 
3:4:2 Early analogue proposals 
Initially, three points of variation were explored as shown in Figure 46. The purpose of these 
primary derivatives was to give insight into the type of functionality which gave rise to an 
increase/decrease in antimalarial activity. Through retrosynthetic analysis the desired 
spirocyclic structure can be synthesised from phenylhydrazine and N-benzylpiperidine-4-
carboxaldehyde.  
 
 
 
 
 
 
Figure 46: Retrosynthesis 
This gave an opportunity to explore: a range of ureas from substituted isocyanate substrates, 
amide derivatives and ketone derivatives from α-halo ketones (see Figure 47).  
 
 
  
 
 
Figure 47: Initial spiroindoline exploration 
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The piperidine starting material was available as N-benzyl and N-carbamate so both were 
used and tested. However, the carbamate group offers an additional hydrogen bond acceptor 
and was found to be easier to synthesise and purify compared to the benzyl protected 
nitrogen. 
Furthermore, the importance of the benzyl group was probed by generating an analogue 
where it was removed. So, an analogue possessing a free piperidine amine was proposed to 
remove all previous hydrophobic interactions and see the effects a hydrogen bond donor has 
on biological activity. 
Meanwhile, the urea linker seen in the initial lead was kept and a small range of substituted 
isocyanates were used to generate ureas X with EWG (CF3) and EDG (OMe) groups. 
Analogues were also made to look at the contribution of the second nitrogen seen in 
MMV668732 by replacing the urea link with an amide link Y. Also, moving the position of 
the carbonyl was also tested with an alternate α-amino ketone linker Z.  
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3:4:3 Synthetic strategy 
The MMV hit and other N-benzyl derivatives were generated by carrying out a Fischer-
Indole reaction with N-benzylpiperidine-4-carboxaldehyde and phenylhydrazine under 
acidic conditions, followed by a straightforward sodium borohydride reduction to the 
indoline (see Scheme 45).  To insert the hit compound urea link, the relevant substituted 
phenyl isocyanate was taken and stirred with the N-benzyl starting material in 
dichloromethane at room temperature overnight. 
Scheme 45: Synthetic route 
Furthermore, to generate the analogue possessing a free amine the carbamate protected 
starting material was first coupled with the urea linker and then, the carbamate was removed 
using Pearlman’s catalyst under a hydrogen atmosphere to reveal the desired derivative (see 
Scheme 46). A nucleophilic substitution reaction can then be performed using the amine to 
insert different functional groups (R2).  
 
 
 
 
Scheme 46: Synthetic route to derivatives 
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To insert the α-amino ketone linkers, an alternate approach was carried using the relevant 3-
chloro-2-bromoacetophenone alongside potassium carbonate in dichloromethane (see 
Scheme 47).  
 
 
 
                           Scheme 47: Ketone insertion 
Finally to create the amide link derivative, 2-(3-chlorophenyl)acetyl chloride had to be 
synthesised which was then coupled to the spirocyclic substrate shown below (see Scheme 
48).  
 
 
 
 
 
 
Scheme 48: Amide insertion  
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3:4:4 Preliminary biological results and discussion  
During the undergraduate 8-week research project, 8 compounds were generated which 
included the original hit compound MMV668732. The IC50 values were originally carried 
out at 48 hours and later at 72 hours. Table 20 displays the biological data obtained for this 
preliminary set of compounds.  
 
 
 
 
Reference R1 Linker R2 IC50/ μM 
48 hour assay 
AKE6 
MMV668732 
benzyl urea Cl 2.45 
AKE5 benzyl -NH N/A 20.0 
AKE9 benzyl urea CF3 3.27 
AKE10 benzyl urea OMe 19.2 
AKE20 benzyl N-C=OC-Ar Cl 15.3 
AKE1 carbamate urea Cl 7.06 
AKE31 carbamate N-CC=O-Ar Cl 11.3 
SA carbamate -NH N/A 26.6 
AKE2 -NH urea Cl 3.40 
Table 20: First generation spiroindoline results 
The biological data shown for the original hit MMV668732 (AKE6) shows a dramatic 
difference in inhibitory concentration when compared to the original data published by 
Avery et al, which found an IC50 of 309 nM whereas for this project an IC50 of 2.45 μM was 
obtained. (72) The data discrepancies are thought to lie within the biological testing 
methodology chosen to run the inhibitory concentration assays.  
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Firstly, visualisation by Avery et al was carried out by detecting specific areas of 
fluorescence within the parasite alongside non-DNA based components whereas, the 
biological data obtained during this project used an alternate fluorescence-based detection 
method known as Malaria SYBR Green I fluorescence (MSF), which uses a DNA 
intercalating agent and measures total fluorescence intensity output. Furthermore, the Avery 
assays were run over 72 hours on ring stage chloroquine sensitive parasites on the other 
hand, to obtain this data 48-hour assays were carried out on trophozoite chloroquine sensitive 
parasites. (73) 
Finally, the growth medium contained 0.5% albumax but was absent of human serum during 
the Avery testing however, the assays ran during this project contained both albumax and 
human serum within the growth medium. Therefore, the latter carries a risk of plasma-
protein binding to the proteins contained within the human serum which subsequently leads 
to reduced bioavailability of the tested drug and in turn, could lead to the increase in 
inhibitory concentration observed. (73) 
From the 48 hour data both SA and AKE5 demonstrate the absence of a linker and 
substituted phenyl group result in a loss of antimalarial activity, as both inhibitory 
concentrations significantly increase (IC50 26.6 μM and 20.0 μM respectively). Therefore, 
when designing future analogue generations, it is important to note both interactions 
provided by the linker and phenyl functionality must be essential for activity. Even though 
only one electron donating group R2 substitution was synthesised, it demonstrated a loss of 
potency (AKE10 IC50 19.2 μM) compared to MMV668732 AKE6 (2.45 μM) thus, 
indicating an electron withdrawing group is necessary for good activity. Inserting a more 
electron withdrawing group such as, a trifluoromethyl group resulted in a good activity 
compound (AKE9 3.27 μM). As the difference in activity was minimal and keeping in mind 
 129 
 
the strong electron withdrawing properties of this moiety it was kept for the next generation 
of derivatives.  
While retaining the original m-chlorine moiety two alternate R1 groups were tested, shown 
in Figure 48. Both the carbamate functional group and free amine resulted in a loss of 
potency, although not as significant as the previous analogues discussed. As a result, it could 
be proposed to keep either the benzyl moiety or free amine for future compound synthesis, 
however they offer significantly different interactions i.e. a large hydrophobic interaction vs 
a single hydrogen bond donor. Therefore, as the lowest activity is seen for the benzyl moiety 
and to simplify analogue comparison this hydrophobic group should be retained and 
investigated further.  
 
 
 
 
 
Figure 48: Analogue comparison 
On the other hand, two compounds were synthesised possessing a ketone and amide linker 
instead of the original urea moiety and both resulted in a loss of potency (see Figure 49). 
The α-amino ketone was the most promising of the two, assuming a direct correlation 
between these analogues and the ureas AKE1 and AKE6. However, the urea linker remained 
the best option and thus was retained for future analogue synthesis.  
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Figure 49: Linker comparison of AKE1 and AKE6 
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3:5 Project proposals  
Due to these preliminary findings, a second generation of analogues were proposed for this 
project, of which all possessed a m-trifluoromethyl phenyl substitution and a urea linker.  
The next generation of spiroindoline compounds possessed one variant (R), with the hope of 
generating a more potent compound than the original MMV668732 hit (see Figure 50). 
Based on previous knowledge gained from the first generation of analogues, the next area 
for investigation was the benzyl moiety. Alternate groups to benzyl moiety were tested to 
explore different functionalities with an attempt to make the compound more drug like. As 
previously stated, the urea link was kept as a significant loss of activity was observed when 
removed. Furthermore, a m-trifluoromethyl group was initially retained as an electron 
withdrawing group was necessary for activity and the isocyanate required for this synthesis 
was readily available in the laboratory.  
 
 
 
 
 
                                          Figure 50: Spiroindoline template (R details below) 
Therefore, seven substituted benzyl derivatives were proposed which included: three 
benzoyl chlorides, two methyl ester groups, morpholine, pyran, piperidine, dimethylamine, 
a butyl chain and other drug-like moieties.  
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Firstly, the benzyl moieties were substituted in the para position, furthest away from the 
central structure to try and achieve a positive interaction within the potential target site. Thus, 
if any of these derivatives displayed fruitful potency, further exploration of substitute 
position could be carried out. Furthermore, a range of functionalities were investigated 
which included: electron withdrawing groups such as, halogens, a nitro moiety and electron 
donating groups such as, a methoxy group, to see the effects these opposing groups have on 
antimalarial activity (see Figure 51).  
 
 
                                              
Figure 51: Benzyl exploration 
Three benzoyl groups were proposed to observe the effects on activity with the addition of 
a hydrogen bond acceptor as well as hoping to reduce the high logP value for this series. A 
further direct comparison can be made between the original MMV compound and a simple 
benzoyl group, allowing conclusions to be made about this additional interaction (see Figure 
52).  
 
 
                                                Figure 52: Benzoyl analogues 
To address the issue of high logP further functional groups possessing more drug-like 
qualities were proposed to combat this, with the hope of also increasing activity (see Figure 
53).  For example, a morpholine group was created as this offers a hydrogen bond acceptor 
and provides an area of electronegativity which could prove to be beneficial. Also, the 
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morpholine group was investigated further by removing the nitrogen and oxygen atom, in 
turn, to see which atom is of importance or to see if both atoms are required for any observed 
activity.  
 
 
 
                                                    
Figure 53: Drug-like moieties 
Finally, a moderately hydrophobic butyl group offers significant van der Waal’s interactions 
whereas, a methyl ester moiety and a dimethyl amide group offers alternate interactions with 
short hydrophobic methyl groups, in combination with a hydrogen bond acceptor (see Figure 
54). Overall, a wide range of functionalities were outlined and from this series of biological 
data, a third generation of compounds were proposed.  
 
 
                                                             
Figure 54: Non-aromatic/aryl functional groups 
 
 
 
.  
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3:5:1 Synthetic strategy  
During this postgraduate research project, the N-carbamate starting material was prepared 
performing a Fischer-Indole reaction using benzyl 4-formyl-1-piperidinecaarboxylate, in 
place of the previously used N-benzyl constituent (see Scheme 49). The carbamate starting 
material was chosen over the N-benzyl as it is easily cleaved further on in the synthetic route 
and is easier to purify.  
 
 
 
Scheme 49: Fischer-Indole (blue), NaBH4 reduction (red) and urea formation (green) 
A one-pot strategy involved carrying out the Fischer-Indole reaction followed by a sodium 
borohydride reduction without isolating the imine intermediate. (74) However, during the 
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purification step much of the mass was found to be the unreduced product and therefore, was 
collected and subject to reduction conditions once more, to obtain the highest possible yield 
of 56%.  
To achieve each novel derivative, the desired substituted phenyl isocyanate was coupled 
with benzyl 4-formyl-1-piperidinecarboxylate and each product purified using column 
chromatography, to produce a urea intermediate. The novel derivatives were then generated 
by stirring the free amine intermediate in acetonitrile along with potassium carbonate and 
the chosen halogen substituted R2 substrate (see Scheme 50). The reaction was left to stir at 
reflux overnight which resulted in each analogue in good yields (see Table 21). 
 
Scheme 50: Synthetic route 
 
 
 
                                    
 
Table 21: Spiroindoline product yields 
 
 
 
Starting 
materials 
 
R1 R2 Yield/% 
3-CF3 Cbz 97 
3,4-Cl2 Cbz 77 
3-Cl Cbz 67 
3-F Cbz 62 
3,4-F2 Cbz 55 
3-CF3 H 67 
3,4-Cl2 H 90 
3-Cl H 97 
3-F H 87 
3,4-F2 H 85 
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Accordingly, the obtained product was coupled with the chosen isocyanate to produce the 
urea linker in good yields. Next, the carbamate protecting group was removed using 
Pd(OH)2/C and H2 to generate the desired free amine in good yield, which could then take 
part in further SN2 substitution to create the set of analogues (see Scheme 50 and Table 21).  
Finally, the multiple R2 groups were created by use of the relevant substituted benzyl 
bromide, phenyl substituted acid chloride, ester/amide acid chloride or alkyl bromide, 
alongside potassium carbonate as the base in acetonitrile at reflux stirring overnight.  
Table 22: Isolated yields from N-alkylation 
For 3-trifluoromethyl phenyl derivatives most products were produced in yields between 
29–88% and this was therefore a useful method of compound generation (see Table 22). 
Table 23 shows the isolated yields for 3-chlorophenyl, 3-fluorophenyl and two disubstituted 
R1 derivatives and overall the compounds were generated in good yield.  
 
R2 and isolated yields 
R1=CF3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
31% 
68% 
85% 
52% 
62% 
59% 
82% 
87% 
69% 
35% 
29% 
80% 59% 
86% 
48% 
88% 
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Table 23: Second generation alkylation product yields 
In one case the imidoyl chloride was not available so a telescoped reaction was carried out 
using triphosgene to create the acid chloride of the spiro starting material in situ which was 
then reacted with the free amine of the R1 substituent (see Scheme 51). Therefore, 1-boc-
piperazine was available and coupled to the spirocyclic acid chloride generated in situ to 
give LVTa12 in 74% yield.  
Scheme 51: Triphosgene approach 
 
 
 
 
 
R1 R2 Yield/% 
3-Cl ethyl piperidine 53 
3-Cl C5H11 70 
3-Cl C6H13 72 
3-F morpholine 70 
3,4-F2 morpholine 66 
3,4-Cl2 morpholine 74 
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3:5:2 Biological results and discussion  
Table 24 displays the inhibitory concentrations obtained for the spiroindoline derivatives 
generated.   
Table 24: Biological data for spiroindoline subseries 
Reference R1 IC50/μM Reference R1 IC50/μM 
 
 Template 
LVT59 
 
1.77 
LVTa18 
 
2.76 
LVTa1 
 
1.15 
AKE6 
MMV668732 
 
2.45 LVTa2 
 
2.09 
LVT66 
 
5.94 LVTa12 
 
3.74 
LVT69 
 
9.07 LVTa4 
 
4.34 
LVT70 
 
6.77 LVTa14 
 
6.72 
LVT72 
 
5.31 LVT54 
 
16.9 
LVT86 
 
0.96 LVTa5 
 
3.85 
LVTa3 
 
18.4 LVT71 
 
7.04 
LVT81 
 
5.41  
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Of this primary series, the compounds showing higher potency than the original MMV lead 
(AKE6, 2.45 µM) have been highlighted. 
The para substituted benzyl analogues all possess moderate activity ranging from 5.31 μM 
for the 4-pyridyl analogue (LVT72) to the poorest activity 9.23 μM for a p-trifluoromethyl 
substitution (LVT69). Surprisingly, both the trifluoromethyl and chloro group caused the 
greatest decrease in activity for an electron withdrawing group and the small electronegative 
fluorine atom (LVT70, 6.77 μM) had the best activity. 
Of the benzoyl derivatives, the best activity was observed for the non-substituted benzoyl 
ring (LVTa5, 3.85 μM). However, the addition of a hydrogen bond acceptor did not increase 
potency beyond the original benzyl hit (AKE6, 2.45 μM). Further evidence is seen in the 
loss of activity with the addition of a carbonyl by comparing the two pyridine derivatives 
LVTa3 (18.4 μM) and LVT72 (5.31 μM). Overall, the benzyl derivative had higher activity 
than the benzoyl analogue. Further derivatives such as the dimethyl amide LVTa4 (4.34 
μM) and carbamate LVTa14 (6.72 µM) possessed moderate potency, but no better than the 
original hit (see Figure 55).  
 
 
 
 
 
 
Figure 55: Urea and carbamate comparison 
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The piperazine LVTa18 (2.76 µM) and was preferred over the N-Boc protected derivative 
LVTa12 (3.74 µM). Even more promising was LVT59 (1.77 μM), which possesses a 
morpholine group and shows an improved inhibitory concentration compared to the original 
hit (2.45μM). Figure 56 displays the structural and activity comparison between the 
morpholine analogue and in turn, removal of the nitrogen and oxygen atom. Compound 
LVTa1 exhibits a second urea moiety and is absent of the morpholine oxygen atom which 
provides a hydrogen bond acceptor. Alternatively, the amide LVTa2 retains the oxygen 
hydrogen bond acceptor. There are small differences in the biological activities thus making 
conclusions regarding the preference over each interaction difficult, even though a 
marginally better activity is seen for LVTa1 (1.15 μM). 
 
Figure 56: Morpholine moiety exploration 
Unexpectedly, the best compound discovered was LVT86 which possesses a butyl chain and 
has an inhibitory concentration of 960 nM. The lipophilic chain provides a mid-length 
hydrophobic interaction and has resulted in the most potent compound of this sub set and, is 
significantly more active than the original MMV hit lead (see Figure 57). Unfortunately, this 
moiety contributes to a disfavoured high logP value thus, making this analogue less drug-
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like. However, this compound should be taken forward and explored further to probe the 
structure-activity relationship and attempt to improve the pharmacokinetic properties. 
 
 
 
 
 
 
 
Figure 57: Aliphatic compound comparison 
Attempts to include a polar group further along the chain resulted in LVT81 and LVT54 
which unfortunately led to a significant loss of activity (see Figure 57).  
Meanwhile, a small set of analogues were generated by an undergraduate project student in 
which the original benzyl R2 group was kept, but the substituents at the R1 were altered. A 
3,4-dichloro R1 phenyl substituent (DD3, 1.63 μM) displayed greater activity than the 
original hit (AKE6, 2.45 μM). On the other hand, a 2,4-dichloro pattern dramatically 
decreases potency (DD1, 18.8 μM) and a 3-bromo moiety causes a marginal decrease (DD2, 
6.52 μM), see Table 25.  
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Table 25: Further analogue data 
Taking into consideration the findings discussed, the next generation of spiroindoline 
derivatives should investigate: the alkyl R2 substitution, the morpholine moiety and 
chloro/fluoro phenyl substitutions.  
 
 
 
 
 
 
 
 
 
Reference R IC50/ μM 
DD1 2,4-Cl2 18.8 
DD2 3-Br 6.52 
DD3 3,4-Cl2 1.63 
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3:6 Next generation compounds  
A third set of analogues were outlined to progress optimisation of the potent novel compound 
discovered during the latest subset of derivatives, LVT86 (IC50 960 nM). To make the 
analogue more drug-like the highly electron withdrawing m-trifluoromethyl group was 
replaced with a m-chloro substitution and m-fluoro (both result in a decrease in logP and 
molecular weight). The favoured 3,4-dichloro pattern found most recently was also 
investigated although, this resulted in higher logP values. The 3,4-difluoro analogue was 
also selected as this lowered logP.  
Furthermore, the fluorine atom has the potential to act as a hydrogen bond donor as well as 
providing a small electronegative interaction. Therefore, both m-fluoro and 3,4-difluoro 
patterns were coupled with a morpholine moiety, with the hope of generating a superior 
analogue (see Figure 58).   
 
 
 
 
 
  
 
Figure 58: Next generation proposals  
Firstly, a R1 m-chloro substitution was paired with a R2 morpholine group, which provided 
high activity previously and can potentially help optimise the pharmacokinetic properties of 
the lipophilic spiroindoline. Additionally, the morpholine group was paired with a 3,4-
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dichloro phenyl substitution as good activity had been observed for both thus, combing them 
could result in a highly potent derivative. Alternatively, an ethyl piperidine moiety was 
proposed to see if a bulkier alkyl group helps to improve biological activity and the nitrogen 
provides a disruption in a dense area of lipophilicity (see Figure 58).  
Meanwhile, a pentane and hexane chain were suggested to observe what happens to activity 
if the aliphatic chain is extended by one or two carbon atoms and, even though logP would 
increase it is important to explore what the optimum chain length would be for high activity 
(Figure 58).  
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3:6:1 Biological results and discussion  
Previous hit LVT59 (1.77 μM) possesses a m-trifluoromethyl group in place of the chlorine 
and this resulted in one of the most active analogues in the second subset of derivatives (see 
Table 26).  
 
 
 
 
 
 
               
 
 
 
                              
 
 
 
Table 26: Biological data collected for final set of derivatives 
To summaries by replacing the original m-CF3 (LVT59) substitution with the alternate 
substitution patterns displayed in Table 26 a loss of activity is seen in the order of 
Reference R1 R2 IC50/ μM 
AKE6 m-Cl CH2Ph 2.45 
LVTa19 H CH2Ph 5.59 
LVT86 m-CF3 C4H9 0.96 
LVTa124 m-Cl C5H11 1.54 
LVTa125 m-Cl C6H13 1.01 
LVT59 m-CF3 
 
1.77 
LVTa128 m-F 
 
6.70 
LVTa10 H 
 
10.7 
LVTa132 3,4-F2 
 
5.75 
LVTa135 3,4-Cl2 
 
4.03 
DD3 3,4-Cl2 CH2Ph 1.63 
LVTa121 m-Cl 
 
3.56 
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F>H>F2>Cl2. These findings were not predicted as LVT59 displayed good activity therefore, 
a combination of a morpholine group with a highly electron withdrawing trifluoromethyl 
group must have provided the low inhibitory concentration in this case and cannot be 
substituted with alternate halogen atoms.  
Compound LVTa135 (4.03 µM) displayed good activity with a 3,4-Cl2 disubstitution pattern 
but, a loss in potency is seen compared to the m-CF3 derivative (LVT59, 1.77 µM). 
However, the 3,4-Cl2 disubstitution pattern in combination with a benzyl R
2 group (DD3, 
1.63 µM) possessed better activity than both LVT59 (1.77 µM) and the MMV compound 
AKE6 (2.45 µM). As a result, including a morpholine moiety within future derivatives may 
not be as useful as first thought, regardless of the contribution it makes to improving 
pharmacokinetic properties. Also, replacement of the original m-Cl group with a hydrogen 
atom (LVTa19, 5.59 µM) gave a drop in activity.  
Both pentane and hexane substituted analogues displayed better inhibitory concentrations 
compared to AKE6, but unfortunately no significant increase in potency was seen when 
compared to LVT86 (960 nM). Although a slight preference is seen for the hexane derivative 
(LVTa125, 1.01 µM), only a small margin of activity difference can be observed and 
therefore, no conclusions can be drawn as to which chain length is optimal for best activity.  
Attempting to introduce a polar group in the chain can been seen for LVTa121 (3.56 µM) 
and displayed good activity but does not provide any improvement in activity when 
compared to AKE6 (2.45 μM) or the more recent LVT86 (960 nM) analogue. In conclusion, 
the alkyl possessing derivatives are proving most activity so, to retain good active and 
optimal pharmacokinetic properties i.e. lower molecular weight and logP, a shorter butyl 
chain should be retained in comparison to either the pentane or hexane chain length.  
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3:7 Future work 
To progress this series of antimalarial spiroindolines, further derivatives need to be generated 
to decipher the best functional group combination for high activity. So far, it has been shown 
either a m-trifluoromethyl or 3,4-dichloro phenyl substitution pattern gives the most active 
derivatives. These substitutions should be retained with caution due to the higher logP 
obtained over, for example the single chloro substituent. Also, more derivatives should probe 
the 3,4-dichloro substitution pattern to see if it is beneficial in other analogues.  
Furthermore, a morpholine moiety provided compound LVT59 (1.77 μM) possessing good 
activity however, when this functionality was probed further a loss of potency was observed 
in later compounds. Therefore, including a morpholine moiety in future analogues will most 
likely provide no significant increase in antimalarial activity or may even cause a loss of 
potency as previously shown. Alternatively, derivative LVTa1 (1.15 μM) displayed the 
lowest activity during the morpholine group exploration therefore this second urea formation 
could be investigated in future derivatives (see Figure 59).  
 
 
 
 
 
 
Figure 59: Piperidine analogue and branched alkyl derivatives 
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Meanwhile during this series of investigations, hydrophobic alkyl chains have provided the 
highest potency compounds when combined with a phenyl m-electron withdrawing group. 
To probe this interaction further branched alkyl chains should be generated such as, 
isopropyl thus showing the effects of spreading out the hydrophobic interaction and the 
impact this has on biological activity (see Figure 59).  
In addition, there is a potential benefit in returning to the original benzyl substitution pattern 
exploration as a single para substitution has only thus far been investigated. Therefore, more 
analogues could explore the significance of substitute position on the benzyl ring i.e. ortho 
and meta, to highlight any favoured position for interaction and potentially leading to a more 
potent compound. For example, moving the nitrogen atom found in LVTa72 (5.45 μM) or 
the fluorine atom seen in LVT70 (6.77 μM) could bring to light a more potent compound 
(see Figure 60).  
 
Figure 60: Benzyl substitution exploration 
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3:8 Summary  
In this sub-series, 40 novel spiroindoline analogues have been generated based on the hit 
compound MMV668732 and tested for their biological activity against Plasmodium 
falciparum.  
 
 
 
 
 
 
 
 
Investigations of the structure-activity relationship has been extensively explored and 
highlighted two compounds which warrant further investigation, LVT86 (960 nM) and 
LVTa1 (1.15 μM). Therefore, to try and improve the logP value of compound LVT86 as 
well as preserve the potent activity, a hybrid of LVT86 and LVTa1 could be generated 
whilst retaining a 3,4-dichloro phenyl substitution pattern (see Figure 61). However, more 
investigation on the dichloro substitution should be carried out first and the m-CF3 group 
should also be probed for this proposed derivative. Furthermore, longer chain lengths could 
be created in the hybrid compound as a simple methyl chain is shown but, this would result 
in an increase in logP.  
Bridge substitution Activity 
Carbonyl favoured with 
urea link + 6 mem 
saturated ring 
Increase 
Aliphatic amide Decrease 
Substitution Activity 
Short greasy chain Increase  
Morpholine moiety Increase  
Both EDG and EWG on 
benzyl ring  
Decrease 
Substitution Activity 
EDG Decrease   
CF3 Small decrease 
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Figure 61: Potential analogue 
Finally, additional work researching a central indole substitution could be carried out, to see 
if any benefit towards activity can be observed. Not only would this new substitution provide 
an additional interaction but would also help block potential sites of metabolic activity which 
could cause problems in later biological testing. Figure 62 displays one suggestion for a 
potential analogue whereby a nitrogen atom has been incorporated into the central structure. 
This variation would block potential oxidation at that exposed ring position and would 
contribute to an overall reduction in logP. To achieve this extra point of variation, a 
substituted hydrazine could be purchased and used to carry out the required Fischer-Indole 
reaction to generate the desired starting material.  
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Figure 62: Candidate suggestion 
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Chapter 4: 2-Iminobenzimidazoles 
4:1 Benzimidazole background  
4:1:1 Biological significance 
The biological activity of benzimidazole 48 was noted in the 1940’s, as Woolley speculated 
benzimidazole to act in a similar way to purines when stimulating a biological response. The 
research undertaken observed the effects of benzimidazole on yeast and bacteria growth 
inhibition and furthermore, examining the effects of reversing this inhibition with purines. 
(75) Examples of purines include DNA bases such as adenine 49 and guanine 50.  
 
 
 
This core feature highlighted above is involved in a wide range of bioactive compounds such 
as: anticonvulsants, analgesics, antihistamines, antihypertensives, antiviral, anticancer, 
antifungal and more significantly, antiparasitics. (76) The benzimidazole structure is readily 
tautomerised due to the nitrogen lone pair and can therefore cause isomerisation in derived 
compounds.  As a result, two numbering systems can be used, shown in Figure 63.  
 
                  
 
 
Figure 63: Isomerisation of benzimidazole 
                                            
Benzimidazole derivatives rose to popularity within the pharmaceutical industry after 
compound 5,6-dimethyl-1-(α-D-ribofuranosyl)benzimidazole now known as α-ribazole 51, 
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was discovered to be an integral part of vitamin B12 during the 1950’s. Consequently in 1962, 
thiabendazole 52 was the first benzimidazole compound licensed for human pharmaceutical 
use. Thiabendazole is an effective fungicide and parasiticide drug which is most commonly 
used to control roundworm and hookworm in: wild animals, livestock and humans. (77) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 154 
 
4:1:2 2-Aminobenzimidazole synthesis  
The general method for synthesis of 2-aminobenzimidazole has remained the same since the 
1940’s. Scheme 52 displays the common method used which generates the desired product 
by reacting 1,2-phenylenediamine with cyanogen bromide in ethanol and water at 70 ºC for 
1 hour. (78) 
 
 
                             Scheme 52: 2-Iminobenzimidazole synthesis  
However, in 2014 Bandyopadhyay and Sathe et al generated a 1,2-diiodobenzene 
intermediate before reacting it with guanidine to create 2-aminobenzimidazole via a copper 
catalysed double amination reaction. Scheme 53 shows the synthesis of 2-
aminobenzimdazole from 1,2-diiodobenzene and guanidine in the presence of copper iodide. 
(79) 
 
                            
Scheme 53: Alternate 2-aminobenzimidazole synthesis 
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4:1:3 Conventional benzimidazole pharmaceuticals  
Antiviral 
Highlighted below are two common aminobenzimidazole antiviral medications Enviradine 
53 and Enviroxime 54 which were first discovered in the 1980’s to use in clinic as a broad-
spectrum inhibitor of RNA viruses. For example, both compounds were found to target 
rhinovirus, responsible for the common cold and, enterovirus, accountable for 
gastrointestinal tract infections. They possess a central 2-aminobenzimidazole core 
alongside a propyl sulfonamine and an sp2 bridge to a phenyl ring.  
 
 
 
 
During biological testing, compound 54 displayed poor oral bioavailability and emetic side 
effects in humans. On the other hand, compound 53 showed superior oral bioavailability in 
rats and dogs as well as no emetic side effects – although very poor oral blood levels were 
found. Therefore, radiolabel studies were carried out and it was found low blood levels of 
53 were due to rapid metabolism, by allylic oxidation of the vinyl methyl group (highlighted 
above). However, both drugs are still used as they exhibit potent broad spectrum anti-
rhinovirus and anti-enterovirus activity which is desirable as ‘colds’ are caused by over 100 
different virus strains. (80) 
Scheme 54 displays the synthetic route to generate 53 which involves the mixing of 2-amino-
5-benzoyl benzimidazole and isopropylsulfonyl chloride. The number of equivalents of 
starting sulfonyl halide used to generate the desired product 5-benzoyl-N′-isopropylsulfonyl-
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o-benzimidazole, was found to be of significance.  If excess sulfonyl halide was used an 
unwanted bissulfonyl product was observed, as well as the wrong mono-sulfonyl compound 
adding to the 2-amino group instead. Therefore, it was found only modest equivalence 
should be used to ensure the chosen phenylenediamine was fully reacted as desired i.e. 1 
equivalents of sulfonyl halide to 1.2 equivalent of phenylenediamine. (81) Also, during this 
step higher temperatures generated more of the undesired isomeric product, adding to the 
amino group.   
Scheme 54: Enviradine synthesis 
The desired trans Grignard product was generated in two steps firstly, 4–6 equivalents of 
the bromo substituted Grignard reagent was reacted with the sulfonyl starting material. 
Furthermore, co-solvents were used during this step such as, dichloromethane and 
tetrahydrofuran as the sulfonyl starting material is not highly soluble in the Grignard solvent 
diethyl ether. The resultant hydroxy intermediate is not isolated and added directly to dilute 
aqueous acid to obtain the dehydrated product. The desired product was easily collected by 
crystallisation from toluene or isopropanol. (81) 
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Proton pump inhibitors 
One of the first licensed drugs containing benzimidazole was omeprazole 55 and is on the 
World Health Organisation’s (WHO) list of essential medicines. This drug decreases the 
amount of acid produced in the stomach by greater than 90% and is prescribed to treat 
gastroesophageal reflux problems and more severely, peptic ulcers. A covalent disulfide 
bond is formed between a cysteine residue of the proton pump enzyme in the stomach and 
the drug itself therefore, irreversibly inhibiting the gastric proton pump within the gastric 
cells, known as parietal cells. (82) 
 
 
 
 
                                                      
Compound 55 exists as a sulfoxide racemic mixture however, the (S)-enantiomer has a better 
metabolic profile. Both enantiomers are equally active, because the chiral centre is destroyed 
before the drug binds to the enzyme. Pure (S)-sulfoxide (Esomeprazole, 56) has been 
synthesised and is marketed as Nexium. (83) Omeprazole can be easily prepared from two 
commercially available 2-thiobenzimidazole 57 and chloromethylpyridine 58.  
 
 
 
Scheme 55 displays the synthetic route to generate Omeprazole and begins with a 
nucleophilic substitution reaction between an alkyl chloride and the thiol moiety of a 
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substituted 2-mercaptobenzimidazole. The resultant sulfide intermediate was then oxidised 
to generate the desired compound 55.  
 
 
 
 
 
 
 
 
 
 
Scheme 55: Omeprazole synthesis (84) 
 
Antitumor  
A compound administered as intravenous chemotherapy is Bendamustine 59, used to treat 
chronic leukemia and non-Hodgkin’s lymphoma. Marketed as Treanda this drug is also on 
the list of WHO essential medicines and interferes with DNA and RNA operations.  
Highlighted below is the key functionality responsible for the mechanism of action, causing 
inter and intra strand cross links between DNA bases. The antitumor agent was originally 
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developed from mustard gas and has recently been administered alongside the antibody 
Rituximab, which has shown to improve drug efficacy.  
 
 
 
                                                       
The efficient synthesis of 59 is displayed in Scheme 56 and begins with an amide coupling 
between, 2,4-dinitroaniline and methyl 4-(chloroformyl)butyrate. (85) 
Scheme 56: Bendamustine synthesis (85) 
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4:1:4 Antimalarial activity   
In 2011 Camacho et al, investigated a novel series of N-substituted-2-(5-nitrofuran or 
nitrothiophene)-3H-benzol[d]imidazole-5-carbohydrazide compounds for their 
antiprotozoal activity (Figure 64).   
 
 
 
 
Figure 64: Analogue under exploration 
Once the nitrofuran or nitrothiophene moiety had become attached it was found to encourage 
antimalarial activity in vivo for Plasmodium berghei. They also reported cytotoxic activity 
against several cancer cell lines as well as showing evidence for antitubercular activity. (86) 
Gomez et al explored the potential of a substituted benzimidazole dimer as an antimicrobial 
and antiprotozoal agent (Figure 65).  
 
 
 
 
 
Figure 65: Benzimidazole dimer 
 161 
 
The novel compound requires an electron donating group positioned on C5 of both 
benzimidazole sections (R1), as well as a pentane spacer for activity against Trichomonas 
vaginalis, Giardia lamblia, Entamoeba histolytica and Leishmania mexicana. However, 
activity against P. berghei was observed when a surprising electron withdrawing group 
(R1=CF3) was substituted onto the benzimidazole component and possessed an inhibitory 
concentration of 6.53 μM.  
Furthermore, in 2011 antiplasmodial agents were considered by Saify et al, who found the 
compound shown in Figure 66 to target P. falciparum plasmepsin II – one of the essential 
components of the P. falciparum hemoglobin-degradation pathway. (87) 
 
 
 
 
Figure 66: Active scaffold R=Cl/NO2 
They discovered the presence of a chloro or nitro moiety substituted on the ketone linked 
phenyl ring was necessary to enhance Plasmodium activity and a further phenyl group 
substituted as R also resulted in higher activity. (88) 
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4:2 Bioactive 2-iminobenzimidazoles 
In 2003 a patent application highlighted a group of guanidine compounds as anaesthetics for 
the treatment of nervous system disorders. These novel compounds possess the general 
formula, shown in Figure 67, and are defined as effective sodium ion channel blockers in 
neuronal mammalian cells. (89) 
 
 
 
Figure 67: Novel core investigated (left) and guanidine (right) 
Their applications include: anaesthetics and/or analgesics – particularly local 
spinal/epidural, for alleviation of neuropathic pain and, for producing anticonvulsant effects.  
(89) 
Furthermore, in 2007 Holloway et al discovered that compounds with an identical core 
structure to the patented compound above displayed good antibacterial activity and was 
found to inhibit Trypanothione reductase. Trypanothione 60 is found in protozoa such as 
leishmania and trypanosomes and is the alternate form to glutathione (two molecules of 
glutathione joined by a polyamine linker). (90) 
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The research group discovered a compound that exhibited one basic side chain in 
combination with an aromatic ring side chain, which subsequently lead to an antibacterial 
hit (see Figure 68). Through removal of the latter aromatic chain, a loss of potency was 
observed as well as, replacing the basic side chain with a hydrophobic group. (90) 
 
 
 
 
 
 
                            Figure 68: Hit compound and key features 
They highlight several features which reduce and enhance potency for example: a piperidine 
or diethylamine basic moiety produces the best activity, a loss of potency was seen on the 
addition of a morpholine group, extension of the basic chain from the benzimidazole 
nitrogen saw a loss of activity, a variety of alcohol substituents were tolerant without 
significant loss of activity, 4-methoxy substitution on the phenyl ring was distinctively less 
favoured and, a second 4-phenyl group saw a loss of activity. They conclude their findings 
to indicate a relatively tolerable binding site with the potential to host a wide range of 
different structures and state this is consistent with previous studies which show inhibitors 
of Trypanothione reductase to have multiple binding modes. (90) 
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4:2:1 2-Iminobenzimidazole antimalarials   
As previously discussed, in June 2013 the Open Access Malaria Box was published to create 
a bank of drug-like and probe-like antimalarial leads for alternative research groups to 
optimise and progress. Their aim was to support the malaria eradication agenda, which 
requires the discovery of new drugs with transmission blocking or liver stage properties. Of 
the thousands of compounds screened and subsequent optimisation to extract a balance 
between potency and chemical diversity, a 2-iminobenzimidazole compound MMV000248 
appears within the final 400 leads. In this publication, Spangenberg et al highlight important 
features of MMV000248 which include: nitrogen + oxygen count=5, number of rotational 
bonds=0, hydrogen bond donors=2, molecular weight 421.36 gmol−1 and logP=4.4. (91) 
 
 
 
 
 
Furthermore, in 2014 Bowman et al investigated antimalarial compounds present within the 
MMV box for their gametocytocidal activity. To evaluate their activity against alternate 
stages of the parasite lifecycle 22 compounds were tested for their gametocyte viability at 5 
μM and those which displayed >85% inhibition were taken forward. Of the original 22 
compounds, 18 were carried forward and of those, 12 displayed an IC50 of <1 μM against 
the gamete stage, as well as acting on the asexual stage, drug resistant and drug sensitive 
parasite. (92) 
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All compounds tested for their gametocytocidal activity were tested alongside a positive 
control epoxomicin 61, which has been previously reported to target the gametocyte stage 
of the parasite lifecycle. (93) 
 
 
 
                            
Primaquine 11 is currently the only antimalarial drug active against late stage gametocytes 
and only a small number of potential candidates are currently going through clinical trials 
this therefore highlighting the need for new leads against this malaria stage. (94) 
MMV000248 showed mid-nanomolar inhibitory concentration in late stage gametocytes 
(NF54 310 nM) and low nanomolar inhibitory concentrations in the asexual stage of the 
parasite (NF54 50 nM and Dd2 90 nM). (92) 
 
Figure 69: 2-Iminobenzimidazole leads 
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Two pharmacophores were identified as an outcome of gametocytocidal exploration of 
which, the benzimidazole imine core was one. Additionally, in 2013 Spangenberg et al found 
four other analogues present within the MMV box possessing the same benzimidazole imine 
scaffold, but lack confirmatory gametocytocidal activity (see Figure 69). (91) Overall, the 
gametocyte activity data obtained indicates strict structural requirements for both 
gametocytocidal and asexual activity within the benzimidazole imine scaffold. From this 
investigation MMV000248 has been highlighted with the potential of having multistage 
activity that could be further optimised to generate a cure and stop malaria transmission. (92) 
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4:3 Alternative therapeutics for 2-iminobenzimidazoles   
In 2015 a research group Rubin et al investigated the inhibition of a gram-negative 
bacterium, Acinetobacter baumannii. This bacterium contributes to multi-drug resistant 
(MDR) in-hospital infections of which, 63% of A. baumannii varieties are MDR.  As a result, 
they screened novel compounds selectively targeting bacterial oxidative phosphorylation 
(OxPhos), which plays an essential role in bacterial energy production in the form of ATP. 
Therefore, inhibition of this pathway is known to significantly impair bacteria viability. (95) 
The research group conducted a high though put screening programme to filter a library of 
compounds that possessed activity towards OxPhos inhibition. Structure-activity exploration 
led to the synthesis of over 100 compounds and uncovered a promising scaffold, shown in 
Figure 70. They state compound A displayed a good spectrum of antibacterial activity 
against A. baumannii and was the most potent amongst the original hits, possessing an 
inhibitory concentration of 1.9 μM for the inhibition of ATP synthesis. (95) 
 
 
 
 
 
 
 
Figure 70: Compound A (bis TFA salt, left) and MMV000444 (right) 
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Structural similarities can be seen with antimalarial compounds 
MMV000444/MMV000445 shown in Figure 70, as identical ether-alcohol moieties are 
present within the linker between a benzimidazole core and substituted phenyl component.  
During the investigation, they probed the SAR by synthesising analogues which removed 
each component they hypothesised to be responsible for activity. Figure 71 highlights four 
key derivatives which indicate the constituents required for overall potency. Replacement of 
the 2-imino group on benzimidazole with a ketone moiety resulted in 6 times decrease in 
biological activity (IC50 12 μM). Also, removal of the alcohol and ether present in the linker 
resulted in over 2 times decrease in potency (5 μM). (95) 
 
                  
 
 
 
 
Figure 71: SAR exploration 
They discovered two compounds which possessed higher potency than the original hit which 
are displayed in Figure 72. Firstly, they solely removed the hydrogen bond donor constituent 
from the phenyl linker, which resulted in 3 times increase in potency (IC50 0.6 μM). 
Secondly, they not only removed the alcohol component but also, the tertiary amine linked 
via an ethyl chain and surprisingly, generated a compound with an IC50 of 0.9 μM, so this 
character may not be necessary for activity (see Figure 72). (95) Exploration of this 
mechanism of action and SAR against A. baumannii is still ongoing.  
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Figure 72: Potent leads 
The exploration of this SAR provides key insight into the moieties required for high activity 
against this bacterium and therefore could be applied to our investigation into analogues 
targeting malaria.                     
To access these analogues Rubin et al performed two consecutive alkylation reactions which 
can be adapted to synthesise the antimalarial compounds proposed in this research project 
(see Scheme 57).  
Scheme 57: Synthesis of benzimidazole derivatives 
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4:4 Postgraduate project    
MMV000248 possess the lowest EC50 of the five MMV structures and highlights some key 
features for high activity (see Figure 73). Firstly, three of the five lead compounds have a 
tertiary amine connected to the benzimidazole core via an ethyl linker. Secondly, two of 
the higher activity derivatives have a chiral alcohol group situated next to a substituted 
phenyl moiety. Thirdly, three analogues have a halogen substituent on the phenyl ring. 
 
 
 
 
 
 
 
 
 
Figure 73: Predicted moieties important for SAR  
Compound MMV396723 retains the 3,4-dichloro moiety seen in MMV000248 but has an 
alternate ketone functionality next to the phenyl ring, and this resulted in a significant loss 
of potency (719 nM to 1.24 μM). Therefore, we reasoned that the alcohol group is required 
for high activity.  
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Figure 74: Alternate 2-iminobenzimidazole leads 
The last two 2-iminobenzimidazole MMV compounds maintain the position of the alcohol 
group, with an ether spacer to the substituted phenyl ring (see Figure 74). The top nitrogen 
is substituted with a straight chain alkyl group (pentyl and hexyl chain). These compounds 
only possess low micromolar activity however, it is unclear whether this is a result of the 
changes to the substituents at N1 or N2.  
As a result, we proposed to synthesise a small library of analogues with single structural 
modifications to allow direct comparisons between structure and activity. Our analogues 
consist of a mixture of the features discussed such as: tertiary amine with ethyl linker; hexane 
and pentane moieties; phenyl substituents with halogen substituents and also; alternative 
electron withdrawing groups such as: 3,5-dichloro, 2,4-dichloro, 3-bromo, 3-chloro, 4-
trifluormethyl and 3-nitro (see Figure 75).  
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Figure 75: 2-Iminobenzimidazole analogue proposals  
As we envisioned these analogues would be synthesised via N-alkylation with a α-bromo 
ketone derivative. Our route would generate the keto form, as seen in the MMV and then 
reduced to the desired alcohol however, both analogues would be retained for testing. The 
ether-linker analogues are limited to the MMV compounds at this stage but, should be 
explored in future.  
To conclude, all R1 substituents should be interchanged with each corresponding substituted 
phenyl R3 and both ketone and alcohol R2 should be tested. This will generate a bank of 50 
2-iminobenzimidazole derivatives for antimalarial screening to probe this structure-activity 
relationship.  
The proposals also include the synthesis of compounds MMV000444/445 which will be 
synthesised from 2-((m-tolyloxy)methyl)oxirane and the relevant pentane/hexane alkylated 
2-iminobenzimidazole.  
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4:5 Results and Discussion   
4:5:1 Substitution of 2-iminobenzimidazole  
To access these novel benzimidazole derivatives two simple consecutive alkylation reactions 
can be carried out on 2-iminobenzimidazole, which is readily available. Previous work 
carried out by an undergraduate student explored alkylation conditions of 2-
iminobenzimidazole to generate MMV000248. During this project several reaction solvents 
and bases were tested and from this the conditions used to generate these analogues were 
developed. For example, alkylation was attempted to form the diethyl ethylamine substrate 
in a 2M NaOH/acetone solution, however after leaving at reflux overnight no product peak 
(233 peak) was observed in the LC-MS chromatogram. Also, potassium hydroxide and 
TBAI were utilised to try and form the pentane compound from chloropentane but, after 
leaving at reflux overnight, no product peak could be seen in the LC-MS chromatogram (see 
Scheme 58).  
 
 
 
 
 
 
 
Scheme 58: Unsuccessful alkylation conditions 
As a result, the reaction conditions shown in Scheme 59 were deduced and the desired 
starting materials and products were generated in good yields. 
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Scheme 59: 2-Iminobenzimidazole derivative synthesis 
a) d/e/f/g, KOH, 60 °C, 1h. acetone., b) DMF, 60 °C, 1 h 
 
Firstly, the chosen alkyl halide/ethyl tertiary amine halide was stirred along with 2-
iminobenzimidazole and potassium hydroxide in acetone at 60 ºC for 1 hour. Once 
completed, the acetone was removed under reduced pressure and the resulting mixture 
partitioned between EtOAc and water. The collected organics were washed with brine, dried 
over magnesium sulfate, filtered and the solvent removed under reduced pressure. For 
purification, ice-cold acetone was added to generate both tertiary amine precipitates, whereas 
the pentane substrate requires cold diethyl ether. The required solvent was cooled in an ice 
bath and added into the relevant reaction flask until a precipitate formed the solid was then 
filtered off via Büchner filtration and subsequently washed through with the ice-cold solvent. 
The hexane substrate was a brown waxy solid, and therefore proves difficult to filter once 
ice cold diethyl ether was added. As a result, the best purification method for this hexane 
intermediate was column chromatography (10% MeOH in CH2Cl2) and is easily separated 
from its constituents and impurities. 
The alkyl halide producing the best result was the iodo- substituted alkyl chain, as both 
chloro- and bromo- starting materials: produced minimal quantities of product or none and 
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had much longer reaction times which allowed impurities to form, giving an unclean reaction 
mixture.  
As we recognised there are two possible sites for alkylation on 2-iminobenzimidazole as 
shown in Figure 76, we ran a nuclear Overhauser effect (nOe) NMR experiment to ascertain 
the actual position of alkylation. To run the experiment a sample of the diethyl ethylamine 
substrate was made up in D6-DMSO and the protons highlighted at 4.00 ppm were irradiated 
and the signal corresponding to the proton at 7.13 ppm was predicted to be enhanced.  
 
 
Figure 76: nOe experiment 
From the nOe spectra displayed in Figure 77, the peak corresponding to the expected 
aromatic proton highlighted above is enhanced (red) when the proton at 4.00 ppm is 
irradiated (blue) and therefore, confirms the structure we desire has been successfully 
synthesised. If the alternate alkylation product had been generated, no aromatic protons 
would have been enhanced.  
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Figure 77: nOe spectrum 
The second alkylation was carried out in DMF and stirred for 1 hour at 60 ºC and found to 
be successful (see Scheme 60). These reaction conditions were based on the previously 
discussed synthetic strategy carried out by Rubin et al.  
 
 
nOe spectrum 
1H NMR 
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Scheme 60: Alkylation exploration (R2=3,4-dichlorophenyl) 
Subsequently, on removal of DMF a white solid appears amongst red coloured impurities in 
all cases. The desired product hydrogen bromide salt is insoluble in acetone and so simply 
filtered via Hirsch funnel under suction and washed with acetone (20 mL) to reveal the pure 
product. Furthermore, the yield range for the ketone analogues was 75–98%, which is very 
good due to little purification needed and each product was confirmed by LC-MS displaying 
the calculated product mass.  
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4:5:2 Ketone reduction 
Approximately 100 mg of each ketone hydrobromide salt was taken and subjected to a 
straightforward NaBH4 reduction stirring in ethanol at reflux for 1 hour (see Scheme 61). A 
small sample was taken from the reaction mixture and ran through LC-MS to ensure all the 
ketone had been reduced. After an aqueous work up the products were isolated in good yield 
with a range of 69–97%, therefore generated sufficient material for both analytical and 
biological assay testing.  
 
 
 
 
Scheme 61: Ketone reduction 
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4:5:3 Epoxide synthesis  
Formation of compounds MMV000444 and MMV000445 require a different synthetic route 
due to the additional ether group and extra carbon atom in the linker connecting the phenyl 
ring to the benzimidazole core. We planned to generate these two compounds from the 
epoxide, as shown in Scheme 62.  
 
 
 
 
 
Scheme 62: Alkylation with m-cresol epoxide 
The m-cresol epoxide was not commercially available we attempted to synthesise it by 
following a literature procedure which involves mixing K2CO3 and m-cresol in acetonitrile 
for 30 minutes at room temperature. Then, epichlorohydrin was added via syringe and the 
resulting reaction mixture was left to stir at reflux for 18 hours. However, the reaction was 
monitored by TLC and at this stage only displayed both starting materials. The literature 
states they experience a problem with a biphasic mixture, so this was thought to be the cause 
for no product formation. (96) As a result, a small volume of DMF was added to increase 
solubility and retain more base within solution, and the reaction was left to stir at reflux for 
a further 12 hours (see Scheme 63). This time the reaction TLC indicated a minimal amount 
of product within the reaction mixture, therefore a more efficient synthesis was required.   
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Scheme 63: Attempted synthesis of epoxide 
In addition, the epichlorohydrin component carries safety concerns due to its link with 
carcinogenicity, therefore this steered the search for an alternate starting material. 
Consequently, a colleague proposed using glycidyl tosylate known from his own previous 
research, which is a stable solid and provides a better tosylate leaving group.  
A stirred solution of m-cresol in DMF under nitrogen was treated with K2CO3 then, (S)-
glycidyl tosylate was added as a DMF solution via needle and syringe then, left to stir at 
room temperature for 10 minutes. The solution was subsequently heated to 60 ºC and left for 
a further 3 hours to generate the desired starting material. (97) The product was obtained in 
excellent yield as a yellow oil and subsequently used in the second alkylation (see Scheme 
64).  
 
 
 
Scheme 64: Tosylate strategy 
To prepare both MMV compounds, K2CO3 was used as the base in the alkylation reaction 
and surprisingly no product could be seen by reaction TLC after 1 hour at 60 ºC. Therefore, 
two equivalents of Cs2CO3 was added and after 1 hour, only minimal product could be 
observed on TLC. As a result, a separate reaction was carried out with KOH as the base, and 
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after 1 hour a larger amount of product could be seen along with a depletion of starting 
material, therefore these conditions were used to generate the two MMV analogues (see 
Scheme 65).  
 
 
 
 
 
Scheme 65: Epoxide alkylation conditions 
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4:6 Biological screening  
Preliminary screening of this series of benzimidazole derivatives has provided essential 
insight into the key structural features required for high antimalarial activity. Initial 
screening tested all analogues for percentage growth at 3 different concentrations: 2 µM, 
400 nM and 80 nM. For example, Figure 78 displays one set of preliminary data obtained 
for a handful of analogues generated and shows the % growth at each concentration.  
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Figure 78: Initial biological screening 
The two best analogues discovered were LVTa95 and LVTa96, displayed in Figure 79 and 
these display better activity than the 5 MMV analogues. Highlighted are the individual 
components predicted to be of importance for high activity such as: a pentane/hexane alkyl 
chain, 2-iminobenzimidazole core linked via an alcohol containing ethyl chain to a phenyl 
ring, so when combined generate two low nanomolar hits against P. falciparum. These two 
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analogues combine structural features from the MMV compounds which had not been 
combined before.  
 
 
 
 
 
 
Figure 79: Hit analogues and key features 
 
Figure 80: Representation of analogue growth rates at 3 different drug concentrations 
 
 
400 nM  
2 µM  
80 nM  
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Figure 80 displays three graphs each representing parasite growth at; 2 µM, 400 nM and 80 
nM drug concentrations. The graph at 2 μM shows the vast majority of analogues to have 
growth rate of ≤50%. However, the five compounds circled in blue and shown in Figure 81 
display the worst activity of this subseries. The compounds include three starting materials 
which were tested alongside analogues for comparative measures and both MMV 
compounds possessing the ether-alcohol moiety (MMV000444/445).  
 
 
 
 
 
Figure 81: Poor activity compounds 
At 400 nM growth rates are evenly spread within this series of benzimidazoles but, at 80 nM 
three analogues are highlighted as having a growth rate of ≤20% (see Figure 82).  
  
 
 
 
 
 
 
Figure 82: Screening data 
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Furthermore, the screening graph in Figure 82 displays the notable difference in activity 
between LVTa95 and LVTa96 with several other good activity derivatives. Also shown are 
compounds LVTa87, LVTa88, LVTa107 and LVTa108, which are derivatives possessing 
some of the next lowest inhibitory concentrations from the series (% growth at 80 nM ~70%), 
and they retain the key features highlighted above. These analogues differ in the substitution 
on the phenyl substituent, with LVTa87/88 possessing a p-trifluoromethyl substituent 
(LVTa87 N1-C5H11 and LVTa88 N
1-C6H13) and LVTa107/108 a 3,4-dichloro substituent 
(LVTa107 N1-C5H11 and LVTa108 N
1-C6H13). Indicating a strong preference for electron 
withdrawing halogen substituents on the phenyl ring but, no electron donating groups have 
been tested in this set of analogues. The combination of a 2,4-dichlorophenyl relationship 
with the pentane substitution and an alcohol substituted linker provides the most potent 
compound of the series (LVTa95). 
Also, the majority of analogues tested with mid-nanomolar activity possess the alcohol 
linker, therefore this feature is highly desirable for antimalarial activity and should be 
retained in future analogues. Whereas, the ketone linker produces high nanomolar/low 
micromolar activity compounds, suggesting a hydrogen bond acceptor is disfavoured over a 
hydrogen bond donor interaction.  
Of the compounds displaying the highest potency, six derivatives underwent inhibitory 
concentration assays of which the results are displayed in Table 27. Furthermore, as LVTa95 
and LVTa96 exist as an enantiomeric mixture separation of the enantiomers was carried out 
using chiral HPLC separation and the individual (+) and (−) enantiomers were tested for 
their biological activity. Also, both separated samples were subjected to optical rotation 
testing to decipher their +/− status and the results are shown in Figure 83.  
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Figure 83: Analogue separation 
 
Reference Inhibitory 
concentration/nM 
IC50 range/nM e.r. 
LVTa95 mix 
(+)-LVTa95_1 
(−)-LVTa95_2 
33.40 30.06–37.11 N/A 
32.13 25.56–35.13 98.5:1.5 
32.44 28.13–36.86 >99.5:<0.5 
LVTa96 mix 
(+)-LVTa96_1 
(−)-LVTa96_2 
40.25 37.51–43.20 N/A 
35.56 30.90–43.57 98.5:1.5 
34.97 29.07–40.29 98.5:1.5 
LVTa87 42.31 71.40–110.9 N/A 
LVTa88 76.17 48.64–59.84 N/A 
LVTa107 69.9 74.04–86.63 N/A 
LVTa108 56.6 54.74–63.78 N/A 
Table 27: Inhibitory concentration assay results 
 
All six compounds display good nanomolar activity and possess features of either a pentane 
or hexane R1 substitution alongside an electron withdrawing R2 group. Furthermore, after 
enantiomeric separation surprisingly both R and S enantiomers show little difference in 
biological activity from the mix of both enantiomers tested. Therefore, expensive separation 
techniques would not be beneficial for this set of benzimidazole derivatives. Three features 
have been brought to light within this series of antimalarials that result in high activity i.e. a 
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linker possessing an alcohol moiety (conformation not significant), a hydrophobic alkyl R1 
chain and an electron withdrawing R2 substituent, of which the position is not critical.  
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4:7 Asymmetric catalytic reduction 
An asymmetric transfer hydrogenation reaction was carried out with Noyori’s catalyst on 
starting ketones LVTa93 and LVTa94 (see Figure 84). Even though biological testing 
revealed no discrepancies in (R) or (S) activity, this strategy was attempted with the hope of 
achieving high enantiomeric excess in one enantiomer. 
 
 
 
 
 
 
 
Figure 84: Activated Noyori’s catalyst (above) and starting materials (below) 
Firstly, the (S,S)- and (R,R)-Noyori catalysts were activated as outlined in Scheme 66. The 
orange solution was subsequently concentrated, and the products dissolved in dry DMF (2 
mL) to create a 0.08 M solution. (98) 
 
Scheme 66: Catalyst activation 
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The activated catalysts were then used to reduce the desired ketone, in turn, to generate four 
products (see Scheme 67). The products were sent for chiral HPLC analysis and retention 
factors compared to the data obtained from the previous HPLC separation which generated 
compounds: LVTa95_1, LVTa95_2, LVTa96_1 and LVTa96_2 previously discussed.  
 
 
 
 
 
Scheme 67: Asymmetric reduction 
The results from HPLC analysis show good enantiomeric ratios in three of the four products 
with an average e.r. of 90:10 however, for LVTa96_NR a much lower e.r. was observed 
(see Table 28). The reasons for this are unknown. 
 
 
 
Table 28: Enantiomeric ratios 
 
 
 
 
Reference e.r. 
LVTa96_NR 78:22 
LVTa96_NS 90.5:9.5 
LVTa95_NR 89.5:10.5 
LVTa95_NS 90:10 
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4:8 Future work 
It is clear the overall pharmacokinetic properties of these highly active compounds need to 
be addressed. For example, the calculated pharmacokinetic parameters for LVTa95 reveal 
this derivative to fall in line with Lapinski’s rule of 5 (RO5). (99) Even though it has ‘RO5’ 
compliance, due to compound LVTa95 being in infant medicinal chemistry development 
the ‘rule of three’ (RO3) should be considered and is an approach used during fragment-
based drug discovery (Table 29). (100) Unfortunately, LVTa95 does not adhere to these tight 
pharmacokinetic restraints therefore, more work needs to be done to adjust them, for 
example: logP, HBD, HBA and rotatable bonds would all ideally need to be reduced to less 
than 3. Although in the case of size a molecular weight of 392.32 gmol−1 is adequate and the 
RO3 can be stretched. In practice it is ideal to keep within these boundaries and a logP 
between 2–3 is aimed for.  
Parameter Value RO5 RO3 
MW/ gmol−1 392.32  < 500  < 300  
Hydrogen BD 2 < 5 < 3 
Hydrogen BA 4 < 10 < 3 
logP 3.98 < 5 < 3 
Rotatable bonds 7 < 10 < 3 
Polar surface area (PSA) 53.94 Å2 < 140 Å2 < 140 Å2 
                       Table 29: LVTa95 pharmacokinetic parameter comparison  
Encouragingly there is still further scope for structural optimisation for this set of 
benzimidazole antimalarial compounds as well as consolidating our understanding of the 
SAR thus deduced. Future investigations should include: chain length variation between the 
phenyl group and benzimidazole core; phenyl EDG substituents; vary chain length between 
the tertiary amine and benzimidazole core; probe non-tertiary amines; substitution of the 
alcohol linker and alternate the alcohol moiety on the linker for different HDBs.  
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As only two carbon chain lengths have been explored to connect the substituted phenyl ring 
to the central benzimidazole moiety a longer chain length should be investigated to observe 
the effects this change has on biological activity. Furthermore, MMV000444 (LVTa65) and 
MMV000445 (LVTa66) are the only two compounds in this set of derivatives which have 
a chain length of 3 carbons and 1 oxygen atom connecting the core to a phenyl ring, as well 
as possessing low micromolar activity. Therefore, it could be hypothesised that the reason 
for less potent activity is due to this chain length feature. As a result, future structures such 
as the compounds suggested in Figure 85 should be synthesised to explore the structure 
activity relationship.  
 
 
 
 
 
 
 
Figure 85: Potential derivatives 
Also, electron donating groups should be explored as electron withdrawing groups have only 
been explored so far. Suggestions for future analogues include a methoxy and a dimethoxy 
group (see Figure 86). We speculate that these analogues would show a decrease in potency 
however, this prediction would need to be proven.  
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Figure 86: EWG phenyl substitution analogues 
To find an alternative group to the non-drug like straight alkyl chain the MMV tertiary amine 
group could be explored further.  Figure 87 displays a potential compound which probes this 
feature further by extending the previous ethyl linker to a propyl chain to see if an extension 
has a positive or negative impact on biological activity.  
 
 
 
 
 
 
Figure 87: Future candidates 
Alternatively, removing alkyl substituents from the tertiary amine would provide insight into 
the type of interactions taking place, for example: the generation of a secondary and primary 
amine moiety would provide additional hydrogen bond donor interactions, therefore what 
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impact would this addition have on biological activity.  Also, removing this side chain 
altogether as seen in previous antibacterial compounds would provide evidence for the 
necessity of this group for antimalarial activity. 
To combat the pharmacokinetic property concerns discussed earlier the greasy alkyl chain 
seen in LVTa95 contributes to the high logP value (3.98) therefore reduction of this value 
is essential. Further support for this came to light during biological sample preparation, 
where both LVTa95 and LVTa96 were not readily soluble in DMSO and required vigorous 
mixing and warmth, so increasing solubility is desirable. 
 
 
 
 
 
 
Figure 88: LVTa95 improved pharmacokinetic properties 
For example, inclusion of a polar functional group such as, a tetrazole moiety which mimics 
an acidic group, would help reduce logP (Figure 88). This exchange would result in the 
removal of the greasy hydrophobic chain which is present within all 6 compound hits. 
However, this should be investigated not only to observe the effect of removing this feature 
but to also observe what happens to biological activity when a more hydrophilic group is 
inserted. Although the tetrazole derivative would lead to an increase in molecular weight 
over 400 and the number of hydrogen bond acceptors would increase for both, so this should 
be kept in mind.   
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Meanwhile, the alcohol containing linker has been highlighted as a key feature for potent 
biological activity and as a result should be probed further. Even though the ketone 
functionality already tested has proven less active overall, replacing the ketone with an 
alternative functional group will prove if the ketone functionality itself is disfavoured or is 
it the hydrogen bond acceptor capabilities present which impact on activity. Figure 89 
displays potential derivatives which could be generated to explore this linker further for 
example: a methyl ether offers a small hydrophobic interaction, an extended alcohol group 
explores the effects of extending the chain length on activity and finally, replacing the 
alcohol altogether with an alternative hydrogen bond donor moiety such as, a primary amine.  
 
 
 
 
 
Figure 89: Alternative compounds 
Investigation into further substitution on the 2-iminobenzimidazole core has not been 
undertaken therefore, future compounds could also explore both EWG and EDG substituted 
on the central ring (highlighted in blue in Figure 89).  
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When a m-chloro substitution replaces the 2,4-dichloro substitution a big reduction in 
molecular weight is seen and logP is reduced to as low as 1.63 with a tetrazole coupling 
(Figure 90).  
 
Figure 90: Further pharmacokinetic improvements 
Meanwhile, replacing the chlorine substitution with a fluorine moiety reduces logP even 
further (1.31) and, offers a hydrogen bond donor interaction on the phenyl ring which is yet 
to be tested (Figure 90). Overall, the electron withdrawing feature is being retained so should 
not impact activity too greatly, but an exchange in the electronegativity properties are being 
made. 
To access the tetrazole substitution the synthetic route outlined in Scheme 68 could be 
employed to generate these potential future analogues in two/step reactions.  
Scheme 68: Proposed synthetic strategy 
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4:9 Summary  
This sub-series of potential antimalarials has been the most fruitful during this project and 
provides the biggest potential for future optimisation. Exploration of analogue SAR has 
brought to light a lead group of six antimalarial candidates: LVTa95, LVTa96, LVTa87, 
LVTa88, LVTa107 and LVTa108.  
 
 
 
 
 
In addition, enantiomeric separation has shown conformation of the alcohol moiety to be 
none significant as differences in biological activity were negligible. Therefore, this small 
set of derivatives can be taken into the next stage of structural optimisation to potentially 
increase potency, whilst keeping within the pharmacokinetic parameters required. Overall 
two antimalarial compounds with an inhibitory concentration of 33.4 nM (LVTa95) and 
40.3 nM (LVTa96) have been discovered and possess further potential for optimisation (see 
Figure 91).  
 
 
 
 
Figure 91: Potent antimalarial leads 
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Chapter 5: Conclusion  
During this research project, approximately 150 novel compounds have been synthesised 
and tested for their biological activity against Plasmodium falciparum. Of the three-subseries 
generated: tetrahydro-β-carboline, spiroindoline and 2-iminobenzimidazole, two potent 
compounds have been discovered. Compounds LVTa95 and LVTa96 possess low 
nanomolar activity and on separation of their enantiomers, it has highlighted a non-
significance of conformation for antimalarial activity (see Figure 92). The alcohol 
component seen in both derivatives is predicted to be a significant interaction for antimalarial 
activity.  
 
 
 
 
 
                                 
Figure 92: Hit benzimidazole derivatives 
Further suggestions have been outlined to improve the hit analogue pharmacokinetic 
properties, in order to progress this potentially lucrative subseries. The area of primary 
optimisation should focus of reducing the lipophilicity of the pentane and hexane chains and 
in turn, reducing the derivative logP. Overall, there is still scope for optimisation in both the 
benzimidazole and spiroindoline series, but this project has provided a heathy bank of 
analogues over the three different classes possessing a range of functionalities. Each 
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subseries has provided an insight into the type of structure activity relationship taking place, 
which has been key when proposing new derivatives.  
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Chapter 6: Experimental  
6:1 General Details  
All reactions were performed under an atmosphere of air and with standard room pressure 
fitted with glass stopped, unless stated otherwise. Solvents for reactions were; 
dichloromethane (VWR, stabilised GPR Rectapur), acetonitrile (Fisher Scientific, HPLC 
reagent grade) and anhydrous DMF (Alpha Aesar, anhydrous amine free). Solvents used for 
chromatography were; methanol (VWR, GPR Rectapur), diethyl ether (Fisher, analytical 
reagent grade) and dichloromethane (VWR, stabilised GPR Rectapur). Column 
chromatography was performed using VWR 40-63 µM silica gel.  
300 MHz for 1H NMR and 75 MHz for 13C NMR spectra were recorded on a Bruker Avance 
300 spectrometer. 376 MHz spectra for 19F NMR was recorded on a Bruker Ascend 
spectrometer. Spectra were referenced to residual chloroform (7.26 ppm, 1H; 77.00 ppm, 
13C) unless stated otherwise. Chemical shifts are reported in ppm, multiplicities are indicated 
by s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet) and br (broad).  Coupling 
constants, J, are reported in Hertz.  Mass spectroscopy was performed on an Agilent 
Technology 6530 Accurate-Mass Q-TOF LC/MS machine. Data are reported in the form of 
(m/z).  Infrared spectra (IR) were recorded for neat samples on a Thermo Scientific Nicolet 
iS10 Diamond FT-IR spectrophotometer in the range of 500−4000 cm−1.  Peaks are reported 
in cm−1 with indicated relative intensities: s (strong, 67−100%); m (medium, 34−66%); w 
(weak, 0−33%).  Elemental analyses were performed by York University.  Melting points 
(mp) were determined on Stuart SMP10 capillary melting point apparatus in sealed tubes 
and are corrected.  Analytical thin-layer chromatography was performed on silica gel plates 
with aluminium backed, precoated UV245nm neutral silica plates.  Visualization was 
accomplished with UV (254 nm) and potassium permanganate (KMnO4) staining solutions. 
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Three specific rotation values were obtained on a Rudolph Research Analytical Autopol I 
automatic polarimeter for optically active compounds and an average value was taken.  
Microwave experiments were carried out in a Biotage Initiator 4.1.2. microwave. For the 
purpose of spectral assignment, compounds are numerically labelled not correlating to 
IUPAC naming conventions. The cis and trans diastereoisomers were assigned by 13C NMR 
spectra, of which, the method can be found in published literature.  
Literature compounds and appendices can be found in the expanded experimental section.  
Biological data 
All biological assays were conducted by colleagues within the biology department at Keele 
University. 48-hour growth inhibition assays were conducted on the novel compounds to 
determine their inhibitory concentration (IC50) values. These assays utilized trophozoite 
stage Dd2Luc Plasmodium falciparum parasites. MSF assays were carried out on the 
candidate compounds that were diluted in a two-fold dilution series using a 60 µM starting 
concentration. The data was normalized and plotted as a log-dose response curve to generate 
IC50 values. For all derivatives three independent biological replicates were carried out on 
assay plates bearing three technical repeats. IC50 graphs and screening graphs can be found 
in the expanded experimental section.  
General Procedures  
Preparation of tetrahydro-β-carboline diastereoisomers: 
Method A: The tryptophan derivative (1 eq.) and 3 Å molecular sieves were placed in a 
round bottom flask under a nitrogen atmosphere and dry CH2Cl2 (10 mL) was added. The 
chosen aldehyde (1.25 eq.) was dissolved separately in dry CH2Cl2 (5 mL) under a nitrogen 
atmosphere and then added via syringe to the main reaction mixture, however if liquid, it 
was added into the mixture directly via syringe. The solution was left to stir overnight and 
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TFA (2 eq.) was subsequently added and the mixture left for a further 4 h to stir at room 
temperature. The mixture was quenched with saturated aqueous NaHCO3 (10 mL), the 
organics extracted with CH2Cl2 (2 × 75 mL), washed with saturated aqueous brine (100 mL), 
dried over MgSO4, filtered and concentrated under reduced pressure. 
Method B: The tryptophan derivative (250 mg, 1 eq.) and aldehyde (1.25 eq.) were placed 
into a microwave vessel (2–5 mL), along with Yb(OTf)3 (0.03 mmol), CH2Cl2 (4 mL) and a 
micro magnetic stirrer. The vessel was capped and stirred under microwave irradiation in a 
Biotage Initiator 4.1.2. microwave at 100 ºC for 0.5 h, after a 30 second pre-stir.  
Preparation of spiroindoline derivatives:  
Method C: The chosen spiro[indoline-3,4'-piperidine]-1'-carboxylate starting material (1 
eq.) was dissolved in CH3CN (25 mL) and then potassium carbonate (2 eq.) was added into 
the stirred solution. The chosen halogen substituted electrophile (2 eq.) was added via 
syringe or via temporary removal of the condenser and the reaction then heated at reflux for 
18 h. After allowing to cool, CH3CN was removed under reduced pressure and the resulting 
mixture was dissolved in CH2Cl2 (20 mL). The solution was transferred to a separating 
funnel and H2O (20 mL) was added. The organics were extracted with further CH2Cl2 (2 × 
25 mL), then collated and washed with saturated aqueous brine (25 mL), dried over MgSO4, 
filtered and concentrated under reduced pressure. 
Preparation of 2-iminobenzimidazole derivatives:  
Method D: The chosen substituted 2-iminobenzimidazole (1 eq.) as well as, the chosen 
substituted bromoacetophenone (1 eq.) were weighed into a round bottom flask (25 mL) and 
the flask put under a nitrogen atmosphere. DMF (10 mL) was then added via syringe and the 
resulting solution stirred at 60 °C for 1 hour. After 1 hour the solution had turned red and 
the solvent was removed under reduced pressure. A colourless solid can be seen to form on 
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reduction of the solvent volume. Acetone (20 mL) was added into the flask and the residual 
colourless solid remained collected via Büchner filtration and washed with further acetone 
(10 mL). 
Method E: The ketone obtained from method D (1 eq.) was dissolved in ethanol (10 mL) 
and the flask fitted with a reflux condenser. NaBH4 (1.5 eq.) was then added through 
temporary removal of the condenser and the mixture was stirred at reflux for 1 hour. The 
solvent was later removed under reduced pressure and the resulting product partitioned 
between EtOAc (20 mL) and H2O (20 mL). The organics were further extracted with EtOAc 
(2 × 25 mL), washed with saturated aqueous brine (50 mL), dried over MgSO4, filtered and 
the solvent removed under reduced pressure. 
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6:2 Specific details and characterisation  
Preparation of Benzyl 1-(3-nitrophenyl)-2,3,4,9-tetrahydro-1H-pyrido-[3,4-b]indol-3-
carboxylate (LVT10-1,2): 
 
 
 
 
Following method A using (S)-Benzyl 2-amino-3-(1H-indol-3yl)propanoate (LVT14) (100 
mg, 0.34 mmol, 1 eq.) and 3-nitrobenzaldehyde (61.9 mg, 0.41 mmol, 1.25 eq.) as starting 
materials. The desired product was purified using column chromatography (SiO2, 19:1 
CH2Cl2:Et2O), to afford, eluting first, the trans diastereoisomer as an orange waxy solid 
(36.0 mg, 0.084 mmol, 25%) and, eluting second, the cis diastereoisomer an orange solid 
(42.0 mg, 0.098 mmol, 29%). 
Following method B using (S)-Benzyl 2-amino-3-(1H-indol-3yl)propanoate (LVT14) (500 
mg, 1.70 mmol, 1 eq.) and 3-nitrobenzaldehyde (321 mg, 2.13 mmol, 1.25 eq.) as starting 
materials. The desired product was purified using column chromatography (SiO2, 19:1 
CH2Cl2:Et2O), to afford, eluting first, the trans diastereoisomer as an orange waxy solid (261 
mg, 0.61 mmol, 36%) and, eluting second, the cis diastereoisomer an orange solid (292 mg, 
0.68 mmol, 40%). 
Trans (1R, 3S) diastereoisomer (LVT10-1)  
1H NMR (300 MHz, CDCl3) δ 3.22 (1H, ddd, J 15.4, 5.6, 1.4 Hz, CH2(10a)), 3.32 (1H, ddd, 
J 15.4, 5.6, 1.4 Hz, CH2(10b)), 4.01 (1H, dd, J 5.6, 5.6 Hz, CH(11)), 5.12 (1H, dd, J 12.3 
Hz, CH2(21a)), 5.18 (1H, d, J 12.3 Hz, CH2(21b)), 5.52 (1H, s, CH(14)), 7.12–7.22 (3H, m, 
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ArCH(1,2,3)), 7.24–7.30 (5H, m, ArCH(23,24,25)), 7.49 (1H, dd, J 8.1, 7.9 Hz, ArCH(17)), 
7.57 (1H, d, J 6.6 Hz, ArCH), 7.63 (1H, d, J 7.9 Hz, ArCH(16)), 8.51 (1H, d, J 8.1 Hz, 
ArCH(18)), 8.20 (1H, s, ArCH(20)) 
13C NMR (75 MHz, CDCl3) δ 24.53 (CH2(10)), 53.12 (CH(14)), 54.22 (CH(11)), 66.83 
(CH2(21)), 108.82 (ArC), 111.02 (ArCH), 118.53 (ArCH(17)), 119.87 (ArCH), 122.47 
(ArCH), 123.22 (ArCH(20)),  123.38 (ArCH(18)), 126.87 (ArC), 128.03 (ArCH(25)), 
128.39 (ArCH(24)), 128.61 (ArCH(23)), 129.71 (ArCH), 131.85 (ArC), 134.57 
(ArCH(16)), 135.51 (ArC), 136.28 (ArC), 144.44 (ArC), 148.50 (ArC), 173.44 (C=O(13)) 
Rf 0.15 (9:1, CH2Cl2:MeOH) 
[α]D
25  −2.0 (c 1.0, MeOH) 
IR ʋ/ cm-1 1174 (C-O, s), 1346 (NO2, s), 1525 (NO2, s), 1727 (C=O, s), 2116 (Ar C-H, w), 
3396 (N-H, m) 
MS (ESI): 428 [M+H+] 
HRMS C25H22N3O4 [M+H
+] requires 428.1605, found 428.1602 (0.7 ppm error) 
Cis (1S, 3S) diastereoisomer (LVT10-2)  
mp 177–179 ºC  
1H NMR (300 MHz, CDCl3) δ 3.02 (1H, ddd, J 15.1, 11.2, 2.5 Hz, CH2(10a)), 3.27 (1H, ddd, 
J 15.1, 4.1, 2.5 Hz, CH2(10b)), 4.01 (1H, dd, J 11.2, 4.1 Hz, CH(11)), 5.23 (1H, d, J 12.2 
Hz, CH2(21a)), 5.29 (1H, d, J 12.2 Hz, CH2(21b)), 5.33 (1H, s, CH(14)), 7.12–7.24 (3H, m, 
ArCH(1,2)), 7.35–7.45 (5H, m, ArCH(23,24,25)), 7.54 (1H, dd, J 8.1, 7.6 Hz, ArCH(17)), 
7.57 (1H, d, J 7.6 Hz, ArCH), 7.76 (1H, d, J 7.6 Hz, ArCH(16)), 8.23 (1H, d, J 7.6 Hz, 
ArCH(18)), 8.29 (1H, s, ArCH(20)) 
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13C NMR (75 MHz, CDCl3) δ 25.47 (CH2(10)), 56.70 (s, CH(14)), 58.09 (CH(11)), 67.14 
(CH2(21)), 109.57 (ArC), 111.05 (ArCH), 118.49 (ArCH(17)), 119.93 (ArCH), 122.41 
(ArCH), 123.63 (ArCH(20)),  123.70 (ArCH(18)), 126.89 (ArC), 128.46 (ArCH(25)), 
128.51 (ArCH(24)), 128.73 (ArCH(23)), 130.02 (ArCH), 133.09 (ArC), 134.96 
(ArCH(16)), 135.03 (ArC), 136.35 (ArC), 143.24 (ArC), 148.46 (ArC), 172.36 (C=O(13)) 
Rf  0.35 (9:1, CH2Cl2:MeOH) 
[α]D
25  +2.0 (c 1.0, MeOH) 
IR ʋ/ cm-1 1138 (C-O, s), 1346 (NO2, s), 1515 (NO2, s), 1715 (C=O, s), 2325 (Ar C-H, w), 
3402 (N-H, m) 
MS (ESI): 428 [M+H+]  
HRMS C25H22O4N3 [M+H
+] requires 428.1605, found 428.1599 (1.4 ppm error) 
 
Preparation of Benzyl 1-(4-(trifluoromethyl)phenyl)-2,3,4,9-tetrahydro-1H-pyrido-[3,4-
b]indol-3-carboxylate (LVT15-1,2): 
 
 
 
 
 
Following method A using (S)-Benzyl 2-amino-3-(1H-indol-3yl)propanoate (LVT14) (100 
mg, 0.34 mmol, 1 eq.) and 4-(trifluoromethyl) benzaldehyde (0.06 mL, 76.5 mg, 0.41 mmol, 
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1.25 eq.) as starting materials. The desired product was purified using column 
chromatography (SiO2, 19:1, CH2Cl2:Et2O), to afford, eluting first, the trans diastereoisomer 
as a colourless solid (44 mg, 0.10 mmol, 29%) and, eluting second, the cis diastereoisomer 
as a colourless solid (49 mg, 0.11 mmol, 32%). 
Following method B using (S)-Benzyl 2-amino-3-(1H-indol-3yl)propanoate (LVT14) (500 
mg, 1.70 mmol, 1 eq.) and 4-(trifluoromethyl) benzaldehyde (0.29 mL, 370 mg, 2.13 mmol, 
1.25 eq.) as starting materials. The desired product was purified using column 
chromatography (SiO2, 19:1 CH2Cl2:Et2O), to afford, eluting first, the trans diastereoisomer 
as a colourless solid (279 mg, 0.62 mmol, 36%) and, eluting second, the cis diastereoisomer 
as a colourless solid (309 mg, 0.69 mmol, 41%). 
Trans (1R, 3S) diastereoisomer (LVT15-1)  
mp 78−81 ºC 
1H NMR (300 MHz, CDCl3) δ 3.21 (1H, dd, J 15.5, 5.4 Hz, CH2(10a)), 3.30 (1H, dd, J 15.5, 
6.1 Hz, CH2(10b)), 4.00 (1H, dd, J 6.1, 5.4 Hz, CH(11)), 5.12 (1H, d, J 12.4 Hz, CH2(20a), 
5.18 (1H, d, J 12.4 Hz, CH2(20b)), 5.47 (1H, s, CH(14)), 7.11–7.21 (3H, m, ArCH(1,2)), 
7.23–7.32 (5H, m, ArCH(22,23,24)), 7.40 (1H, d, J 8.0 Hz, ArCH), 7.53 (2H, d, J 8.0 Hz, 
ArCH(16)), 7.58 (2H, d, J 8.0 Hz, ArCH(17)) 
13C NMR (75 MHz, CDCl3) δ 24.61 (s, CH2(10)), 52.94 (s, CH(14)), 54.45 (s, CH(11)), 
66.80 (s, CH2(20)), 110.98 (s, ArC), 111.0 (s, ArCH), 118.43 (s, ArCH), 119.77 (s, ArCH), 
122.30 (s, ArCH), 125.73 (q, 3JC-F 3.6 Hz, ArCH(17)), 126.80 (s, ArC), 128.07 (s, 
ArCH(24)), 128.37 (q, 1JC-F 272 Hz, CF3(19)), 128.43 (q, 
2JC-F 32 Hz, ArC(18)), 128.51 (s, 
ArCH(16)), 128.61 (s, ArCH(23)), 128.83 (s, ArCH(22)), 131.59 (s, ArC), 134.36 (s, ArC), 
135.53 (s, ArC), 137.89 (s, ArC), and 173.15 (s, C=O(13)) 
19F NMR (376 MHz, CDCl3) δ −62.5 (s, Ar-CF3(19)) 
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Rf 0.20 (9:1, CH2Cl2:MeOH) 
[α]D
25  −4.0 (c 1.0, MeOH) 
IR ʋ/ cm-1 1164 (C-O, s), 1728 (C=O, s), 3062 (Ar C-H, w), 3391 (N-H, m) 
MS (ESI): 451 [M+H+] 
HRMS C26H22F3N2O2 [M+H
+] requires 451.1628, found 451.1619 (2.0 ppm error) 
Cis (1S, 3S) diastereoisomer (LVT15-2)  
mp 168−171 ºC 
1H NMR (300 MHz, CDCl3) δ 3.00 (1H, dd, J 15.1, 11.1 Hz, CH2(10a)), 3.23 (1H, dd, J 
15.1, 4.1 Hz, CH2(10b)), 3.99 (1H, dd, J 11.1, 4.1 Hz, CH(11)), 5.22 (1H, d, J 12.2 Hz, 
CH2(20a)), 5.27 (1H, d, J 12.2 Hz, CH2(20b)), 5.28 (1H, s, CH(14)), 7.11–7.24 (3H, m, 
ArCH(1,2)), 7.32–7.41 (5H, m, ArCH(22,23,24)), 7.50 (2H, d, J 8.2 Hz, ArCH(16)), 7.54 
(1H, d, J 6.6 Hz, ArCH), 7.61 (2H, d, J 8.2 Hz, ArCH(17)) 
13C NMR (75 MHz, CDCl3) δ 25.57 (s, CH2(10)), 56.80 (s, CH(14)), 58.29 (s, CH(11)), 
67.09 (s, CH2(20)), 109.23 (s, ArC), 111.01 (s, ArCH), 118.40 (s, ArCH), 119.84 (s, ArCH), 
122.26 (s, ArCH), 125.88 (q, 3JC-F 3.7 Hz, ArCH(17)), 126.95 (s, ArC), 128.46 (s, 
ArCH(24)), 128.53 (ArCH(16)), 128.72 (s, ArCH(23)), 129.10 (s, ArCH(22)), 130.51 (q, 
1JC-F 267 Hz, CF3(19)), 131.05 (q,
 2JC-F 32 Hz, ArC(18)), 133.69 (s, ArC), 135.45 (s, ArC), 
136.24 (s, ArC), 172.49 (s, C=O(13)) 
19F NMR (376 MHz, CDCl3) δ −62.5 (s, Ar-CF3(19)) 
Rf 0.43 (9:1, CH2Cl2:MeOH) 
[α]D
25  +4.0 (c 1.0, MeOH) 
IR ʋ/ cm-1 1164 (C-O, s), 1731 (C=O, s), 3062 (Ar C-H, w), 3392 (N-H, m) 
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MS (ESI): 451 [M+H+]  
HRMS C26H22F3N2O2 [M+H
+] requires 451.1628, found 451.1618 (2.2 ppm error) 
 
Preparation of Benzyl 1-(3-(trifluoromethyl)phenyl)-2,3,4,9-tetrahydro-1H-pyrido-[3,4-
b]indol-3-carboxylate (LVT16-1,2): 
 
 
 
 
 
Following method A using (S)-Benzyl 2-amino-3-(1H-indol-3yl)propanoate (LVT14) (100 
mg, 0.34 mmol, 1 eq.) and 3-(trifluoromethyl) benzaldehyde (0.05 mL, 65.1 mg, 0.41 mmol, 
1.25 eq.) as starting materials. The desired product was purified using column 
chromatography (SiO2, 19:1, CH2Cl2:Et2O), to afford, eluting first, the trans diastereoisomer 
as a colourless solid (39 mg, 0.09 mmol, 26%) and, eluting second, the cis diastereoisomer 
as a colourless solid (35 mg, 0.08 mmol, 23%). 
Following method B using (S)-Benzyl 2-amino-3-(1H-indol-3yl)propanoate (LVT14) (500 
mg, 1.70 mmol, 1 eq.) and 3-(trifluoromethyl) benzaldehyde (0.28 mL, 364 mg, 2.13 mmol, 
1.25 eq.) as starting materials. The desired product was purified using column 
chromatography (SiO2, 19:1 CH2Cl2:Et2O), to afford, eluting first, the trans diastereoisomer 
as a colourless solid (267 mg, 0.59 mmol, 35%) and, eluting second, the cis diastereoisomer 
as a colourless solid (281 mg, 0.62 mmol, 36%). 
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Trans (1R, 3S) diastereoisomer (LVT16-1) 
mp 171−173 ºC 
1H NMR (300 MHz, CDCl3) δ 3.23 (1H, dd, J 15.6, 5.6 Hz, CH2(10a)), 3.31 (1H, dd, J 15.6, 
5.6 Hz, CH2(10b)), 4.03 (1H, dd, J 5.6, 5.6 Hz, CH(11)), 5.14 (1H, d, J 9.3 Hz, CH2(22a)), 
5.19 (1H, d, J 9.3 Hz, CH2(22b)), 5.48 (1H, s, CH(14)), 7.11–7.21 (3H, m, ArCH(1,2)), 
7.25–7.31 (6H, m, ArCH(16,24,25,26)), 7.44–7.47 (2H, m, ArCH(17)), 7.56–7.60 (2H, m, 
ArCH(18,20)) 
13C NMR (75 MHz, CDCl3) δ 24.49 (s, CH2(10)), 53.14 (s, CH(14)), 54.51 (s, CH(11)), 
66.78 (s, CH2(22)), 110.99 (s, ArC), 110.95 (s, ArCH), 118.45 (s, ArCH), 119.73 (s, ArCH), 
122.26 (s, ArCH), 124.00 (q, 1JC-F 272 Hz, CF3(21)), 125.14 (2C, dq, 
3JC-F 3.8 Hz, 
ArCH(18,20)), 127.10 (s, ArC), 128.05 (s, ArCH(26)), 128.53 (s, ArCH(25)), 128.61 (s, 
ArCH(24)), 129.26 (s, ArCH), 131.17 (q, 2JC-F 32 Hz, ArC(19)), 131.83 (s, ArC), 132.43 (s, 
ArC), 135.63 (s, ArC), 136.28 (s, ArC), 143.20 (s, ArC), 173.50 (s, C=O(13)) 
19F NMR (376 MHz, CDCl3) δ −62.4 (s, Ar-CF3(21)) 
Rf 0.25 (9:1, CH2Cl2:MeOH) 
[α]D
25  +4.0 (c 1.0, MeOH) 
IR ʋ/ cm-1 1166 (C-O, s), 1721 (C=O, s), 3033 (Ar C-H, w), 3354 (N-H, m) 
MS (ESI): 451 [M+H+]  
HRMS C26H22F3N2O2 [M+H
+] requires 451.1628, found 451.1624 (0.9 ppm error) 
Cis (1S, 3S) diastereoisomer (LVT16-2)  
mp 77−79 ºC 
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1H NMR (300 MHz, CDCl3) δ 3.04 (1H, ddd, J 15.2, 11.1, 2.3 Hz, CH2(10a)), 3.27 (1H, ddd, 
J 15.2, 4.3, 2.3 Hz, CH2(10b)), 4.01 (1H, dd, J 11.1, 4.3 Hz, CH(11)), 5.24 (1H, d, J 8.5 Hz, 
CH2(22a)), 5.29 (1H, d, J 8.5 Hz, CH2(22b)), 5.31 (1H, s, CH(14)), 7.12–7.52 (3H, m, 
ArCH), 7.34–7.42 (5H, m, ArCH(24,25,26)), 7.46–7.64 (4H, m, ArCH(16,17,18)), 7.68 
(1H, s, ArCH(20)) 
13C NMR (75 MHz, CDCl3) δ 25.57 (s, CH2(10)), 56.89 (s, CH(14)), 58.45 (s, CH(11)), 
67.03 (s, CH2(22)), 109.36 (s, ArCH), 111.0 (s, ArCH), 118.38 (s, ArCH), 119.83 (s, ArCH), 
122.24 (s, ArCH), 123.94 (q, 1JC-F 272 Hz, CF3(21)), 125.44 (2C, q, 
3JC-F 3.6 Hz, 
ArCH(18,20)), 127.03 (s, ArC), 128.40 (s, ArCH), 128.43 (s, ArCH), 128.68 (s, ArCH), 
129.50 (s, ArCH), 131.326 (q, 2JC-F 32 Hz, ArC(19)), 132.10 (s, ArC), 134.72 (s, ArC), 
135.51 (s, ArC), 136.31 (s, ArC), 141.96 (s, ArC), 172.44 (s, C=O(13)) 
19F NMR (376 MHz, CDCl3) δ −62.4 (s, Ar-CF3(21)) 
Rf 0.45 (9:1, CH2Cl2:MeOH) 
[α]D
25  −4.0 (c 1.0, MeOH) 
IR ʋ/ cm-1 1166 (C-O, s), 1721 (C=O, s), 3033 (Ar C-H, w), 3354 (N-H, m) 
MS (ESI): 451 [M+H+] 
HRMS C26H22F3N2O2 [M+H
+] requires 451.1628, found 451.1616 (2.6 ppm error) 
 
Preparation of Methyl 1-(2,4-bis(trifluoromethyl)phenyl)-2,3,4,9-tetrahydro-1H-pyrido-
[3,4-b]indol-3-carboxylate (LVT19-1,2): 
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Following method A using (S)-Methyl 2-amino-3-(1H-indol-3yl)propanoate (500 mg, 2.29 
mmol, 1 eq.) and 2,4-bis(trifluoromethyl) benzaldehyde (0.45 mL, 666 mg, 2.86 mmol, 1.25 
eq.) as starting materials. The desired product was purified using column chromatography 
(SiO2, 98:2, CH2Cl2:MeOH), to afford, eluting first, the trans diastereoisomer as a colourless 
solid (427 mg, 0.97 mmol, 42%) and, eluting second, the cis diastereoisomer as a colourless 
solid (80 mg, 0.09 mmol, 8%). 
Following method B using (S)-Methyl 2-amino-3-(1H-indol-3yl)propanoate (500 mg, 2.29 
mmol, 1 eq.) and 2,4-bis(trifluoromethyl) benzaldehyde (0.45 mL, 666 mg, 2.86 mmol, 1.25 
eq.) as starting materials. The desired product was purified using column chromatography 
(SiO2, 100% CH2Cl2), to afford, eluting first, the trans diastereoisomer as a colourless solid 
(371 mg, 0.84 mmol, 37%) and, eluting second, the cis diastereoisomer as a colourless solid 
(405 mg, 0.92 mmol, 40%). 
Trans (1R, 3S) diastereoisomer (LVT19-1)  
mp 136−138 ºC 
1H NMR (300 MHz, CDCl3) δ 3.28 (1H, dd, J 15.9, 5.1 Hz, CH2(10a)), 3.34 (1H, dd, J 15.9, 
5.1 Hz, CH2(10b)), 3.71 (3H, s, CH3(23)), 4.05 (1H, dd, J 5.1, 5.1 Hz, CH(11)), 5.98 (1H, s, 
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CH(14)), 7.12–7.25 (3H, m, ArCH(1,2)), 7.46 (1H, s, NH(7)), 7.51 (1H, d, J 8.1, ArCH(16)), 
7.58 (1H, d, J 7.1, ArCH), 7.69 (1H, d, J 8.1, ArCH(17)), 7.99 (1H, s, ArCH(19)) 
13C NMR (75 MHz, CDCl3) δ 24.02 (s, CH2(10)), 49.85 (s, OCH3(23)), 52.22 (s, CH(14)), 
53.27 (s, CH(11)), 109.10 (s, ArC), 111.01 (s, ArCH), 118.50 (s, ArCH), 119.87 (s, ArC), 
122.16 (q, 1JC-F 272 Hz, ArCF3), 122.52 (s, ArCH), 123.03 (q, 
3JC-F 9.7 Hz, ArCH(19)), 
123.80 (q, 1JC-F 274 Hz, ArCF3), 126.73 (s, ArC), 128.95 (q, 
3JC-F 9.7 Hz, ArCH(17)), 129.72 
(q, 2JC-F 33 Hz, ArC(20)), 130.23 (q, 
2JC-F 33 Hz, ArC(18)), 131.61 (s, ArCH), 132.22 (s, 
ArCH), 136.41 (s, ArC), 145.21 (s, ArC), 173.82 (s, C=O(13)) 
19F NMR (376 MHz, CDCl3) δ −57.7 (s, Ar-CF3) and −62.9 (s, Ar-CF3) 
Rf 0.59 (19:1, CH2Cl2:Et2O) 
[α]D
25  −31.0 (c 1.0, MeOH)  
IR ʋ/ cm-1 1164 (C-O, s), 1723 (C=O, s), 3047 (Ar C-H, w), 3387 (N-H, m)  
MS (ESI): 443 [M+H+]  
HRMS C21H17F6N2O2 [M+H
+] requires 443.1189, found 443.1184 (1.1 ppm error) 
Analysis calculated for C21H15F6N2O2: C, 57.0%; H, 5.65%; N 6.33%. Found C, 56.8%; H, 
5.31%; N, 6.09%. 
Cis (1S, 3S) diastereoisomer (LVT19-2)  
1H NMR (300 MHz, CDCl3) δ 3.07 (1H, ddd, J 15.1, 11.9, 2.9 Hz, CH2(10a)), 3.28 (1H, dd, 
J 15.1, 5.2 Hz, CH2(10b)), 3.83 (3H, s, OCH3(23)), 4.01 (1H, dd, J 11.9, 5.2 Hz, CH(11)), 
5.75 (1H, s, CH(14)), 7.11–7.22 (3H, m, ArCH(1,2)), 7.35 (1H, s, NH), 7.56 (1H, d, J 8.2, 
ArCH), 7.72 (1H, d, J 8.2, ArCH(16)), 7.78 (1H, d, J 8.2, ArCH(17)), 7.98 (1H, s, 
ArCH(19)) 
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13C NMR (75 MHz, CDCl3) δ 25.35 (s, CH2(10)), 52.39 (s, OCH3(23)), 53.34 (s, CH(14)), 
56.54 (s, CH(11)), 109.79 (s, ArC), 111.04 (s, ArCH), 118.43 (s, ArCH), 119.99 (s, sArCH), 
123.23 (q, 1JC-F 272 Hz, ArCF3), 123.77 (q, 
1JC-F 274 Hz, ArCF3), 122.49 (s, ArCH), 122.62 
(q, 3JC-F 10 Hz, ArCH(19)), 126.75 (s, ArC), 129.32 (q, 
3JC-F 8.1 Hz, ArCH(17)), 129.74 (q, 
2JC-F 32 Hz, ArC), 130.64 (q, 
2JC-F 33 Hz, ArC), 132.96 (s, ArCH), 133.08 (s, ArC), 136.49 
(s, ArC), 144.66 (s, ArC), 172.69 (s, C=O(13)) 
19F NMR (376 MHz, CDCl3) δ −57.4 (s, Ar-CF3) and −62.9 (s, Ar-CF3) 
Rf 0.41 (19:1, CH2Cl2:Et2O) 
[α]D
29 +31.0 (c 1.0, MeOH) 
IR ʋ/ cm-1 1168 (C-O, s), 1731 (C=O, s), 3060 (Ar C-H, w), 3383 (N-H, m) 
MS (ESI): 443 [M+H+]  
HRMS C21H17F6N2O2 [M+H
+] requires 443.1189, found 443.1181 (1.7 ppm error) 
 
Preparation of Methyl 1-(2-(trifluoromethyl)phenyl)-2,3,4,9-tetrahydro-1H-pyrido-[3,4-
b]indol-3-carboxylate (LVT20-1,2): 
 
 
 
 
Following method A using (S)-Methyl 2-amino-3-(1H-indol-3yl)propanoate (500 mg, 2.29 
mmol, 1 eq.) and 2-(trifluoromethyl)benzaldehyde (0.36 mL, 475 mg, 2.86 mmol, 1.25 eq.) 
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as starting materials. The desired product was purified using column chromatography (SiO2, 
9:1, CH2Cl2:Et2O), to afford, eluting first, the trans diastereoisomer as a colourless solid 
(149 mg, 0.41 mmol, 18%) and, eluting second, the cis diastereoisomer as an opaque glass 
solid (85 mg, 0.23 mmol, 10%). 
Following method B using (S)-Methyl 2-amino-3-(1H-indol-3yl)propanoate (500 mg, 2.29 
mmol, 1 eq.) and 2-(trifluoromethyl)benzaldehyde (0.36 mL, 475 mg, 2.86 mmol, 1.25 eq.) 
as starting materials. The desired product was purified using column chromatography (SiO2, 
9:1, CH2Cl2:Et2O), to afford, eluting first, the trans diastereoisomer as a colourless solid 
(317 mg, 0.85 mmol, 37%) and, eluting second, the cis diastereoisomer as a light yellow 
solid (326 mg, 0.87 mmol, 38%). 
Trans (1R, 3S) diastereoisomer (LVT20-1)  
mp 85–87 ºC 
1H NMR (300 MHz, CDCl3) δ 3.24 (1H, dd, J 15.4, 5.4 Hz, CH2(10a)), 3.33 (1H, dd, J 15.4, 
5.4 Hz, CH2(10b)), 3.72 (3H, s, OCH3(22)), 4.04 (1H, dd, J 5.4, 5.4 Hz, CH(11)), 5.91 (1H, 
s, CH(14)), 7.10–7.24 (3H, m, ArCH(1,2,3)), 7.29 (1H, d, J 6.8 Hz, ArCH(16)), 7.40–7.44 
(2H, m, ArCH(17,18)), 7.48 (1H, s, NH), 7.58 (1H, d, J 5.6 Hz, ArCH), 7.74 (1H, d, J 6.8 
Hz, ArCH) 
13C NMR (75 MHz, CDCl3) δ 24.12 (s, CH2(10)), 50.05 (s, OCH3(22)), 52.23 (s, CH(14)), 
53.08 (s, CH(11)), 108.87 (s, ArC), 110.94 (s, ArCH), 118.39 (s, ArCH), 119.64 (s, ArCH), 
122.17 (s, ArCH), 123.61 (q, 1JC-F 272 Hz, CF3(21)), 125.89 (q, 
3JC-F 10 Hz s, ArCH(19)), 
126.80 (s, ArCH), 128.06 (s, ArCH), 131.03 (s, ArCH), 132.27 (s, ArC), 132.66 (q, 2JC-F 25 
Hz, ArC(20)), 134.72 (s, ArC), 136.26 (s, ArC), 140.62 (s, ArC), 173.93 (s, C=O(13))  
19F NMR (376 MHz, CDCl3) δ −57.4 (s, Ar-CF3(21)) 
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Rf 0.24 (19:1, CH2Cl2:Et2O) 
[α]D
27  +11.0 (c 1.0, MeOH) 
IR ʋ/ cm-1 1160 (C-O, s), 1713 (C=O, s), 3070 (Ar C-H, w), 3390 (N-H, m)  
MS (ESI): 375 [M+H+]  
HRMS C20H18F3N2O2 [M+H
+] requires 375.1315, found 375.1314 (0.2 ppm error) 
Cis (1S, 3S) diastereoisomer (LVT20-2)  
mp 93–96 ºC 
1H NMR (300 MHz, CDCl3) δ 3.06 (1H, ddd, J 15.1, 11.1 Hz, CH2(10a)), 3.26 (1H, ddd, J 
15.1, 4.0 Hz, CH2(10b)), 3.80 (3H, s, OCH3(22)), 3.99 (1H, dd, J 11.1, 4.0 Hz, CH(11)), 
5.68 (1H, s, CH(14)), 7.08–7.20 (3H, m, ArCH(1,2)), 7.42 (1H, s, NH), 7.38–7.48 (2H, m, 
ArCH), 7.53–7.57 (2H, m, ArCH(17)), 7.72 (1H, d, J 8.1 Hz, ArCH(16)) 
13C NMR (75 MHz, CDCl3) δ 25.46 (s, CH2(10)), 52.39 (s, OCH3(22)), 53.59 (s, CH(14)), 
56.75 (s, CH(11)), 109.31 (s, ArC), 111.01 (s, ArCH), 118.32 (s, ArCH), 119.76 (s, ArCH), 
122.14 (s, ArCH), 124.55 (q, 1JC-F 274 Hz, CF3(21)), 125.41 (q, 
3JC-F 5.8 Hz s, ArCH(19)), 
126.85 (s, ArC), 128.30 (s, ArCH), 129.15 (q, 2JC-F 30 Hz, ArC(20)), 131.64 (s, ArCH), 
132.69 (s, ArCH), 134.61 (s, ArC), 136.29 (s, ArC), 140.08 (s, ArC), 172.97 (s, C=O(13)) 
19F NMR (376 MHz, CDCl3) δ −57.1 (s, Ar-CF3(21)) 
Rf 0.35 (19:1, CH2Cl2:Et2O) 
[α]D
27  −11.0 (c 1.0, MeOH) 
IR ʋ/ cm-1 1163 (C-O, s), 1732 (C=O, s), 3060 (Ar C-H, w), 3396 (N-H, m) 
MS (ESI): 375 [M+H+]  
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HRMS C20H18F3N2O2 [M+H
+] requires 375.1315, found 375.1313 (0.5 ppm error) 
 
Preparation of Methyl 1-(2-acetamido-5-chlorophenyl)-2,3,4,9-tetrahydro-1H-pyrido-[3,4-
b]indol-3-carboxylate (LVT24-1,2): 
 
 
 
 
 
Following method A using (S)-Methyl 2-amino-3-(1H-indol-3yl)propanoate (500 mg, 2.29 
mmol, 1 eq.) and 2-acetamido-5-chlorobenzaldehyde (LVT23) (565 mg, 2.86 mmol, 1.25 
eq.) as starting materials. The desired product was purified using column chromatography 
(SiO2, 3:1 CH2Cl2:Et2O), to afford, eluting first, the trans diastereoisomer as an off-white 
solid (178 mg, 0.45 mmol, 20%) and eluting second, the cis diastereoisomer as an off-white 
solid (98 mg, 0.25 mmol, 11%). 
Trans (1S, 3S) diastereoisomer (LVT24-1)  
mp 121–124 °C 
1H NMR (400 MHz, CDCl3) δ 1.87 (3H, s, CH3(23)), 3.23 (1H, dd, J 15.5, 5.2 Hz, CH2(10a)), 
3.33 (1H, dd, J 15.5, 5.2 Hz, CH2(10b)), 3.73 (3H, s, OCH3(23)), 4.04 (1H, dd, J 5.2, 5.2 Hz, 
CH(11)), 5.45 (1H, s, CH(14)), 7.12–7.29 (5H, m, ArCH(1,2,3,6,16)), 7.52 (1H, d, J 7.6 Hz, 
ArCH(19)), 7.79 (1H, br. s, NH), 8.03 (1H, d, J 7.6 Hz, ArCH(18)) 9.81 (1H, s, NH) 
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13C NMR (400 MHz, CDCl3) δ 24.19 (CH3(23)), 24.43 (CH2(10)), 30.40 (CH3(24)), 52.48 
(CH(14)), 53.43 (CH(11)), 107.55 (ArC), 111.43 (ArCH), 118.22 (ArCH(19)), 119.87 
(ArCH), 122.59 (ArCH), 124.37 (ArCH(18)), 125.62 (ArC), 126.75 (ArC), 129.22 (ArCH), 
129.62 (ArCH(16)), 130.59 (ArC), 131.17 (ArC), 136.19 (ArC), 136.61 (ArC), 168.48 
(C=O(22)), 173.64 (C=O(13))  
Rf 0.24 (3:1, CH2Cl2:Et2O) 
[α]D
25  −12.0 (c 1.0, MeOH) 
IR ʋ/ cm-1 741 (C-Cl, s), 1130 (C-O, s), 1672 (C=O, s), 1728 (C=O, s), 2997 (Ar C-H, w), 
3395 (N-H, m) 
MS (ESI): 398/400 [M+H+]  
HRMS C21H21
35ClN3O2 [M+H
+] requires 398.1266, found 398.1267 (0.3 ppm error) 
Cis (1R, 3S) diastereoisomer (LVT24-2)  
mp 103–107 °C 
1H NMR (400 MHz, CDCl3) δ 1.66 (3H, s, CH3(23)), 3.00 (1H, ddd, J 15.4, 11.2 Hz, 
CH2(10a)), 3.36 (1H, ddd, J 15.4, 4.1 Hz, CH2(10b)), 3.87 (3H, s, OCH3(24)), 3.95 (1H, dd, 
J 11.2, 4.1 Hz, CH(11)), 5.28 (1H, s, CH(14)), 7.11–7.21 (3H, m, ArCH(1,2)), 7.33–7.35 
(2H, m, ArCH(6,16)), 7.51 (1H, d, J 6.9 Hz, ArCH), 8.06 (1H, d, J 8.6 Hz, ArCH), 9.75 
(1H, br. s, NH) 
13C NMR (100 MHz, CDCl3) δ 24.03 (CH3(23)), 25.41 (CH2(10)), 30.34 (CH3(24)), 52.59 
(CH(14)), 56.66 (CH(11)), 108.05 (ArC), 111.41 (ArCH), 117.95 (ArCH(19)), 119.99 
(ArCH), 122.50 (ArCH(18)), 124.53 (ArC), 125.19 (ArCH), 126.63 (ArC), 129.55 (ArCH), 
129.70 (ArCH(16)), 132.13 (ArC), 136.32 (ArC), 136.84 (ArC), 168.24 (C=O(22)), 172.33 
(C=O(13))  
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Rf 0.45 (3:1, CH2Cl2:Et2O) 
[α]D
25  +12.0 (c 1.0, MeOH) 
IR ʋ/ cm-1 741 (C-Cl, s), 1126 (C-O, s), 1665 (C=O, s), 1739 (C=O, s), 3013 (Ar C-H, w), 
3384 (N-H, m) 
MS (ESI): 398/400 [M+H+] 
HRMS C21H21
35ClN3O2 [M+H
+] requires 398.1266, found 398.1265 (0.2 ppm error) 
 
Preparation of (3S)-N-Benzyl-1-(4-(trifluoromethyl)phenyl)-2,3,4,9-tetrahydro-1H-
pyrido[3,4-b]indole-3-carboxamide (LVT27-1,2):  
 
 
 
 
 
Following method A using (S)-2-Amino-N-benzyl-3-(1H-indol-3-yl) propanamide (LVT26) 
(100 mg, 0.34 mmol, 1 eq.) and 4-(trifluoromethyl) benzaldehyde (0.05 mL, 64 mg, 0.37 
mmol, 1.25 eq.) as starting materials. The desired product was purified using column 
chromatography (SiO2, 9:1 CH2Cl2:Et2O), to afford, eluting first the trans diastereoisomer 
as an off-white solid (15 mg, 0.03 mmol, 9%) and, eluting second the cis diastereoisomer as 
an off-white solid (79 mg, 0.18 mmol, 53%). 
Following method B using (S)-2-Amino-N-benzyl-3-(1H-indol-3-yl) propanamide (LVT26) 
(500 mg, 1.70 mmol, 1 eq.) and 4-(trifluoromethyl) benzaldehyde (0.29 mL, 370 mg, 2.13 
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mmol, 1.25 eq.) as starting materials. The desired product was purified using column 
chromatography (SiO2, 9:1 CH2Cl2:Et2O), to afford, eluting first the trans diastereoisomer 
as an off-white solid (156 mg, 0.35 mmol, 21%) and eluting second the cis diastereoisomer 
as an off-white solid (161 mg, 0.36 mmol, 21%). 
Trans (1R, 3S) diastereoisomer (LVT27-1) 
mp 237–240 °C 
1H NMR (300 MHz, CDCl3) δ 2.97 (1H, dd, J 16.2, 9.8 Hz, CH2(10a)), 3.39 (1H, dd, J 16.2, 
4.9 Hz, CH2(10b)), 3.62 (1H, dd, J 9.8, 4.9 Hz, CH(11)), 5.42 (1H, dd, J 15.3 Hz, CH2(21a)), 
5.44 (1H, dd, J 15.3 Hz, CH2(21b)), 5.31 (1H, s, CH(14)), 7.15–7.20 (3H, m, ArCH(1,2)), 
7.23–7.33 (5H, m, ArCH(23,24,25)), 7.35 (2H, d, J 7.1 Hz, ArCH(16)), 7.60 (1H, d, J 7.1 
Hz, ArCH), 7.70 (2H, d, J 7.1 Hz, ArCH(17))  
13C NMR (100 MHz, CDCl3) δ 25.64 (s, CH2(10)), 43.24 (s, CH2(21)), 58.16 (s, CH(14)), 
58.66 (s, CH(11)), 77.32 (s, CH2(23)), 110.52 (s, ArC), 111.01 (s, ArCH), 118.58 (s, ArCH), 
119.96 (s, ArCH), 122.49 (s, ArCH), 123.80 (q, 1JC-F 272 Hz, CF3(19)), 126.11 (q, 
3JC-F 5.8 
Hz, ArCH(17)), 127.60 (s, ArCH), 128.00 (s, ArCH), 128.76 (s, ArCH), 129.03 (s, ArCH), 
130.06 (s, ArC), 131.90 (q, 2JC-F 32 Hz, ArC(18)), 133.35 (s, ArC), 136.32 (s, ArC), 138.21 
(s, ArC), 144.45 (s, ArC), 172.29 (s, C=O(13)) 
19F NMR (376 MHz, CDCl3) δ −62.5 (s, Ar-CF3(19)) 
Rf 0.18 (9:1, CH2Cl2:Et2O) 
[α]D
25  +30.0 (c 1.0, MeOH) 
IR ʋ/ cm-1 1363 (C-O, s), 1656 (C=O, s), 3066 (Ar C-H, w), 3271 (N-H, m) 
MS (ESI): 450 [M+H+]  
HRMS C26H23F3N3O [M+H
+] requires 450.1788, found 450.1786 (0.4 ppm error) 
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Cis (1S, 3S) diastereoisomer (LVT27-2) 
mp 97–101 °C 
1H NMR (300 MHz, CDCl3) δ 2.92 (1H, ddd, J 15.7, 11.2 Hz, CH2(10a)), 3.41 (1H, ddd, J 
15.7, 4.4 Hz, CH2(10b)), 3.82 (1H, dd, J 11.2, 4.4 Hz, CH(11)), 4.44 (1H, dd, J 14.7, 6.1 Hz, 
CH2(21a)), 4.53 (1H, dd, J 14.7, 6.1 Hz, CH2(21b)), 5.27 (1H, s, CH(14)), 7.12–7.20 (3H, 
m, ArCH(1,2)), 7.27–7.37 (5H, m, ArCH(23,24,25)), 7.45 (2H, d, J 8.1 Hz, ArCH(16)), 7.58 
(1H, d, J 7.0 Hz, ArCH), 7.64 (2H, d, J 8.1 Hz, ArCH(17))  
13C NMR (75 MHz, CDCl3) δ 24.84 (s, CH2(10)), 43.34 (s, CH2(21)), 52.52 (s, sCH(14)), 
55.11 (s, CH(11)), 77.25 (s, CH2(23)), 110.93 (s, ArC), 111.08 (s, ArCH), 118.73 (s, ArCH), 
120.03 (s, ArCH), 122.69 (s, ArCH), 125.58 (q, 1JC-F 272 Hz, CF3(19)), 126.61 (q, 
3JC-F 5.8 
Hz, ArCH(17)), 127.49 (s, ArCH), 127.54 (s, ArCH), 127.62 (s, ArCH), 128.77 (s, ArCH), 
128.83 (s, ArCH), 129.09 (s, ArCH), 130.39 (q, 2JC-F 32 Hz, ArC(18)), 132.08 (s, ArC), 
136.37 (s, ArC), 138.31 (s, ArC), 139.06 (s, ArC), 145.13 (s, ArC), 172.52 (s, C=O(13)) 
19F NMR (376 MHz, CDCl3) δ −62.6 (s, Ar-CF3(19)) 
Rf 0.24 (9:1, CH2Cl2:Et2O) 
[α]D
25  −30.0 (c 1.0, MeOH) 
IR ʋ/ cm-1 1164 (C-O, s), 1652 (C=O, s), 3067 (Ar C-H, w), 3272 (N-H, m)  
MS (ESI): 450 [M+H+]  
HRMS C26H23F3N3O [M+H
+] requires 450.1788, found 450.1786 (0.4 ppm error) 
 
Preparation of (3S)-N-Benzyl-1-(3-(trifluoromethyl)phenyl)-2,3,4,9-tetrahydro-1H-
pyrido[3,4-b]indole-3-carboxamide (LVT28-1,2):  
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Following method A using (S)-2-Amino-N-benzyl-3-(1H-indol-3-yl) propanamide (LVT26) 
(85 mg, 0.29 mmol, 1 eq.) and 3-(trifluoromethyl) benzaldehyde (0.05 mL, 65 mg, 0.36 
mmol, 1.25 eq.) as starting materials. The desired product was purified using column 
chromatography (SiO2, 9:1 CH2Cl2:Et2O), to afford, eluting first the cis diastereoisomer a 
colourless glass solid (10 mg, 0.02 mmol, 8%) and, eluting second the trans diastereoisomer 
as a colourless solid (20 mg, 0.04 mmol, 15%). 
Following method B using (S)-2-Amino-N-benzyl-3-(1H-indol-3-yl) propanamide (LVT26) 
(500 mg, 1.70 mmol, 1 eq.) and 3-(trifluoromethyl) benzaldehyde (0.28 mL, 364 mg, 2.13 
mmol, 1.25 eq.) as starting materials. The desired product was purified using column 
chromatography (SiO2, 9:1 CH2Cl2:Et2O), to afford, eluting first the cis diastereoisomer as 
an off-white solid (182 mg, 0.40 mmol, 24%) and eluting second the trans diastereoisomer 
as an off-white solid (176 mg, 0.39 mmol, 23%). 
Trans (1R, 3S) diastereoisomer (LVT28-1)  
1H NMR (300 MHz, CDCl3) δ 2.97 (1H, ddd, J 16.2, 9.8 Hz, CH2(10a)), 3.39 (1H, dd, J 
16.2, 4.9 Hz, CH2(10b)), 3.62 (1H, dd, J 9.8, 4.9 Hz, CH(11)), 5.42 (1H, dd, J 15.3 Hz, 
CH2(21a)), 5.44 (1H, dd, J 15.3 Hz, CH2(21b)), 5.31 (1H, s, CH(14)), 7.15–7.20 (3H, m, 
ArCH(1,2)), 7.23–7.33 (5H, m, ArCH(23,24,25)), 7.35 (2H, d, J 7.1 Hz, ArCH(16)), 7.60 
(1H, d, J 7.1 Hz, ArCH), 7.70 (2H, d, J 7.1 Hz, ArCH(17))  
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13C NMR (400 MHz, CDCl3) δ 25.64 (s, CH2(10)), 43.24 (s, CH2(23)), 58.16 (s, CH(14)), 
58.66 (s, CH(11)), 110.52 (s, ArC), 111.01 (s, ArCH), 118.58 (s, ArCH), 119.96 (s, ArCH), 
122.49 (s, ArCH), 123.80 (q, 1JC-F 272 Hz, CF3(19)), 126.11 (q, 
3JC-F 5.8 Hz, ArCH(17)), 
127.60 (s, ArCH), 128.00 (s, ArCH), 128.76 (s, ArCH), 129.03 (s, ArCH), 130.06 (s, ArC), 
131.90 (q, 2JC-F 32 Hz, ArC(18)), 133.35 (s, ArC), 136.32 (s, ArC), 138.21 (s, ArC), 144.45 
(s, ArC), 172.29 (s, C=O(13)) 
19F NMR (376 MHz, CDCl3) δ −62.4 (s, Ar-CF3(21)) 
Rf 0.43 (5:1, CH2Cl2:Et2O) 
[α]D
25  +16.0 (c 1.0, MeOH) 
IR ʋ/ cm-1 1163 (C-O, s), 1717 (C=O, s), 2923 (Ar C-H, w), 3271 (N-H, m)  
MS (ESI): 450 [M+H+]  
HRMS C26H23F3N3O [M+H
+] requires 450.1788, found 450.1785 (0.6 ppm error) 
Cis (1S, 3S) diastereoisomer (LVT28-2)  
mp 85–88 °C 
1H NMR (300 MHz, CDCl3) δ 2.94 (1H, dd, J 15.7, 11.2 Hz, CH2(10a)), 3.45 (1H, dd, J 
15.7, 4.4 Hz, CH2(10b)), 3.85 (1H, dd, J 11.2, 4.4 Hz, CH(11)), 4.46 (1H, dd, J 14.7, 5.8 Hz, 
CH2(21a)), 4.56 (1H, dd, J 14.7, 5.8 Hz, CH2(21b)), 5.29 (1H, s, CH(14)), 7.15–7.24 (3H, 
m, ArCH), 7.28–7.35 (5H, m, ArCH), 7.49–7.65 (5H, m, ArCH) 
13C NMR (75 MHz, CDCl3) δ 25.62 (s, CH2(10)), 43.22 (s, CH2(23)), 58.22 (s, CH(14)), 
58.79 (s, CH(11)), 110.56 (s, ArC), 111.04 (s, ArCH), 118.59 (s, ArCH), 119.95 (s, ArCH), 
122.49 (s, ArCH), 123.82 (q, 1JC-F 272 Hz, CF3(19)), 125.53 (q, 
3JC-F 5.8 Hz, ArCH(17)), 
127.59 (s, ArCH), 127.99 (s, ArCH), 128.75 (s, ArCH), 129.68 (s, ArCH), 130.06 (s, ArC), 
 223 
 
131.93 (q, 2JC-F 32 Hz, ArC(18)), 133.35 (s, ArC), 136.32 (s, ArC), 138.21 (s, ArC), 144.45 
(s, ArC), 172.23 (s, C=O(13)) 
19F NMR (376 MHz, CDCl3) δ −62.46 (s, Ar-CF3(21)) 
Rf 0.61 (5:1, CH2Cl2:Et2O) 
[α]D
25  −16.0 (c 1.0, MeOH) 
IR ʋ/ cm-1 1163 (C-O, s), 1650 (C=O, s), 2988 (Ar C-H, w), 3282 (N-H, m)  
MS (ESI): 450 [M+H+]  
HRMS C26H23F3N3O [M+H
+] requires 450.1788, found 450.1784 (0.8 ppm error) 
 
Preparation of (3R)-3-Methyl-1-(4-(trifluoromethyl)phenyl)-2,3,4,9-tetrahydro-1H-
pyrido[3,4-b]indole (LVT33-1,2):  
 
 
 
 
 
4-(Trifluoromethyl)benzaldehyde (0.57 mL, 727 mg, 4.40 mmol, 2 eq.) was stirred for 0.5 h 
in a mixture of water (25 mL) and 5 drops of concentrated H2SO4. 1-(1H-Indol-3-yl)propan-
2-amine (LVT31) (443 mg, 2.19 mmol, 1 eq.) was then added to the solution and left to stir 
under reflux overnight. The solution was allowed to cool and carefully quenched with 2M 
NaOH solution (20 mL), the organics were extracted with CH2Cl2 (3 × 75 mL), washed with 
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saturated aqueous brine (100 mL), dried over MgSO4, filtered and concentrated under 
reduced pressure. The desired product purified using column chromatography (SiO2, 93:7, 
CH2Cl2/MeOH), to afford, eluting first, the 1R, 3R enantiomer as an off-white solid (91.4 
mg, 0.30 mmol, 13%) and eluting second the 1S, 3R enantiomer as an off-white solid (120 
mg, 0.40 mmol, 17%). 
1R, 3R enantiomer (LVT-331)  
mp 106–109 °C 
1H NMR (300 MHz, CDCl3) δ 1.21 (3H, d, J 6.3 Hz, CH3(19)), 2.50 (1H, dd, J 15.5, 6.3 Hz, 
CH2(13a)), 2.93 (1H, dd, J 15.5, 4.2 Hz, CH2(13b)), 3.16 (1H, dqd, J 12.7, 6.3, 4.2 Hz, 
CH(12)), 5.22 (1H, s, CH(10)), 7.11–7.20 (3H, m, ArCH(1,2)), 7.24 (1H, d, J 6.5 Hz, 
ArCH), 7.31 (2H, d, J 7.7 Hz, ArCH(15)), 7.56 (2H, d, J 7.7 Hz, ArCH(16)), 7.78 (1H, br. 
s, NH) 
13C NMR (75 MHz, CDCl3) δ 21.89 (s, CH3(19)), 29.86 (s, CH2(13)), 44.08 (s, CH(10)), 
55.29 (s, sCH(12)), 110.95 (s, ArC), 111.16 (s, ArCH), 118.37 (s, ArCH), 119.57 (s, ArCH), 
122.10 (s, ArCH), 124.08 (q, 1JC-F 272 Hz, CF3(18)), 125.45 (q, 
3JC-F 6.8 Hz, ArCH(16)), 
127.09 (s, ArC), 128.68 (ArCH(15)), 129 (q, 2JC-F  33 Hz, ArC(17)), 132.01 (s, ArC), 136.33 
(s, ArC), 146.62 (s, ArC) 
19F NMR (376 MHz, CDCl3) δ −62.4 (s, Ar-CF3(18))  
Rf 0.19 (9:1, CH2Cl2:MeOH) 
IR ʋ/ cm-1 1523 (C-F, s), 3056 (Ar C-H, w), 3353 (N-H, w) 
MS (ESI): 331 [M+H+]  
HRMS C19H18F3N2 [M+H
+] requires 331.1417, found 331.1419 (0.7 ppm error) 
1S, 3R enantiomer (LVT-332)  
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mp 124–126 °C 
1H NMR (300 MHz, CDCl3) δ 1.26 (3H, d, J 6.3 Hz, CH3(19)), 2.53 (1H, ddd, J 15.2, 8.2, 
6.3 Hz, CH2(13a)), 2.85 (1H, ddd, J 15.2, 6.3, 4.3 Hz, CH2(13b)), 3.22 (1H, dqd, J 16.5 Hz, 
8.2, 4.3 CH(12)), 5.11 (1H, s, CH(10)), 7.05–7.07 (3H, m, ArCH(1,2)), 7.32 (2H, d, J 8.0 
Hz, ArCH(15)), 7.50 (3H, m, ArCH(16)), 7.81 (1H, br. s, NH) 
13C NMR (75 MHz, CDCl3) δ 22.39 (s, CH3(19)), 30.45 (s, CH2(13)), 50.66 (s, CH(10)), 
59.00 (s, CH(12)), 110.86 (s, ArC), 110.99 (s, ArCH), 118.41 (s, ArCH), 119.57 (s, ArCH), 
120.50 (q, 3JC-F 272 Hz, CF3(16)), 121.95 (s, ArCH), 125.86 (q, 
1JC-F 6.7 Hz, ArCH(18)), 
127.16 (s, ArC), 129.11 (s, ArCH(15)), 130.58 (q, 2JC-F 32 Hz, ArC(17)), 133.91 (s, ArC), 
136.32 (s, ArC), 145.74 (s, ArC) 
19F NMR (376 MHz, CDCl3) δ −62.5 (s, Ar-CF3(18)) 
Rf 0.19 (9:1, CH2Cl2:MeOH) 
IR ʋ/ cm-1 1524 (C-F, s), 3129 (Ar C-H, w), 3357 (N-H, w) 
MS (ESI): 331 [M+H+] 
HRMS C19H18F3N2 [M+H
+] requires 331.1417, found 331.1423 (1.8 ppm error) 
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Preparation of (3R)-Methyl 1-(2-(trifluoromethyl)phenyl)-2,3,4,9-tetrahydro-1H-
pyrido[3,4-b]indole-3-carboxylate (LVT37-1,2):  
 
 
 
 
 
Following method A using (R)-Methyl 2-amino-3-(1H-indol-3yl)propanoate (500 mg, 2.29 
mmol, 1 eq.) and 2-(trifluoromethyl) benzaldehyde (0.36 mL, 475 mg, 2.86 mmol, 1.25 eq.) 
as starting materials . The desired product was purified using column chromatography (SiO2, 
19:1, CH2Cl2:Et2O), to afford, eluting first, the trans diastereoisomer as a colourless solid 
(161 mg, 0.43 mmol, 19%) and, eluting second, the cis diastereoisomer as a colourless solid 
(179 mg, 0.48 mmol, 21%). 
Following method B using (R)-Methyl 2-amino-3-(1H-indol-3yl)propanoate (250 mg, 1.15 
mmol, 1 eq.) and 2-(trifluoromethyl) benzaldehyde (0.18 mL, 238 mg, 1.38 mmol, 1.25 eq.) 
starting material. The desired product was purified using column chromatography (SiO2, 
19:1, CH2Cl2:Et2O), to afford, eluting first, the trans diastereoisomer as a colourless solid 
(152 mg, 0.41 mmol, 36%) and, eluting second, the cis diastereoisomer as a colourless solid 
(161 mg, 0.43 mmol, 37%). 
Trans (1S, 3R) diastereoisomer (LVT37-1)  
mp 87–91 °C 
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1H NMR (300 MHz, CDCl3) δ 3.24 (1H, dd, J 15.4, 5.3 Hz, CH2(10a)), 3.32 (1H, dd, J 15.4, 
5.3 Hz, CH2(10b)), 3.72 (3H, s, OCH3(22)), 4.05 (1H, dd, J 5.3, 5.3 Hz, CH(11)), 5.91 (1H, 
s, CH(14)), 7.12–7.22 (3H, m, ArCH(1,2,3)), 7.29 (1H, d, J 6.9 Hz, ArCH(16)), 7.39–7.43 
(2H, m, ArCH(6,17)), 7.49 (1H, br. s, NH), 7.51 (1H, d, J 8.1 Hz, ArCH(18)), 7.73 (1H, d, 
J 8.1 Hz, ArCH(19)) 
13C NMR (75 MHz, CDCl3) δ 24.15 (s, CH2(10)), 50.09 (s, CH(14)), 52.15 (s, OCH3(22)), 
53.12 (s, CH(11)), 108.9 (s, ArC), 110.9 (s, ArCH), 118.4 (s, ArCH), 119.65 (s, ArCH), 
122.18 (s, ArCH), 121.92 (q, 1JC-F 274 Hz, CF3(21)), 125.99 (q, 
3JC-F 5.8 Hz, ArCH(19)), 
126.9 (s, ArCH), 128.0 (s, ArCH), 128.9 (q, 2JC-F 29 Hz, ArC(20)), 131.05 (s, ArCH), 132.26 
(s, ArC), 132.53 (s, ArC), 136.33 (s, ArC), 140.70 (s, ArC), 173.90 (s, C=O(13)) 
19F NMR (376 MHz, CDCl3) δ −57.4 (Ar-CF3(21)) 
Rf 0.30 (19:1, CH2Cl2: Et2O) 
[α]D
25  −4.0 (c 1.0, MeOH) 
IR ʋ/ cm-1 1165 (C-O, s), 1738 (C=O, s), 3105 (Ar C-H, w)  
MS (ESI): 375 [M+H+]  
HRMS C20H18F3O2N2 [M+H
+] requires 375.1320, found 375.1326 (2.6 ppm error) 
Cis (1R, 3R) diastereoisomer (LVT37-2)  
mp 97–99 °C 
1H NMR (300 MHz, CDCl3) δ 3.06 (1H, dd, J 15.0, 8.8 Hz, CH2(10a)), 3.26 (1H, dd, J 15.0, 
3.9 Hz, CH2(10b)), 3.82 (3H, s, OCH3(22)), 4.00 (1H, dd, J 8.8, 3.9 Hz, CH(11)), 5.96 (1H, 
s, CH(14)), 7.10–7.21 (3H, m, ArCH(1,2)), 7.35–7.49 (4H, m, ArCH(6,16,17), NH), 7.56 
(1H, dd, J 7.5, 7.5 Hz, ArCH(18)), 7.72 (1H, d, J 7.5 Hz, ArCH(19)) 
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13C NMR (75 MHz, CDCl3) δ 25.48 (s, CH2(10)), 52.30 (s, OCH3(22)), 53.64 (s, CH(14)), 
56.80 (s, CH(11)), 109.36 (s, ArC), 111.0 (s, ArCH), 118.31 (s, ArCH), 119.77 (s, ArCH), 
122.14 (s, ArCH), 124.55 (q, 1JC-F 274 Hz, CF3(21)), 125.41 (q, 
3JC-F 5.7 Hz, ArCH(19)), 
126.9 (s, ArC), 126.99 (s, ArCH), 128.27 (s, ArC), 128.8 (q, 2JC-F 30 Hz, ArC(20)), 131.6 
(s, ArCH), 132.7 (s, ArCH), 134.16 (s, ArC), 136.35 (s, ArC), 140.14 (s, ArC), 172.92 (s, 
C=O(13)) 
19F NMR (376 MHz, CDCl3) δ −57.1 (Ar-CF3(21)) 
Rf 0.43 (19:1, CH2Cl2: Et2O) 
[α]D
25  +4.0 (c 1.0, MeOH) 
IR ʋ/ cm-1 1165 (C-O, s), 1734 (C=O, s), 3093 (Ar C-H, w)  
MS (ESI): 375 [M+H+]  
HRMS C20H18F3O2N2 [M+H
+] requires 375.1320, found 375.1321 (1.6 ppm error) 
 
Preparation of (3R)-Methyl 1-(2,4-bis(trifluoromethyl)phenyl)-2,3,4,9-tetrahydro-1H-
pyrido[3,4-b]indole-3-carboxylate (LVT38-1,2):  
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Following method A using (R)-Methyl 2-amino-3-(1H-indol-3yl)propanoate (500 mg, 2.29 
mmol, 1 eq.) and 2,4-bis(trifluoromethyl) benzaldehyde (0.45 mL, 666 mg, 2.86 mmol, 1.25 
eq.) as starting materials. The desired product was purified using column chromatography 
(SiO2, 100%, CH2Cl2), to afford, eluting first, the trans diastereoisomer as a colourless solid 
(56.0 mg, 0.13 mmol, 6%) and, eluting second, the cis diastereoisomer as a colourless solid 
(41.3 mg, 0.09 mmol, 4%). 
Following method B using (R)-Methyl 2-amino-3-(1H-indol-3yl)propanoate (250 mg, 1.15 
mmol, 1 eq.) and 2,4-bis(trifluoromethyl) benzaldehyde (0.24 mL, 355 mg, 1.44 mmol, 1.25 
eq.) as starting materials. The desired product was purified using column chromatography 
(SiO2, 100% CH2Cl2), to afford, eluting first, the trans diastereoisomer as a colourless solid 
(82.4 mg, 0.19 mmol, 37%) and, eluting second, the cis diastereoisomer as a colourless solid 
(70.1 mg, 0.16 mmol, 31%). 
Trans (1S, 3R) diastereoisomer (LVT38-1)  
mp 89–93 °C 
1H NMR (300 MHz, CDCl3) δ 3.28 (1H, dd, J 15.5, 5.1 Hz, CH2(10a)), 3.34 (1H, dd, J 15.5, 
5.1 Hz, CH2(10b)), 3.72 (3H, s, OCH3(23)), 4.05 (1H, dd, J 5.1, 5.1 Hz, CH(11)), 5.98 (1H, 
s, CH(14)), 7.13–7.25 (3H, m, ArCH(1,2)), 7.47 (br. s, NH), 7.51 (1H, d, J 8.2 Hz, ArCH), 
7.58 (1H, d, J 8.2 Hz, ArCH(16)), 7.69 (1H, d, J 8.2 Hz, ArCH(17)), 7.98 (1H, s, ArCH(19)) 
13C NMR (75 MHz, CDCl3) δ 23.99 (s, CH2(10)), 49.82 (s, CH(14)), 52.30 (s, OCH3(23)), 
53.22 (s, CH(11)), 109.11 (s, ArC), 111.13 (s, ArCH), 118.51 (s, ArCH), 119.88 (s, ArCH), 
122.53 (s, ArCH), 123.10 (q, 3JC-F  4.7 Hz, ArCH(17)), 123.26 (q, 
1JC-F  272 Hz, ArCF3(22)), 
126.72 (q, 1JC-F  270 Hz, ArCF3(21)), 126.74 (s, ArC), 129.00 (q, 
3JC-F  6.3 Hz, ArCH(19)), 
129.58 (q, 2JC-F  30 Hz, ArC(20)), 130.57 (q, 
2JC-F  33 Hz, ArC(18)), 131.62 (s, ArC), 132.23 
(s, ArCH), 136.42 (s, ArC), 145.22 (s, ArC), 173.83 (s, C=O(13)) 
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19F NMR (376 MHz, CDCl3) δ −57.7 (Ar-CF3) and −62.9 (Ar-CF3) 
Rf 0.18 (100%, CH2Cl2) 
IR ʋ/ cm-1 1164 (C-O, s), 1742 (C=O, s), 3123 (Ar C-H, w)  
MS (ESI): 443 [M+H+] 
HRMS C21H17F6O2N2 [M+H
+] requires 443.1194, found 443.1204 (2.9 ppm error) 
Cis (1R, 3R) diastereoisomer (LVT38-2)  
mp 95–97 °C 
1H NMR (300 MHz, CDCl3) δ 3.09 (1H, dd, J 15.1, 3.4 Hz, CH2(10a)), 3.28 (1H, dd, J 15.1, 
11.0 Hz, CH2(10b)), 3.83 (3H, s, OCH3(23)), 4.01 (1H, dd, J 11.0, 3.4 Hz, CH(11)), 5.75 
(1H, s, CH(14)), 7.12–7.25 (3H, m, ArCH(1,2)), 7.34 (br. s, NH), 7.56 (1H, d, J 8.2 Hz, 
ArCH), 7.72 (1H, d, J 8.2 Hz, ArCH(16)), 7.79 (1H, d, J 8.2 Hz, ArCH(17)), 7.98 (1H, s, 
ArCH(19)) 
13C NMR (75 MHz, CDCl3) δ 25.33 (s, CH2(10)), 52.38 (s, OCH3(23)), 53.35 (s, CH(14)), 
56.54 (s, CH(11)), 109.79 (s, ArC), 111.03 (s, ArCH), 118.43 (s, ArCH), 119.99 (s, ArCH), 
122.49 (s, ArCH), 122.64 (q, 3JC-F 5.8 Hz, ArCH(17)), 123.22 (q, 
1JC-F  272 Hz, ArCF3(22)), 
123.76 (q, 1JC-F  274 Hz, ArCF3(21)), 126.74 (s, ArC), 129.30 (q, 
3JC-F  5.5 Hz, ArCH(19)), 
129.42 (q, 2JC-F  31 Hz, ArC(20)), 130.80 (q, 
2JC-F  33 Hz, ArC(18)), 123.95 (s, ArCH), 
133.07 (s, ArC), 136.47 (s, ArC), 144.65 (s, ArC), 172.67 (s, C=O(13)) 
19F NMR (376 MHz, CDCl3) δ −57.4 (Ar-CF3) and −62.9 (Ar-CF3) 
Rf 0.55 (100%, CH2Cl2) 
IR ʋ/ cm-1 1165 (C-O, s), 1740 (C=O, s), 3159 (Ar C-H, w) 
MS (ESI): 443 [M+H+]  
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HRMS C21H17F6O2N2 [M+H
+] requires 443.1194, found 443.1191 (0.01 ppm error) 
 
Preparation of (3R)-Benzyl 1-(2,4-dichlorophenyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-
b]indole-3-carboxylate (LVT50-1,2): 
 
 
 
 
 
Following method A using (R)-Benzyl 2-amino-3-(1H-indol-3-yl)propanoate (474 mg, 1.61 
mmol, 1 eq.) and 2,4-dichloro benzaldehyde (352 mg, 2.01 mmol, 1.25 eq.) as starting 
materials. The desired product was purified using column chromatography (SiO2, 99:1, 
CH2Cl2:MeOH), to afford, eluting first, the cis diastereoisomer as an off-white solid (72.2 
mg, 0.16 mmol, 13%) and, eluting second, the trans diastereoisomer as an off-white solid 
(67.3 mg, 0.15 mmol, 12%). 
Following method B using (R)-Benzyl 2-amino-3-(1H-indol-3-yl)propanoate (500 mg, 1.70 
mmol, 1 eq.) and 2,4-dichloro benzaldehyde (372 mg, 2.13 mmol, 1.25 eq.) as starting 
materials. The desired product was purified using column chromatography (SiO2, 99:1, 
CH2Cl2:MeOH), to afford, eluting first, the cis diastereoisomer as an off-white solid (241 
mg, 0.53 mmol, 31%) and, eluting second, the trans diastereoisomer as an off-white solid 
(267 mg, 0.59 mmol, 35%). 
Trans (1S, 3R) diastereoisomer (LVT50-1)  
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mp 97–100 °C 
1H NMR (300 MHz, CDCl3) δ 3.15 (1H, dd, J 15.3, 6.5 Hz, CH2(10a)), 3.27 (1H, dd, J 15.3, 
5.0 Hz, CH2(10b)), 3.91 (1H, dd, J 6.5, 5.0 Hz, CH(11)), 5.15 (2H, dd, J 12.3, 2.7 Hz, 
CH2(21)), 5.87 (1H, s, CH(14)), 7.10–7.22 (3H, m, ArCH(1,2)), 7.29–7.31 (6H, m, 
ArCH(16,23,24,25)), 7.46 (1H, d, J 6.9 Hz, ArCH), 7.56 (1H, d, J 6.9 Hz, ArCH), 7.67 (1H, 
s, ArCH(19)), 8.01 (1H, br. s, NH) 
13C NMR (75 MHz, CDCl3) δ 25.42 (CH2(10)), 51.17 (CH(14)), 52.62 (CH(11)), 67.13 
(CH2(21)), 109.32 (ArC), 111.09 (ArCH), 118.43 (ArCH(17)), 119.89 (ArCH), 122.55 
(ArCH), 126.63 (ArCH), 127.40 (ArC), 128.19 (ArCH), 128.42 (ArCH(25)), 128.61 
(ArCH(24)), 128.69 (ArCH(23)), 129.79 (ArC), 130.61 (ArCH(19)), 131.22 (ArCH), 
134.54 (ArC), 134.92 (ArC), 135.32 (ArC), 136.39 (ArC), 136.54 (ArC), 173.29 (C=O(13))  
Rf 0.21 (99:1, CH2Cl2/MeOH) 
[α]D
25  +12.0 (c 1.0, MeOH) 
IR ʋ/ cm-1 1734 (C=O, s), 3179 (Ar C-H, w) 
MS (ESI): 451/453 [M+H+] 
HRMS C25H21
35Cl2N2O2 [M+H
+] requires 451.0980, found 451.1003 (4.2 ppm error) 
Cis (1R, 3R) diastereoisomer (LVT50-2)  
mp 161–163 °C 
1H NMR (300 MHz, CDCl3) δ 3.03 (1H, dd, J 15.0, 11.0 Hz, CH2(10a)), 3.26 (1H, dd, J 
15.0, 4.0 Hz, CH2(10b)), 4.03 (1H, dd, J 11.0, 4.0 Hz, CH(11)), 5.23 (1H, d, J 12.3, 6.7 Hz, 
CH2(21a)), 5.25 (1H, d, J 12.3, 6.7 Hz, CH2(21b)), 5.79 (1H, s, CH(14)), 7.09–7.23 (3H, m, 
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ArCH(1,2)), 7.38–7.42 (6H, m, ArCH(16,23,24,25)), 7.47 (1H, d, J 5.0 Hz, ArCH), 7.52–
7.55 (2H, m, ArCH(17,19)) 
13C NMR (75 MHz, CDCl3) δ 25.41 (CH2(10)), 53.85 (CH(14)), 56.68 (CH(11)), 67.00 
(CH2(21)), 109.33 (ArC), 110.94 (ArCH), 118.30 (ArCH(17)), 119.78 (ArCH), 122.20 
(ArCH), 126.89 (ArC), 128.03 (ArCH), 128.34 (ArCH(25)), 128.48 (ArCH(24)), 128.67 
(ArCH(23)), 129.39 (ArCH(19)), 131.47 (ArCH), 133.22 (ArC), 134.08 (ArC), 134.63 
(ArC), 135.51 (ArC), 136.21 (ArC), 137.32 (ArC), 172.39 (C=O(13)) 
Rf 0.62 (99:1, CH2Cl2/MeOH) 
[α]D
25  −12.0 (c 1.0, MeOH) 
IR ʋ/ cm-1 1725 (C=O, s), 3323 (Ar C-H, w)   
MS (ESI): 451/453 [M+H+] 
HRMS C25H21
35Cl2N2O2 [M+H
+] requires 451.0980, found 451.0957 (4.3 ppm error) 
 
Preparation of (3S)-Benzyl 1-(2,4-dichlorophenyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-
b]indole-3-carboxylate (LVT51-1,2): 
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Following method A using (S)-Benzyl 2-amino-3-(1H-indol-3-yl)propanoate (578 mg, 1.91 
mmol, 1 eq.) and 2,4-dichloro benzaldehyde (430 mg, 2.46 mmol, 1.25 eq.) as starting 
materials. The desired product was purified using column chromatography (SiO2, 99:1, 
CH2Cl2/MeOH), to afford, eluting first, the cis diastereoisomer as an off-white solid (109 
mg, 0.24 mmol, 20%) and, eluting second, the trans diastereoisomer as a clear glass solid 
(81.4 mg, 0.18 mmol, 15%). 
Following method B using (S)-Benzyl 2-amino-3-(1H-indol-3-yl)propanoate (500 mg, 1.70 
mmol, 1 eq.) and 2,4-dichloro benzaldehyde (372 mg, 2.13 mmol, 1.25 eq.) as starting 
materials. The desired product was purified using column chromatography (SiO2, 99:1, 
CH2Cl2/MeOH), to afford, eluting first, the cis diastereoisomer as an off-white solid (273 
mg, 0.60 mmol, 30%) and, eluting second, the trans diastereoisomer as a clear glass solid 
(289 mg, 0.64 mmol, 32%). 
Trans (1R, 3S) diastereoisomer (LVT51-1)  
mp 96–98 °C 
1H NMR (300 MHz, CDCl3) δ 3.15 (1H, dd, J 15.4, 7.1 Hz, CH2(10a)), 3.27 (1H, dd, J 15.4, 
5.1 Hz, CH2(10b)), 3.91 (1H, dd, J 7.1, 5.1 Hz, CH(11)), 5.17 (1H, d, J 12.6, 2.5 Hz, 
CH2(21a)), 5.20 (1H, d, J 12.6, 2.5 Hz, CH2(21b)), 5.87 (1H, s, CH(14)), 6.94 (1H, s, NH), 
7.09–7.21 (3H, m, ArCH(1,2)), 7.28–7.31 (7H, m, ArCH), 7.45 (1H, d, J 7.0 Hz, ArCH(17)), 
7.56 (1H, d, J 7.0 Hz, ArCH(19)), 7.67 (1H, br. s, NH)  
13C NMR (75 MHz, CDCl3) δ 24.75 (CH2(10)), 51.06 (CH(14)), 52.67 (CH(11)), 66.84 
(CH2(21)), 109.52 (ArC), 110.96 (ArCH), 118.40 (ArCH(17)), 119.76 (ArCH), 122.32 
(ArCH), 126.81 (ArC), 127.27 (ArCH), 127.97 (ArCH), 128.13 (ArCH(25)), 128.33 
(ArCH(24)), 128.49 (ArCH(23)), 128.58 (ArCH(19)), 129.69 (ArCH), 130.96 (ArCH), 
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131.64 (ArC), 134.33 (ArC), 134.38 (ArC), 135.54 (ArC), 136.24 (ArC), 137.92 (ArC), 
173.17 (C=O(13))  
Rf 0.27 (99:1, CH2Cl2/MeOH) 
[α]D
25  +16.0 (c 1.0, MeOH) 
IR ʋ/ cm-1 1728 (C=O, s), 3383 (Ar C-H, w)  
MS (ESI): 451/453 [M+H+]  
HRMS C25H21
35Cl2N2O2 [M+H
+] requires 451.0980, found 451.0982 (1.7 ppm error) 
Cis (1S, 3S) diastereoisomer (LVT51-2)  
mp 175–178 °C 
1H NMR (300 MHz, CDCl3) δ 3.01 (1H, dd, J 14.2, 10.9 Hz, CH2(10a)), 3.25 (1H, dd, J 
14.2, 4.0 Hz, CH2(10b)), 4.02 (1H, dd, J 10.9, 4.0 Hz, CH(11)), 5.24 (1H, d, J 9.5, 6.8 Hz, 
CH2(21a)), 5.27 (2H, dd, J 9.5, 6.8 Hz, CH2(21b)), 5.79 (1H, s, CH(14)), 7.08–7.23 (4H, m, 
ArCH(1,2,23)), 7.37–7.41 (6H, m, ArCH(18,19,20)), 7.47 (1H, d, J 7.0 Hz, ArCH(17)), 7.53 
(1H, d, J 8.3 Hz, ArCH(19)), 7.59 (1H, br. s, NH)  
13C NMR (75 MHz, CDCl3) δ 25.42 (CH2(10)), 53.90 (CH(14)), 56.70 (CH(11)), 67.01 
(CH2(21)), 109.34 (ArC), 110.95 (ArCH), 118.31 (ArCH(17)), 119.80 (ArCH), 122.20 
(ArCH), 126.91 (ArC), 128.05 (ArCH), 128.35 (ArCH(25)), 128.49 (ArCH(24)), 128.69 
(ArCH(23)), 129.41 (ArCH(19)), 131.42 (ArCH), 131.48 (ArCH), 133.24 (ArC), 134.08 
(ArC), 134.65 (ArC), 135.53 (ArC), 136.21 (ArC), 137.33 (ArC), 172.39 (C=O(13))  
Rf 0.61 (99:1, CH2Cl2/MeOH) 
[α]D
25  −16.0 (c 1.0, MeOH) 
IR ʋ/ cm-1 1724 (C=O, s), 3429 (Ar C-H, w)  
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MS (ESI): 451/453 [M+H+]  
HRMS C25H21
35Cl2N2O2 [M+H
+] requires 451.0980, found 451.0983 (1.7 ppm error) 
 
Preparation of (S)-4-Fluorobenzyl 2-((tert-butoxycarbonyl)amino)-3-(1H-indol-3-
yl)propanoate (LVT90):  
 
 
 
 
N-((Tert-butoxy)carbonyl)-L-tryptophan (409 mg, 1.35 mmol, 1 eq.) was dissolved in 
methanol (6 mL) and water (1 mL). Cs2CO3 (219 mg, 0.68 mmol, 0.5 eq.) was dissolved 
separately in water (4 mL) and then added into the main reaction mixture. The reaction 
mixture was azeotroped with DMF (3 × 2 mL) and then DMF (10 mL) added under a 
nitrogen atmosphere. Then, 4-fluorobenzyl bromide (0.33 mL, 500 mg, 2.70 mmol, 2 eq.) 
was added dropwise via syringe and the reaction left to stir overnight at room temperature. 
The DMF was removed under reduced pressure and the remaining mixture was partitioned 
between EtOAc (25 mL) and water (25 mL). The organics were extracted with further EtOAc 
(3 × 75 mL), washed with saturated aqueous brine (50 mL), dried over MgSO4, filtered and 
concentrated under reduced pressure. The crude product was purified using column 
chromatography (SiO2, 97:3, CH2Cl2:Et2O). The product LVT90 is a colourless solid (312 
mg, 0.76 mmol, 56%).  
Data for LVT90 
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mp 127–129 °C 
1H (300 MHz, CDCl3) δ 1.41 (9H, s, CH3(21)), 3.26 (2H, d, J 5.5 Hz, CH2(12)), 4.67 (1H, 
dd, J 13.5, 5.5 Hz, CH(11)), 4.94 (1H, d, J 12.2 Hz, CH2(14a)), 5.01 (1H, d, J 12.2 Hz, 
CH2(14b)), 5.16 (1H, d, J 8.0 Hz, NH(10)), 6.78 (1H, s, CH(8)), 6.95 (2H, dd, J 8.5, 8.5 Hz, 
ArCH(1,2)), 7.06–7.18 (4H, m, ArCH(16,17)), 7.30 (1H, d, J 7.7 Hz, ArCH), 7.52 (1H, d, J 
7.7 Hz, ArCH), 8.48 (1H, br. s, NH(7)) 
13C (75 MHz, CDCl3) δ 28.02 (s, CH2(12)), 28.37 (s, CH3(21)), 54.42 (s, CH(11)),  66.39 
(s, CH2(14)), 80.09 (s, C(22)), 109.68 (s, ArC), 111.39 (s, ArCH), 115.31 (s, ArCH), 115.59 
(s, ArCH), 118.70 (s, ArCH), 119.58 (s, ArCH(16)), 122.14 (s, ArCH), 123.07 (s, ArCH(8)), 
127.61 (s, ArC), 130.41 (d, 2JC-F 8.3 Hz, ArCH(17)), 131.20 (s, ArC(15)), 136.23 (s, 
ArC(9)), 155.45 (s, C=O(20)), 162.68 (d, 1JC-F 247 Hz, ArC(18)), 172.37 (s, C=O(13)) 
19F (376 MHz, CDCl3) δ −113.3 (s, ArC-F(19)) 
Rf  0.38 (97:3, CH2Cl2:Et2O) 
[α]D
29  −3.0 (c 1.0, MeOH) 
IR ʋ/ cm-1 1178 (C-O, s), 1698 (C=O, s), 1726 (C=O, s), 3156 (Ar C-H, w), 3353 (N-H, w) 
MS (ESI): 413 [M+H+]  
HRMS C23H26FN2O4 [M+H
+] requires 413.1871, found 413.1875 (0.9 ppm error) 
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Preparation of (S)-4-Fluorobenzyl 2-amino-3-(1H-indol-3-yl)propanoate (LVT90a):   
 
 
 
(S)-4-Fluorobenzyl 2-((tert-butoxycarbonyl)amino)-3-(1H-indol-3-yl)propanoate (LVT90) 
(312 mg, 0.70 mmol, 1 eq.) was dissolved in CH2Cl2 (10 mL) and MeOH (0.1 mL). TFA (8 
mL) was added portionwise via syringe and the reaction left to stir for 1 h under a nitrogen 
atmosphere. The reaction mixture was azeotroped with CH2Cl2 (2 × 5 mL) and then 
partitioned between CH2Cl2/saturated aqueous NaHCO3 (50 mL/50 mL). The organics were 
extracted with CH2Cl2 (2 × 75 mL), washed with saturated aqueous brine (75 mL), dried 
over MgSO4, filtered and concentrated under reduced pressure. The product LVT90a is a 
glass (156 mg, 0.50 mmol, 71%). 
Data for LVT90a 
1H (300 MHz, CDCl3) δ 3.06 (1H, dd, J 14.3, 7.6 Hz, CH2(11a)), 3.25 (1H, dd, J 14.3, 7.6 
Hz, CH2(11b)), 3.84 (1H, t, J 7.6 Hz, CH(10)), 5.04 (2H, s, CH2(13), 6.90 (1H,  s, ArCH(8)), 
6.99 (2H, dd, J 8.6, 8.6 Hz, ArCH(1,2)), 7.09–7.22 (4H, m, ArCH(15,16)), 7.38 (1H, d, J 
7.7 Hz, ArCH), 7.57 (1H, d, J 7.7 Hz, ArCH), 8.44 (1H, br. s, NH(7)) 
13C (75 MHz, CDCl3) δ 30.73 (s, CH2(11)), 55.01 (s, CH(10ab)), 66.08 (s, CH2(13)), 110.65 
(s, ArC), 111.34 (s, ArCH), 115.36 (s, ArCH), 115.65 (s, ArCH), 118.74 (s, ArCH), 119.53 
(s, ArCH), 122.15 (s, ArCH), 123.16 (s, ArCH(8)), 127.44 (s, ArC), 130.40 (d, 2JC-F  8.3 Hz, 
ArCH(16)), 131.47 (d, 4JC-F 3.2 Hz, ArC(14)), 136.28 (s, ArC(9)), 162.67 (d, 
1JC-F 247 Hz, 
ArC(17)), 175.13 (s, C=O(12)) 
19F (376 MHz, CDCl3) δ −113.3 (s, Ar-F(18)) 
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Rf  0.13 (97:3, CH2Cl2:Et2O) 
[α]D
27  +16.0 (c 1.0, MeOH) 
IR ʋ/ cm-1 1215 (C-O, s), 1724 (C=O, s), 3159 (Ar C-H, w), 3273 (N-H, w) 
MS (ESI): 313 [M+H+]  
HRMS C18H18FN2O2 [M+H
+] requires 313.1352, found 313.1367 (4.6 ppm error) 
 
Preparation of (R)-4-Fluorobenzyl 2-((tert-butoxycarbonyl)amino)-3-(1H-indol-3-
yl)propanoate (LVT91):  
 
 
 
N-((Tert-Butoxy)carbonyl)-D-tryptophan (421 mg, 1.38 mmol, 1 eq.) was dissolved in 
methanol (6 mL) and water (1 mL). Then, Cs2CO3 (224 mg, 0.69 mmol, 0.5 eq.) was 
dissolved separately in water (4 mL) and then added into the main reaction mixture. The 
reaction mixture was azeotroped with DMF (3 × 2 mL) and then anhydrous DMF (10 mL) 
was added under a nitrogen atmosphere. Next, 4-fluorobenzyl bromide (0.34 mL, 516 mg, 
2.76 mmol, 2 eq.) was added dropwise via syringe and the reaction left to stir overnight at 
room temperature. The DMF was removed under reduced pressure and the remaining 
mixture was partitioned between EtOAc (25 mL) and water (25 mL). The organics were 
extracted with further EtOAc (3 × 75 mL), washed with saturated aqueous brine (50 mL), 
dried over MgSO4, filtered and concentrated under reduced pressure. The crude product was 
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purified using column chromatography (SiO2, 97:3, CH2Cl2:Et2O). The product LVT91 is a 
colourless solid (361 mg, 0.88 mmol, 64%).  
Data for LVT91 
mp 126‒129 °C 
1H (300 MHz, CDCl3) δ 1.41 (9H, s, CH3(21)), 3.26 (2H, d, J 5.5 Hz, CH2(12)), 4.70 (1H, 
dd, J 13.6, 5.5 Hz, CH(11)), 4.99 (1H, d, J 12.0, 12.0 Hz, CH2(14a)), 5.02 (1H, d, J 12.0, 
12.0 Hz, CH2(14b)), 5.12 (1H, d, J 8.0 Hz, NH(10)), 6.81 (1H, s, CH(8)), 6.97 (2H, dd, J 
8.6, 8.6 Hz, ArCH(1,2)), 7.07–7.20 (4H, m, ArCH(16,17)), 7.32 (1H, d, J 7.8 Hz, ArCH), 
7.53 (1H, d, J 7.8 Hz, ArCH), 8.29 (1H, br. s, NH(7)) 
13C (75 MHz, CDCl3) δ 28.01 (s, CH2(12)), 28.35 (s, CH3(21)), 54.34 (s, CH(11ab)),  66.36 
(s, CH2(14)), 80.02 (s, C(22)), 109.84 (s, ArC), 111.29 (s, ArCH), 115.30 (s, ArCH), 115.58 
(s, ArCH), 118.73 (s, ArCH), 119.62 (s, ArCH(16)), 122.19 (s, ArCH(16)), 122.93 (s, 
ArCH(8)), 127.62 (s, ArC), 130.41 (d, 2JC-F 8.2 Hz, ArCH(17)), 131.18 (d, 
4JC-F 3.1 Hz, 
ArC(15)), 136.15 (s, ArC), 155.34 (s, C=O(20)), 162.67 (d, 1JC-F 247 Hz, ArC(18)), 172.28 
(s, C=O(13)) 
19F (376 MHz, CDCl3) δ −113.3 (s, Ar-F(19)) 
Rf  0.49 (97:3, CH2Cl2:Et2O) 
[α]D
29  +3.0 (c 1.0, MeOH) 
IR ʋ/ cm-1 1168 (C-O, s), 1698 (C=O, s), 1725 (C=O, s), 3158 (Ar C-H, w), 3319 (N-H, w) 
MS (ESI): 413 [M+H+]  
HRMS C23H26FN2O4 [M+H
+] requires 413.1871, found 413.1874 (0.7 ppm error) 
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Preparation of (R)-4-Fluorobenzyl 2-amino-3-(1H-indol-3-yl)propanoate (LVT91a):   
 
 
 
(R)-4-Fluorobenzyl 2-((tert-butoxycarbonyl)amino)-3-(1H-indol-3-yl)propanoate (LVT91) 
(361 mg, 0.81 mmol, 1 eq.) was dissolved in CH2Cl2 (10 mL) and MeOH (0.1 mL). TFA (8 
mL) was added portionwise via syringe and the reaction left to stir for 1 h under a nitrogen 
atmosphere. The reaction mixture was azeotroped with CH2Cl2 (2 × 5 mL) and then 
partitioned between CH2Cl2/saturated aqueous NaHCO3 (50 mL/50 mL). The organics were 
extracted with CH2Cl2 (2 × 75 mL), washed with saturated aqueous brine (75 mL), dried 
over MgSO4, filtered and concentrated under reduced pressure. The product LVT91a is a 
glass like solid (228 mg, 0.73 mmol, 90%). 
Data for LVT91a 
1H (300 MHz, CDCl3) δ 3.07 (1H, dd, J 14.2, 7.3 Hz, CH2(11a)), 3.25 (1H, dd, J 14.2, 5.1 
Hz, CH2(11b)), 3.86 (1H, dd, J 7.3, 5.1 Hz, CH(10)), 5.05 (2H, s, CH2(13ab), 6.89 (1H, s, 
ArCH(8)), 6.99 (2H, dd, J 8.6, 8.6 Hz, ArCH(1,2)), 7.07–7.21 (4H, m, ArCH(15,16)), 7.31 
(1H, d, J 7.3 Hz, ArCH), 7.58 (1H, d, J 7.3 Hz, ArCH), 8.46 (1H, br. s, NH(7)) 
13C (75 MHz, CDCl3) δ 30.78 (s, CH2(11)), 55.04 (s, CH(10ab)), 66.08 (s, CH2(13)), 110.66 
(s, ArC), 111.34 (s, ArCH), 115.36 (s, ArCH), 115.65 (s, ArCH), 118.75 (s, ArCH), 119.52 
(s, ArCH), 122.14 (s, ArCH), 123.15 (s, ArCH(8)), 127.45 (s, ArC), 130.39 (d, 2JC-F 8.7 Hz, 
ArCH(16)), 131.48 (d, 4JC-F 3.5 Hz, ArC(14)), 136.29 (s, ArC), 162.67 (d, 
1JC-F 247 Hz, 
ArC(17)), 175.21 (s, C=O(12)) 
19F (376 MHz, CDCl3) δ −113.3 (s, Ar-F(18)) 
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Rf  0.15 (97:3, CH2Cl2:Et2O) 
[α]D
27  −16.0 (c 1.0, MeOH) 
IR ʋ/ cm-1 1173 (C-O, s), 1723 (C=O, s), 3153 (ArC-H, w), 3254 (N-H, w) 
MS (ESI): 313 [M+H+] 
HRMS C18H18FN2O2 [M+H
+] requires 313.1352, found 313.1358 (1.9 ppm error) 
 
Preparation of (S)-4-(Trifluoromethyl)benzyl 2-((tert-butoxycarbonyl)amino)-3-(1H-indol-
3-yl)propanoate (LVT92):  
 
 
 
 
N-((Tert-Butoxy)carbonyl)-L-tryptophan (438 mg, 1.44 mmol, 1 eq.) was dissolved in 
methanol (6 mL) and water (1 mL). Cs2CO3 (234 mg, 0.72 mmol, 0.5 eq.) was dissolved 
separately in water (4 mL) and then added into the main reaction mixture. The reaction 
mixture was azeotroped with DMF (3 × 2 mL) and then DMF (10 mL) added under a 
nitrogen atmosphere. 4-(Trifluoromethyl)benzyl bromide (0.45 mL, 696 mg, 2.88 mmol, 2 
eq.) was added dropwise via syringe and the reaction left to stir overnight at room 
temperature. The DMF was removed under reduced pressure and the remaining mixture was 
partitioned between EtOAc (25 mL) and water (25 mL). The organics were extracted with 
further EtOAc (3 × 75 mL), washed with saturated aqueous brine (50 mL), dried over 
MgSO4, filtered and concentrated under reduced pressure. The crude product was purified 
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using column chromatography (SiO2, 97:3, CH2Cl2:Et2O). The product LVT92 is a 
colourless solid (511 mg, 1.10 mmol, 77%).  
Data for LVT92 
mp 143–146 °C 
1H (300 MHz, CDCl3) δ 1.42 (9H, s, CH3(21)), 3.28 (2H, d, J 5.7 Hz, CH2(12)), 4.70 (1H, 
dd, J 13.8, 5.7 Hz, CH(11)), 5.04 (1H, d, J 12.5, 12.5 Hz, CH2(14a)), 5.07 (1H, d, J 12.5, 
12.5 Hz, CH2(14b)), 5.11 (1H, d, J 7.3 Hz, NH(10)), 6.86 (1H, s, CH(8)), 7.10 (2H, dd, J 
7.4, 7.4 Hz, ArCH(1,2)), 7.17–7.25 (4H, m, ArCH(16,17)), 7.33 (1H, d, J 8.0 Hz, ArCH), 
7.51–7.55 (2H, m, ArCH(17)), 8.19 (1H, br. s, NH(7)) 
13C (75 MHz, CDCl3) δ 28.10 (s, CH2(12)), 28.32 (s, CH3(21)), 54.31 (s, CH(11ab)),  66.00 
(s, CH2(14)), 80.09 (s, C(22)), 109.89 (s, ArC), 111.27 (s, ArCH), 118.71 (s, ArCH), 119.70 
(s, ArCH), 122.30 (s, ArCH), 122.84 (s, ArCH(8)), 124.01 (q, 1JC-F 272 Hz, ArCF3(19)), 
125.45 (q, 3JC-F 3.5 Hz, ArCH(17)), 128.19 (s, ArCH(16)), 130.33 (q, 
2JC-F 33 Hz, ArC(18)), 
136.14 (s, ArC), 139.23 (s, ArC(15)), 155.31 (s, C=O(20)), 172.23 (s, C=O(13)) 
19F (376 MHz, CDCl3) δ −62.5 (s, Ar-CF3(19)) 
Rf  0.66 (97:3, CH2Cl2:Et2O) 
[α]D
27  –1.0 (c 1.0, MeOH) 
IR ʋ/ cm-1 1093 (C-O, s), 1675 (C=O, s), 1726 (C=O, s), 3221 (Ar C-H, w), 3298 (N-H, w) 
MS (ESI): 463 [M+H+] 
HRMS C24H26F3N2O4 [M+H
+] requires 463.1845, found 463.1840 (0.2 ppm error) 
Analysis calculated for C24H25F3N2O4: C, 62.33%; H, 5.45%; N 6.06%. Found C, 62.12%; 
H, 5.36%; N, 5.91%. 
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Preparation of (S)-4-(Trifluoromethyl)benzyl 2-amino-3-(1H-indol-3-yl)propanoate 
(LVT92a):   
 
 
 
(S)-4-(Trifluoromethyl)benzyl 2-((tert-butoxycarbonyl)amino)-3-(1H-indol-3-
yl)propanoate (LVT92) (511 mg, 1.10 mmol, 1 eq.) was dissolved in CH2Cl2 (10 mL) and 
MeOH (0.1 mL). TFA (8 mL) was added portionwise via syringe and the reaction left to stir 
for 1 h under a nitrogen atmosphere. The reaction mixture was azeotroped with CH2Cl2 (2 × 
5 mL) and then partitioned between CH2Cl2/ saturated aqueous NaHCO3 (50 mL/50 mL). 
The organics were extracted with CH2Cl2 (2 × 75 mL), washed with saturated aqueous brine 
(75 mL), dried over MgSO4, filtered and concentrated under reduced pressure. The product 
LVT92a is a glass like solid (321 mg, 0.89 mmol, 81%). 
Data for LVT92a 
1H (300 MHz, CDCl3) δ 3.10 (1H, dd, J 14.2, 6.5 Hz, CH2(11a)), 3.27 (1H, dd, J 14.2, 5.2 
Hz, CH2(11b)), 3.91 (1H, dd, J 6.5, 5.2 Hz, CH(10)), 5.12 (2H, s, CH2(13ab)), 6.93 (1H, s, 
ArCH(8)), 7.10 (1H, dd, J 7.4, 7.4 Hz, ArCH), 7.19 (1H, dd, J 7.4, 7.4 Hz ArCH), 7.24–
7.34 (3H, m, ArCH(16)), 7.53–7.60 (3H, m, ArCH(15)), 8.36 (1H, br. s, NH(7)) 
13C (75 MHz, CDCl3) δ 30.93 (s, CH2(11)), 55.08 (s, CH(10ab)), 65.75 (s, CH2(13)), 110.70 
(s, ArC), 111.34 (s, ArCH), 118.72 (s, ArCH), 119.58 (s, ArCH), 122.22 (s, ArCH), 123.08 
(s, ArCH(8)), 125.51 (q, 3JC-F 3.7 Hz, ArCH(16)), 126.97 (q, 
1JC-F 272 Hz, ArCF3(18)), 
127.40 (s, ArC), 128.23 (s, ArCH), 130.34 (q, 2JC-F 32 Hz, ArCH(17)), 136.28 (s, ArC), 
139.53 (s, ArC(14)), 175.14 (s, C=O(12)) 
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19F (376 MHz, CDCl3) δ −62.5 (s, Ar-CF3(18)) 
Rf  0.13 (97:3, CH2Cl2:Et2O) 
[α]D
29  +21.0 (c 1.0, MeOH) 
IR ʋ/ cm-1 1164 (C-O, s), 1721 (C=O, s), 3166 (Ar C-H, w), 3234 (N-H, w)  
MS (ESI): 363 [M+H+]  
HRMS C19H18F3N2O2 [M+H
+] requires 363.1320, found 363.1316 (0.1 ppm error) 
 
Preparation of (R)-4-(Trifluoromethyl)benzyl 2-((tert-butoxycarbonyl)amino)-3-(1H-indol-
3-yl)propanoate (LVT93):  
 
 
 
 
N-((Tert-Butoxy)carbonyl)-D-tryptophan (402 mg, 1.32 mmol, 1 eq.) was dissolved in 
methanol (6 mL) and water (1 mL). Cs2CO3 (215 mg, 0.66 mmol, 0.5 eq.) was dissolved 
separately in water (4 mL) and then added into the main reaction mixture. The reaction 
mixture was azeotroped with DMF (3 × 2 mL) and then DMF (10 mL) added under a 
nitrogen atmosphere. 4-(Trifluoromethyl)benzyl bromide (0.41 mL, 634 mg, 2.64 mmol, 2 
eq.) was added dropwise via syringe and the reaction left to stir overnight at room 
temperature. The DMF was removed under reduced pressure and the remaining mixture was 
partitioned between EtOAc (25 mL) and water (25 mL). The organics were extracted with 
further EtOAc (3 × 75 mL), washed with saturated aqueous brine (50 mL), dried over 
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MgSO4, filtered and concentrated under reduced pressure. The crude product was purified 
using column chromatography (SiO2, 97:3, CH2Cl2:Et2O). The product LVT93 is a 
colourless solid (479 mg, 0.97 mmol, 74%).  
Data for LVT93 
mp 102–105 °C 
1H (300 MHz, CDCl3) δ 1.42 (9H, s, CH3(21)), 3.27 (2H, d, J 5.7 Hz, CH2(12)), 4.63 (1H, 
d, J 13.8 Hz, CH(11a)), 4.75 (1H, d, J 5.7 Hz, CH(11b)), 5.04 (1H, d, J 12.6, 12.6 Hz, 
CH2(14a)), 5.08 (1H, d, J 12.6, 12.6 Hz, CH2(14b)), 5.13 (1H, d, J 7.3 Hz, NH(10)), 6.85 
(1H, s, CH(8)), 7.07–7.23 (4H, m, ArCH(1,2)), 7.32 (1H, d, J 8.0 Hz, ArCH), 7.49–7.54 
(4H, m, ArCH(16,17)), 8.29 (1H, br. s, NH(7)) 
13C (75 MHz, CDCl3) δ 28.10 (s, CH2(12)), 28.33 (s, CH3(21)), 54.35 (s, CH(11ab)),  66.03 
(s, CH2(14)), 80.01 (s, C(22)), 109.79 (s, ArC), 111.34 (s, ArCH), 118.68 (s, ArCH), 119.68 
(s, ArCH), 122.27 (s, ArCH), 122.92 (s, ArCH(8)), 125.441 (q, 3JC-F 3.6 Hz, ArCH(17)), 
125.45 (q, 1JC-F 272 Hz, ArCH(19)), 127.52 (s, ArC), 128.19 (s, ArCH(16)), 130.32 (q, 
2JC-
F 32 Hz, ArC(18)), 136.19 (s, ArC), 139.24 (s, ArC(15)), 155.37 (s, C=O(20)), 172.28 (s, 
C=O(13)) 
19F (376 MHz, CDCl3) δ −62.5 (s, Ar-CF3(19)) 
Rf  0.53 (97:3, CH2Cl2:Et2O) 
[α]D
29  +1.0 (c 1.0, MeOH) 
IR ʋ/ cm-1 1173 (C-O, s), 1676 (C=O, s), 1726 (C=O, s), 3186 (Ar C-H, w), 3353 (N-H, w) 
MS (ESI): 463 [M+H+]  
HRMS C24H26F3N2O4 [M+H
+] requires 463.1845, found 463.1851 (2.3 ppm error) 
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Preparation of (R)-4-(Trifluoromethyl)benzyl 2-amino-3-(1H-indol-3-yl)propanoate 
(LVT93a):   
 
 
 
(R)-4-(Trifluoromethyl)benzyl 2-((tert-butoxycarbonyl)amino)-3-(1H-indol-3-
yl)propanoate (LVT93) (479 mg, 1.32 mmol, 1 eq.) was dissolved in CH2Cl2 (10 mL) and 
MeOH (0.1 mL). TFA (8 mL) was added portionwise via syringe and the reaction left to stir 
for 1 h under a nitrogen atmosphere. The reaction mixture was azeotroped with CH2Cl2 (2 × 
5 mL) and then partitioned between CH2Cl2/saturated aqueous NaHCO3 (50 mL/50 mL). 
The organics were extracted with CH2Cl2 (2 × 75 mL), washed with saturated aqueous brine 
(75 mL), dried over MgSO4, filtered and concentrated under reduced pressure. The product 
LVT93a is a glass like solid (378 mg, 1.04 mmol, 79%). 
Data for LVT93a 
1H (300 MHz, CDCl3) δ 3.10 (1H, dd, J 14.3, 7.2 Hz, CH2(11a)), 3.27 (1H, dd, J 14.3, 5.4 
Hz, CH2(11b)), 3.91 (1H, dd, J 7.2, 5.4 Hz, CH(10)), 5.12 (2H, s, CH2(13ab)), 6.93 (1H, s, 
ArCH(8)), 7.10 (1H, dd, J 7.1, 7.1 Hz, ArCH), 7.18 (1H, dd, J 7.1, 7.1 Hz ArCH), 7.24–
7.34 (3H, m, ArCH(16)), 7.53–7.60 (3H, m, ArCH(15)), 8.37 (1H, br. s, NH(7)) 
13C (75 MHz, CDCl3) δ 30.98 (s, CH2(11)), 55.12 (s, CH(10ab)), 65.73 (s, CH2(13)), 110.72 
(s, ArC), 111.34 (s, ArCH), 115.35 (s, ArCH), 115.64 (s, ArCH), 118.73 (s, ArCH), 119.58 
(s, ArCH), 122.21 (s, ArCH), 123.07 (s, ArCH(8)), 125.47 (s, ArCH), 125.50 (q, 3JC-F 3.7 
Hz, ArCH(16)), 127.41 (s, ArC), 127.64 (q, 1JC-F 272 Hz, ArCF3(18)), 128.23 (s, ArCH), 
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130.45 (q, 2JC-F 32 Hz, ArCH(17)), 136.28 (s, ArC), 139.53 (s, ArC(14)), 175.18 (s, 
C=O(12)) 
19F (376 MHz, CDCl3) δ −62.5 (s, Ar-CF3(19)) 
Rf  0.15 (97:3, CH2Cl2:Et2O) 
[α]D
29  −21.0 (c 1.0, MeOH) 
IR ʋ/ cm-1 1098 (C-O, s), 1724 (C=O, s), 3156 (Ar C-H, w), 3273 (N-H, w) 
MS (ESI): 363 [M+H+] 
HRMS C19H18F3N2O2 [M+H
+] requires 363.1320, found 363.1333 (2.7 ppm error) 
 
Preparation of (3S)-4-Fluorobenzyl 1-(2,4-dichlorophenyl)-2,3,4,9-tetrahydro-1H-
pyrido[3,4-b]indole-3-carboxylate (LVT94-1,2): 
 
 
 
 
 
Following method A using (S)-4-Fluorobenzyl 2-amino-3-(1H-indol-3-yl)propanoate 
(LVT90a) (356 mg, 1.14 mmol, 1 eq.) and 2,4-dichlorobenzaldehyde (250 mg, 1.43 mmol, 
1.25 eq.) as starting materials. The desired product was purified using preparative thin layer 
chromatography (SiO2, 19:1, CH2Cl2/MeOH), to afford, the cis diastereoisomer as an off-
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white solid (145 mg, 0.31 mmol, 27%) and, eluting second, the trans diastereoisomer an off-
white solid (190 mg, 0.41 mmol, 36%). 
Following method B using (S)-4-Fluorobenzyl 2-amino-3-(1H-indol-3-yl)propanoate 
(LVT90a) (156 mg, 0.50 mmol, 1 eq.) and 2,4-dichlorobenzaldehyde (175 mg, 1.00 mmol, 
1.25 eq.) as starting materials. The desired product was purified using preparative thin layer 
chromatography (SiO2, 19:1, CH2Cl2/MeOH), to afford, the cis diastereoisomer as an off-
white solid (58 mg, 0.12 mmol, 24%) and, eluting second, the trans diastereoisomer an off-
white solid (71 mg, 0.15 mmol, 30%). 
Cis (1S, 3S) diastereoisomer (LVT94-1)  
mp 81–84 ºC 
1H NMR (300 MHz, CDCl3) δ 3.15 (1H, dd, J 15.0, 11.0 Hz, CH2(11a)), 3.26 (1H, dd, J 
15.0, 4.0 Hz, CH2(11b)), 3.90 (1H, dd, J 11.0, 4.0 Hz, CH(10)), 5.09 (1H, d, J 12.2, 6.7 Hz, 
CH2(13a)), 5.11 (1H, d, J 12.2, 6.7 Hz, CH2(13b)),5.86 (1H, s, CH(21)), 6.95–6.99 (3H, m, 
ArCH(1,2,3)), 7.10–7.15 (5H, m, ArCH(15,16,24)), 7.46 (1H, s, ArCH(26)), 7.55 (1H, d, J 
7.6 Hz, ArCH(23)), 7.64 (1H, s, NH(7)) 
13C NMR (75 MHz, CDCl3) δ 25.42 (s, CH2(11ab)), 56.67 (s, CH(10)), 66.29 (s, CH2(13)), 
109.29 (s, ArC), 110.97 (s, ArCH), 115.54 (s, ArCH), 115.75 (s, ArCH), 118.29 (s, 
ArCH(23)), 119.82 (s, ArCH), 122.24 (s, ArCH), 126.89 (s, ArC), 128.06 (s, ArCH), 129.42 
(s, ArCH(26)), 130.43 (d, 2JC-F 8.2 Hz, ArCH(16)), 131.42 (d, 
4JC-F 3.6 Hz, ArC(14)), 133.19 
(s, ArC), 134.10 (s, ArC), 134.69 (s, ArC), 136.21 (s, ArC), 137.29 (s, ArC), 162.82 (d, 1JC-
F 247 Hz, ArC(17)), 173.24 (s, C=O(12)) 
19F NMR (376 MHz, CDCl3) δ −123.7 (Ar-F(19)) 
Rf 0.44 (99:1, CH2Cl2/MeOH) 
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IR ʋ/ cm-1 1510 (C-F, s), 1729 (C=O, s), 2923 (C-H, w), 3386 (ArC-H, w) 
MS (ESI): 469/471 [M+H+]  
HRMS C25H20
35Cl2FN2O2 [M+H
+] requires 468.0800, found 469.0894 (3.2 ppm error) 
Trans (1R, 3S) diastereoisomer (LVT94-2)  
mp 178–181 ºC 
1H NMR (300 MHz, CDCl3) δ 3.01 (1H, dd, J 14.7, 13.0 Hz, CH2(11a)), 3.24 (1H, d, J 14.7, 
10.6 Hz, CH2(11b)), 4.01 (1H, dd, J 13.0, 10.6 Hz, CH(10)), 5.20 (1H, d, J 12.4, 12.1 Hz, 
CH2(13a)), 5.22 (1H, d, J 12.4, 12.1 Hz, CH2(13b)), 5.79 (1H, s, CH(21)), 7.06–7.23 (6H, m 
ArCH(23,24)), 7.38–7.40 (2H, m, ArCH(16)), 7.47 (1H, s, ArCH(26)), 7.53 (2H, d, J 8.0 
Hz, ArCH(15)) 
13C NMR (75 MHz, CDCl3) δ 25.42 (s, CH2(11ab)), 53.86 (s, CH2(21)), 56.67 (s, CH(10)), 
66.29 (s, CH2(13)), 109.29 (s, ArC), 110.97 (s, ArCH), 115.54 (s, ArCH), 115.75 (s, ArCH), 
118.29 (s, ArCH(23)), 119.82 (s, ArCH), 122.24 (s, ArCH), 126.89 (s, ArC), 128.06 (s, 
ArCH), 129.42 (s, ArCH(26)), 130.43 (d, 2JC-F 8.2 Hz, ArCH(16)), 131.42 (d, 
4JC-F 3.6 Hz, 
ArC(14)), 133.19 (s, ArC), 134.10 (s, ArC), 134.69 (s, ArC), 136.21 (s, ArC), 137.29 (s, 
ArC), 162.82 (d, 1JC-F 247 Hz, ArC(17)), 172.36 (s, C=O(12)) 
19F NMR (376 MHz, CDCl3) δ −123.7 (Ar-F(19)) 
Rf 0.47 (99:1, CH2Cl2:MeOH) 
IR ʋ/ cm-1 1512 (C-F, s), 1724 (C=O, s), 2937 (C-H, w), 3321 (ArC-H, w) 
MS (ESI): 469/471 [M+H+]  
HRMS C25H20
35Cl2FN2O2 [M+H
+] requires 468.0800, found 469.0886 (1.6 ppm error) 
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Preparation of (3R)-4-(Trifluoromethyl)benzyl 1-(2,4-dichlorophenyl)-2,3,4,9-tetrahydro-
1H-pyrido[3,4-b]indole-3-carboxylate (LVT95-1,2): 
 
 
 
 
 
Following method A using (R)-4-(Trifluoromethyl)benzyl 2-amino-3-(1H-indol-3-
yl)propanoate (LVT93a) (430 mg, 1.19 mmol, 1 eq.) and 2,4-dichlorobenzaldehyde (260 
mg, 1.49 mmol, 1.25 eq.) as starting materials. The desired product was purified using 
preparative thin layer chromatography (SiO2, 19:1, CH2Cl2/MeOH), to afford, the trans 
diastereoisomer as an off-white solid (178 mg, 0.34 mmol, 27%) and, eluting second, the cis 
diastereoisomer a colourless solid (120 mg, 0.23 mmol, 36%). 
Following method B using (R)-4-(Trifluoromethyl)benzyl 2-amino-3-(1H-indol-3-
yl)propanoate (LVT93a) (200 mg, 0.55 mmol, 1 eq.) and 2,4-dichlorobenzaldehyde (121 
mg, 0.69 mmol, 1.25 eq.) as starting materials. The desired product was purified using 
preparative thin layer chromatography (SiO2, 19:1, CH2Cl2/MeOH), to afford, the trans 
diastereoisomer as an off-white solid (69 mg, 0.13 mmol, 24%) and, eluting second, the cis 
diastereoisomer a colourless solid (75 mg, 0.14 mmol, 25%). 
Trans (1R, 3S) diastereoisomer (LVT95-1)  
mp 178−180 ºC 
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1H NMR (300 MHz, CDCl3) δ 3.22 (1H, dd, J 14.5, 13.0 Hz, CH2(11a)), 3.28 (1H, dd, J 
14.5, 10.6 Hz, CH2(11b)), 3.97 (1H, d, J 13.0, 10.6 Hz, CH(10)), 5.19 (1H, d, J 12.4, 12.2 
Hz, CH2(13a)), 5.21 (1H, d, J 12.4, 12.2 Hz, CH2(13a)), 5.89 (1H, s, CH(20)), 6.98 (1H, s, 
NH(19)), 7.11–7.20 (3H, m ArCH(1,2)), 7.33–7.35 (2H, d, J 7.5 Hz, ArCH(22,23)), 7.46–
7.55 (4H, m, ArCH(15,16)), 7.66 (1H, s, ArCH(25)) 
13C NMR (75 MHz, CDCl3) δ 24.68 (s, CH2(11ab)), 51.03 (s, CH(20)), 52.72 (s, CH(10)), 
65.81 (s, CH2(13)), 109.27 (s, ArC), 111.02 (s, ArCH), 118.34 (s, ArCH(22)), 119.87 (s, 
ArCH(23)), 122.45 (s, ArCH), 125.55 (q, 3JC-F 7.5 Hz, ArCH(16)), 126.76 (s, ArC), 127.39 
(s, ArCH(25)), 127.94 (q, 1JC-F 272 Hz, ArCF3(18)), 128.01 (s, ArCH), 129.71 (s, ArCH), 
130.13 (q, 2JC-F 32 Hz, ArC(17)), 131.00 (s, ArC), 131.58 (s, ArC), 134.31 (s, ArC), 134.50 
(s, ArC), 136.27 (s, ArC), 137.80 (s, ArC(26)), 139.49 (s, ArC(24)), 172.99 (s, C=O(12)) 
19F NMR (376 MHz, CDCl3) δ −62.61 (Ar-CF3(18)) 
Rf 0.33 (99:1, CH2Cl2/MeOH) 
IR ʋ/ cm-1 1323 (C-F, s), 1733 (C=O, s), 2942 (C-H, w), 3388 (ArC-H, w) 
MS (ESI): 519/521 [M+H+]  
HRMS C26H20
35Cl2F3N2O2 [M+H
+] requires 519.0845, found 519.0872 (4.9 ppm error) 
Cis (1S, 3S) diastereoisomer (LVT95-2)  
mp 96–99 ºC 
1H NMR (300 MHz, CDCl3) δ 3.04 (1H, dd, J 15.0, 12.9 Hz, CH2(11a)), 3.26 (1H, d, J 15.0, 
10.8 Hz, CH2(11b)), 4.05 (1H, dd, J 12.9, 10.8 Hz, CH(10)), 5.28 (1H, d, J 12.8, 10.6 Hz, 
CH2(13a)), 5.30 (1H, d, J 12.8, 10.6 Hz, CH2(13b)), 5.80 (1H, s, CH(20)), 7.10–7.23 (3H, m 
ArCH(1,2)), 7.38 (1H, d, J 8.40 Hz, ArCH), 7.47 (1H, s, ArCH(25)), 7.50–7.54 (4H, m, 
ArCH(15,22,23)), 7.65–7.67 (2H, m, ArCH(16)) 
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13C NMR (75 MHz, CDCl3) δ 25.46 (s, CH2(11ab)), 53.89 (s, CH(20)), 56.64 (s, CH(10)), 
65.99 (s, CH2(13)), 109.19 (s, ArC), 110.99 (s, ArCH), 118.27 (s, ArCH(22)), 119.86 (s, 
ArCH(23)), 122.29 (s, ArCH), 125.71 (q, 1JC-F 7.8 Hz, ArCH(16)), 126.86 (s, ArC), 127.98 
(q, 1JC-F 272 Hz, ArCF3(18)), 128.07 (s, ArCH), 128.31 (s, ArCH(15)), 129.45 (s, 
ArCH(25)), 130.69 (q, 2JC-F 32 Hz, ArC(17)), 131.40 (s, ArCH(25)), 133.16 (s, ArC), 134.12 
(s, ArC), 134.73 (s, ArC), 136.22 (s, ArC), 137.23 (s, ArC(26)), 139.46 (s, ArC(24)), 172.26 
(s, C=O(12)) 
19F NMR (376 MHz, CDCl3) δ −62.62 (s, Ar-CF3(18)) 
Rf 0.49 (99:1, CH2Cl2:MeOH) 
IR ʋ/ cm-1 1324 (C-F, s), 1729 (C=O, s), 2898 (C-H, w), 3420 (ArC-H, w) 
MS (ESI): 519/521 [M+H+]  
HRMS C26H20
35Cl2F3N2O2 [M+H
+] requires 519.0845, found 519.0865 (2.8 ppm error) 
 
Preparation of (3R)-4-Fluorobenzyl 1-(2,4-dichlorophenyl)-2,3,4,9-tetrahydro-1H-
pyrido[3,4-b]indole-3-carboxylate (LVT96-1,2):  
 
 
 
 
 
Following method A using (R)-4-Fluorobenzyl 2-amino-3-(1H-indol-3-yl)propanoate 
(LVT91a) (328 mg, 1.05 mmol, 1 eq.) and 2,4-dichlorobenzaldehyde (229 mg, 1.31 mmol, 
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1.25 eq.) as starting materials. The desired product was purified using preparative thin layer 
chromatography (SiO2, 97:3, CH2Cl2/MeOH), to afford, the trans diastereoisomer as an 
orange wax solid (90.4 mg, 0.19 mmol, 18%) and, the cis diastereoisomer a colourless solid 
(156 mg, 0.33 mmol, 32%). 
Following method B using (R)-4-Fluorobenzyl 2-amino-3-(1H-indol-3-yl)propanoate 
(LVT91a) (228 mg, 0.73 mmol, 1 eq.) and 2,4-dichlorobenzaldehyde (159 mg, 0.91 mmol, 
1.25 eq.) as starting materials. The desired product was purified using preparative thin layer 
chromatography (SiO2, 97:3, CH2Cl2/MeOH), to afford, the trans diastereoisomer as an 
orange wax solid (113 mg, 0.24 mmol, 33%) and, the cis diastereoisomer a colourless solid 
(124 mg, 0.26 mmol, 36%). 
Trans (1R, 3S) diastereoisomer (LVT96-1)  
1H NMR (300 MHz, CDCl3) δ 3.15 (1H, dd, J 15.8, 6.1 Hz, CH2(11a)), 3.26 (1H, dd, J 15.8, 
6.8 Hz, CH2(11b)), 3.90 (1H, dd, J 6.8, 6.1 Hz, CH(10)), 5.10 (1H, d, J 13.4, 10.1 Hz, 
CH2(13a)), 5.13 (1H, d, J 13.4, 10.1 Hz, CH2(13b)), 5.87 (1H, s, CH(20)), 6.95–7.05 (3H, 
m, ArCH(1,2)), 7.10–7.15 (3H, m, ArCH(15,23)), 7.35 (2H, d, J 8.3 Hz, ArCH(16)), 7.47 
(1H, s, ArCH(25)), 7.56 (1H, d, J 8.3 Hz, ArCH), 7.65–7.70 (2H, m, NH, ArCH(22)) 
13C NMR (75 MHz, CDCl3) δ 25.72 (s, CH2(11ab)), 51.04 (s, CH(20)), 52.79 (s, CH(10)), 
66.10 (s, CH2(13)), 109.43 (s, ArC), 110.98 (s, ArCH), 115.40 (s, ArCH), 115.61 (s, ArCH), 
118.37 (s, ArCH(22)), 119.80 (s, ArCH(23)), 122.37 (s, ArCH), 126.81 (s, ArC), 127.33 (s, 
ArCH), 128.76 (d, 3JC-F 7.2 Hz, ArCH(15)), 129.70 (s, ArCH(25)), 130.12 (d, 
2JC-F 7.9 Hz, 
ArC(16)), 130.97 (s, ArC), 131.66 (s, ArC), 134.32 (s, ArC), 134.95 (s, ArC), 136.27 (s, 
ArC(24)), 137.95 (s, ArC(26)), 162.67 (d, 1JC-F 244 Hz, ArC(17)), 173.14 (s, C=O(12)) 
19F NMR (376 MHz, CDCl3) δ −113.3 (s, Ar-F(18)) 
Rf 0.24 (99:1, CH2Cl2/MeOH) 
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[α]D
25  −6.0 (c 1.0, MeOH) 
IR ʋ/ cm-1 1510 (C-F, s), 1729 (C=O, s), 2924 (C-H, w), 3314 (ArC-H, w)  
MS (ESI): 469/470 [M+H+] 
HRMS C25H20
35Cl2FN2O2 [M+H
+] requires 469.0886, found 469.0900 (4.0 ppm error) 
Cis (1S, 3S) diastereoisomer (LVT96-2)  
mp 191–193ºC 
1H NMR (300 MHz, CDCl3) δ 3.01 (1H, dd, J 14.7, 12.9 Hz, CH2(11a)), 3.24 (1H, dd, J 
14.7, 10.8 Hz, CH2(11b)), 4.02 (1H, dd, J 12.9, 10.8 Hz, CH(10)), 5.11 (1H, d, J 12.1, 12.1 
Hz, CH2(13a)), 5.14 (1H, d, J 12.1, 12.1 Hz, CH2(13b)), 5.79 (1H, s, CH(20)), 7.07–7.23 
(5H, m, ArCH(15)), 7.38–7.40 (3H, m, ArCH(16), 7.47 (1H, s, ArCH(25)), 7.53 (2H, d, J 
8.0 Hz, ArCH(22,23)), 7.56 (1H, s, NH(7))  
13C NMR (75 MHz, CDCl3) δ 25.42 (s, CH2(11ab)), 53.81 (s, CH(20)), 56.29 (s, CH(10)), 
66.29 (s, CH2(13)), 109.29 (s, ArC), 110.97 (s, ArCH), 115.53 (s, ArCH), 115.75 (s, ArCH), 
118.29 (s, ArCH(22)), 119.81 (s, ArCH(23)), 122.24 (s, ArCH), 126.66 (s, ArC), 128.05 (d, 
3JC-F 8.0 Hz, ArCH(15)), 129.42 (s, ArCH(25)), 130.43 (d, 
2JC-F 8.0 Hz, ArC(16)), 131.37 
(d, 4JC-F 3.4 Hz, ArC(14)), 133.19 (s, ArC), 134.10 (s, ArC), 134.69 (s, ArC), 136.21 (s, 
ArC(24)), 137.28 (s, ArC(26)), 162.82 (d, 1JC-F 247 Hz, ArC(17)), 172.35 (s, C=O(12)) 
19F NMR (376 MHz, CDCl3) δ −113.1 (s, Ar-F(18)) 
Rf 0.50 (99:1, CH2Cl2:MeOH) 
[α]D
25  +6.0 (c 1.0, MeOH) 
IR ʋ/ cm-1 1512 (C-F, s), 1724 (C=O, s), 2890 (C-H, w), 3413 (ArC-H, w) 
MS (ESI): 469/470 [M+H+] 
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HRMS C25H20
35Cl2FN2O2 [M+H
+] requires 469.0886, found 469.0884 (0.4 ppm error) 
 
Preparation of (3S)-4-(Trifluoromethyl)benzyl 1-(2,4-dichlorophenyl)-2,3,4,9-tetrahydro-
1H-pyrido[3,4-b]indole-3-carboxylate (LVT97-1,2): 
 
 
 
 
 
Following method A using (S)-4-(Trifluoromethyl)benzyl 2-amino-3-(1H-indol-3-
yl)propanoate (LVT92a) (421 mg, 1.16 mmol, 1 eq.) and 2,4-dichlorobenzaldehyde (253 
mg, 1.45 mmol, 1.25 eq.) as starting materials. The desired product was purified using 
preparative thin layer chromatography (SiO2, 97:3, CH2Cl2/MeOH), to afford, the trans 
diastereoisomer as an amorphous solid (168 mg, 0.32 mmol, 28%) and, the cis 
diastereoisomer a colourless solid (82 mg, 0.16 mmol, 14%). 
Following method B using (S)-4-(Trifluoromethyl)benzyl 2-amino-3-(1H-indol-3-
yl)propanoate (LVT92a) (321 mg, 0.89 mmol, 1 eq.) and 2,4-dichlorobenzaldehyde (194 
mg, 1.11 mmol, 1.25 eq.) as starting materials. The desired product was purified using 
preparative thin layer chromatography (SiO2, 97:3, CH2Cl2/MeOH), to afford, the trans 
diastereoisomer as an amorphous solid (124 mg, 0.24 mmol, 27%) and, the cis 
diastereoisomer a colourless solid (136 mg, 0.26 mmol, 29%). 
Trans (1R, 3S) diastereoisomer (LVT97-1)  
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1H NMR (300 MHz, CDCl3) δ 3.19 (1H, dd, J 14.6, 7.4 Hz, CH2(11a)), 3.29 (1H, dd, J 14.6, 
5.7 Hz, CH2(11b)), 3.96 (1H, dd, J 7.4, 5.7 Hz, CH(10)), 5.16 (1H, d, J 12.9, 3.7 Hz, 
CH2(13a)), 5.18 (1H, d, J 12.9, 3.7 Hz, CH2(13b)), 5.88 (1H, s, CH(20)), 6.97 (1H, s, 
NH(19)), 7.12–7.23 (4H, m ArCH(1,2,3,6)), 7.35 (2H, d, J 8.0 Hz, ArCH(15)), 7.46 (2H, d, 
J 8.0 Hz, ArCH(16)),  7.50–7.57 (3H, m, ArCH(22,23,25)), 7.65 (1H, s, NH(7)) 
13C NMR (75 MHz, CDCl3) δ 24.74 (s, CH2(11ab)), 50.99 (s, CH(20)), 52.81 (s, CH(10)), 
65.79 (s, CH2(13)), 109.29 (s, ArC), 111.02 (s, ArCH), 118.34 (s, ArCH(22)), 119.84 (s, 
ArCH(23)), 122.42 (s, ArCH), 125.53 (q, 3JC-F 7.5 Hz, ArCH(16)), 126.1 (s, ArC), 127.36 
(s, ArCH(25)), 127.87 (q, 1JC-F 272 Hz, ArCF3(18)), 128.02 (s, ArCH), 129.70 (s, 
ArCH(23)), 130.96 (s, ArCH(15)), 130.88 (q, 2JC-F 32 Hz, ArC(17)), 131.62 (s, ArC), 131.58 
(s, ArC), 134.28 (s, ArC), 134.44 (s, ArC), 136.20 (s, ArC), 137.84 (s, ArC(26)), 139.45 (s, 
ArC(24)), 173.08 (s, C=O(12)) 
19F NMR (376 MHz, CDCl3) δ −62.63 (s, Ar-CF3(18)) 
Rf 0.21 (99:1, CH2Cl2/MeOH) 
IR ʋ/ cm-1 1323 (C-F, s), 1732 (C=O, s), 2961 (C-H, w), 3392 (ArC-H, w)  
MS (ESI): 519/521 [M+H+] 
HRMS C26H20
35Cl2F3N2O2 [M+H
+] requires 519.0845, found 519.0861 (1.8 ppm error) 
Cis (1S, 3S) diastereoisomer (LVT97-2)  
mp 208–212 ºC 
1H NMR (300 MHz, CDCl3) δ 3.05 (1H, dd, J 13.4, 11.1 Hz, CH2(11a)), 3.26 (1H, d, J 13.4, 
4.0 Hz, CH2(11b)), 4.06 (1H, dd, J 11.1, 4.0 Hz, CH(10)), 5.28 (1H, d, J 12.8, 10.2 Hz, 
CH2(13a)), 5.30 (1H, d, J 12.8, 10.2 Hz, CH2(13b)),5.80 (1H, s, CH(20)), 7.11–7.24 (3H, m 
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ArCH), 7.39 (1H, d, J 8.4 Hz, ArCH), 7.47 (2H, d, J 5.6 Hz, ArCH(22,23)),  7.52–7.54 (3H, 
m, ArCH(15,25)), 7.66 (2H, d, J 8.4 Hz, ArCH(16)) 
13C NMR (75 MHz, CDCl3) δ 24.47 (s, CH2(11ab)), 53.87 (s, CH(20)), 56.65 (s, CH(10)), 
65.99 (s, CH2(13)), 109.20 (s, ArC), 110.99 (s, ArCH), 118.28 (s, ArCH(22)), 119.86 (s, 
ArCH(23)), 122.30 (s, ArCH), 125.70 (q, 3JC-F 7.4 Hz, ArCH(16)), 126.70 (q, 
1JC-F 275 Hz, 
ArCF3(18)), 126.86 (s, ArC), 128.08 (s, ArCH(25)), 128.31 (s, ArCH), 129.47 (s, 
ArCH(23)), 130.70 (q, 2JC-F 32 Hz, ArC(17)), 131.41 (s, ArCH(15)), 133.17 (s, ArC), 134.12 
(s, ArC), 134.74 (s, ArC), 136.22 (s, ArC), 137.23 (s, ArC), 139.46 (s, ArC(24)), 173.08 (s, 
C=O(12)) 
19F NMR (376 MHz, CDCl3) δ −62.62 (s, Ar-CF3(18)) 
Rf 0.50 (99:1, CH2Cl2:MeOH) 
IR ʋ/ cm-1 1325 (C-F, s), 1727 (C=O, s), 2898 (C-H, w), 3416 (ArC-H, W) 
MS (ESI): 519/521 [M+H+]  
HRMS C26H20
35Cl2F3N2O2 [M+H
+] requires 519.0845, found 519.0871 (4.1 ppm error) 
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Preparation of Benzyl 1-((3-(trifluoromethyl)phenyl)carbamoyl)spiro[indoline-3,4'-
piperidine]-1'-carboxylate (LVT52): 
 
 
 
 
 
 
Benzyl spiro[indoline-3,4'-piperidine]-1'-carboxylate (LVTa46) (1.00 g, 3.12 mmol, 1 eq.) 
was dissolved in CH2Cl2 (20 mL) under a nitrogen atmosphere. 3-(Trifluoromethyl) 
isocyanate (0.52 mL, 707 mg, 3.75 mmol, 1.2 eq.) was added slowly via syringe and the 
resulting solution turned dark green on leaving to stir for 4 hours. The solvent was removed 
under reduced pressure, yielding a cream solid LVT52 (1.55 g, 3.04 mmol, 97%), which 
required no purification. 
Data for LVT52 
mp 101–105 ºC 
1H (300 MHz, CDCl3) δ 1.69 (2H, br. d, J 14.2 Hz, CH2(9a)), 1.88 (2H, br. dd, J 14.2, 12.7 
Hz, CH2(9b)), 2.95 (2H, br. dd, J 12.7, 12.7 Hz, CH2(10a)), 3.94 (2H, s, CH2(7)), 4.26 (2H, 
br. d, J 12.7 Hz, CH2(10b)), 5.17 (2H, s, CH2(21)), 6.92 (1H, br. s, NH), 7.06 (1H, dd, J 7.0, 
7.0 Hz, ArCH(1,2)), 7.13 (1H, d, J 7.0 Hz, ArCH), 7.23–7.46 (7H, m, ArCH(23,24,25)), 
7.72 (1H, d, J 7.6 Hz, ArCH(15)), 7.76 (1H, s, ArCH(18)), 7.85 (1H, d, J 8.0 Hz, ArCH(14))  
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13C (75 MHz, CDCl3) δ 36.26 (s, CH2(9ab)), 41.01 (s, CH2(10ab)), 42.95 (s, C(8)), 56.89 (s, 
CH2(21)), 67.39 (s, CH2(7)), 115.02 (s, ArCH(14)), 116.75 (q, 
3JC-F 4.9 Hz, ArCH(18)), 
120.16 (q, 3JC-F 7.6 Hz, ArCH(16)), 122.83 (s, ArCH), 123.15 (s, ArCH), 123.18 (s, ArCH), 
123.92 (q, 1JC-F 272 Hz, CF3(19)), 127.97 (s, ArCH), 128.21 (s, ArCH), 128.60 (s, ArCH), 
128.74 (s, ArCH), 129.56 (s, ArCH(15)), 131.34 (q, 2JC-F 32 Hz, ArC(17)), 136.54 (s, 
ArC(13)), 138.01 (s, ArC(22)), 138.83 (s, ArC), 141.82 (s, ArC), 151.92 (s, C=O(13)), 
155.35 (s, C=O(20))       
19F (376 MHz, CDCl3) δ −62.6 (Ar-CF3(19))          
Rf 0.44 (97:3, CH2Cl2:MeOH),   
IR ʋ/ cm-1 1328 (C-F, s), 1674 (C=O, s), 3335 (Ar C-H, w) 
MS (ESI): 510 [M+H+]  
HRMS C28H27F3N3O3 [M+H
+] requires 510.2005, found 510.2013 (2.3 ppm error) 
 
Preparation of N-(3-(Trifluoromethyl)phenyl)spiro[indoline-3,4'-piperidine]-1-carboxamide 
hydrochloride (LVT53): 
 
 
 
 
Benzyl 1-((3-(trifluoromethyl)phenyl)carbamoyl)spiro[indoline-3,4'-piperidine]-1'-
carboxylate (LVT52) (1.35 g, 3.04 mmol, 1 eq.) was dissolved in MeOH (15 mL) and then, 
Pearlman’s catalyst (213 mg, 0.30 mmol, 0.1 eq.) was added into the solution. The reaction 
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mixture was sparged with a balloon of hydrogen until deflated and then left under an 
atmosphere of hydrogen overnight. The methanol was removed under reduced pressure and 
the reaction mixture was filtered through celite with CH2Cl2 (100 mL) to collect any 
remaining starting material. The eluent mixture of 10% MeOH/CH2Cl2 (200 mL) was 
subsequently passed through the celite to elute the desired product. The product LVT53 is a 
brown amorphous solid (709 mg, 1.89 mmol, 62%).  
Data for LVT53 
1H (300 MHz, D4-MeOH) δ 1.95 (2H, br. d, J 14.4 Hz, CH2(9a)), 2.18 (2H, br. dd, J 14.4, 
12.4 Hz, CH2(9b)), 3.24 (2H, br. dd, J 12.4, 12.4 Hz, CH2(10a)), 3.49 (2H, br. d, J 12.4 Hz, 
CH2(10b)), 4.22 (2H, s, CH2(7)), 7.04 (1H, dd, J 8.0, 8.0 Hz, ArCH), 7.24–7.27 (2H, m, 
ArCH), 7.33 (1H, d, J 7.9 Hz, ArCH(17)), 7.49 (1H, dd, J 7.9, 7.9 Hz, ArCH(16)), 7.83 (1H, 
d, J 8.0 Hz, ArCH(6)), 7.93 (1H, d, J 7.9 Hz, ArCH(15)), 8.00 (1H, s, ArCH(19)) 
13C (75 MHz, D4-MeOH) δ 34.21 (s, CH2(9ab)), 41.54 (s, C(8)), 42.69 (s, CH2(10ab)), 42.96 
(s, CH2(10)), 58.17 (s, CH2(7)), 116.18 (s, ArCH(16)), 118.25 (q, 
3JC-F 5.8 Hz, ArCH(19)), 
120.68 (q, 3JC-F 4.7 Hz, ArCH(17)), 120.97 (q, 
1JC-F 272 Hz, CF3(20)), 123.62 (s, ArCH), 
124.12 (s, ArCH), 125.11 (s, ArCH), 129.82 (s, ArCH), 130.52 (s, ArCH(16)), 131.42 (q, 
2JC-F 31 Hz, ArC(18)), 141.32 (s, ArC), 143.73 (s, ArC), 154.64 (s, C=O(12)) 
19F (376 MHz, D4-MeOH) δ −64.1 (s, Ar-CF3(20)) 
IR ʋ/ cm-1 1326 (C-F, s), 1673 (C=O, s), 3297 (Ar C-H, w) 
MS (ESI): 376 [M+H+]  
HRMS C20H21F3N3O [M+H
+] requires 376.1637, found 376.1636 (1.7 ppm error) 
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Preparation of Methyl 2-(1-((3-(trifluoromethyl)phenyl)carbamoyl)spiro[indoline-3,4'-
piperidin]-1'-yl)acetate (LVT54):  
 
 
 
 
 
 
Following method C using Benzyl 1-((3-(trifluoromethyl)phenyl)carbamoyl)spiro[indoline-
3,4'-piperidine]-1'-carboxylate (LVT53) (200 mg, 0.53 mmol, 1 eq.), methyl bromoacetate 
(0.10 mL, 161 mg, 1.06 mmol, 2 eq.) and K2CO3 (147 mg, 1.06 mmol, 2 eq.) as starting 
materials. The desired product was purified using column chromatography (SiO2, 14:1, 
CH2Cl2:MeOH) to afford, the pure product (LVT54) as a colourless solid (85 mg, 0.19 
mmol, 35%).  
Data for LVT54  
mp 128–131 ºC 
1H (300 MHz, CDCl3) δ 1.73 (2H, d, J 13.0 Hz, CH2(9a)), 2.10 (2H, dd, J 13.0, 11.3 Hz, 
CH2(9b)), 2.43 (2H, dd, J 11.3, 11.3 Hz, CH2(10a)), 2.99 (2H, d, J 11.3 Hz, CH2(10b)), 3.34 
(2H, s, CH2(20)), 3.75 (3H, s, OCH3(22)), 3.93 (2H, s, CH2(7)), 7.03 (1H, s, NH), 7.19 (1H, 
dd, J 7.7, 7.7 Hz, ArCH), 7.22 (2H, m, ArCH(1,3)), 7.35 (1H, d, J 8.0 Hz, ArCH(16)), 7.44 
(1H, dd, J 8.0, 8.0 Hz, ArCH(15)), 7.72 (1H, d, J 7.5 Hz, ArCH) 7.76 (1H, s, ArCH(18)), 
7.87 (1H, d, J 8.0 Hz, ArCH(14))  
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13C (75 MHz, CDCl3) δ 37.00 (s, CH2(9ab)), 42.47 (s, C(8)), 50.11 (s, CH2(10ab)), 51.76 (s, 
OCH3(22)), 57.44 (s, CH2(7)), 59.40 (s, CH2(20)), 114.99 (s, ArCH(14)), 116.75 (q, 
3JC-F 
5.7 Hz, ArCH(18)), 120.14 (q, 3JC-F 3.6 Hz, ArCH(16)), 122.58 (s, ArCH), 122.92 (s, 
ArCH), 123.13 (s, ArCH), 123.18 (s, ArCH), 123.94 (q, 1JC-F 272 Hz, CF3(19)), 128.47 (s, 
ArCH), 129.51 (s, ArCH(15)), 131.36 (q, 2JC-F 32 Hz, ArC(17)),  138.61 (s, ArC), 138.87 
(s, ArC(13)), 141.91 (s, ArC), 151.93 (s, C=O(11)), 170.85 (s, C=O(21))  
19F (376 MHz, CDCl3) δ −62.4 (s, ArCF3(19)) 
Rf 0.58 (93:7, CH2Cl2:MeOH) 
IR ʋ/ cm-1 1361 (C-F, s), 1676 (C=O, s), 1738 (C=O, s), 3381 (Ar C-H, w)  
MS (ESI): 448 [M+H+]  
HRMS C23H25F3N3O3 [M+H
+] requires 448.1848, found 448.1849 (1.6 ppm error) 
 
Preparation of 1'-(Morpholine-4-carbonyl)-N-(3-(trifluoromethyl)phenyl)spiro[indoline-
3,4'-piperidine]-1-carboxamide (LVT59): 
 
 
 
 
 
Following method C using Benzyl 1-((3-(trifluoromethyl)phenyl)carbamoyl)spiro[indoline-
3,4'-piperidine]-1'-carboxylate (LVT53) (276 mg, 0.74 mmol, 1 eq.), 4-morpholinecarbonyl 
chloride (0.17 mL, 218 mg, 1.50 mmol, 2 eq.) and K2CO3 (207 mg, 1.50 mmol, 2 eq.) as 
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starting materials. The desired product was purified using column chromatography (SiO2, 
93:7, CH2Cl2:MeOH) to afford, the pure product (LVT59) as a light cream solid (296 mg, 
0.61 mmol, 82%).  
Data for LVT59 
mp 221–223 ºC 
1H (300 MHz, CDCl3) δ 1.71 (2H, d, J 11.5 Hz, CH2(9a)), 1.94 (2H, dd, J 12.8, 11.5 Hz, 
CH2(9b)), 2.91 (2H, dd, J 12.8, 12.8 Hz, CH2(10a)), 3.29–3.33 (4H, m, CH2(22)), 3.67–3.71 
(6H, m, CH2(10b,21)), 4.00 (2H, s, CH2(7)), 7.02 (1H, dd, J 7.3, 7.3 Hz, ArCH), 7.15 (1H, 
d, J 7.3 Hz, ArCH), 7.22–7.26 (1H, m, ArCH), 7.31 (1H, d, J 7.6 Hz, ArCH(17)), 7.41 (1H, 
dd, J 7.6, 7.6 Hz, ArCH), 7.51 (1H, s, NH), 7.75 (2H, br. s, ArCH), 7.92 (1H, d, J 8.0 Hz, 
ArCH(14)) 
13C (75 MHz, CDCl3) δ 36.59 (s, CH2(9ab)), 43.32 (s, C(8)), 44.29 (s, CH2(10ab)), 47.29 (s, 
CH2(22)), 57.20 (s, CH2(7)), 66.63 (s, CH2(21)), 115.30 (s, ArCH(14)), 116.85 (q, 
3JC-F 3.8 
Hz, ArCH(18)), 120.01 (q, 3JC-F 3.6 Hz, ArCH(16)), 122.71 (s, ArCH), 123.06 (s, ArCH), 
123.36 (s, ArCH), 126.73 (q, 1JC-F 272 Hz, ArCF3(19)), 128.71 (s, ArCH), 129.48 (s, ArCH), 
131.22 (q, 2JC-F 32 Hz, ArC(17)), 137.94 (s, ArC), 139.24 (s, ArC(13)), 142.14 (s, ArC), 
152.32 (s, C=O(11)), 164.28 (s, C=O(20)) 
19F (376 MHz, CDCl3) δ −62.3 (s, ArCF3(19)) 
Rf 0.52 (93:7, CH2Cl2:MeOH) 
IR ʋ/ cm-1 1345 (C-F, s), 1622 (C=O, s), 1678 (C=O, s), 3334 (Ar C-H, w) 
MS (ESI): 489 [M+H+]  
HRMS C25H28F3N4O3 [M+H
+] requires 489.2108, found 489.2097 (2.3 ppm error) 
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Preparation of 1'-(4-Nitrobenzyl)-N-(3-(trifluoromethyl)phenyl)spiro[indoline-3,4'-
piperidine]-1-carboxamide (LVT66): 
 
 
 
 
 
 
 
Following method C using Benzyl 1-((3-(trifluoromethyl)phenyl)carbamoyl)spiro[indoline-
3,4'-piperidine]-1'-carboxylate (LVT53) (96.0 mg, 0.26 mmol, 1 eq.), 4-nitrobenzyl bromide 
(112 mg, 0.52 mmol, 2 eq.) and K2CO3 (71.9 mg, 0.52 mmol, 2 eq.) as starting materials. 
The desired product was purified using column chromatography (SiO2, 93:7, 
CH2Cl2:MeOH) to afford, the pure product (LVT66) as a golden brown amorphous solid 
(41.0 mg, 0.08 mmol, 31%).  
Data for LVT66 
1H (300 MHz, CDCl3) δ 1.73 (2H, d, J 12.9 Hz, CH2(9a)), 2.05 (2H, dd, J 12.9, 11.8 Hz, 
CH2(9b)), 2.20 (2H, dd, J 11.8, 11.8 Hz, CH2(10a)), 2.91 (2H, d, J 11.8 Hz, CH2(10b)), 3.66 
(2H, s, CH2(20)), 3.93 (2H, s, CH2(7)), 6.73 (1H, br. s, NH), 7.05 (1H, dd, J 7.2, 7.2 Hz, 
ArCH), 7.23 (2H, d, J 7.5 Hz, ArCH), 7.34 (1H, d, J 7.5 Hz, ArCH), 7.45 (1H, dd, J 7.7, 7.7 
Hz, ArCH(15)), 7.56 (2H, d, J 7.7 Hz, ArCH), 7.72 (2H, m, ArCH(22)), 7.82 (1H, d, J 7.7 
Hz, ArCH), 8.20 (2H, d, J 7.7 Hz, ArCH(23))  
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13C (75 MHz, CDCl3) δ 37.10 (s, CH2(9ab)), 42.79 (s, C(8)), 50.78 (s, CH2(10ab)), 57.63 (s, 
CH2(7)), 65.52 (s, CH2(20)), 114.87 (s, ArCH), 116.65 (q, 
3JC-F 7.7 Hz, ArCH(18)), 120.18 
(q, 3JC-F 3.9 Hz, ArCH(16)), 122.94 (s, ArCH), 123.09 (s, ArCH), 123.15 (s, ArCH), 123.64 
(s, ArCH(14)), 123.93 (q, 1JC-F 272 Hz, ArCF3(19)), 128.52 (s, ArCH), 129.44 (s, ArCH), 
129.57 (s, ArCH), 131.45 (q, 2JC-F 32 Hz, ArC(20)), 138.81 (s, ArC), 138.85 (s, ArC(13)), 
141.86 (s, ArC), 146.27 (s, ArC(21)), 147.31 (s, ArC(24)), 151.86 (s, C=O(11)) 
Rf 0.44 (93:7, CH2Cl2:MeOH) 
19F (376 MHz, CDCl3) δ −64.5 (s, Ar-CF3(19)) 
IR ʋ/ cm-1  743 (C-F, s), 1328 (NO2, s), 1516 (NO2, s), 1656 (C=O, s), 3307 (Ar C-H, w)  
MS (ESI): 511 [M+H+]  
HRMS C27H26N4F3O3 [M+H
+] requires 511.1952, found 511.1942 (1.9 ppm error) 
 
Preparation of 1'-(4-Chlorobenzyl)-N-(3-(trifluoromethyl)phenyl)spiro[indoline-3,4'-
piperidine]-1-carboxamide (LVT69): 
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Following method C using Benzyl 1-((3-(trifluoromethyl)phenyl)carbamoyl)spiro[indoline-
3,4'-piperidine]-1'-carboxylate (LVT53) (61.0 mg, 0.16 mmol, 1 eq.), 4-chlorobenzyl 
bromide (71.9 mg, 0.32 mmol, 2 eq.) and K2CO3 (44.2 mg, 0.32 mmol, 2 eq.) as starting 
materials. The desired product was purified using column chromatography (SiO2, 94:6, 
CH2Cl2:MeOH) to afford, the pure product (LVT69) as a golden brown glass solid (47.0 
mg, 0.09 mmol, 59%).  
Data for LVT69 
1H (300 MHz, CDCl3) δ 1.70 (2H, d, J 12.6 Hz, CH2(9a)), 2.02 (2H, dd, J 12.6, 12.0 Hz, 
CH2(9b)), 2.12 (2H, dd, J 12.0, 12.0 Hz, CH2(10a)), 2.92 (2H, d, J 12.0 Hz, CH2(10b)), 3.54 
(2H, s, CH2(20)), 3.91 (2H, s, CH2(7)), 6.72 (1H, br. s, NH), 7.04 (1H, dd, J 7.2, 7.2 Hz, 
ArCH), 7.21–7.24 (2H, m, ArCH(1,3)), 7.30–7.35 (5H, m, ArCH(22,23)), 7.45 (1H, dd, J 
7.7, 7.7 Hz, ArCH(15)), 7.70–7.74 (2H, m, ArCH(16,18), 7.84 (1H, d, J 7.7 Hz, ArCH(14)) 
13C (75 MHz, CDCl3) δ 37.17 (s, CH2(9ab)), 42.94 (s, C(8)), 50.56 (s, CH2(10ab)), 57.64 (s, 
CH2(7)), 62.63 (s, CH2(20)), 114.91 (s, ArCH(14)), 116.65 (q, 
3JC-F 3.8 Hz, ArCH(18)), 
120.1 (q, 3JC-F 7.5 Hz, ArCH(16)), 122.93 (s, ArCH), 123.11 (s, ArCH), 123.94 (q, 
1JC-F 272 
Hz, Ar-CF3(19)), 128.43 (s, ArCH), 128.49 (s, ArCH), 129.55 (s, ArCH(15)), 130.38 (s, 
ArCH), 131.59 (q, 2JC-F 32 Hz, ArC(17)), 132.92 (s, ArC), 136.64 (s, ArC(13)), 138.88 (s, 
ArC(21)), 138.93 (s, ArC(24)), 141.88 (s, ArC), 151.88 (s, C=O(11)) 
19F (376 MHz, CDCl3) δ −64.5 (s, Ar-CF3(19)) 
Rf 0.44 (94:6, CH2Cl2:MeOH) 
IR ʋ/ cm-1 1653 (C=O, s), 3291 (Ar C-H, w) 
MS (ESI): 500/502 [M+H+]  
HRMS C27H26
35ClF3N3O [M+H
+] requires 500.1711, found 500.1700 (2.2 ppm error) 
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Preparation of 1'-(4-Fluorobenzyl)-N-(3-(trifluoromethyl)phenyl)spiro[indoline-3,4'-
piperidine]-1-carboxamide (LVT70): 
 
 
 
 
 
 
 
Following method C using Benzyl 1-((3-(trifluoromethyl)phenyl)carbamoyl)spiro[indoline-
3,4'-piperidine]-1'-carboxylate (LVT53) (55.0 mg, 0.15 mmol, 1 eq.), 4-fluorobenzyl 
bromide (0.04 mL, 60.7 mg, 0.29 mmol, 2 eq.) and K2CO3 (40.1 mg, 0.29 mmol, 2 eq.) as 
starting materials. The desired product was purified using column chromatography (SiO2, 
93:7, CH2Cl2:MeOH) to afford, the pure product (LVT70) as a yellow glass solid (49.0 mg, 
0.10 mmol, 68%).  
Data for LVT70 
1H (300 MHz, CDCl3) δ 1.71 (2H, d, J 12.7 Hz, CH2(9a)), 2.03 (2H, dd, J 12.7, 12.1 Hz, 
CH2(9b)), 2.12 (2H, dd, J 12.1, 12.1 Hz, CH2(10a)), 2.93 (2H, d, J 12.1 Hz, CH2(10b)), 3.54 
(2H, s, CH2(20)), 3.91 (2H, s, CH2(7)), 6.68 (1H, br. s, NH(12)), 7.01–7.05 (3H, m, ArCH), 
7.22 (1H, dd, J 8.0, 8.0 Hz, ArCH), 7.32–7.48 (3H, m, ArCH), 7.46 (1H, dd, J 7.8, 7.8 Hz, 
ArCH(15)), 7.71–7.74 (2H, m, ArCH(18)), 7.84 (1H, d, J 7.8 Hz, ArCH(14)) 
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13C (75 MHz, CDCl3) δ 37.18 (s, CH2(9ab)), 42.98 (s, C(8)), 50.53 (s, CH2(10ab)), 57.65 (s, 
CH2(7)), 62.63 (s, CH2(20)), 114.90 (s, ArCH), 115.04 (s, ArCH(17)), 115.25 (s, ArCH), 
116.66 (q, 3JC-F 3.7 Hz, ArCH(18)), 120.1 (q, 
3JC-F 3.5 Hz, ArCH(16)), 122.94 (s, 
ArCH(15)), 123.11 (s, ArCH), 123.94 (q, 1JC-F 272 Hz, Ar-CF3(19)), 128.43 (s, ArCH), 
129.56 (s, ArCH), 130.54 (s, ArCH), 130.62 (s, ArCH), 131.46 (q, 2JC-F 32 Hz, ArC(17)), 
133.77 (s, ArC), 133.80 (s, ArC(13)), 138.87 (s, ArC(21)), 138.97 (s, ArC(24)), 141.87 (s, 
ArC), 151.85 (s, C=O(11)), 162.11 (d, 1JC-F 245 Hz, ArC-F(25)) 
19F (376 MHz, CDCl3) δ −64.5 (s, Ar-CF3(19)) and −113.3 (s, ArC-F(25)) 
Rf 0.40 (94:6, CH2Cl2:MeOH) 
IR ʋ/ cm-1 743(C-F, s), 1654 (C=O, s), 3295 (Ar C-H, w)  
MS (ESI): 484 [M+H+] 
HRMS C27H26F4N3O [M+H
+] requires 483.1900, found 484.2018 (2.0 ppm error) 
 
Preparation of 1'-(4-Bromobenzoyl)-N-(3-(trifluoromethyl)phenyl)spiro[indoline-3,4'-
piperidine]-1-carboxamide (LVT71): 
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Following method C using Benzyl 1-((3-(trifluoromethyl)phenyl)carbamoyl)spiro[indoline-
3,4'-piperidine]-1'-carboxylate (LVT53) (50.0 mg, 0.13 mmol, 1 eq.), 4-bromobenzoyl 
chloride (58.4 mg, 0.27 mmol, 2 eq.) and K2CO3 (37.3 mg, 0.27 mmol, 2 eq.) as starting 
materials. The desired product was purified using column chromatography (SiO2, 94:6, 
CH2Cl2:MeOH) to afford, the pure product (LVT71) as a colourless solid (44.0 mg, 0.08 
mmol, 59%).  
Data for LVT71 
mp 154−158 ºC 
1H (400 MHz, D6-DMSO) δ 1.68 (2H, d, J 12.7 Hz, CH2(9a)), 1.90 (2H, dd, J 12.7, 12.7 Hz, 
CH2(9b)), 2.96 (1H, br., CH2(10a)), 3.21 (1H, br., CH2(10b)), 3.61 (1H, br., CH2(10a)), 4.16 
(2H, s, CH2(7)), 4.57 (1H, br., CH2(10b)), 6.98 (1H, dd, J 7.4, 7.4 Hz, ArCH), 7.19 (1H, dd, 
J 8.3, 8.3 Hz, ArCH), 7.36 (2H, d, J 7.3 Hz, ArCH(16)), 7.45 (2H, d, J 8.3 Hz, ArCH(22)), 
7.55 (1H, dd, J 7.3, 7.3 Hz, ArCH(15)), 7.68 (1H, d, J 8.3 Hz, ArCH(23)), 7.90 (1H, d, J 
7.3, Hz, ArCH), 8.01 (1H, s, ArCH(18)), 8.92 (1H, br. s, NH(12)) 
13C (100 MHz, D6-DMSO) δ 36.57 (s, CH2(9)), 43.47 (s, C(8)), 50.53 (s, CH2(10)), 56.97 
(s, CH2(7)), 115.43 (s, ArCH), 116.46 (q, 
3JC-F 3.6 Hz, ArCH(18)), 119.09 (q, 
3JC-F 3.7 Hz, 
ArCH(16)), 122.71 (s, ArCH), 123.28 (s, ArC), 123.47 (s, ArCH), 123.88 (s, ArCH),  
124.75 (q, 1JC-F 272 Hz, Ar-CF3(19)), 128.37 (s, ArCH), 129.50 (s, ArCH(22)), 129.72 (q, 
2JC-F 31 Hz, ArC(17)), 130.10 (s, ArCH), 131.96 (s, ArCH(23)), 135.86 (s, ArC), 138.67 (s, 
ArC), 141.08 (s, ArC), 143.01 (s, ArC), 152.74 (s, C=O(11)), 168.60 (s, C=O(20)) 
19F (376 MHz, D6-DMSO) δ −61.2 (s, Ar-CF3(19)) 
Rf 0.43 (94:6, CH2Cl2:MeOH) 
IR ʋ/ cm-1 1653 (C=O, s), 1728 (C=O, s), 3285 (Ar C-H, w)  
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MS (ESI): 558/560 [M+H+] 
HRMS C27H24
79BrF3N3O2 [M+H
+] requires 558.1004, found 558.1016 (2.9 ppm error) 
 
Preparation of 1'-(Pyridin-4-ylmethyl)-N-(3-(trifluoromethyl)phenyl)spiro[indoline-3,4'-
piperidine]-1-carboxamide (LVT72): 
 
 
 
 
 
 
Following method C using Benzyl 1-((3-(trifluoromethyl)phenyl)carbamoyl)spiro[indoline-
3,4'-piperidine]-1'-carboxylate (LVT53) (59.0 mg, 0.16 mmol, 1 eq.), 4-
(bromomethyl)pyridine hydrobromide (78.4 mg, 0.32 mmol, 2 eq.) and K2CO3 (44.2 mg, 
0.32 mmol, 2 eq.) as starting materials. The desired product was purified using column 
chromatography (SiO2, 94:6, CH2Cl2:MeOH) to afford, the pure product (LVT72) as a light 
orange solid (36.1 mg, 0.08 mmol, 48%).  
Data for LVT72 
mp 223–225 ºC 
1H (300 MHz, CDCl3) δ 1.72 (2H, d, J 12.1 Hz, CH2(9a)), 2.05 (2H, dd, J 12.1, 11.7 Hz, 
CH2(9b)), 2.16 (2H, dd, J 11.7, 11.7 Hz, CH2(10a)), 2.91 (2H, d, J 11.7 Hz, CH2(10b)), 3.57 
(2H, s, CH2(20)), 3.92 (2H, s, CH2(7)), 6.82 (1H, br. s, NH), 7.05 (1H, dd, J 7.7, 7.7 Hz, 
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ArCH), 7.22–7.25 (2H, m, ArCH), 7.32–7.35 (3H, m, ArCH), 7.45 (1H, dd, J 7.7, 7.7 Hz, 
ArCH(15)), 7.71–7.75 (2H, m, ArCH), 7.84 (1H, d, J 7.7 Hz, ArCH(14)), 8.57 (2H, s, 
ArCH(23)) 
13C (75 MHz, CDCl3) δ 37.10 (s, CH2(9)), 42.78 (s, C(8)), 50.74 (s, CH2(10)), 57.63 (s, 
CH2(7)), 62.10 (s, CH2(20)), 114.91 (s, ArCH(14)), 116.65 (q, 
3JC-F 4.0 Hz, ArCH(18)), 
120.14 (q, 3JC-F 3.8 Hz, ArCH(16)), 122.91 (s, ArCH), 123.11 (s, ArCH), 123.84 (s, ArCH), 
123.93 (q, 1JC-F 272 Hz, Ar-CF3(19)), 128.49 (s, ArCH), 128.49 (s, ArCH), 129.55 (s, 
ArCH(15)), 131.41 (q, 2JC-F 32 Hz, ArC(17)), 138.80 (s, ArC), 138.90 (s, ArC(13)), 141.9 
(s, ArC), 147.52 (s, ArC(21)), 149.89 (s, ArCH(23)), 151.91 (s, C=O(11)) 
19F (376 MHz, CDCl3) δ −64.5 (s, Ar-CF3(19)) 
Rf 0.33 (94:6, CH2Cl2:MeOH) 
IR ʋ/ cm-1 743 (C-F, s), 1667 (C=O, s), 3354 (Ar C-H, w)  
MS (ESI): 467 [M+H+]  
HRMS C26H26F3N4O [M+H
+] requires 467.2059, found 467.2066 (3.1 ppm error) 
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Preparation of 1'-(2-Morpholinoethyl)-N-(3-(trifluoromethyl)phenyl)spiro[indoline-3,4'-
piperidine]-1-carboxamide (LVT81): 
 
 
 
 
 
 
 
 
Benzyl 1-((3-(trifluoromethyl)phenyl)carbamoyl)spiro[indoline-3,4'-piperidine]-1'-
carboxylate (LVT53) (94.0 mg, 0.25 mmol, 1 eq.), potassium carbonate (69.0 mg, 0.48 
mmol, 2 eq.) and CH3CN (25 mL) were added into a round bottom flask. Then, TBAI (184 
mg, 0.50 mmol, 2 eq.) was added by way of, temporary removal of the condenser and left to 
stir for 30 minutes. The reaction was put under an atmosphere of nitrogen and 4-(2-
Chloroethyl)morpholine hydrochloride (93.0 mg, 0.50 mmol, 2 eq.) was added as a CH3CN 
solution (2 mL) solution via needle and syringe. The final mixture was heated at reflux for 
12 h. After allowing to cool, the solvent was removed under reduced pressure and the 
mixture dissolved in CH2Cl2 (25 mL). The solution was transferred to a separating funnel 
and H2O (20 mL) was added. The organics were extracted with further CH2Cl2 (2 × 25 mL) 
then collated, washed with saturated aqueous NH4Cl (25 mL), dried over MgSO4, filtered 
and concentrated under reduced pressure. The desired product was purified using column 
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chromatography (SiO2, 92.5:7.5, CH2Cl2:MeOH), to afford, the pure product (LVT81) as an 
off-white solid (64.0 mg, 0.13 mmol, 52%).  
Data for LVT81 
mp 174−177 ºC 
1H (300 MHz, CDCl3) δ 1.73 (2H, d, J 12.3 Hz, CH2(9a)), 2.04 (2H, dd, J 12.3, 11.8 Hz, 
CH2(9b)), 2.17 (2H, dd, J 11.8, 11.8 Hz, CH2(10a)), 2.52 (4H, s, CH2(20,21)), 2.60 (4H, s, 
CH2(22)), 3.03 (2H, d, J 11.8 Hz, CH2(10b)), 3.73 (4H, s, (23)), 3.92 (2H, s, CH2(7)), 6.76 
(1H, s, NH(12)), 7.04 (1H, dd, J 6.7, 6.7 Hz, ArCH), 7.20–7.25 (2H, m, ArCH), 7.34 (1H, 
d, J 7.6 Hz, ArCH(16)), 7.45 (1H, dd, J 7.6, 7.6 Hz, ArCH), 7.71–7.75 (2H, m, ArCH), 7.83 
(1H, d, J 7.6 Hz, ArCH(14)) 
13C (75 MHz, CDCl3) δ 37.02 (s, CH2(9ab)), 42.84 (s, C(8)), 51.22 (s, CH2(10ab)), 54.19 
(CH2(20,21)), 55.92 (s, CH2(22)), 57.66 (s, CH2(7)), 66.93 (s, CH2(23)), 114.89 (s, 
ArCH(17)), 116.68 (q, 3JC-F 7.8 Hz, ArCH(18)), 120.11 (q, 
3JC-F 3.7 Hz, ArCH(16)), 122.95 
(s, ArCH), 123.12 (s, ArCH), 123.14 (s, ArCH), 123.94 (1JC-F 272 Hz, ArC(19)), 128.47 (s, 
ArCH), 129.55 (s, ArCH), 131.43 (q, 2JC-F 32 Hz, ArC(17)), 138.81 (s, ArC), 138.88 (s, 
ArC(13)), 141.87 (s, ArC), 151.89 (s, C=O(11)) 
19F (376 MHz, CDCl3) δ −64.5 (s, Ar-CF3(19)) 
Rf 0.23 (92.5:7.5, CH2Cl2:MeOH) 
IR ʋ/ cm-1 1326 (C-F, s), 1664 (C=O, s), 2956 (Ar C-H, w) 
MS (ESI): 489 [M+H+] 
HRMS C26H32F3N4O2 [M+H
+] requires 489.2477, found 489.2460 (2.2 ppm error) 
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Preparation of 1'-Butyl-N-(3-(trifluoromethyl)phenyl)spiro[indoline-3,4'-piperidine]-1-
carboxamide (LVT86): 
 
 
 
 
 
 
Following method C using Benzyl 1-((3-(trifluoromethyl)phenyl)carbamoyl)spiro[indoline-
3,4'-piperidine]-1'-carboxylate (LVT53) (79.0 mg, 0.21 mmol, 1 eq.), 1-bromobutane (0.05 
mL, 63.8 mg, 0.42 mmol, 2 eq.) and K2CO3 (58.0 mg, 0.42 mmol, 2 eq.) as starting materials. 
The desired product was purified using column chromatography (SiO2, 92:8, 
CH2Cl2:MeOH) to afford, the pure product (LVT86) as a golden brown solid (57.0 mg, 0.13 
mmol, 62%).  
Data for LVT86 
mp 69‒72 ºC 
1H (300 MHz, CDCl3) δ 0.94 (3H, t, J 6.7 Hz, CH3(23)), 1.37 (2H, m, CH2(22)), 1.53 (2H, 
m, CH2(21)), 1.73 (2H, d, J 10.5 Hz, CH2(9a)), 2.02 (2H, dd, J 11.0, 10.5 Hz, CH2(9b)), 2.07 
(2H, dd, J 11.0, 11.0 Hz, CH2(10a)), 2.39 (2H, t, J 7.4 Hz, CH2(20)), 2.98 (2H, d, J 11.0, 
11.0 Hz, CH2(10b)), 3.91 (2H, s, CH(7)), 6.77 (1H, s, NH(12)), 7.03 (1H, dd, J 7.0, 7.0 Hz, 
ArCH), 7.20–7.24 (2H, m, ArCH), 7.34 (1H, d, J 7.6 Hz, ArCH), 7.43 (1H, dd, J 7.6, 7.6 
Hz, ArCH), 7.70–7.74 (2H, m, ArCH(18)), 7.85 (1H, d, J 7.6 Hz, ArCH(14)) 
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13C (75 MHz, CDCl3) δ 14.07 (s, CH3(23)), 20.87 (s, CH2(22)), 29.21 (s, CH2(21)), 37.22 
(s, CH2(9ab)), 43.08 (s, C(8)), 50.79 (s, CH2(10ab)), 57.68 (s, CH(7)), 58.90 (s, CH2(20)), 
114.92 (s, ArCH), 116.69 (q, 3JC-F 3.8 Hz, ArCH(18)), 120.12 (q, 
3JC-F 3.7 Hz, ArCH(16)), 
122.94 (s, ArCH), 123.12 (s, ArCH), 123.14 (s, ArCH), 123.95 (q, 1JC-F 272 Hz, ArCH(19)), 
131.40 (q, 2JC-F 32 Hz, ArCH(17)), 138.92 (s, ArC(13)), 139.00 (s, ArC), 141.90 (s, ArC), 
151.94 (s, C=O(11))  
19F (376 MHz, CDCl3) δ −64.5 (s, Ar-CF3(19)) 
Rf 0.42 (92:8, CH2Cl2:MeOH) 
IR ʋ/ cm-1 1322 (C-F, s), 1672 (C=O, s), 2897 (Ar C-H, w) 
MS (ESI): 431 [M+H+] 
HRMS C24H29F3N3O [M+H
+] requires 431.2200, found 432.2266 (2.0 ppm error) 
 
Preparation of 1'-(Piperidine-1-carbonyl)-N-(3-(trifluoromethyl)phenyl)spiro[indoline-3,4'-
piperidine]-1-carboxamide (LVTa1): 
 
 
 
 
 
Following method C using Benzyl 1-((3-(trifluoromethyl)phenyl)carbamoyl)spiro[indoline-
3,4'-piperidine]-1'-carboxylate (LVT53) (253 mg, 0.67 mmol, 1 eq.), 1-piperidinecarbonyl 
chloride (0.17 mL, 200 mg, 1.34 mmol, 2 eq.) and K2CO3 (185 mg, 1.34 mmol, 2 eq.) as 
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starting materials. The desired product was purified using column chromatography (SiO2, 
93:7, CH2Cl2:MeOH), to afford, the pure product (LVTa1) as a yellow solid (226 mg, 0.46 
mmol, 69%).  
Data for LVTa1 
mp 104‒107 ºC 
1H (300 MHz, CDCl3) δ 1.73 (2H, br. d, J 13.5 Hz, CH2(9a)), 1.96 (2H, br. dd, J 13.5, 12.6 
Hz, CH2(9b)), 2.29 (2H, br. dd, J 12.6, 12.6 Hz, CH2(10a)), 3.16–3.18 (6H, m, CH2(22,23)), 
3.24–3.25 (4H, m, CH2(21)), 3.69 (2H, br. d, J 13.5 Hz, CH2(10b)), 4.01 (2H, s, CH2(7)), 
7.03 (1H, t, J 7.9 Hz, ArCH), 7.20 (1H, d, J 8.0 Hz, ArCH), 7.24 (1H, dd, J 7.9, 7.9 Hz, 
ArCH), 7.33 (1H, d, J 7.6 Hz, ArCH(16)), 7.44 (1H, dd, J 7.6, 7.6 Hz, ArCH(15)), 7.56 (1H, 
d, J 7.9 Hz, ArCH), 7.79 (1H, s, ArCH(18)), 7.92 (1H, d, J 8.0 Hz, ArCH(14)) 
13C (75 MHz, CDCl3) δ 36.66 (s, CH2(9ab)), 43.41 (s, C(7)), 44.38 (s, CH2(10ab)), 47.82 (s, 
CH2(21)), 47.94 (3C, s, CH2(22)CH(23)), 57.20 (s, CH2(7)), 115.21 (s, ArCH(14)), 116.75 
(q, 3JC-F 4.8 Hz, ArCH(18)), 119.90 (q, 
3JC-F 4.7 Hz, ArCH(16)), 120.99 (q, 
1JC-F 272 Hz, 
CF3(19)), 122.75 (s, ArCH), 122.97 (s, ArCH), 123.13 (s, ArCH), 128.62 (s, ArCH), 129.44 
(s, ArCH(15)), 131.12 (q, 2JC-F 32 Hz, ArC(17)), 138.18 (s, ArC), 139.19 (s, ArC), 142.09 
(s, ArC(13)), 152.17 (s, C=O(11)), 164.62 (s, C=O(20)) 
19F (376 MHz, CDCl3) δ −64.7 (s, Ar-CF3(19)) 
Rf 0.26 (93:7, CH2Cl2:MeOH) 
IR ʋ/ cm-1 1549 (C-F, s), 1633 (C=O, s), 1683 (C=O, s), 2850 (C-H, w), 3309 (Ar C-H, w) 
MS (ESI): 487 [M+H+]  
HRMS C26H30F3N4O2 [M+H
+] requires 487.2315, found 487.2304 (2.3 ppm error) 
 278 
 
 
Preparation of 1'-(Piperidine-1-carbonyl)-N-(3-(trifluoromethyl)phenyl)spiro[indoline-3,4'-
piperidine]-1-carboxamide (LVTa2): 
 
 
 
 
 
 
 
Following method C using Benzyl 1-((3-(trifluoromethyl)phenyl)carbamoyl)spiro[indoline-
3,4'-piperidine]-1'-carboxylate (LVT53) (210 mg, 0.56 mmol, 1 eq.), tetrahydro-2H-pyran-
4-carbonyl chloride (0.14 mL, 168 mg, 1.11 mmol, 2 eq.) and K2CO3 (153 mg, 1.11 mmol, 
2 eq.) as starting materials. The desired product was purified using column chromatography 
(SiO2, 93:7, CH2Cl2:MeOH), to afford, the pure product (LVTa2) as an off-white solid (231 
mg, 0.47 mmol, 85%).  
Data for LVTa2 
mp 206‒210 ºC 
1H (300 MHz, CDCl3) δ 1.83–2.03 (4H, m, CH2(22)), 2.70–2.84 (3H, m, CH2(10a), CH(21)), 
3.26 (2H, dd, J 8.6, 8.6 Hz, CH2(9a)), 3.43 (2H, dd, J 8.0, 8.0 Hz, CH2(23)), 3.98–4.04 (6H, 
m, CH2(7,9b,23)), 4.70 (2H, d, J 12.9 Hz, CH2(10b)), 7.05 (1H, dd, J 7.4, 7.4 Hz, ArCH), 
7.14 (1H, d, J 7.4 Hz, ArCH), 7.29 (1H, dd, J 7.4, 7.4 Hz, ArCH), 7.35 (1H, d, J 7.6 Hz, 
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ArCH(16)), 7.46 (1H, dd, J 8.0, 8.0 Hz, ArCH(15)), 7.71–7.73 (2H, m, ArCH(18)), 7.83 
(1H, d, J 8.0 Hz, ArCH(14)) 
13C (75 MHz, CDCl3) δ 29.01 (s, CH2(22)), 29.27 (s, CH2(22)), 37.69 (s, CH(21)), 38.99 (s, 
CH2(10ab)), 42.55 (CH2(9ab)), 43.23 (s, C(8)),  57.16 (s, CH2(7)), 67.21 (s, CH2(23)), 114.92 
(s, ArCH(14)), 116.60 (q, 3JC-F 4.9 Hz, ArCH(18)), 120.21 (q, 
3JC-F 4.5 Hz, ArCH(16)), 
120.73 (q, 1JC-F 272 Hz, CF3(19)), 122.85 (s, ArCH), 123.10 (s, ArCH), 123.26 (s, ArCH), 
128.86 (s, ArCH), 129.59 (s, ArCH(15)), 131.35 (q, 2JC-F 32 Hz, ArC(17)), 137.71 (s, ArC), 
138.73 (s, ArC), 141.77 (s, ArC(13)), 151.89 (s, C=O(11)), 172.96 (s, C=O(20)) 
19F (376 MHz, CDCl3) δ −64.6 (s, Ar-CF3(19)) 
Rf 0.27 (93:7, CH2Cl2:MeOH) 
IR ʋ/ cm-1 1549 (C-F, s), 1616 (C=O, s), 1690 (C=O, s), 2852 (C-H, w), 3313 (Ar C-H, w) 
MS (ESI): 488 [M+H+]  
HRMS C26H29F3N3O3 [M+H
+] requires 488.2156, found 488.2147 (1.7 ppm error) 
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Preparation of 1'-Isonicotinoyl-N-(3-(trifluoromethyl)phenyl)spiro[indoline-3,4'-
piperidine]-1-carboxamide (LVTa3): 
 
 
 
 
 
 
 
Following method C using Benzyl 1-((3-(trifluoromethyl)phenyl)carbamoyl)spiro[indoline-
3,4'-piperidine]-1'-carboxylate (LVT53) (250 mg, 0.67 mmol, 1 eq.), isonicotinoyl chloride 
hydrochloride (134 mg, 1.34 mmol, 2 eq.) and K2CO3 (185 mg, 1.34 mmol, 2 eq.) as starting 
materials. The desired product was purified using column chromatography (SiO2, 93:7, 
CH2Cl2:MeOH), to afford, the pure product (LVTa3) a light cream solid (277 mg, 0.58 
mmol, 86%).  
Data for LVTa3 
mp 132‒136 ºC 
1H (300 MHz, CDCl3) δ 2.99 (2H, dd, J 12.9, 10.6 Hz, CH2(10a)), 3.23 (2H, dd, J 11.0, 10.6 
Hz, CH2(9a)), 3.70 (2H, d, J 12.9, 11.0 Hz, CH2(9b)), 4.02 (2H, s, CH2(7)), 4.78 (2H, d, J 
12.9, 12.9 Hz, CH2(10b)), 6.90 (1H, s, NH(12)), 7.07 (1H, dd, J 7.5, 7.5 Hz, ArCH), 7.19 
(1H, d, J 7.5 Hz, ArCH), 7.29 (1H, d, J 7.5, 7.5 Hz, ArCH), 7.33 (2H, d, J 7.5 Hz, ArCH(22)), 
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7.35 (1H, d, J 8.5 Hz, ArCH(16)), 7.45 (1H, dd, J 8.1, 8.1 Hz, ArCH(15)), 7.68–7.72 (2H, 
m, ArCH(18)), 7.79 (1H, d, J 8.1 Hz, ArCH(14)), 8.71 (2H, d, J 7.5 Hz, ArCH(23)) 
13C (75 MHz, CDCl3) δ 39.28 (s, CH2(10ab)), 43.14 (s, C(8)), 44.65 (s, CH2(9ab)), 57.19 (s, 
CH2(7)), 114.84 (s, ArCH(14)), 116.60 (q, 
3JC-F 7.9 Hz, ArCH(18)), 120.30 (q, 
3JC-F 6.9 Hz, 
ArCH(16)), 121.06 (s, ArCH(22)), 123.06 (s, ArCH), 123.33 (s, ArCH), 122.91 (s, ArCH), 
123.87 (q, 1JC-F 272 Hz, CF3(19)), 129.00 (s, ArCH), 129.62 (s, ArCH(15)), 131.39 (q, 
2JC-
F 32 Hz, ArC(17)), 137.50 (s, ArC), 138.65 (s, ArC), 141.71 (s, ArC(13)), 143.25 (s, 
ArC(21)), 150.46 (s, ArCH(23)), 151.82 (s, C=O(11)), 167.97 (s, C=O(20)) 
19F (376 MHz, CDCl3) δ −64.7 (s, Ar-CF3(19)) 
Rf 0.33 (93:7, CH2Cl2:MeOH), 
IR ʋ/ cm-1 1544 (C-F, s), 1624 (C=O, s), 1721 (C=O, s), 2938 (C-H, w), 3308 (Ar C-H, w) 
MS (ESI): 481 [M+H+]  
HRMS C26H24F3N4O2 [M+H
+] requires 481.1846, found 481.1836 (2.1 ppm error) 
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Preparation of N1', N1'-Dimethyl-N1-(3-(trifluoromethyl)phenyl)spiro[indoline-3,4'-
piperidine]-1,1'-dicarboxamide (LVTa4): 
 
 
 
 
 
 
Following method C using Benzyl 1-((3-(trifluoromethyl)phenyl)carbamoyl)spiro[indoline-
3,4'-piperidine]-1'-carboxylate (LVT53) (250 mg, 0.67 mmol, 1 eq.), dimethylcarbonyl 
chloride (0.12 mL, 140 mg, 1.34 mmol, 2 eq.) and K2CO3 (185 mg, 1.34 mmol, 2 eq.) as 
starting materials. The desired product was purified using column chromatography (SiO2, 
93:7, CH2Cl2:MeOH), to afford, the pure product (LVTa4) a light cream solid (239 mg, 0.54 
mmol, 80%).  
Data for LVTa4 
mp 199‒202 ºC 
1H (300 MHz, D4-MeOH) δ 1.71 (2H, d, J 13.1 Hz, CH2(9a)), 1.96 (2H, dd, J 14.0, 13.1 Hz, 
CH2(9b)), 2.89 (6H, s, CH3(21)), 3.00 (2H, d, J 14.0, 13.1 Hz, CH2(10a)), 3.71 (2H, d, J 13.8 
Hz, CH2(10b)), 4.10 (2H, s, CH2(7)), 7.07 (1H, dd, J 7.4, 7.4 Hz, ArCH), 7.16–7.23 (2H, m, 
ArCH), 7.34 (1H, d, J 7.7 Hz, ArCH(16)), 7.50 (1H, dd, J 7.7, 7.7 Hz, ArCH(15)), 7.79 (1H, 
d, J 8.7 Hz, ArCH), 7.90 (1H, s, ArCH(18)), 7.93 (1H, d, J 7.7 Hz, ArCH(14)) 
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13C (75 MHz, CDCl3) δ 36.65 (s, CH2(9ab)), 38.41 (s, CH3(21)), 43.33 (s, C(8)), 44.30 (s, 
CH2(10ab)), 57.18 (s, CH2(7)), 115.34 (s, ArCH(14)), 116.77 (q, 
3JC-F 7.9 Hz, ArCH(18)), 
119.83 (q, 3JC-F 6.9 Hz, ArCH(16)), 122.62 (s, ArCH), 122.91 (s, ArCH), 123.30 (s, ArCH), 
124.00 (q, 1JC-F 272 Hz, CF3(19)), 128.61 (s, ArCH), 129.38 (s, ArCH(15)), 131.33 (q, 
2JC-
F 32 Hz, ArC(17)), 138.02 (s, ArC), 139.35 (s, ArC), 142.21 (s, ArC(13)), 152.32 (s, 
C=O(11)), 165.28 (s, C=O(20)) 
19F (376 MHz, CDCl3) δ −64.7 (s, Ar-CF3(19)) 
Rf 0.38 (93:7, CH2Cl2:MeOH), 
IR ʋ/ cm-1 1552 (C-F, s), 1675 (C=O, s), 1739 (C=O, s), 2844 (C-H, w), 3379 (Ar C-H, w) 
MS (ESI): 447 [M+H+] 
HRMS C23H26F3N4O2 [M+H
+] requires 447.2002, found 447.1998 (1.0 ppm error) 
 
Preparation of 1'-Benzoyl-N-(3-(trifluoromethyl)phenyl)spiro[indoline-3,4'-piperidine]-1-
carboxamide (LVTa5): 
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Following method C using Benzyl 1-((3-(trifluoromethyl)phenyl)carbamoyl)spiro[indoline-
3,4'-piperidine]-1'-carboxylate (LVT53) (200 mg, 0.53 mmol, 1 eq.), benzoyl chloride (0.13 
mL, 157 mg, 1.07 mmol, 2 eq.) and K2CO3 (148 mg, 1.07 mmol, 2 eq.) as starting materials. 
The desired product was purified using column chromatography (SiO2, 93:7, 
CH2Cl2:MeOH), to afford, the pure product (LVTa5) a light cream solid (223 mg, 0.47 
mmol, 88%).  
Data for LVTa5 
mp 243–246 ºC 
1H (300 MHz, CDCl3) δ 2.94 (2H, d, J 13.5 Hz, CH2(10a)), 3.12 (2H, dd, J 13.5, 13.1 Hz, 
CH2(9a)), 3.81 (2H, d, J 13.1, 12.5 Hz, CH2(9b)), 4.04 (2H, s, CH2(7)), 4.73 (2H, d, J 13.5 
Hz, CH2(10b)), 7.05 (1H, dd, J 7.4, 7.4 Hz, ArCH), 7.17 (1H, d, J 7.9 Hz, ArCH), 7.23–7.31 
(2H, m, ArCH(16)), 7.36–7.42 (6H, m, ArCH(15,22,23,24)), 7.70–7.72 (2H, m, ArCH(18)), 
7.93 (1H, d, J 7.9 Hz, ArCH(14)) 
13C (75 MHz, CDCl3) δ 39.47 (s, CH2(10ab)), 43.23 (s, C(8)), 44.76 (s, CH2(9ab)), 57.07 (s, 
CH2(7)), 115.24 (s, ArCH(14)), 116.84 (q, 
3JC-F  4.9 Hz, ArCH(18)), 120.00 (q, 
3JC-F 5.9 Hz, 
ArCH(16)), 122.70 (s, ArCH), 123.10 (s, ArCH), 123.34 (s, ArCH), 123.98 (q, 1JC-F 272 Hz, 
CF3(19)), 126.76 (s, ArCH(24)), 128.73 (s, ArCH(23)), 128.83 (s, ArCH(22)), 129.41 (s, 
ArCH), 130.11 (s, ArCH(15)), 131.11 (q, 2JC-F 32 Hz, ArC(17)), 135.42 (s, ArC(15)), 137.48 
(s, ArC), 139.08 (s, ArC), 142.09 (s, ArC(13)), 152.25 (s, C=O(11)), 170.92 (s, C=O(20)) 
19F (376 MHz, CDCl3) δ −64.6 (s, Ar-CF3(19)) 
Rf 0.39 (93:7, CH2Cl2:MeOH) 
IR ʋ/ cm-1 1539 (C-F, s), 1620 (C=O, s), 1677 (C=O, s), 2847 (C-H, w), 3331 (Ar C-H, w) 
MS (ESI): 480 [M+H+] 
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HRMS C27H25F3N3O2 [M+H
+] requires 480.1893, found 480.1880 (2.8 ppm error) 
 
Preparation of Benzyl 1-(phenylcarbamoyl)spiro[indoline-3,4'-piperidine]-1'-carboxylate 
(LVTa7): 
 
 
 
 
 
 
 
Benzyl spiro[indoline-3,4'-piperidine]-1'-carboxylate (300 mg, 0.94 mmol, 1 eq.) was 
dissolved in CH2Cl2 (20 mL) under a nitrogen atmosphere. Phenyl isocyanate (0.12 mL, 131 
mg, 1.13 mmol, 1.2 eq.) was added slowly via syringe and the resulting solution stirred for 
4 hours at room temperature. The solvent was removed under reduced pressure and the 
product purified using column chromatography (SiO2, 97:3 CH2Cl2:MeOH) to yield a cream 
solid LVTa7 (410 mg, 0.93 mmol, 99%). 
Data for LVTa7 
mp 106–108 °C 
1H (300 MHz, CDCl3) δ 1.66 (2H, br. d, J 13.4 Hz, CH2(9a)), 1.83 (2H, br. dd, J 13.4, 10.0 
Hz, CH2(9b)), 2.91 (2H, br. dd, CH2(10a)), 3.91 (2H, s, CH2(7)), 4.21 (2H, br. d, CH2(10b)), 
5.16 (1H, s, ArCH(18)), 6.86 (1H, s, NH), 6.99 (1H, dd, J 7.0, 7.0 Hz, ArCH), 7.05–7.10 
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(2H, m, ArCH), 7.18–7.33 (3H, m, ArCH), 7.36–7.37 (4H, m, ArCH), 7.46 (2H, d, J 7.6 Hz, 
ArCH), 7.85 (1H, d, J 8.0 Hz, ArCH) 
13C (75 MHz, CDCl3) δ 36.38 (CH2(10ab)), 41.06 (CH2(9ab)), 42.88 (ArC(8)), 57.01 
(CH2(7)), 67.36 (CH2(18)), 114.93 (ArCH), 120.02 (ArCH), 120.42 (ArCH), 122.75 
(ArCH), 122.83 (ArCH), 123.25 (ArCH), 123.82 (ArCH), 127.96 (ArCH), 128.17 (ArCH), 
128.59 (ArCH), 128.65 (ArCH), 129.04 (ArCH), 136.65 (ArC), 138.04 (ArC), 138.18 
(ArC), 142.20 (ArC(13)), 152.45 (C=O(11)), 155.37 (C=O(17)) 
Rf 0.44 (98:2, CH2Cl2:MeOH) 
IR ʋ/ cm-1 1624 (C-O, s), 1697 (C=O, s), 1723 (C=O, s), 2679 (C-H, w)  
MS (ESI): 442 [M+H+]  
HRMS C27H28NO3 [M+H
+] requires 442.2131, found 442.2134 (2.3 ppm error) 
 
Preparation of N-Phenylspiro[indoline-3,4'-piperidine]-1-carboxamide (LVTa9): 
 
 
 
 
 
 
Benzyl 1-(phenylcarbamoyl)spiro[indoline-3,4'-piperidine]-1'-carboxylate (LVTa7) (410 
mg, 0.93 mmol, 1 eq.) was dissolved in MeOH (15 mL) and then, Pearlman’s catalyst (65.3 
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mg, 0.09 mmol, 0.1 eq.) was added into the solution. The reaction mixture was purged with 
a balloon of hydrogen until deflated and then left under an atmosphere of hydrogen 
overnight. The methanol was removed under reduced pressure and the reaction mixture was 
filtered through celite with CH2Cl2 (100 mL) to collect any remaining starting material. The 
eluent 10% MeOH/CH2Cl2 (200 mL) was subsequently passed through the celite to elute the 
desired product. The product LVTa9 is an off-white amorphous solid (200 mg, 0.65 mmol, 
70%).  
Data for LVTa9 
mp 98–101 °C 
1H (300 MHz, CDCl3) δ 1.70 (2H, d, J 12.5 Hz, CH2(9a)), 1.90 (2H, dd, J 15.0, 12.5 Hz, 
CH2(9b)), 2.78 (2H, dd, J 12.5, 12.5 Hz, CH2(10a)), 3.14 (2H, d, J 15.0 Hz, CH2(10b)), 3.96 
(2H, s, CH2(7)), 6.58 (1H, s, NH(12)), 7.02 (1H, dd, J 7.3, 7.3 Hz, ArCH), 7.10 (1H, dd, J 
7.3, 7.3 Hz, ArCH), 7.20 (1H, d, J 7.3 Hz, ArCH), 7.24 (1H, dd, J 7.5, 7.5 Hz, ArCH(16)), 
7.35 (2H, dd, J 8.6, 8.6 Hz, ArCH(15)), 7.48 (2H, d, J 8.5 Hz, ArCH(14)), 7.97 (1H, d, J 7.3 
Hz, ArCH) 
13C (75 MHz, CDCl3) δ 37.70 (CH2(9ab)), 43.34 (C(8)), 43.54 (CH2(10ab)), 57.69 (CH2(7)), 
114.78 (ArCH(6)), 120.08 (ArCH(14)), 122.74 (ArCH), 122.85 (ArCH), 123.67 (ArCH), 
128.33 (ArCH(16)), 129.05 (ArCH(15)), 138.13 (ArC), 139.16 (ArC), 142.03 (ArC(13)), 
152.22 (C=O(11)) 
IR ʋ/ cm-1 1652 (C=O, s), 2929 (C-H, w), 3290 (Ar C-H, w) 
MS (ESI): 308 [M+H+] 
HRMS C19H22N3O [M+H
+] requires 308.1763, found 308.1762 (1.9 ppm error) 
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Preparation of 1'-(Morpholine-4-carbonyl)-N-phenylspiro[indoline-3,4'-piperidine]-1-
carboxamide (LVTa10): 
 
 
 
 
 
 
 
Following method C using N-Phenylspiro[indoline-3,4'-piperidine]-1-carboxamide 
(LVTa9) (200 mg, 0.65 mmol, 1 eq.), 4-morpholinecarbonyl chloride (0.14 mL, 179 mg, 
1.24 mmol, 2 eq.) and K2CO3 (167 mg, 1.24 mmol, 2 eq.) as starting materials. The desired 
product was purified using column chromatography (SiO2, 93:7, CH2Cl2:MeOH), to afford, 
the pure product (LVTa10) a brown solid (80.2 mg, 0.19 mmol, 29%).  
Data for LVTa10 
mp 133–136 ºC 
1H (300 MHz, CDCl3) δ 1.75 (2H, d, J 13.8 Hz, CH2(9a)), 1.94 (2H, dd, J 13.8, 13.1 Hz, 
CH2(9b)), 2.97 (2H, dd, J 13.1, 13.1 Hz, CH2(10a)), 3.26–3.34 (4H, m, CH2(18)), 3.67–3.73 
(4H, m, CH2(19)), 3.76 (2H, d, J 13.1 Hz, CH2(10b)), 3.98 (2H, s, CH2(7)), 6.62 (1H, s, 
NH(12)), 7.02 (1H, dd, J 7.3, 7.3 Hz, ArCH), 7.12 (1H, dd, J 7.3, 7.3 Hz, ArCH), 7.18 (1H, 
d, J 7.3 Hz, ArCH), 7.25 (1H, dd, J 7.7, 7.7 Hz, ArCH(16)), 7.35 (2H, dd, J 7.7, 7.7 Hz, 
ArCH(15)), 7.47 (2H, d, J 7.7 Hz, ArCH(14)), 7.82 (1H, d, J 7.3 Hz, ArCH) 
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13C (75 MHz, CDCl3) δ 36.46 (CH2(9ab)), 43.22 (C(8)), 44.06 (CH2(10ab)), 47.34 (CH2(18)), 
57.16 (CH2(7)), 66.66 (CH2(19)), 114.76 (ArCH), 120.07 (ArCH(14)), 122.81 (ArCH), 
123.65 (ArCH), 123.78 (ArCH), 128.65 (ArCH(16)), 129.08 (ArCH(15)), 138.02 (ArC), 
138.13 (ArC), 142.07 (ArC(13)), 152.162 (C=O(11)), 164.03 (C=O(17)) 
Rf 0.31 (9:1, CH2Cl2:MeOH) 
IR ʋ/ cm-1 1623 (C=O, s), 1674 (C=O, s), 2852 (C-H, w), 3324 (Ar C-H, w) 
MS (ESI): 421 [M+H+]  
HRMS C24H29N4O3 [M+H
+] requires 421.2234, found 421.2233 (0.3 ppm error) 
 
Preparation of Tert-butyl 4-(1-((3-(trifluoromethyl)phenyl)carbamoyl)spiro[indoline-3,4'-
piperidin]-1'-ylcarbonyl)piperazine-1-carboxylate (LVTa12): 
 
 
 
 
 
 
 
Triphosgene (56.4 mg, 0.19 mmol, 1eq.) was dissolved in anhydrous CH2Cl2 (15 mL) under 
a nitrogen atmosphere and stirred in an ice bath for 15 minutes. N-(3-
(Trifluoromethyl)phenyl)spiro[indoline-3,4'-piperidine]-1-carboxamide hydrochloride 
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(LVT53) (200 mg, 0.53 mmol, 1 eq.) was dissolved separately in anhydrous CH2Cl2 (10 mL) 
under a nitrogen atmosphere and subsequently added into the reaction flask slowly. The 
resulting solution was stirred for 30 minutes. Triethylamine (0.06 mL, 43.6 mg, 0.42 mmol, 
2.2 eq.) was then dissolved in anhydrous CH2Cl2 (5 mL) under a nitrogen atmosphere and 
transferred into the main reaction flask via syringe slowly and stirred for a further 20 
minutes. 1-Boc-piperazine (89.4 mg, 0.48 mmol, 2.52 eq.) was next dissolved in anhydrous 
CH2Cl2 (10 mL) under a nitrogen atmosphere and triethylamine (0.06 mL, 43.6 mg, 0.42 
mmol, 2.2 eq.) subsequently added into this mixture. The secondary reaction mixture was 
added slowly via syringe into the primary reaction flask and stirred for 1 hour. The reaction 
was quenched with saturated aqueous NaHCO3 (50 mL), followed by the addition of H2O 
(30 mL).  Organics were extracted with CH2Cl2 (2 × 20 mL), washed with saturated aqueous 
brine (30 mL), dried over MgSO4, filtered and solvent removed under reduced pressure. The 
product was purified by column chromatography (SiO2, 93:7, CH2Cl2:MeOH), which 
revealed LVTa12 as a light cream solid (231 mg, 0.39 mmol, 74%).  
Data for LVTa12 
mp 128‒131 ºC 
1H (300 MHz, CDCl3) δ 1.47 (9H, s, CH3(25)), 1.74 (2H, d, J 13.4 Hz, CH2(9a)), 1.96 (2H, 
dd, J 13.4, 12.7 Hz, CH2(9b)), 2.96 (2H, dd, J 12.7, 12.7 Hz, CH2(10a)), 3.23–3.27 (4H, m, 
CH2(22)), 3.40–3.43 (4H, m, CH2(21)), 3.74 (2H, d, J 13.4 Hz, CH2(10b)), 4.00 (2H, s, 
CH2(7)), 6.98 (1H, s, NH(12)), 7.05 (1H, dd, J 7.3, 7.3 Hz, ArCH), 7.19 (1H, d, J 7.3 Hz, 
ArCH), 7.18 (1H, dd, J 7.3, 7.3 Hz, ArCH), 7.34 (1H, d, J 7.9 Hz, ArCH(16)), 7.45 (1H, dd, 
J 7.9, 7.9 Hz, ArCH(15)), 7.71–7.75 (2H, m, ArCH(18)), 7.86 (1H, d, J 7.9 Hz, ArCH(14)) 
13C (75 MHz, CDCl3) δ 28.38 (s, CH3(25)), 36.46 (s, CH2(9ab)), 43.30 (s, C(8)), 44.14 (4C, 
s, CH2(10ab,21)), 46.66 (s, CH2(22)), 57.16 (s, CH2(7)), 80.20 (s, C(24)), 115.00 (s, 
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ArCH(14)), 116.61 (q, 3JC-F 7.3 Hz, ArCH(18)), 120.12 (q, 
3JC-F 7.6 Hz, ArCH(16)), 122.87 
(s, ArCH), 123.08 (s, ArCH), 123.14 (s, ArCH), 123.90 (q, 1JC-F 272 Hz, ArCH(19)), 128.71 
(s, ArCH), 129.54 (s, ArCH(15)), 131.33 (q, 2JC-F 32 Hz, ArC(17)), 138.07 (s, ArC), 138.85 
(s, ArC), 141.84 (s, ArC(13)), 151.92 (s, C=O(11)), 154.70 (s, C=O(20)), 164.05 (s, 
C=O(23)) 
19F (376 MHz, CDCl3) δ −64.7 (s, Ar-CF3(19)) 
Rf 0.42 (93:7, CH2Cl2:MeOH) 
IR ʋ/ cm-1 1545 (C-F, s), 1602 (C=O, s), 1627 (C=O, s), 1680 (C=O, s), 2854 (C-H, w), 3326 
(Ar C-H, w) 
MS (ESI): 588 [M+H+] 
HRMS C30H37F3N5O4 [M+H
+] requires 588.2792, found 588.2787 (0.9 ppm error) 
 
Preparation of Methyl 1-((3-(trifluoromethyl)phenyl)carbamoyl)spiro[indoline-3,4'-
piperidine]-1'-carboxylate (LVTa14): 
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Triphosgene (48.0 mg, 0.16 mmol, 1eq.) was dissolved in anhydrous CH2Cl2 (15 mL) under 
a nitrogen atmosphere and stirred in an ice bath for 15 minutes. N-(3-
(trifluoromethyl)phenyl)spiro[indoline-3,4'-piperidine]-1-carboxamide hydrochloride 
(LVT53) (164 mg, 0.44 mmol, 1 eq.) was dissolved separately in anhydrous CH2Cl2 (10 mL) 
under a nitrogen atmosphere and subsequently added into the reaction flask slowly. The 
resulting solution was stirred for 30 minutes. Triethylamine (0.05 mL, 36.3 mg, 0.35 mmol, 
2.2 eq.) was then dissolved in anhydrous CH2Cl2 (5 mL) under a nitrogen atmosphere and 
transferred into the main reaction flask via syringe slowly and stirred for a further 20 
minutes. 4-Aminophenol (44.0 mg, 0.40 mmol, 2.52 eq.) was next dissolved in anhydrous 
CH2Cl2 (10 mL) under a nitrogen atmosphere and triethylamine (0.05 mL, 36.3 mg, 0.35 
mmol, 2.2 eq.) subsequently added into this mixture. The secondary reaction mixture was 
added slowly via syringe into the primary reaction flask and stirred for 1 hour. The reaction 
was quenched with saturated aqueous NaHCO3 (50 mL), followed by the addition of H2O 
(30 mL).  Organics were extracted with CH2Cl2 (2 × 20 mL), washed with saturated aqueous 
brine (30 mL), dried over MgSO4, filtered and solvent removed under reduced pressure. The 
product was purified by column chromatography (SiO2, 99:1, CH2Cl2:MeOH), which 
revealed the side product LVTa14 as a light cream solid (20 mg, 0.05 mmol, 29%).  
Data for LVTa14 
mp 112–116 ºC 
1H (300 MHz, CDCl3) δ 1.72 (2H, d, J 13.4 Hz, CH2(9a)), 1.89 (2H, dd, J 13.4, 12.8 Hz, 
CH2(9b)), 2.95 (2H, dd, J 12.8, 12.8 Hz, CH2(10a)), 3.74 (3H, s, CH3(21)), 3.99 (2H, s, 
CH2(7)), 4.22 (2H, d, J 12.8 Hz, CH2(10b)), 6.92 (1H, s, NH(12)), 7.05 (1H, dd, J 7.2, 7.2 
Hz, ArCH), 7.14 (1H, d, J 7.2 Hz, ArCH), 7.27 (1H, dd, J 7.2, 7.2 Hz, ArCH), 7.34 (1H, d, 
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J 7.7 Hz, ArCH(16)), 7.44 (1H, dd, J 7.7, 7.7 Hz, ArCH(15)), 7.71 (1H, d, J 8.0 Hz, ArCH), 
7.75 (1H, s, ArCH(18)), 7.85 (1H, d, J 8.0 Hz, ArCH(14)) 
13C (75 MHz, CDCl3) δ 36.35 (s, CH2(9ab)), 40.94 (s, CH2(10ab)), 42.98 (s, C(8)), 52.83 (s, 
CH3(21)), 56.94 (s, CH2(7)), 114.98 (s, ArCH(14)), 116.65 (q, 
3JC-F 7.6 Hz, ArCH(18)), 
120.10 (q, 3JC-F 7.5 Hz, ArCH(16)), 122.84 (s, ArCH), 123.14 (s, ArCH), 123.19 (s, ArC), 
123.91 (q, 1JC-F 272 Hz, ArCH(19)), 128.71 (s, ArCH), 129.54 (s, ArCH(15)), 131.34 (q, 
2JC-F 32 Hz, ArC(17)), 138.07 (s, ArC), 138.77 (s, ArC), 141.79 (s, ArC(13)), 151.91 (s, 
C=O(11)), 155.95 (s, C=O(20)) 
19F (376 MHz, CDCl3) δ −64.7 (s, Ar-CF3(19)) 
Rf 0.42 (99:1, CH2Cl2:MeOH) 
IR ʋ/ cm-1 1328 (C-O, s), 1540 (C-F, s), 1600 (C=O, s), 1675 (C=O, s), 2860 (C-H, w), 3325 
(Ar C-H, w) 
MS (ESI): 434 [M+H+]  
HRMS C22H23F3N3O3 [M+H
+] requires 434.1686, found 434.1685 (0.2 ppm error) 
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Preparation of 1'-(4-Methylpiperazine-1-carbonyl)-N-(3-
(trifluoromethyl)phenyl)spiro[indoline-3,4'-piperidine]-1-carboxamide (LVTa18): 
 
 
 
 
 
 
 
Following method C using Benzyl 1-((3-(trifluoromethyl)phenyl)carbamoyl)spiro[indoline-
3,4'-piperidine]-1'-carboxylate (LVT53) (119 mg, 0.32 mmol, 1 eq.), 4-methyl-1-
piperazinecarbonyl chloride hydrochloride (127 mg, 0.64 mmol, 2 eq.) and K2CO3 (88.4 mg, 
0.64 mmol, 2 eq.) as starting materials. The desired product was purified using column 
chromatography (SiO2, 93:7, CH2Cl2:MeOH), to afford, the pure product (LVTa18) a light 
cream solid (139 mg, 0.28 mmol, 87%).  
Data for LVTa18 
mp 110–114 ºC 
1H (300 MHz, CDCl3) δ 1.73 (2H, d, J 13.3 Hz, CH2(9a)), 1.95 (2H, dd, J 13.3, 12.8 Hz, 
CH2(9b)), 2.29 (3H, s, CH3(23)), 2.37–2.39 (4H, m, CH2(21)), 2.91 (2H, dd, J 12.8, 12.8 Hz, 
CH2(10a)), 3.35–3.36 (4H, m, CH2(22)), 3.70 (2H, d, J 12.8 Hz, CH2(10b)), 4.01 (2H, s, 
CH2(7)), 7.03 (1H, dd, J 7.4, 7.4 Hz, ArCH), 7.18 (1H, d, J 7.4 Hz, ArCH), 7.26 (1H, dd, J 
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7.4, 7.4 Hz, ArCH), 7.32 (1H, d, J 7.6 Hz, ArCH(16)), 7.45 (1H, dd, J 7.6, 7.6 Hz, 
ArCH(15)), 7.76–7.78 (2H, m, ArCH(18)), 7.92 (1H, d, J 7.6 Hz, ArCH(14)) 
13C (75 MHz, CDCl3) δ 36.57 (s, CH2(9ab)), 43.32 (s, C(8)), 44.36 (s, CH2(10ab)), 46.13 (s, 
CH3(21)), 46.64 (s, CH2(21)), 54.75 (s, CH2(22)), 57.14 (s, CH2(7)), 115.22 (s, ArCH(14)), 
116.72 (q, 3JC-F 6.8 Hz, ArCH(18)), 119.96 (q, 
3JC-F 7.2 Hz, ArCH(16)), 122.70 (s, ArCH), 
122.98 (s, ArCH), 123.18 (s, ArCH), 123.91 (q, 1JC-F 272 Hz, ArCH(19)), 128.66 (s, ArCH), 
129.44 (s, ArCH(15)), 131.39 (q, 2JC-F 32 Hz, ArC(17)), 137.98 (s, ArC), 139.16 (s, ArC), 
142.08 (s, ArC(13)), 152.17 (s, C=O(11)), 164.16 (s, C=O(20)) 
19F (376 MHz, CDCl3) δ −64.7 (s, Ar-CF3(19)) 
Rf 0.40 (93:7, CH2Cl2:MeOH) 
IR ʋ/ cm-1 1328 (C-O, s), 1545 (C-F, s), 1622 (C=O, s), 1656 (C=O, s), 2848 (C-H, w), 3313 
(Ar C-H, w) 
MS (ESI): 502 [M+H+] 
HRMS C26H31F3N5O2 [M+H
+] requires 502.2424, found 502.2417 (1.5 ppm error) 
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Preparation of 1'-Benzyl-N-phenylspiro[indoline-3,4'-piperidine]-1-carboxamide 
(LVTa19): 
 
 
 
 
 
 
 
1'-Benzylspiro[indoline-3,4'-piperidine] (121 mg, 0.43 mmol, 1 eq.) was dissolved in 
CH2Cl2 (20 mL) under a nitrogen atmosphere. Phenyl isocyanate (0.06 mL, 65.4 mg, 0.52 
mmol, 1.2 eq.) was added slowly via syringe and the solution stirred for 4 hours. The solvent 
was removed under reduced pressure and the product purified using column chromatography 
(SiO2, 93:7, CH2Cl2:MeOH), yielding a golden brown solid LVTa19 (136 mg, 0.34 mmol, 
80%).  
Data for LVTa19 
mp 84‒88 ºC 
1H (300 MHz, CDCl3) δ 1.68 (2H, d, J 8.9 Hz, CH2(9a)), 1.97–2.14 (4H, m, CH2(9b,10a)), 
2.94 (2H, d, J 8.9 Hz, CH2(10b)), 3.58 (2H, s, CH2(17)), 3.89 (2H, s, CH2(7)), 6.58 (1H, s, 
NH(12)), 7.01 (1H, dd, J 7.3, 7.3 Hz, ArCH), 7.09 (1H, dd, J 7.3, 7.3 Hz, ArCH), 7.20 (1H, 
d, J 7.3 Hz, ArCH), 7.28–7.36 (7H, m, ArCH(16,19-21)), 7.47 (2H, d, J 7.5 Hz, ArCH(14)), 
7.84 (1H, d, J 7.3 Hz, ArCH) 
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13C (75 MHz, CDCl3) δ 37.12 (CH2(9ab)), 42.86 (C(8)), 50.55 (CH2(10ab)), 57.56 (CH2(7)), 
63.44 (CH2(17)), 114.76 (ArCH), 120.21 (ArCH(15)), 120.53 (ArCH(16)), 122.73 (ArCH), 
122.85 (ArCH), 123.72 (ArCH), 127.19 (ArC(18)), 128.31 (ArCH(21)), 129.03 
(ArCH(20)), 129.22 (ArCH(19)), 138.09 (ArC), 138.91 (ArC), 142.13 (ArC(13)), 152.30 
(C=O(11)) 
Rf 0.47 (3:1, EtOAc:Pet.ether) 
IR ʋ/ cm-1 1651 (C=O, s), 2804 (C-H, w), 3291 (Ar C-H, w) 
MS (ESI): 398 [M+H+] 
HRMS C26H28N3O [M+H
+] requires 398.2227, found 398.2226 (0.02 ppm error) 
 
Preparation of Benzyl 1-((3-chlorophenyl)carbamoyl)spiro[indoline-3,4'-piperidine]-1'-
carboxylate (LVTa117): 
 
 
 
 
 
 
 
Benzyl spiro[indoline-3,4'-piperidine]-1'-carboxylate (LVTa46) (1.00 g, 3.12 mmol, 1 eq.) 
was dissolved in CH2Cl2 (20 mL) under a nitrogen atmosphere. 3-Chlorophenyl isocyanate 
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(0.46 mL, 120 mg, 3.75 mmol, 1.2 eq.) was added slowly via syringe and the resulting 
solution, turned dark green on leaving to stir, for 4 hours. The solvent was removed under 
reduced pressure and the product purified using column chromatography (SiO2, 99:1, 
CH2Cl2:MeOH), which yielded an off-white solid LVTa117 (1.00 g, 2.10 mmol, 67%). 
Data for LVTa117 
mp 106–109 ºC 
1H (300 MHz, CDCl3) δ 1.68 (2H, br. d, J 12.4 Hz, CH2(9a)), 1.88 (2H, br. dd, J 12.7, 12.4 
Hz, CH2(9b)), 2.94 (2H, br. dd, J 12.7, 12.7 Hz, CH2(10a)), 3.92 (2H, s, CH2(7)), 4.23 (2H, 
br. d, J 12.7 Hz, CH2(10b)), 5.17 (2H, s, CH2(20)), 7.03 (1H, br. s, NH(12)), 7.07–7.07 (3H, 
m, ArCH), 7.13 (1H, d, J 7.0 Hz, ArCH), 7.20–7.38 (7H, m, ArCH(16,18,22-24)), 7.57 (1H, 
dd, J 8.0, 8.0 Hz, ArCH(15)), 7.83 (1H, d, J 8.0 Hz, ArCH(14))  
13C (75 MHz, CDCl3) δ 36.35 (CH2(9ab)), 41.01 (CH2(10ab)), 42.93 (C(8)), 56.89 (CH2(7)), 
67.39 (CH2(20)), 114.96 (ArCH(14)), 118.08 (ArCH(16)), 120.15 (ArCH(15)), 122.83 
(ArCH), 123.12 (ArCH), 123.73 (ArCH), 127.97 (ArCH(24)), 128.20 (ArCH(23)), 128.59 
(ArCH(22)), 128.73 (ArCH), 130.01 (ArCH(18)), 134.64 (ArC), 136.54 (ArC), 138.01 
(ArC(13)), 139.38 (ArC(21)), 141.88 (ArC(17)), 151.93 (C=O(11)), 155.35 (C=O(19))       
Rf 0.15 (99:1, CH2Cl2:MeOH) 
IR ʋ/ cm-1 1590 (C-O, s), 1674 (C=O, s), 2853 (C-H, w), 3032 (Ar C-H, w) 
MS (ESI): 476/478 [M+H+]  
HRMS C27H27
35ClN3O3 [M+H
+] requires 476.1741, found 476.1751 (2.7 ppm error) 
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Preparation of N-(3-Chlorophenyl)spiro[indoline-3,4'-piperidine]-1-carboxamide 
hydrochloride (LVTa118): 
 
 
 
 
 
 
Benzyl 1-((3-chlorophenyl)carbamoyl)spiro[indoline-3,4'-piperidine]-1'-carboxylate 
(LVTa117) (1.00 g, 2.10 mmol, 1 eq.) was dissolved in MeOH (15 mL) and then, Pearlman’s 
catalyst (147 mg, 0.21 mmol, 0.1 eq.) was added into the solution. The reaction mixture was 
purged with a balloon of hydrogen until deflated and then left under an atmosphere of 
hydrogen overnight. The methanol was removed under reduced pressure and the reaction 
mixture was filtered through celite with CH2Cl2 (100 mL) to collect any remaining starting 
material. The solvent 10% MeOH/CH2Cl2 (200 mL) was subsequently passed through the 
celite to elute the desired product. The product LVTa118 is a brown amorphous solid (693 
mg, 2.03 mmol, 97%).  
Data for LVTa118 
1H (300 MHz, D4-MeOH) δ 1.91 (2H, br. d, J 14.2 Hz, CH2(9a)), 2.17 (2H, br. dd, J 14.2, 
12.2 Hz, CH2(9b)), 3.22 (2H, br. dd, J 12.5, 12.2 Hz, CH2(10a)), 3.46 (2H, br. d, J 12.2 Hz, 
CH2(10b)), 4.17 (2H, s, CH2(7)), 7.01 (1H, dd, J 7.4, 7.4 Hz, ArCH), 7.08 (1H, dd, J 7.4, 7.4 
Hz, ArCH), 7.19–7.25 (2H, m, ArCH), 7.31 (1H, dd, J 7.6, 7.6 Hz, ArCH(16)), 7.52–7.55 
(2H, m, ArCH(17,18)), 7.91 (1H, d, J 7.6 Hz, ArCH(15)) 
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13C (75 MHz, D4-MeOH) δ 34.24 (CH2(9ab)), 42.70 (CH2(10ab)), 42.91 (C(8)), 58.19 
(CH2(7)), 116.69 (ArCH(15)), 122.57 (2C, ArCH(17,19)), 122.20 (2C, ArCH(3,6)), 122.51 
(ArCH), 123.40 (ArCH)), 129.75 (ArCH(16)), 138.10 (2C, ArC), 140.10 (ArC(14)), 143.93 
(ArC(18)), 155.16 (C=O(12))  
IR ʋ/ cm-1 695 (C-Cl, s), 1663 (C=O, s), 3187 (Ar C-H, w) 
MS (ESI): 342/344 [M+H+]  
HRMS C19H21
35ClN3O [M+H
+] requires 342.1373, found 342.1436 (1.7 ppm error) 
 
Preparation of N-(3-Chlorophenyl)-1'-(2-(piperidin-1-yl)ethyl)spiro[indoline-3,4'-
piperidine]-1-carboxamide (LVTa121): 
 
 
  
 
 
 
 
Following method C using N-(3-Chlorophenyl)spiro[indoline-3,4'-piperidine]-1-
carboxamide hydrochloride (LVTa118) (200 mg, 0.59 mmol, 1 eq.), 1-(2-chloroethyl) 
piperidine hydrochloride (217 mg, 1.18 mmol, 2 eq.) and K2CO3 (163 mg, 1.18 mmol, 2 eq.) 
as starting materials. The desired product was purified using column chromatography (SiO2, 
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4:1, CH2Cl2:MeOH), to afford, the pure product (LVTa121) as an off-white solid (141 mg, 
0.31 mmol, 53%).  
Data for LVTa121 
mp 254–257 ºC 
1H (300 MHz, CDCl3) δ 1.56–1.61 (2H, m, CH2(23)), 1.73 (2H, d, J 12.7 Hz, CH2(9a)), 
1.86–1.94 (4H, m, CH2(22)), 2.00 (2H, dd, J 15.0, 12.7 Hz, CH2(9b)), 2.26 (2H, dd, J 12.7, 
11.7 Hz, CH2(10a)), 2.86–2.98 (8H, m, CH2(19,20,21)), 3.01 (2H, d, J 11.7 Hz, CH2(10b)), 
3.95 (2H, s, CH2(7)), 6.90 (1H, br. s, NH(12)), 7.00 (1H, dd, J 7.4, 7.4 Hz, ArCH), 7.09 (1H, 
dd, J 7.4, 7.4 Hz, ArCH), 7.16–7.24 (2H, m, ArCH), 7.34 (2H, dd, J 8.0, 8.0 Hz, ArCH(15)), 
7.54–7.56 (2H, m, ArCH(16,18)), 7.89 (1H, d, J 8.0 Hz, ArCH(14)) 
13C (75 MHz, CDCl3) δ 22.90 (CH2(23)), 23.89 (CH2(23)), 36.88 (CH2(9ab)), 42.66 (C(8)), 
50.90 (CH2(10ab)), 54.42 (4C, CH2(19,20,21)), 57.54 (CH2(7)), 114.98 (ArCH(14)), 120.22 
(2C, ArCH(16,18)), 122.64 (2C, ArCH), 123.58 (2C, ArCH), 128.47 (ArCH)), 128.98 
(ArCH(15)), 138.30 (2C, ArC), 138.36 (ArC(17)), 142.36 (ArC(13)), 152.39 (C=O(11))  
Rf 0.29 (4:1, CH2Cl2:MeOH) 
IR ʋ/ cm-1 1658 (C=O, s), 2788 (C-H, w), 3244 (Ar C-H, w) 
MS (ESI): 453/455 [M+H+] 
HRMS C26H34
35ClN4O [M+H
+] requires 453.2421, found 453.2430 (3.8 ppm error) 
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Preparation of N-(3-Chlorophenyl)-1'-pentylspiro[indoline-3,4'-piperidine]-1-carboxamide 
(LVTa124): 
 
 
  
 
 
 
 
Following method C using N-(3-Chlorophenyl)spiro[indoline-3,4'-piperidine]-1-
carboxamide hydrochloride (LVTa118) (100 mg, 0.29 mmol, 1 eq.), iodopentane (0.08 mL, 
121 mg, 0.58 mmol, 2 eq.) and K2CO3 (80.2 mg 0.58 mmol, 2 eq.) as starting materials. The 
desired product was purified using column chromatography (SiO2, 4:1, CH2Cl2:MeOH), to 
afford, the pure product (LVTa124) as an off-white solid (83.0 mg, 0.20 mmol, 70%).  
Data for LVTa124 
mp 100–105 ºC 
1H (300 MHz, CDCl3) δ 0.92 (3H, t, J 7.9 Hz, CH2(23)), 1.29–1.37 (4H, m, CH2(21,22)), 
1.52–1.58 (2H, m, CH2(20)), 1.75 (2H, dd, J 14.9, 14.0 Hz, CH2(9a)), 2.09–2.15 (4H, m, 
CH2(9b,10a)), 2.43 (2H, t, J 8.1 Hz, CH2(19)), 3.03 (2H, d, J 14.0 Hz, CH2(10b)), 3.91 (2H, 
s, CH2(7)), 6.60 (1H, br. s, NH(12)), 7.04 (1H, dd, J 7.4, 7.4 Hz, ArCH), 7.10 (1H, dd, J 7.4, 
7.4 Hz, ArCH), 7.22 (2H, d, J 7.5 Hz, ArCH), 7.34 (2H, dd, J 7.8, 7.8 Hz, ArCH(15)), 7.46–
7.49 (2H, m, ArCH(16,18)), 7.83 (1H, d, J 7.8 Hz, ArCH(14)) 
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13C (75 MHz, CDCl3) δ 14.08 (CH3(23)), 22.62 (CH2(22)), 26.51 (CH2(20)), 29.82 
(CH2(21)), 36.83 (CH2(9ab)), 42.81 (C(8)), 50.72 (CH2(10ab)), 57.60 (CH2(7)), 59.11 
(CH2(19)), 114.70 (ArCH(14)), 120.14 (2C, ArCH(16,18)), 122.78 (2C, ArCH), 123.70 
(2C, ArCH), 128.41 (ArCH), 129.06 (ArCH(15)), 138.13 (2C, ArC), 138.71 (ArC(17)), 
142.12 (ArC(13)), 152.25 (C=O(11))  
Rf 0.29 (93:7, CH2Cl2:MeOH) 
IR ʋ/ cm-1 1652 (C=O, s), 2859 (C-H, w), 3043 (Ar C-H, w)  
MS (ESI): 412/414 [M+H+] 
HRMS C24H31
35ClN3O [M+H
+] requires 412.2156, found 412.2167 (3.9 ppm error) 
 
Preparation of N-(3-Chlorophenyl)-1'-hexylspiro[indoline-3,4'-piperidine]-1-carboxamide 
(LVTa125): 
 
 
 
 
 
 
Following method C using N-(3-Chlorophenyl)spiro[indoline-3,4'-piperidine]-1-
carboxamide hydrochloride (LVTa118) (100 mg, 0.29 mmol, 1 eq.), iodohexane (0.09 mL, 
129 mg, 0.58 mmol, 2 eq.) and K2CO3 (80.2 mg, 0.58 mmol, 2 eq.) as starting materials. The 
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desired product was purified using column chromatography (SiO2, 4:1, CH2Cl2:MeOH), to 
afford, the pure product (LVTa125) as a light cream solid (89.0 mg, 0.21 mmol, 72%).  
Data for LVTa125 
mp 115–117 ºC 
1H (300 MHz, CDCl3) δ 0.90 (3H, t, J 7.4 Hz, CH2(24)), 1.29–1.34 (6H, m, CH2(21,22,23)), 
1.56–1.59 (2H, m, CH2(20)), 1.75 (2H, dd, J 12.9, 12.9 Hz, CH2(9a)), 2.09–2.18 (4H, m, 
CH2(9b,10a)), 2.46 (2H, t, J 7.9 Hz, CH2(19)), 3.05 (2H, d, J 12.9 Hz, CH2(10b)), 3.93 (2H, 
s, CH2(7)), 6.68 (1H, br. s, NH(12)), 7.01 (1H, dd, J 7.4, 7.4 Hz, ArCH), 7.09 (1H, dd, J 7.4, 
7.4 Hz, ArCH), 7.21 (2H, d, J 8.0 Hz, ArCH), 7.34 (2H, dd, J 8.0, 8.0 Hz, ArCH(15)), 7.48–
7.50 (2H, m, ArCH(16,18)), 7.83 (1H, d, J 8.0 Hz, ArCH(14)) 
13C (75 MHz, CDCl3) δ 14.06 (CH3(24)), 22.59 (CH2(23)), 26.60 (CH2(20)), 27.25 
(CH2(22)), 31.72 (CH2(21)), 36.62 (CH2(9ab)), 42.71 (C(8)), 50.64 (CH2(10ab)), 57.62 
(CH2(7)), 59.01 (CH2(19)), 114.72 (ArCH(14)), 120.17 (2C, ArCH(16,18)), 122.80 
(ArCH), 122.90 (ArCH), 123.67 (ArCH), 128.42 (ArCH), 129.01 (ArCH(15)), 138.15 (2C, 
ArC), 138.53 (ArC(17)), 142.12 (ArC(13)), 152.27 (C=O(11))  
Rf 0.19 (93:7, CH2Cl2:MeOH) 
IR ʋ/ cm-1 1647 (C=O, s), 2854 (C-H, w), 3322 (Ar C-H, w)  
MS (ESI): 426/428 [M+H+]  
HRMS C25H33
35ClN3O [M+H
+] requires 426.2307, found 426.2305 (0.4 ppm error) 
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Preparation of Benzyl 1-((3-fluorophenyl)carbamoyl)spiro[indoline-3,4'-piperidine]-1'-
carboxylate (LVTa126): 
 
 
 
 
 
 
 
Benzyl spiro[indoline-3,4'-piperidine]-1'-carboxylate (LVTa46) (200 mg, 0.62 mmol, 1 eq.) 
was dissolved in CH2Cl2 (20 mL) under a nitrogen atmosphere. 3-Fluorophenyl isocyanate 
(0.08 mL, 96.1 mg, 0.74 mmol, 1.2 eq.) was added slowly via syringe and the resulting 
solution, turned dark green on leaving to stir, for 4 hours. The solvent was removed under 
reduced pressure and the product purified using column chromatography (SiO2, 99:1 
CH2Cl2:MeOH), which yielded an off-white solid LVTa126 (271 mg, 0.59 mmol, 95%). 
Data for LVTa126 
mp 107–109 ºC 
1H (300 MHz, CDCl3) δ 1.70 (2H, d, J 13.3 Hz, CH2(9a)), 1.89 (2H, dd, J 13.3, 10.9 Hz, 
CH2(9b)), 2.94 (2H, dd, J 12.3, 10.9 Hz, CH2(10a)), 3.93 (2H, s, CH2(7)), 4.25 (2H, d, J 12.3 
Hz, CH2(10b)), 5.17 (2H, s, CH2(21)), 6.76–6.81 (2H, m, ArCH), 7.03 (1H, dd, J 7.8, 7.8 
Hz, ArCH(15)), 7.11–7.16 (2H, m, ArCH), 7.23–7.41 (7H, m, ArCH), 7.82 (1H, d, J 7.8 Hz, 
ArCH(14)) 
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13C (75 MHz, CDCl3) δ 36.29 (s, CH2(9ab)), 40.98 (s, CH2(10ab)), 42.88 (s, C(8)), 56.78 (s, 
CH2(7)), 67.39 (s, CH2(21)), 107.78 (d, 
2JC-F 26 Hz, ArCH(16)), 110.59 (s, ArCH), 110.87 
(s, ArCH), 115.02 (s, ArCH(14)), 115.27 (d, 3JC-F 4.7 Hz, ArCH(15)), 122.75 (s, ArCH), 
123.04 (s, ArCH), 127.92 (s, ArCH(25)), 128.12 (s, ArCH(24)), 128.60 (s, ArCH(26)), 
128.69 (d, 2JC-F 9.4 Hz, ArCH(16)), 130.06 (d, 
2JC-F 11.0 Hz, ArC(18)), 136.54 (s, ArC), 
137.94 (s, ArC), 140.02 (d, 3JC-F 4.7 Hz, ArC(13)), 141.97 (s, ArC(22)), 151.98 (s, 
C=O(11)), 155.38 (s, C=O(20)), 162.98 (d, 1JC-F 244 Hz, ArC(17)) 
19F (376 MHz, CDCl3) δ −111.63 (ArF(19)) 
Rf 0.13 (49:1, CH2Cl2:MeOH) 
IR ʋ/ cm-1 1582 (C-O, s), 1667 (C=O, s), 2878 (C-H, w), 3112 (Ar C-H, w)  
MS (ESI): 460 [M+H+]  
HRMS C27H27FN3O3 [M+H
+] requires 460.2036, found 460.2051 (1.4 ppm error) 
 
Preparation of N-(3-Fluorophenyl)spiro[indoline-3,4'-piperidine]-1-carboxamide 
hydrochloride (LVTa127): 
 
 
 
 
 
 
 307 
 
Benzyl 1-((3-fluorophenyl)carbamoyl)spiro[indoline-3,4'-piperidine]-1'-carboxylate 
(LVTa126) (176 mg, 0.38 mmol, 1 eq.) was dissolved in MeOH (15 mL) and then, 
Pearlman’s catalyst (26.7 mg, 0.04 mmol, 0.1 eq.) was added into the solution. The reaction 
mixture was purged with a balloon of hydrogen until deflated and then left under an 
atmosphere of hydrogen overnight. The methanol was removed under reduced pressure and 
the reaction mixture was filtered through celite with CH2Cl2 (100 mL) to collect any 
remaining starting material. The solvent 10% MeOH/CH2Cl2 (200 mL) was subsequently 
passed through celite to elute the desired product. The product LVTa127 is an amorphous 
solid (109 mg, 0.33 mmol, 87%).  
Data for LVTa127 
1H (300 MHz, D4-MeOH) δ 1.94 (2H, d, J 14.4 Hz, CH2(9a)), 2.17 (2H, dd, J 14.4, 13.9 Hz, 
CH2(9b)), 3.22 (2H, dd, J 13.9, 12.2 Hz, CH2(10a)), 3.49 (2H, d, J 12.2 Hz, CH2(10b)), 4.19 
(2H, s, CH2(7)), 6.79 (1H, dd, J 7.8, 7.8 Hz, ArCH), 7.03 (1H, dd, J 7.8, 7.8 Hz, ArCH)), 
7.20–7.35 (4H, m, ArCH(16,19)), 7.48 (1H, d, J 8.9 Hz, ArCH(17)), 7.92 (1H, d, J 7.9 Hz, 
ArCH(15)) 
13C (75 MHz, D4-MeOH) δ 34.22 (s, CH2(9ab)), 42.70 (s, CH2(10ab)), 42.94 (s, C(8)), 58.12 
(s, CH2(7)), 108.78 (d, 
2JC-F 26 Hz, ArCH(17)), 110.59 (s, ArCH), 110.87 (s, ArCH), 116.79 
(s, ArCH(15)), 117.31 (d, 3JC-F 2.7 Hz, ArCH(16)), 123.57 (s, ArCH), 124.06 (s, ArCH), 
129.80 (s, ArCH), 131.00 (d, 2JC-F 9.4 Hz, ArCH(19)), 138.12 (s, ArC), 142.24 (d, 
3JC-F 11.0 
Hz, ArC(14)), 143.79 (s, ArC), 154.63 (s, C=O(12)), 164.32 (d, 1JC-F 242 Hz, ArC(18)) 
19F (376 MHz, CDCl3) δ −114.5 (ArF(20)) 
IR ʋ/ cm-1 1524 (C-F, s), 1671 (C=O, s), 3287 (Ar C-H, w) 
MS (ESI): 326 [M+H+] 
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HRMS C19H21FN3O [M+H
+] requires 326.1669, found 326.1655 (1.9 ppm error) 
 
Preparation of N-(3-Fluorophenyl)-1'-(morpholine-4-carbonyl)spiro[indoline-3,4'-
piperidine]-1-carboxamide (LVTa128): 
 
 
 
 
 
 
 
Following method C using N-(3-Fluorophenyl)spiro[indoline-3,4'-piperidine]-1-
carboxamide hydrochloride (LVTa127) (109 mg, 0.33 mmol, 1 eq.), 4-morpholinecarbonyl 
chloride (0.08 mL, 103 mg, 0.66 mmol, 2 eq.) and K2CO3 (91.2 mg, 0.66 mmol, 2 eq.) as 
starting materials. The desired product was purified using column chromatography (SiO2, 
100% EtOAc), to afford, the pure product (LVTa128) as an off-white solid (100 mg, 0.23 
mmol, 70%).  
Data for LVTa128 
mp 139–143 ºC  
1H (300 MHz, CDCl3) δ 1.73 (2H, d, J 13.6 Hz, CH2(9a)), 1.94 (2H, dd, J 13.6, 13.0 Hz, 
CH2(9b)), 2.94 (2H, dd, J 16.0, 13.0 Hz, CH2(10a)), 3.31–3.34 (4H, m, CH2(21)), 3.69–3.75 
(6H, m, CH2(10b,22)), 3.98 (2H, s, CH2(7)), 6.79 (1H, dd, J 8.2, 8.2 Hz, ArCH), 6.96 (1H, 
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s, ArCH(18)), 7.30 (1H, dd, J 8.2, 8.2 Hz, ArCH), 7.15–7.18 (2H, m, ArCH(3,6)), 7.23–
7.31 (1H, m, ArCH), 7.42 (1H, d, J 8.0 Hz, ArCH(16)), 7.42 (1H, d, J 8.0 Hz, ArCH(14)) 
13C (75 MHz, CDCl3) δ 36.48 (s, CH2(9ab)), 43.26 (s, CH2(10ab)), 44.11 (s, CH2(21)), 47.28 
(s, C(8)), 57.11 (s, CH2(7)), 66.63 (s, CH2(22)), 107.35 (d, 
2JC-F 26 Hz, ArCH(16)), 110.10 
(s, ArCH), 110.39 (s, ArCH), 114.95 (s, ArCH(14)), 115.13 (d, 3JC-F 2.7 Hz, ArCH(18)), 
122.79 (s, ArCH), 122.98 (s, ArCH), 128.67 (s, ArCH), 130.04 (d, 2JC-F 9.4 Hz, ArCH(15)), 
138.05 (s, ArC), 139.91 (d, 3JC-F 10.9 Hz, ArC(13)), 141.95 (s, ArC), 151.90 (s, C=O(11)), 
163.08 (d, 1JC-F 245 Hz, ArC(17)), 164.09 (s, C=O(20)) 
19F (376 MHz, CDCl3) δ −113.62 (ArF(19)) 
Rf 0.25 (100% EtOAc) 
IR ʋ/ cm-1 1601 (C=O, s), 1677 (C=O, s), 2853 (C-H, w), 3319 (ArC-H, w)  
MS (ESI): 439 [M+H+]  
HRMS C24H28FN4O3 [M+H
+] requires 439.2140, found 439.2140 (0.0 ppm error) 
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Preparation of Benzyl 1-((3,4-difluorophenyl)carbamoyl)spiro[indoline-3,4'-piperidine]-1'-
carboxylate (LVTa130): 
 
 
 
 
 
 
 
 
Benzyl spiro[indoline-3,4'-piperidine]-1'-carboxylate (LVTa46) (200 mg, 0.62 mmol, 1 eq.) 
was dissolved in CH2Cl2 (20 mL) under a nitrogen atmosphere. 3, 4-Difluorophenyl 
isocyanate (0.07 mL, 92.8 mg, 0.62 mmol, 1 eq.) was added slowly via syringe and the 
resulting solution stirred at room temperature for 30 minutes. The solvent was removed 
under reduced pressure and the product purified using column chromatography (SiO2, 99:1, 
CH2Cl2:MeOH), which yielded an off-white solid LVTa130 (163 mg, 0.34 mmol, 55%). 
Data for LVTa130 
mp 91–94 ºC 
1H (300 MHz, CDCl3) δ 1.69 (2H, d, J 13.5 Hz, CH2(9a)), 1.89 (2H, dd, J 13.5, 10.6 Hz, 
CH2(9b)), 2.93 (2H, dd, J 11.4, 10.6 Hz, CH2(10a)), 3.90 (2H, m, CH2(7)), 4.26 (2H, d, J 
11.4, 10.6 Hz, CH2(10b)), 5.17 (2H, s, CH2(22)), 6.74 (1H, br. s, NH(12)), 7.00–7.14 (4H, 
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s, ArCH(1,2,3,6)), 7.28–7.38 (7H, m, ArCH(18,24,25,26)), 7.50–7.57 (1H, m, ArCH(15)), 
7.83 (1H, d, J 8.0 Hz, ArCH(14)) 
13C (75 MHz, CDCl3) δ 36.89 (s, CH2(9ab)), 41.83 (s, CH2(10ab)), 43.27 (s, C(8)), 56.80 (s, 
CH2(7)), 109.71 (d, 
2JC-F 21 Hz, ArCH(16)), 109.84 (s, ArCH), 110.13 (s, ArCH), 114.94 
(s, ArCH(15)), 116.24 (d, 2JC-F 26 Hz, ArCH(19)), 122.83 (s, ArCH), 123.16 (s, ArCH), 
128.75 (s, ArCH), 134.69 (d, 3JC-F 8.7 Hz, ArC(14)), 136.52 (s, ArC), 137.95 (s, ArC), 
141.82 (s, ArC), 152.61 (s, C=O(11)) 
19F (376 MHz, CDCl3) δ  −113.6 and −113.6 (s, Ar-F(19 and 20)) 
Rf 0.16 (99:1, CH2Cl2:MeOH) 
IR ʋ/ cm-1 1623 (C-O, s), 1679 (C=O, s), 2832 (C-H, w), 3029 (Ar C-H, w) 
MS (ESI): 478 [M+H+] 
HRMS C27H26F2N3O3 [M+H
+] requires 478.1942, found 478.1959 (3.4 ppm error) 
 
Preparation of N-(3,4-Difluorophenyl)spiro[indoline-3,4'-piperidine]-1-carboxamide 
hydrochloride (LVTa131): 
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Benzyl 1-((3,4-difluorophenyl)carbamoyl)spiro[indoline-3,4'-piperidine]-1'-carboxylate 
(LVTa130) (163 mg, 0.34 mmol, 1 eq.) was dissolved in MeOH (15 mL) and then, 
Pearlman’s catalyst (23.9 mg, 0.034 mmol, 0.1 eq.) was added into the solution. The reaction 
mixture was purged with a balloon of hydrogen until deflated and then left under an 
atmosphere of hydrogen overnight. The methanol was removed under reduced pressure and 
the reaction mixture was filtered through celite with CH2Cl2 (100 mL) to collect any 
remaining starting material. The solvent 10% MeOH/CH2Cl2 (200 mL) was subsequently 
passed through celite to elute the desired product. The product LVTa131 is a light brown 
amorphous solid (98.0 mg, 0.29 mmol, 85%).  
Data for LVTa131 
1H (300 MHz, D4-MeOH) δ 1.96 (2H, d, J 14.4 Hz, CH2(9a)), 2.16 (2H, dd, J 14.4, 12.4 Hz, 
CH2(9b)), 3.22 (2H, dd, J 12.4, 12.4 Hz, CH2(10a)), 3.46 (2H, d, J 12.4 Hz, CH2(10b)), 4.19 
(2H, s, CH2(7)), 7.03–7.11 (2H, m, ArCH), 7.17–7.20 (1H, m, ArCH), 7.23–7.35 (2H, m, 
ArCH(16,19)), 7.90 (1H, d, J 7.5 Hz, ArCH(15)) 
13C (75 MHz, D4-MeOH) δ 34.22 (s, CH2(9ab)), 42.70 (s, CH2(10ab)), 42.94 (s, C(8)), 58.12 
(s, CH2(7)), 110.59 (s, ArCH), 110.87 (s, ArCH), 116.79 (s, ArCH(15)), 117.31 (d, 
3JC-F 2.7 
Hz, ArCH(16)), 123.57 (s, ArCH), 124.06 (s, ArCH), 129.80 (s, ArCH), 131.00 (d, 2JC-F 9.2 
Hz, ArCH(19)), 138.12 (s, ArC), 142.24 (d, 3JC-F 11.0 Hz, ArC(14)), 143.79 (s, ArC), 154.63 
(s, C=O(12)), 164.32 (d, 1JC-F 242 Hz, ArC), 164.51 (d, 
1JC-F 242 Hz, ArC) 
19F (376 MHz, CDCl3) δ  −114.63 and −114.65 (s, Ar-F(19 and 20)) 
IR ʋ/ cm-1 1326 (C-F, s), 1691 (C=O, s), 3156 (Ar C-H, w)  
MS (ESI): 344 [M+H+] 
HRMS C19H20F2N3O [M+H
+] requires 344.1574, found 344.1579 (2.7 ppm error) 
 313 
 
Preparation of N-(3,4-Difluorophenyl)-1'-(morpholine-4-carbonyl)spiro[indoline-3,4'-
piperidine]-1-carboxamide (LVTa132): 
 
 
 
 
 
 
 
Following method C using N-(3,4-Difluorophenyl)spiro[indoline-3,4'-piperidine]-1-
carboxamide hydrochloride (LVTa131) (98.0 mg, 0.29 mmol, 1 eq.), 4-morpholinecarbonyl 
chloride (0.07 mL, 89.7 mg, 0.58 mmol, 2 eq.) and K2CO3 (80.2 mg, 0.58 mmol, 2 eq.) as 
starting materials. The desired product was purified using column chromatography (SiO2, 
100% EtOAc), to afford, the pure product (LVTa132) as an off-white solid (87.2 mg, 0.19 
mmol, 66%).  
Data for LVTa132  
mp 110–114 ºC 
1H (300 MHz, CDCl3) δ 1.74 (2H, d, J 13.1 Hz, CH2(9a)), 1.94 (2H, dd, J 13.1, 13.1 Hz, 
CH2(9b)), 2.96 (2H, dd, J 13.1, 12.9 Hz, CH2(10a)), 3.31–3.34 (4H, m, CH2(22)), 3.70–3.76 
(6H, m, CH2(10b,23)), 3.96 (2H, m, CH2(7)), 6.68 (1H, br. s, NH(12)), 6.98–7.19 (5H, s, 
ArCH(18)), 7.55–7.57 (1H, m, ArCH(15)), 7.82 (1H, d, J 7.83 Hz, ArCH(14)) 
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13C (75 MHz, CDCl3) δ 36.47 (s, CH2(9ab)), 43.30 (s, CH2(10ab)), 44.09 (s, CH2(22)), 47.30 
(s, C(8)), 57.14 (s, CH2(7)), 66.64 (s, CH2(23)), 109.99 (d, 
2JC-F 23 Hz, ArCH(15)), 109.84 
(s, ArCH), 110.13 (s, ArCH), 114.86 (s, ArCH(14)), 117.26 (d, 2JC-F 26 Hz, ArCH(18)), 
122.89 (s, ArCH), 123.10 (s, ArCH), 125.53 (s, ArCH), 128.70 (s, ArCH), 134.70 (d, 3JC-F 
4.2 Hz, ArC(13)), 138.09 (s, ArC), 141.82 (s, ArC), 151.86 (s, C=O(11)), 164.07 (s, 
C=O(21)) 
19F (376 MHz, CDCl3) δ  −113.6 and −113.6 (s, Ar-F(19 and 20)) 
Rf 0.29 (100% EtOAc) 
IR ʋ/ cm-1 1627 (C=O, s), 1664 (C=O, s), 2858 (C-H, w), 3330 (ArC-H, w) 
MS (ESI): 457 [M+H+]  
HRMS C24H27F2N4O3 [M+H
+] requires 457.2051, found 457.2023 (4.7 ppm error) 
 
Preparation of Benzyl 1-((3,4-dichlorophenyl)carbamoyl)spiro[indoline-3,4'-piperidine]-1'-
carboxylate (LVTa133): 
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Benzyl spiro[indoline-3,4'-piperidine]-1'-carboxylate (LVTa46) (200 mg, 0.62 mmol, 1 eq.) 
was dissolved in CH2Cl2 (20 mL) under a nitrogen atmosphere. 3, 4-Dichlorophenyl 
isocyanate (139 mg, 0.74 mmol, 1.2 eq.) was added slowly via syringe and the resulting 
solution stirred at room temperature for 1 hour. The solvent was removed under reduced 
pressure and the product purified using column chromatography (SiO2, 14:1, 
CH2Cl2:MeOH), which yielded a dark green solid LVTa133 (243 mg, 0.48 mmol, 77%). 
Data for LVTa133 
mp 107–111 ºC 
1H (300 MHz, CDCl3) δ 1.63 (2H, d, J 13.4 Hz, CH2(9a)), 1.83 (2H, dd, J 13.4, 12.7 Hz, 
CH2(9b)), 2.88 (2H, dd, J 12.7, 10.0 Hz, CH2(10a)), 3.83 (2H, m, CH2(7)), 4.22 (2H, d, J 
10.0, 10.0 Hz, CH2(10b)), 5.15 (2H, s, CH2(20)), 7.00–7.11 (3H, s, ArCH), 7.21–7.38 (7H, 
m, ArCH(24,25,26)), 7.70 (1H, d, J 8.0 Hz, ArCH(15)), 7.88 (1H, d, J 8.0 Hz, ArCH(14)) 
13C (75 MHz, CDCl3) δ 36.22 (CH2(9ab)), 40.90 (CH2(10ab)), 42.83 (C(8)), 56.58 (CH2(7)), 
67.38 (2C, CH2(20)), 115.14 (ArCH(14)), 119.39 (ArCH), 122.96 (ArCH), 123.13 (ArCH),  
126.60 (ArCH), 127.78 (ArCH(24)), 128.12 (ArCH(23)), 128.58 (ArCH(22)), 130.36 
(ArCH), 132.54 (ArC(16)), 136.41 (ArC), 137.72 (ArC), 137.98 (ArC(17)), 141.84 
(ArC(13)), 151.84 (C=O(11)), 155.39 (C=O(19)) 
Rf 0.27 (99:1, CH2Cl2:MeOH) 
IR ʋ/ cm-1 1666 (C=O, s), 1682 (C=O, s), 2861 (C-H, w), 3331 (ArC-H, w) 
MS (ESI): 510/512 [M+H+] 
HRMS C27H26
35Cl2N3O3 [M+H
+] requires 510.1351, found 510.1366 (3.3 ppm error) 
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Preparation of N-(3,4-Dichlorophenyl)spiro[indoline-3,4'-piperidine]-1-carboxamide 
hydrochloride (LVTa134): 
 
 
 
 
 
 
 
Benzyl 1-((3,4-dichlorophenyl)carbamoyl)spiro[indoline-3,4'-piperidine]-1'-carboxylate 
(LVTa133) (243 mg, 0.48 mmol, 1 eq.) was dissolved in MeOH (15 mL) and then, 
Pd(OH)2/C (33.7 mg, 0.05 mmol, 0.1 eq.) was added into the solution. The reaction mixture 
was purged with a balloon of hydrogen until deflated and then left under an atmosphere of 
hydrogen overnight. The methanol was removed under reduced pressure and the reaction 
mixture was filtered through celite with CH2Cl2 (100 mL) to collect any remaining starting 
material. The solvent 10% MeOH/CH2Cl2 (200 mL) was subsequently passed through the 
celite to elute the desired product. The product LVTa134 is an amorphous solid (163 mg, 
0.43 mmol, 90%).  
Data for LVTa134 
1H (300 MHz, D4-MeOH) δ 1.94 (2H, d, J 14.1 Hz, CH2(9a)), 2.19 (2H, dd, J 14.1, 14.1 Hz, 
CH2(9b)), 3.22 (2H, dd, J 14.1, 14.1 Hz, CH2(10a)), 3.45 (2H, d, J 14.1 Hz, CH2(10b)), 4.20 
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(2H, m, CH2(7)), 6.99–7.10 (2H, m, ArCH), 7.19–7.35 (3H, m, ArCH), 7.54 (1H, d, J 8.0 
Hz, ArCH(16)), 7.89 (1H, d, J 8.0 Hz, ArCH(15)) 
13C (75 MHz, D4-MeOH) δ 36.22 (CH2(9ab)), 40.90 (CH2(10ab)), 42.83 (C(8)), 56.58 
(CH2(7)), 116.82 (ArCH(15)), 121.45 (ArCH(16)), 122.52 (ArCH(19)), 123.88 (ArCH), 
124.75 (ArCH),  126.60 (ArCH), 131.30 (ArCH), 133.07 (ArC), 138.15 (ArC), 138.23 
(ArC), 143.70 (ArC(14)), 154.41 (C=O(12)) 
IR ʋ/ cm-1 785 (C-Cl, s), 1676 (C=O, s), 3323 (Ar C-H, w) 
MS (ESI): 376/378 [M+H+]  
HRMS C19H20
35Cl2N3O [M+H
+] requires 376.0983, found 376.0976 (1.1 ppm error) 
 
Preparation of N-(3,4-Dichlorophenyl)-1'-(morpholine-4-carbonyl)spiro[indoline-3,4'-
piperidine]-1-carboxamide (LVTa135): 
 
 
 
 
 
 
 
Following method C using N-(3,4-Dichlorophenyl)spiro[indoline-3,4'-piperidine]-1-
carboxamide hydrochloride (LVTa133) (100 mg, 0.27 mmol, 1 eq.), 4-morpholinecarbonyl 
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chloride (0.04 mL, 51.3 mg, 0.32 mmol, 2 eq.) and K2CO3 (44.2 mg, 0.32 mmol, 2 eq.) as 
starting materials. The desired product was purified using column chromatography (SiO2, 
100% EtOAc), to afford, the pure product (LVTa135) as a light brown solid (96.1 mg, 0.20 
mmol, 74%).  
Data for LVTa135 
mp 126–130 ºC 
1H (300 MHz, CDCl3) δ 1.74 (2H, d, J 13.0 Hz, CH2(9a)), 1.93 (2H, dd, J 13.0, 13.0 Hz, 
CH2(9b)), 2.93 (2H, dd, J 13.0, 11.2 Hz, CH2(10a)), 3.30–3.36 (4H, m, CH2(20)), 3.64–3.71 
(6H, m, CH2(10b,21)), 3.98 (2H, m, CH2(7)), 6.81 (1H, br. s, NH(12)), 7.00–7.36 (5H, m, 
ArCH(18)), 7.46 (1H, d, J 8.0 Hz, ArCH(15)), 7.84 (1H, d, J 8.0 Hz, ArCH(14)) 
13C (75 MHz, CDCl3) δ 36.51 (CH2(9ab)), 43.24 (CH2(10ab)), 44.11 (CH2 (20)), 47.28 (C(8)), 
57.14 (CH2(7)), 66.66 (CH2(21)), 114.89 (ArCH(14)), 120.22 (ArCH(15)), 122.52 
(ArCH(18)), 123.79 (ArCH), 124.75 (ArCH),  126.62 (ArCH), 130.43 (ArCH), 132.62 
(ArC(17)), 137.98 (ArC), 138.06 (ArC), 141.92 (ArC(16)), 142.15 (ArC(13)), 151.86 
(C=O(11)), 152.33 (C=O(19)) 
Rf 0.24 (100% EtOAc) 
IR ʋ/ cm-1 1629 (C=O, s), 1671 (C=O, s), 2858 (C-H, w), 3330 (ArC-H, w) 
MS (ESI): 489/491 [M+H+] 
HRMS C24H26
35Cl2N4O3 [M+H
+] requires 489.1460, found 489.1464 (1.0 ppm error) 
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Preparation of 1-(3,4-Dichlorophenyl)-2-(3-(2-(diethylamino)ethyl)-2-imino-2,3-dihydro-
1H-benzo[d]imidazol-1-yl)ethan-1-one hydrobromide (LVTa52):  
 
 
 
 
 
 
 
 
Following method D using 1-(2-(Diethylamino)ethyl)-1H-benzo[d]imidazol-2-amine 
(LVTa47) (275 mg, 0.43 mmol, 1 eq.) and 2-bromo-3,4-dichloroacetophenone (318 mg, 
0.43 mmol 1 eq.) as starting materials. The colourless solid LVTa52 (209 mg, 0.41 mmol, 
97%) required no further purification.  
Data for LVTa52 
mp 212–213 ºC  
1H (400 MHz, D6-DMSO) δ 1.44 (6H, t, J 6.9 Hz, CH3(11)), 3.12 (4H, dq, J 6.9, 6.9 Hz, 
CH2(10)), 3.37 (2H, t, J 7.9 Hz, CH2(9)), 4.83 (2H, t, J 7.9 Hz, CH2(8)), 6.48 (2H, s, 
CH2(12)), 7.83 (1H, dd, J 7.6, 7.6 Hz, ArCH), 7.90 (1H, dd, J 7.6, 7.6 Hz, ArCH), 8.06 (1H, 
d, J 7.8 Hz, ArCH), 8.10 (1H, d, J 7.8 Hz, ArCH), 8.40 (1H, d, J 8.3 Hz, ArCH(16)), 8.57 
(1H, d, J 8.3 Hz, ArCH(15)), 8.86 (1H, s, ArCH(19)) 
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13C (100 MHz, D6-DMSO) δ 10.22 (CH3(11)), 41.71 (CH2(8)), 45.61 (CH2(10)), 49.14 
(CH2(12)), 50.06 (CH2(9)), 109.36 (ArCH), 109.70 (ArCH), 122.36 (ArCH), 122.74 
(ArCH), 127.26 (ArCH(15)), 129.27 (ArC(18)), 129.35 (ArC(17)), 129.51 (ArCH(19)), 
130.21 (ArCH(16)), 131.41 (ArC), 133.44 (ArC), 136.55 (ArC(14)), 150.50 (C=NH(7)), 
188.75 (C=O(13)) 
IR ʋ/ cm-1 743 (C-Cl, s), 1682 (C=O, s), 1698 (C=N, s), 2970 (C-H, w), 3206 (Ar C-H, w)    
MS (ESI): 418/420/422 [M+H+]  
HRMS C21H25
35Cl2N4O [M+H-Br−]+ requires 419.1405, found 419.1414 (3.8 ppm error) 
 
Preparation of 1-(3,4-Dichlorophenyl)-2-(3-(2-(diethylamino)ethyl)-2-imino-2,3-dihydro-
1H-benzo[d]imidazol-1-yl)ethanol hydrobromide (LVTa54):  
 
 
 
 
 
 
 
 
Following method E using 1-(3,4-Dichlorophenyl)-2-(3-(2-(diethylamino)ethyl)-2-imino-
2,3-dihydro-1H-benzo[d]imidazol-1-yl)ethan-1-one hydrobromide ( LVTa52) (100 mg, 
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0.20 mmol, 1 eq.) as starting materials. The glass like solid LVTa54 (98.0 mg, 0.196 mmol, 
98%) required no purification.  
Data for LVTa54 
1H (300 MHz, CDCl3) δ 1.03 (6H, t, J 7.1 Hz, CH3(11)), 2.60 (4H, dq, J 7.1, 7.1 Hz, 
CH2(10)), 2.71 (2H, t, J 6.5 Hz, CH2(9)), 3.83 (2H, t, J 6.5 Hz, CH2(8)), 4.16 (2H, d, J 4.4 
Hz, CH2(12)), 5.10 (1H, t, J 4.4 Hz, CH(13)), 6.67 (1H, d, J 6.9 Hz, ArCH), 6.87 (1H, d, J 
8.7 Hz, ArCH), 6.95–7.04 (2H, m, ArCH(1,2)), 7.30 (1H, d, J 6.9 Hz, ArCH(17)), 7.37 (1H, 
d, J 6.9 Hz, ArCH(16)), 7.58 (1H, s, ArCH(20)) 
13C (100 MHz, D6-DMSO) δ 10.68 (CH3(11)), 39.58 (CH2(8)), 45.98 (CH2(10)), 48.53 
(CH2(12)), 49.31 (CH2(9)), 69.78 (CH(13)), 106.01 (ArCH), 106.20 (ArCH), 119.40 
(ArCH), 119.54 (ArCH), 125.39 (ArCH(16)), 127.33 (ArC(20)), 128.91 (ArC), 129.10 
(ArCH(17)), 130.14 (ArC), 130.58 (ArC(19)), 130.76 (ArC(18)), 143.17 (ArC(15)), 153.61 
(C=NH(7))  
IR ʋ/ cm-1 731 (C-Cl, s), 2812 (C-H, w), 3254 (Ar C-H, w), 3478 (O-H, br.)  
MS (ESI): 420/422/424 [M+H+]  
HRMS C21H27
35Cl2N4O [M+H-Br−]+ requires 421.1562, found 421.1566 (2.7 ppm error) 
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Preparation of 1-(3,4-Dichlorophenyl)-2-(2-imino-3-(2-(piperidin-1-yl)ethyl)-2,3-dihydro-
1H-benzo[d]imidazol-1-yl)ethanone hydrobromide (LVTa57):  
 
 
 
 
 
 
 
 
Following method D using 1-(2-(Piperidin-1-yl)ethyl)-1H-benzo[d]imidazol-2-amine 
(LVTa49) (200 mg, 0.82 mmol, 1 eq.) and 2-bromo-3,4-dichloroacetophenone (220 mg, 
0.82 mmol 1 eq.) as starting materials. The colourless solid LVTa57 (403 mg, 0.79 mmol, 
96%) required no further purification.  
Data for LVTa57 
mp 222–225 ºC 
1H (300 MHz, CDCl3) δ 1.44–1.49 (2H, m, CH2(12)), 1.59–1.62 (4H, m, CH2(11)), 2.44–
2.50 (4H, m, CH2(10)), 2.60 (2H, t, J 7.1 Hz, CH2(9)), 3.89 (2H, t, J 7.1 Hz, CH2(8)), 5.26 
(2H, s, CH2(13)), 6.70 (1H, d, J 7.5 Hz, ArCH), 6.87 (1H, d, J 7.5 Hz, ArCH), 6.92–7.02 
(2H, m, ArCH), 7.56 (1H, d, J 8.3 Hz, ArCH(17)), 7.93 (1H, d, J 8.3 Hz, ArCH(16)), 8.20 
(1H, s, ArCH(19)) 
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13C (75 MHz, CDCl3) δ 24.16 (CH2(12)), 25.97 (CH2(11)), 40.40 (CH2(8)), 48.26 
(CH2(13)), 55.06 (CH2(10)), 56.45 (CH2(9)), 106.46 (ArCH), 106.67 (ArCH), 120.97 
(ArCH), 121.01 (ArCH), 127.44 (ArCH(16)), 130.43 (ArCH(17)), 130.94 (ArCH(20)), 
131.47 (ArC(19)), 131.49 (ArC(18)), 133.14 (ArC), 134.14 (ArC), 138.49 (ArC(15)), 
154.52 (C=NH(7)), 191.60 (C=O(14)) 
IR ʋ/ cm-1 743 (C-Cl, s), 1662 (C=O, s), 1699 (C=N, s), 2937 (C-H, w), 3165 (Ar C-H, w) 
MS (ESI): 430/432/434 [M+H+] 
HRMS C22H25
35Cl2N4O [M+H-Br−]+ requires 431.1405, found 431.1412 (3.2 ppm error) 
 
Preparation of 1-(3-Bromophenyl)-2-(2-imino-3-(2-(piperidin-1-yl)ethyl)-2,3-dihydro-1H-
benzo[d]imidazol-1-yl)ethanone hydrobromide (LVTa58):  
 
 
 
 
 
 
 
Following method D using 1-(2-(Piperidin-1-yl)ethyl)-1H-benzo[d]imidazol-2-amine 
(LVTa49) (200 mg, 0.82 mmol, 1 eq.) and 2-bromo-3,4-dichloroacetophenone (228 mg, 
0.82 mmol 1 eq.) as starting materials. The cream solid LVTa58 (358 mg, 0.69 mmol, 84%) 
required no further purification.  
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Data for LVT58 
mp 201–204 ºC 
1H (400 MHz, D6-DMSO) δ 1.37–1.39 (2H, m, CH2(12)), 1.43–1.45 (4H, m, CH2(11)), 
2.48–2.51 (4H, m, CH2(10)), 2.67 (2H, t, J 7.0 Hz, CH2(9)), 4.34 (2H, t, J 7.0 Hz, CH2(8)), 
5.97 (2H, s, CH2(13)), 7.29 (1H, dd, J 7.5, 7.5 Hz, ArCH), 7.37 (1H, dd, J 7.5, 7.5 Hz, 
ArCH), 7.60–7.64 (3H, m, ArCH(17)), 7.99 (2H, d, J 8.4 Hz, ArCH(18)), 8.07 (1H, d, J 8.4 
Hz, ArCH(16)), 8.27 (1H, s, ArCH(20)) 
13C (100 MHz, D6-DMSO) δ 23.53 (CH2(12)), 25.39 (CH2(11)), 41.09 (CH2(8)), 50.09 
(CH2(13)), 53.98 (CH2(10)), 55.76 (CH2(9)), 110.44 (ArCH), 110.71 (ArCH), 122.07 (s, 
ArC(19)), 123.44 (ArCH), 123.54 (ArCH), 127.35 (ArCH(16)), 129.81 (ArC), 130.11 
(ArC), 131.09 (2C, ArCH), 136.08 (ArC(15)), 136.72 (ArCH(18)), 150.79 (C=NH(7)), 
190.40 (C=O(14)) 
IR ʋ/ cm-1 1662 (C=O, s), 1698 (C=N, s), 2929 (C-H, w), 3161 (Ar C-H, w)  
MS (ESI): 440/442 [M+H+]  
HRMS C22H26
79BrN4O [M+H-Br−]+ requires 441.1290, found 441.1292 (0.5 ppm error) 
Analysis calculated for C22H26BrN4O: C, 48.91%; H, 5.22%; N 10.37%. Found C, 49.02%; 
H, 4.70%; N, 10.28%. 
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Preparation of 1-(3-Bromophenyl)-2-(2-imino-3-(2-(piperidin-1-yl)ethyl)-2,3-dihydro-1H-
benzo[d]imidazol-1-yl)ethanol hydrobromide (LVTa59):  
 
 
 
 
 
 
 
 
Following method E using 1-(3-Bromophenyl)-2-(2-imino-3-(2-(piperidin-1-yl)ethyl)-2,3-
dihydro-1H-benzo[d]imidazol-1-yl)ethanone hydrobromide ( LVTa58) (100 mg, 0.23 
mmol, 1 eq.) as starting materials. The colourless solid LVTa59 (83.0 mg, 0.16 mmol, 70%) 
required no purification.  
Data for LVTa59 
mp 64–67 °C 
1H (400 MHz, D6-DMSO) δ 1.34–1.37 (2H, m, CH2(12)), 1.45–1.47 (4H, m, CH2(11)), 
2.44–2.50 (6H, m, CH2(9,10)), 3.89 (2H, t, J 6.6 Hz, CH2(8)), 3.89–4.05(2H, m, CH2(13)), 
4.96 (1H, t, J 7.6 Hz, CH(14)), 6.81–6.93 (4H, m, ArCH), 7.24 (1H, dd, J 7.7, 7.7 Hz, 
ArCH(18)), 7.38–7.43 (2H, m, ArCH(17,19)), 7.62 (1H, s, ArCH(21)) 
13C (100 MHz, D6-DMSO) δ 24.60 (CH2(12)), 26.26 (CH2(11)), 39.41 (CH2(8)), 49.98 
(CH2(13)), 55.00 (CH2(10)), 56.52 (CH2(9)), 71.31 (CH(14)), 106.99 (ArCH), 107.45 
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(ArCH), 120.50 (ArCH), 120.57 (ArCH), 122.10 (ArC(20)), 125.82 (ArCH(19)), 129.50 
(ArCH(21)), 130.53 (ArCH(17)), 130.78 (ArC(18)), 132.04 (ArC), 132.53 (ArC), 146.59 
(ArCH(16)), 154.71 (C=NH(7)) 
IR ʋ/ cm-1 1625 (C=N, s), 2849 (C-H, w), 3162 (Ar C-H, w), 3359 (O-H, br.) 
MS (ESI): 442/444 [M+H+] 
HRMS C22H28
79BrN4O [M+H-Br−]+ requires 443.1446, found 443.1448 (0.6 ppm error) 
 
Preparation of 1-(3,4-Dichlorophenyl)-2-(2-imino-3-(2-(piperidin-1-yl)ethyl)-2,3-dihydro-
1H-benzo[d]imidazol-1-yl)ethanol hydrobromide (LVTa60):  
 
 
 
 
 
 
 
 
Following method E using 1-(3,4-Dichlorophenyl)-2-(2-imino-3-(2-(piperidin-1-yl)ethyl)-
2,3-dihydro-1H-benzo[d]imidazol-1-yl)ethanone hydrobromide (LVTa57) (100 mg, 0.20 
mmol, 1 eq.) as starting materials. The colourless solid LVTa60 (77.0 mg, 0.15 mmol, 75%) 
required no purification.  
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Data for LVT60 
mp 86–89 °C 
1H (400 MHz, D6-DMSO) δ 1.42–1.44 (2H, m, CH2(12)), 1.51–1.55 (4H, m, CH2(11)), 
2.44–2.46 (4H, m, CH2(10)), 2.55 (2H, t, J 6.2 Hz, CH2(9)), 3.87 (2H, t, J 6.2 Hz, CH2(8)), 
4.12–4.21(2H, m, CH2(13)), 5.12 (2H, t, J 4.6 Hz, CH(14)), 6.73 (1H, d, J 7.5 Hz, ArCH), 
6.87–6.97 (1H, m, ArCH(1,2)), 7.38 (1H, d, J 8.3 Hz, ArCH(18)), 7.42 (1H, d, J 8.3 Hz, 
ArCH(17)), 7.61 (1H, s, ArCH(21)) 
13C (100 MHz, D6-DMSO) δ 23.22 (CH2(12)), 25.14 (CH2(11)), 39.28 (CH2(8)), 49.41 
(CH2(13)), 53.90 (CH2(10)), 55.52 (CH2(9)), 71.76 (CH(14)), 105.71 (ArCH), 106.21 
(ArCH), 119.71 (ArCH), 119.76 (ArCH), 125.28 (ArCH(18)), 127.36 (ArCH(21)), 129.24 
(ArCH(17)), 130.27 (ArCH(20)), 130.60 (ArC(19)), 131.00 (ArC), 131.02 (ArC), 143.50 
(ArCH(16)), 155.63 (C=NH(7)) 
IR ʋ/ cm-1 2783 (C-H, w), 3060 (Ar C-H, w), 3356 (O-H, br.) 
MS (ESI): 432/434/436 [M+H+] 
HRMS C22H27
35Cl2N4O [M+H-Br−]+ requires 433.1562, found 433.1568 (1.1 ppm error) 
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Preparation of 1-(2-Imino-3-pentyl-2,3-dihydro-1H-benzo[d]imidazol-1-yl)-3-(m-
tolyloxy)propan-2-ol (LVTa65):  
 
 
 
 
 
 
 
 
1-Pentyl-1H-benzo[d]imidazol-2-amine (LVTa55) (626 mg, 3.05 mmol, 1 eq.) and Cs2CO3 
(1.98 g, 6.1 mmol, 2 eq.) were weighed into a round bottom flask (25 mL) and the flask put 
under a nitrogen atmosphere. Anhydrous DMF (10 mL) was then added via syringe, 
followed by the addition of 2-[(3-methylphenoxy)methyl]oxirane (500 mg, 3.05 mmol, 1 
eq.) via syringe and the resulting solution stirred at 100 °C for 1 hour. After 1 hour the 
solution had turned dark brown and the solvent removed under reduced pressure. The 
product was partitioned between EtOAc (20 mL) and H2O (20 mL), organics were extracted 
with further EtOAc (2 × 25 mL), washed with saturated aqueous brine (50 mL), dried over 
Na2SO4, filtered and solvent removed under reduced pressure. The product was purified 
using column chromatography (SiO2, 5:1, EtOAc:Pet ether) followed by an additional 
purification step using column chromatography (SiO2, 100%, CH2Cl2), which yielded a 
yellow wax LVTa65 (439 mg, 1.19 mmol, 39%) 
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Data for LVT65  
1H (400 MHz, CDCl3) δ 0.85 (3H, t, J 6.9 Hz, CH3(13)), 1.28–1.33 (4H, m, CH2(11,12)), 
1.66–1.75 (2H, m, CH2(10)), 2.31 (3H, s, CH3(24)), 3.68–3.77 (1H, m, CH2(14a)), 3.83 (2H, 
t, J 7.2 Hz, CH2(9)), 3.88–4.95 (1H, m, CH2(14b)), 4.00 (1H, ddd, J 16.7, 9.2, 6.3 Hz, 
CH2(17)), 4.23–4.30 (1H, m, CH(15)), 4.73 (1H, t, J 5.2 Hz), 6.69–6.79 (2H, m, 
ArCH(21,23)), 7.05–7.12 (3H, m, ArCH), 7.16 (2H, dd, J 6.7, 6.7 Hz, ArCH), 7.43 (1H, d, 
J 6.7 Hz, ArCH) 
13C (100 MHz, CDCl3) δ 13.84 (CH3(13)), 21.50 (CH2(12)), 22.31 (CH3(24)),  28.67 
(CH2(11)), 29.08 (CH2(10)), 42.53 (CH2(9)), 47.10 (CH2(14)), 69.04 (CH2(17)), 70.23 
(CH(15)), 107.52 (ArCH), 111.46 (ArCH(21)), 115.34 (ArCH(23)), 116.39 (ArCH), 119.94 
(ArCH(19)), 121.44 (ArCH), 121.96 (ArCH), 129.30 (ArCH(20)), 134.47 (ArCH(22)), 
139.64 (ArC), 141.09 (ArC), 154.70 (C=NH(7)), 158.57 (ArC(18)) 
IR ʋ/ cm-1 1657 (C-O, s), 1690 (C=N, s), 2821 (C-H, w), 3382 (O-H, br.)  
Rf 0.52 (3:1, EtOAc/Pet. ether) 
MS (ESI): 368 [M+H+]  
HRMS C22H30N3O2 [M+H
+] requires 368.2338, found 368.2339 (1.9 ppm error) 
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Preparation of 1-(3-Hexyl-2-imino-2,3-dihydro-1H-benzo[d]imidazol-1-yl)-3-(m-
tolyloxy)propan-2-ol (LVTa66):  
 
 
 
 
 
 
 
1-Hexyl-1H-benzo[d]imidazol-2-amine (LVTa56) (133 mg, 0.61 mmol, 1 eq.) and Cs2CO3 
(185 mg, 1.34 mmol, 2 eq.) were weighed into a round bottom flask (25 mL) and the flask 
put under a nitrogen atmosphere. Anhydrous DMF (10 mL) was then added via syringe, 
followed by the addition of 2-[(3-methylphenoxy)methyl]oxirane (100 mg, 0.61 mmol, 1 
eq.) via syringe and the resulting solution stirred at 100 °C for 1 hour. After 1 hour the 
solution had turned dark brown and the solvent removed under reduced pressure. The 
product was partitioned between EtOAc (20 mL) and H2O (20 mL), organics were extracted 
with further EtOAc (2 × 25 mL), washed with saturated aqueous brine (50 mL), dried over 
Na2SO4, filtered and solvent removed under reduced pressure. The product was purified 
using preparative thin layer chromatography (SiO2, 5:1, EtOAc:Pet. ether), which yielded a 
yellow wax solid LVTa66 (89 mg, 0.23 mmol,  37%). 
Data for LVTa66 
mp 84–87 ºC 
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1H (300 MHz, CDCl3) δ 0.85 (3H, t, J 6.6 Hz, CH3(14)), 1.21–1.34 (6H, m, CH2(11,12,13)), 
1.65–1.75 (2H, m, CH2(10)), 2.32 (3H, s, CH3(25)), 3.68–3.77 (1H, m, CH2(15a)), 3.83 (2H, 
t, J 7.3 Hz, CH2(9)), 3.88–4.01 (1H, m, CH2(15b)), 3.95 (1H, dd, J 7.6, 9.2 Hz, CH2(18a)), 
4.06 (1H, dd, J 9.2, 5.2 Hz, CH2(18b)), 4.23–4.30 (1H, m, CH(16)), 4.68 (1H, t, J 5.1 Hz), 
6.70–6.73 (2H, m, ArCH(22,24)), 6.78 (1H, d, J 7.4 Hz, ArCH(20)), 7.07 (2H, dd, J 5.5, 5.5 
Hz, ArCH), 7.10–7.13 (1H, m, ArCH), 7.16 (1H, dd, J 6.3, 6.3 Hz, ArCH(21)), 7.43 (1H, d, 
J 6.3 Hz, ArCH) 
13C (75 MHz, CDCl3) δ 14.01 (CH3(14)), 21.55 (CH3(25)), 22.49 (CH2(11)), 26.70 
(CH2(13)), 28.95 (CH2(10)), 31.39 (CH2(12)), 42.56 (CH2(9)), 68.80 (CH2(18)), 70.24 
(CH(16)), 107.54 (ArCH), 111.37 (ArCH(22)), 115.23 (ArCH(24)), 116.35 (ArCH), 119.95 
(ArCH(20)), 121.45 (ArCH), 121.92 (ArCH), 129.31 (ArCH(21)), 134.41 (ArC(23)), 
139.65 (ArC), 140.94 (ArC), 154.68 (C=NH(7)), 158.49 (ArC-O(19)) 
IR ʋ/ cm-1 1607 (C=N, s), 1624 (C-O, s), 2679 (C-H, w), 3364 (O-H, br.) 
Rf 0.50 (3:1, EtOAc/Pet. ether) 
MS (ESI): 382 [M+H+]  
HRMS C23H32N3O2 [M+H
+] requires 382.2489, found 382.2489 (0.0 ppm error) 
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Preparation of 1-(3-Chlorophenyl)-2-(3-(2-(diethylamino)ethyl)-2-imino-2,3-dihydro-1H-
benzo[d]imidazol-1-yl)ethanone hydrobromide (LVTa67):  
 
 
 
 
 
 
 
Following method D using 1-(2-(Diethylamino)ethyl)-1H-benzo[d]imidazol-2-amine 
(LVTa47) (200 mg, 0.86 mmol, 1 eq.) and 3-chlorophenacyl bromide (201 mg, 0.86 mmol 
1 eq.) as starting materials. The colourless solid LVTa67 (349 mg, 0.75 mmol, 87%) 
required no further purification.  
Data for LVT67 
mp 201–203 ºC 
1H (300 MHz, CDCl3) δ 1.05 (6H, t, J 7.1 Hz, CH3(11)), 2.61 (4H, dq, J 7.1, 7.1 Hz, 
CH2(10)), 2.72 (2H, t, J 7.1 Hz, CH2(9)), 3.85 (2H, t, J 7.1 Hz, CH2(8)), 5.29 (2H, s, 
CH2(12)), 6.69 (1H, d, J 7.1 Hz, ArCH), 6.87 (1H, d, J 7.1 Hz, ArCH), 6.92–7.03 (2H, m, 
ArCH), 7.44 (1H, dd, J 7.8, 7.8 Hz, ArCH(16)), 7.58 (1H, d, J 7.8 Hz, ArCH(17)), 7.98 (1H, 
d, J 7.8 Hz, ArCH(15)), 8.06 (1H, s, ArCH(19)) 
13C (75 MHz, CDCl3) δ 12.02 (CH3(11)), 41.41 (CH2(8)), 47.71 (CH2(10)), 48.19 
(CH2(12)), 50.74 (CH2(9)), 106.38 (ArCH), 106.61 (ArCH), 120.86 (ArCH), 120.91 
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(ArCH), 126.43 (ArCH(15)), 128.43 (ArCH(19)), 130.19 (ArCH(16)), 131.61 (ArC), 
131.81 (ArC), 133.80 (ArCH(17)), 135.17 (ArC(18)), 136.20 (ArCH(14)), 154.73 
(C=NH(7)), 192.07 (C=O(13)) 
IR ʋ/ cm-1 1672 (C=O, s), 1698 (C=N, s), 2927 (C-H, w), 3159 (Ar C-H, w) 
MS (ESI): 385/387 [M+H+]  
HRMS C21H26
35ClN4O [M+H-Br−]+ requires 385.1795, found 385.1800 (1.2 ppm error) 
 
Preparation of 1-(2,4-Dichlorophenyl)-2-(3-(2-(diethylamino)ethyl)-2-imino-2,3-dihydro-
1H-benzo[d]imidazol-1-yl)ethanone hydrobromide (LVTa68):  
 
 
 
 
 
 
 
 
Following method D using 1-(2-(Diethylamino)ethyl)-1H-benzo[d]imidazol-2-amine 
(LVTa47) (173 mg, 0.75 mmol, 1 eq.) and 2-bromo-2,4-dichloro acetophenone (201 mg, 
0.75 mmol 1 eq.) as starting materials. The colourless solid LVTa68 (236 mg, 0.56 mmol, 
75%) required no further purification.  
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Data for LVTa68 
1H (400 MHz, D6-DMSO) δ 0.83 (6H, t, J 7.1 Hz, CH3(11)), 2.51 (4H, dq, J 7.1, 7.1 Hz, 
CH2(10)), 2.75 (2H, t, J 7.1 Hz, CH2(9)), 4.30 (2H, t, J 7.1 Hz, CH2(8)), 5.85 (2H, s, 
CH2(12)), 7.29–7.38 (2H, m, ArCH), 7.61 (2H, d, J 8.9 Hz, ArCH), 7.76 (1H, d, J 8.9 Hz, 
ArCH(16)), 7.90 (1H, s, ArCH(18)), 8.12 (1H, d, J 8.9 Hz, ArCH(15)) 
13C (75 MHz, CDCl3) δ 11.57 (CH3(11)), 42.03 (CH2(8)), 46.34 (CH2(10)), 50.27 (CH2(9)), 
51.68 (CH2(12)), 110.41 (ArCH), 110.82 (ArCH), 123.48 (ArCH), 123.60 (ArCH), 127.59 
(ArCH(16)), 129.92 (2C, ArC), 130.82 (ArCH(18)), 132.29 (ArC(17)), 132.40 (ArCH(15)), 
132.97 (ArC(19)), 137.91 (ArC(14)), 150.71 (C=NH(7)), 190.89 (C=O(13)) 
IR ʋ/ cm-1 1698 (C=O, s), 1672 (C=O, s), 2956 (C-H, w), 3207 (Ar C-H, w) 
MS (ESI): 419/421 [M+H+]  
HRMS C21H25
35Cl2N4O [M+H-Br−]+ requires 419.1405, found 419.1409 (2.5 ppm error) 
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Preparation of 1-(3-Chlorophenyl)-2-(3-(2-(diethylamino)ethyl)-2-imino-2,3-dihydro-1H-
benzo[d]imidazol-1-yl)ethanol hydrobromide (LVTa69):  
 
 
 
 
 
 
 
 
Following method E using 1-(3-Chlorophenyl)-2-(3-(2-(diethylamino)ethyl)-2-imino-2,3-
dihydro-1H-benzo[d]imidazol-1-yl)ethanone hydrobromide (LVTa67) (100 mg, 0.21 
mmol, 1 eq.) as starting materials. The clear glass LVTa69 (79.0 mg, 0.17 mmol, 81%) 
required no purification.  
Data for LVTa69 
1H (400 MHz, D6-DMSO) δ 0.89 (6H, t, J 7.1 Hz, CH3(11)), 2.50 (4H, dq, J 7.1, 7.1 Hz, 
CH2(10)), 2.57 (2H, t, J 6.7 Hz, CH2(9)), 3.83 (2H, t, J 6.7 Hz, CH2(8)), 3.93–4.09 (2H, m, 
CH2(12)), 4.98 (1H, t, J 6.1 Hz, CH(13)), 6.80–6.91 (4H, m, ArCH), 7.25 (2H, d, J 7.5 Hz, 
ArCH(18)), 7.30 (1H, dd, J 7.5, 7.5 Hz, ArCH(17)), 7.38 (1H, d, J 7.5 Hz, ArCH(16)), 7.48 
(1H, s, ArCH(20)) 
13C (75 MHz, CDCl3) δ 11.90 (CH3(11)), 39.59 (CH2(8)), 46.67 (CH2(10)), 49.28 (CH2(9)), 
49.77 (CH2(12)), 71.81 (CH(13)), 106.14 (ArCH), 106.62 (ArCH), 119.74 (ArCH), 119.76 
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(ArCH), 124.73 (ArCH(16)), 125.91 (ArCH(20)), 126.89 (ArCH(18)), 129.77 (ArCH(17)), 
131.46 (ArC), 131.85 (ArC), 132.71 (ArC(19)), 145.71 (ArC(15)), 154.12 (C=NH(7)) 
IR ʋ/ cm-1 1607 (C-O, s), 1624 (C=N, s), 2812 (C-H, w), 3061 (Ar C-H, w), 3356 (O-H, br.) 
MS (ESI): 387/389 [M+H+]  
HRMS C21H28
35ClN4O [M+H-Br−]+ requires 387.1952, found 387.1952 (1.8 ppm error) 
 
Preparation of 1-(2,4-Dichlorophenyl)-2-(3-(2-(diethylamino)ethyl)-2-imino-2,3-dihydro-
1H-benzo[d]imidazol-1-yl)ethanol hydrobromide (LVTa70):  
 
 
 
 
 
 
 
Following method E using 1-(2,4-Dichlorophenyl)-2-(3-(2-(diethylamino)ethyl)-2-imino-
2,3-dihydro-1H-benzo[d]imidazol-1-yl)ethanone hydrobromide (LVTa68) (100 mg, 0.20 
mmol, 1 eq.) as starting materials. The colourless solid LVTa70 (80.0 mg, 0.16 mmol, 80%) 
required no purification.  
Data for LVTa70 
mp 93–95 °C 
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1H (300 MHz, D6-DMSO) δ 0.89 (6H, t, J 7.0 Hz, CH3(11)), 2.49 (4H, dq, J 7.0, 6.7 Hz, 
CH2(10)), 2.56 (2H, t, J 6.7 Hz, CH2(9)), 3.86 (2H, t, J 6.7 Hz, CH2(8)), 4.02 (2H, d, J 5.0 
Hz, CH2(12)), 5.23 (1H, t, J 5.0 Hz, CH(13)), 6.76 (1H, d, J 7.1 Hz, ArCH), 6.82–6.91 (2H, 
m, ArCH), 6.94 (1H, d, J 7.1 Hz, ArCH), 7.41 (1H, d, J 8.4 Hz, ArCH(17)), 7.54 (1H, s, 
ArCH(19)), 7.66 (1H, d, J 8.4 Hz, ArCH(16)) 
13C (75 MHz, D6-DMSO) δ 11.88 (CH3(11)), 39.71 (CH2(8)), 46.64 (CH2(10)), 47.79 
(CH2(12)), 49.79 (CH2(9)), 68.28 (CH(13)), 106.26 (ArCH), 106.54 (ArCH), 119.92 
(ArCH), 120.08 (ArCH), 127.37 (ArCH(17)), 128.21 (ArCH(19)), 129.79 (ArCH(16)), 
131.48 (ArC), 131.57 (ArC), 131.67 (ArC(20)), 132.44 (ArC(18)), 139.20 (ArC(15)), 
154.27 (C=NH(7)) 
IR ʋ/ cm-1 730 (C-Cl, s), 1609 (C-O, s), 1622 (C=N, s), 2809 (C-H, w), 3240 (O-H, br.), 
3340 (Ar C-H, w) 
MS (ESI): 421/423 [M+H+] 
HRMS C21H27
35Cl2N4O [M+H-Br−]+ requires 421.1562, found 421.1565 (2.6 ppm error) 
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Preparation of 1-(3-Chlorophenyl)-2-(2-imino-3-(2-(piperidin-1-yl)ethyl)-2,3-dihydro-1H-
benzo[d]imidazol-1-yl)ethanone hydrobromide (LVTa71): 
 
 
 
 
 
 
 
Following method D using 1-(2-(Piperidin-1-yl)ethyl)-1H-benzo[d]imidazol-2-amine 
(LVTa49) (200 mg, 0.82 mmol, 1 eq.) and 3-chlorophenacyl bromide (192 mg, 0.82 mmol 
1 eq.) as starting materials. The cream solid LVTa71 (316 mg, 0.66 mmol, 81%) required 
no further purification.  
Data for LVTa71 
mp 207–210 ºC 
1H (300 MHz, CDCl3) δ 1.43–1.49 (2H, m, CH2(12)), 1.58–1.65 (4H, m, CH2(11)), 2.48–
2.51 (4H, m, CH2(10)), 2.61 (2H, t, J 7.2 Hz, CH2(9)), 3.90 (2H, t, J 7.2 Hz, CH2(10)), 5.29 
(2H, s, CH2(13)), 6.69 (1H, d, J 7.1 Hz, ArCH), 6.88 (1H, d, J 7.1 Hz, ArCH), 6.91–7.02 
(2H, m, ArCH), 7.44 (1H, dd, J 7.7, 7.7 Hz, ArCH(17)), 7.57 (1H, d, J 7.7 Hz, ArCH(18)), 
7.97 (1H, d, J 7.7 Hz, ArCH(16)), 8.06 (1H, s, ArCH(20)) 
13C (75 MHz, CDCl3) δ 24.18 (CH2(12)), 25.98 (CH2(11)), 40.32 (CH2(8)), 48.20 
(CH2(13)), 55.06 (CH2(10)), 56.42 (CH2(9)), 106.40 (ArCH), 106.62 (ArCH), 120.89 (2C, 
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ArCH), 126.43 (ArCH(16)), 128.43 (ArCH(20)), 130.18 (ArCH(17)), 131.62 (ArC), 131.64 
(ArC), 133.80 (ArCH(18)), 135.16 (ArC(19)), 136.18 (ArC(15)), 154.66 (C=NH(7)), 
192.05 (C=O(14)) 
IR ʋ/ cm-1 742 (C-Cl, s), 1664 (C=O, s), 1698 (C=N, s), 2932 (C-H, w), 3155 (Ar C-H, w) 
MS (ESI): 396/398 [M+H+]  
HRMS C22H26
35ClN4O [M+H-Br−]+ requires 397.1795, found 397.1799 (2.9 ppm error) 
 
Preparation of 1-(2,4-Dichlorophenyl)-2-(2-imino-3-(2-(piperidin-1-yl)ethyl)-2,3-dihydro-
1H-benzo[d]imidazol-1-yl)ethanone hydrobromide (LVTa72): 
 
 
 
 
 
 
 
Following method D using 1-(2-(Piperidin-1-yl)ethyl)-1H-benzo[d]imidazol-2-amine 
(LVTa49) (200 mg, 0.82 mmol, 1 eq.) and 2-bromo-2,4-dichloro acetophenone (220 mg, 
0.82 mmol 1 eq.) as starting materials. The light orange solid LVTa72 (317 mg, 0.62 mmol, 
76%) required no further purification.  
Data for LVTa72 
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mp 212–214 ºC 
1H (300 MHz, D6-DMSO) δ 1.38–1.41 (2H, m, CH2(12)), 1.44–1.46 (4H, m, CH2(11)), 
2.46–2.48 (4H, m, CH2(10)), 2.69 (2H, t, J 7.2 Hz, CH2(9)), 4.37 (2H, t, J 7.2 Hz, CH2(10)), 
5.89 (2H, s, CH2(13)), 7.30–7.43 (2H, m, ArCH), 7.60–7.64 (2H, m, ArCH), 7.76 (1H, d, J 
7.7 Hz, ArCH(17)), 7.89 (1H, s, ArCH(19)), 8.24 (1H, d, J 7.7 Hz, ArCH(16)) 
13C (75 MHz, D6-DMSO) δ 23.49 (CH2(12)), 25.33 (CH2(11)), 41.15 (CH2(8)), 51.66 
(CH2(13)), 53.95 (CH2(10)), 55.68 (CH2(9)), 110.40 (ArCH), 110.71 (ArCH), 123.52 
(ArCH), 123.63 (ArCH), 127.60 (ArCH(17)), 129.92 (ArC), 129.94 (ArC), 130.84 
(ArCH(19)), 132.39 (ArCH(18)), 132.41 (ArC(20)), 133.01 (ArCH(16)), 137.94 (ArC(15)), 
150.81 (C=NH(7)), 190.89 (C=O(14)) 
IR ʋ/ cm-1 743 (C-Cl, s), 1667 (C=O, s), 1698 (C=N, s), 2851 (C-H, w), 3002 (Ar C-H, w) 
MS (ESI): 430/432/434 [M+H+]  
HRMS C22H25
35Cl2N4O [M+H-Br−]+ requires 431.1405, found 431.1408 (2.2 ppm error) 
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Preparation of 1-(3-Chlorophenyl)-2-(2-imino-3-(2-(piperidin-1-yl)ethyl)-2,3-dihydro-1H-
benzo[d]imidazol-1-yl)ethanol hydrobromide (LVTa73):  
 
 
 
 
 
 
 
Following method E using 1-(3-Chlorophenyl)-2-(2-imino-3-(2-(piperidin-1-yl)ethyl)-2,3-
dihydro-1H-benzo[d]imidazol-1-yl)ethanone hydrobromide (LVTa71) (112 mg, 0.26 
mmol, 1 eq.) as starting materials. The clear glass LVTa73 (94.0 mg, 0.20 mmol, 77%) 
required no purification.  
Data for LVTa73 
1H (300 MHz, D6-DMSO) δ 1.36–1.38 (2H, m, CH2(12)), 1.43–1.50 (4H, m, CH2(11)), 
2.42–2.46 (6H, m, CH2(9,10)), 3.90 (2H, t, J 6.6 Hz, CH2(8)), 3.98–4.03 (2H, m, CH2(13)), 
4.98 (1H, dd, J 6.7, 3.8 Hz, CH(14)), 6.83–6.95 (4H, m, ArCH), 7.26–7.31 (2H, m, 
ArCH(18,19)), 7.39 (1H, d, J 7.2 Hz, ArCH(17)), 7.48 (1H, s, ArCH(21)),  
13C (75 MHz, D6-DMSO) δ 23.91 (CH2(12)), 25.55 (CH2(11)), 38.87 (CH2(8)), 49.26 
(CH2(13)), 54.30 (CH2(10)), 55.26 (CH2(9)), 70.58 (CH(14)), 106.41 (ArCH), 106.86 
(ArCH), 119.94 (2C, ArCH), 124.75 (ArCH(17)), 125.92 (ArCH(21)), 126.95 (ArCH(18)), 
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129.79 (ArCH(19)), 131.21 (ArC), 131.76 (ArC), 132.72 (ArC(20)), 145.62 (ArC(16)), 
153.86 (C=NH(7)) 
IR ʋ/ cm-1 731 (C-Cl, s), 1608 (C-O, s), 1625 (C=N, s), 2849 (C-H, w), 3059 (Ar C-H, w), 
3280 (O-H, br.) 
MS (ESI): 398/400/402 [M+H+]  
HRMS C22H28
35ClN4O [M+H-Br−]+ requires 399.1952, found 399.1971 (0.7 ppm error) 
 
Preparation of 1-(2,4-Dichlorophenyl)-2-(2-imino-3-(2-(piperidin-1-yl)ethyl)-2,3-dihydro-
1H-benzo[d]imidazol-1-yl)ethanol hydrobromide (LVTa74):  
 
 
 
 
 
 
 
Following method E using 1-(2,4-Dichlorophenyl)-2-(2-imino-3-(2-(piperidin-1-yl)ethyl)-
2,3-dihydro-1H-benzo[d]imidazol-1-yl)ethanone hydrobromide (LVTa72) (100 mg, 0.20 
mmol, 1 eq.) as starting materials. The colourless solid LVTa74 (78.0 mg, 0.15 mmol, 78%) 
required no purification.  
Data for LVTa74 
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mp 159–162 °C 
1H (300 MHz, CDCl3) δ 1.46-1.49 (2H, m, CH2(12)), 1.60–1.67 (4H, m, CH2(11)), 2.50–
2.52 (4H, m, CH2(10)), 2.62 (2H, t, J 6.5 Hz, CH2(9)), 3.91 (2H, t, J 6.5 Hz, CH2(8)), 4.27 
(2H, d, J 4.3 Hz, CH2(13)), 5.44 (1H, dd, J 4.3, 4.3 Hz, CH(14), 6.78–6.91 (2H, m, ArCH), 
6.97–7.05 (2H, m, ArCH), 7.21 (1H, d, J 8.4 Hz, ArCH(18)), 7.34 (1H, s, ArCH(20)), 7.76 
(1H, d, J 8.4 Hz, ArCH(17)) 
13C (75 MHz, CDCl3) δ 23.89 (CH2(12)), 25.55 (CH2(11)), 39.12 (CH2(8)), 47.83 
(CH2(13)), 24.29 (CH2(10)), 55.83 (CH2(9)), 68.12 (CH(14)), 106.42 (ArCH), 106.76 
(ArCH), 120.13 (2C, ArCH), 127.37 (ArCH(20)), 128.20 (ArCH(18)), 129.81 (ArCH(17)), 
131.33 (ArC), 131.45 (ArC), 131.69 (ArC(19)), 132.46 (ArC(21)), 139.17 (ArC(16)), 
154.02 (C=NH(7)) 
IR ʋ/ cm-1 732 (C-Cl, s), 1608 (C-O, s), 1622 (C=N, s), 2856 (C-H, w), 2019 (Ar C-H, w), 
3296 (O-H, br.) 
MS (ESI): 432/434/436 [M+H+]  
HRMS C22H27
35Cl2N4O [M+H-Br−]+ requires 433.1562, found 433.1572 (3.3 ppm error) 
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Preparation of 1-(3-Bromophenyl)-2-(3-(2-(diethylamino)ethyl)-2-imino-2,3-dihydro-1H-
benzo[d]imidazol-1-yl)ethanone hydrobromide (LVTa75):  
 
 
 
 
 
 
 
Following method D using 1-(2-(Diethylamino)ethyl)-1H-benzo[d]imidazol-2-amine 
(LVTa47) (200 mg, 0.83 mmol, 1 eq.) and 2-bromo-2,4-dichloro acetophenone (228 mg, 
0.83 mmol 1 eq.) as starting materials. The colourless solid LVTa75 (333 mg, 0.65 mmol, 
79%) required no further purification.  
Data for LVTa75 
mp 212–214 ºC 
1H (400 MHz, D6-DMSO) δ 0.82 (6H, t, J 6.8 Hz, CH3(11)), 2.51 (4H, dq, J 6.8, 6.8 Hz, 
CH2(10)), 2.75 (2H, t, J 7.0 Hz, CH2(9)), 4.30 (2H, t, J 7.0 Hz, CH2(8)), 5.96 (2H, s, 
CH2(12)), 7.28 (1H, dd, J 7.5, 7.5 Hz, ArCH), 7.35 (1H, dd, J 7.5, 7.5 Hz, ArCH), 7.60–
7.63 (3H, m, ArCH(16)), 7.99 (1H, d, J 7.4 Hz, ArCH(17)), 8.07 (1H, d, J 7.4 Hz, 
ArCH(15)), 8.27 (1H, s, ArCH(19)) 
13C (100 MHz, D6-DMSO) δ 12.13 (CH3(11)), 42.55 (CH2(8)), 46.88 (CH2(10)), 50.41 
(CH2(9)), 50.92 (CH2(12)), 110.91 (ArCH), 111.30 (ArCH), 122.60 (ArC(18)), 124.06 
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(ArCH), 124.07 (ArCH), 127.79 (ArCH(15)), 130.58 (ArC), 130.59 (ArC), 131.60 (2C, 
ArCH), 136.62 (ArC(14)), 137.24 (ArC(17)), 151.27 (C=NH(7)), 190.77 (C=O(13)) 
IR ʋ/ cm-1 1662 (C=O, s), 1696 (C=N, s), 2984 (C-H, w), 3162 (Ar C-H, w)  
MS (ESI): 428/431 [M+H+]  
HRMS C21H26
79BrN4O [M+H-Br−]+ requires 429.1290, found 429.1292 (1.5 ppm error) 
 
Preparation of 1-(3-Bromophenyl)-2-(3-(2-(diethylamino)ethyl)-2-imino-2,3-dihydro-1H-
benzo[d]imidazol-1-yl)ethanol hydrobromide (LVTa76):  
 
 
 
 
 
 
 
Following method E using 1-(3-Bromophenyl)-2-(3-(2-(diethylamino)ethyl)-2-imino-2,3-
dihydro-1H-benzo[d]imidazol-1-yl)ethanone hydrobromide (LVTa76) (111 mg, 0.22 
mmol, 1 eq.) as starting materials. The clear glass LVTa76 (83.0 mg, 0.16 mmol, 74%) 
required no purification.  
Data for LVTa76 
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1H (300 MHz, D6-DMSO) δ 1.46–1.49 (6H, m, CH3(11)), 1.60–1.67 (4H, m, CH2(10)), 
2.50–2.62 (2H, t, J 6.5 Hz, CH2(9)), 3.91 (2H, t, J 6.5 Hz, CH2(8)), 4.27 (2H, d, J 4.3 Hz, 
CH2(12)), 5.44 (1H, dd, J 4.3, 4.3 Hz, CH(13)), 6.78–6.91 (2H, m, ArCH), 6.97–7.05 (2H, 
m, ArCH), 7.21 (1H, d, J 8.4 Hz, ArCH(18)), 7.34 (1H, s, ArCH(20)), 7.76 (1H, d, J 8.4 Hz, 
ArCH(17)) 
13C (75 MHz, D6-DMSO) δ 11.90 (CH3(11)), 39.63 (CH2(8)), 46.67 (CH2(10)), 49.26 
(CH2(12)), 49.79 (CH2(9)), 70.63 (CH(13)), 106.19 (ArCH), 106.71 (ArCH), 119.70 
(ArCH), 119.82 (ArCH), 121.41 (ArCH(16)), 125.13 (ArC(19)), 128.80 (ArCH(20)), 
130.03 (ArCH(18)), 130.09 (ArCH(17)), 131.43 (ArC), 131.83 (ArC), 145.92 (ArC(15)), 
154.06 (C=NH(7)) 
IR ʋ/ cm-1 1607 (C-O, s), 1624 (C=N, s), 2810 (C-H, w), 3059 (Ar C-H, w), 3334 (O-H, br.)  
MS (ESI): 430/432 [M+H+]  
HRMS C21H28
79BrN4O [M+H-Br−]+ requires 431.1446, found 431.1441 (0.4 ppm error) 
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Preparation of 2-(2-Imino-3-(2-(piperidin-1-yl)ethyl)-2,3-dihydro-1H-benzo[d]imidazol-1-
yl)-1-(4-(trifluoromethyl)phenyl)ethanone hydrobromide (LVTa77):  
 
 
 
 
 
 
 
Following method D using 1-(2-(Piperidin-1-yl)ethyl)-1H-benzo[d]imidazol-2-amine 
(LVTa49) (200 mg, 0.82 mmol, 1 eq.) and 4-(trifluoromethyl)phenacyl bromide (219 mg, 
0.82 mmol 1 eq.) as starting materials. The cream solid LVTa77 (399 mg, 0.78 mmol, 95%) 
required no further purification.  
Data for LVTa77 
mp 218–220 ºC 
1H (300 MHz, CDCl3) δ 1.44–1.49 (2H, m, CH2(12)), 1.57–1.65 (4H, m, CH2(11)), 2.44–
2.51 (4H, m, CH2(10)), 2.61 (2H, t, J 7.1 Hz, CH2(9)), 3.89 (2H, t, J 7.1 Hz, CH2(8)), 5.33 
(2H, s, CH2(13)), 6.70 (1H, d, J 7.2 Hz, ArCH), 6.88 (1H, d, J 7.2 Hz, ArCH), 6.92–7.02 
(2H, m, ArCH), 7.75 (2H, d, J 7.7 Hz, ArCH(17)), 8.20 (2H, d, J 7.7 Hz, ArCH(16)) 
13C (75 MHz, D6-DMSO) δ 23.58 (s, CH2(12)), 25.44 (s, CH2(11)), 41.20 (s, CH2(8)), 50.21 
(s, CH2(13)), 54.01 (s, CH2(10)), 55.75 (s, CH2(9)), 110.46 (s, ArCH), 110.70 (s, ArCH), 
123.44 (s, ArCH), 123.57 (s, ArCH), 123.68 (q, 1JC-F 272 Hz, ArCF3(19)), 125.80 (q, 
3JC-F 
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3.7 Hz, ArCH(17)), 129.32 (s, ArCH(16)), 130.06 (s, ArC), 130.09 (s, ArC), 133.28 (q, 2JC-
F 32 Hz, ArC(18)), 137.23 (s, ArC(15)), 150.81 (s, C=NH(7)), 190.85 (s, C=O(14)) 
19F (376 MHz, D6-DMSO) δ −61.6 (s, Ar-CF3(19)) 
IR ʋ/ cm-1 734 (C-F, s), 1664 (C=O, s), 1697 (C=N, s), 2856 (C-H, w), 3154 (Ar C-H, w)  
MS (ESI): 431 [M+H+] 
HRMS C23H26F3N4O [M+H-Br−]+ requires 431.2059, found 431.2064 (0.5 ppm error) 
 
Preparation of 2-(3-(2-(Diethylamino)ethyl)-2-imino-2,3-dihydro-1H-benzo[d]imidazol-1-
yl)-1-(4-(trifluoromethyl)phenyl)ethanone hydrobromide (LVTa78):  
 
 
 
 
 
 
 
Following method D using 1-(2-(Diethylamino)ethyl)-1H-benzo[d]imidazol-2-amine 
(LVTa47) (200 mg, 0.86 mmol, 1 eq.) and 4-(trifluoromethyl)phenacyl bromide (230 mg, 
0.86 mmol 1 eq.) as starting materials. The light orange solid LVTa78 (307 mg, 0.62 mmol, 
72%) required no further purification.  
Data for LVTa78 
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mp 205–208 ºC 
1H (400 MHz, D6-DMSO) δ 0.83 (6H, t, J 6.4 Hz, CH3(12)), 2.45–2.51 (4H, m, CH2(10)), 
2.75 (2H, t, J 6.9 Hz, CH2(9)), 4.31 (2H, t, J 6.9 Hz, CH2(8)), 6.02 (2H, s, CH2(12)), 7.29 
(1H, dd, J 7.6, 7.6 Hz, ArCH), 7.36 (1H, dd, J 7.6, 7.6 Hz, ArCH), 7.64 (2H, d, J 7.7 Hz, 
ArCH), 8.05 (2H, d, J 7.9 Hz, ArCH(16)), 8.30 (2H, d, J 7.9 Hz, ArCH(15)) 
13C (75 MHz, D6-DMSO) δ 12.13 (s, CH3(11)), 42.56 (s, CH2(8)), 46.88 (s, CH2(10)), 50.63 
(s, CH2(12)), 50.90 (s, CH2(9)), 110.96 (s, ArCH), 111.32 (s, ArCH), 123.94 (s, ArCH), 
124.09 (s, ArCH), 124.20 (q, 1JC-F 273 Hz, ArCF3(18)), 126.29 (q, 
3JC-F 7.2 Hz, ArCH(16)), 
129.81 (s, ArCH(15)), 130.57 (s, ArC), 130.59 (s, ArC), 133.84 (q, 2JC-F 32 Hz, ArC(17)), 
137.80 (s, ArC(14)), 151.27 (s, C=NH(7)), 191.27 (s, C=O(13)) 
19F (376 MHz, D6-DMSO) δ −61.6 (s, Ar-CF3(18)) 
IR ʋ/ cm-1 744 (C-F, s), 1662 (C=O, s), 1698 (C=N, s), 2898 (C-H, w), 3103 (Ar C-H, w) 
MS (ESI): 419 [M+H+] 
HRMS C22H26F3N4O [M+H-Br−]+ requires 419.2059, found 419.2064 (0.4 ppm error) 
Analysis calculated for C22H26F3N4O: C, 52.91%; H, 5.25%; N 11.22%. Found C, 52.57%; 
H, 5.04%; N, 11.01%. 
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Preparation of 2-(2-Imino-3-(2-(piperidin-1-yl)ethyl)-2,3-dihydro-1H-benzo[d]imidazol-1-
yl)-1-(4-(trifluoromethyl)phenyl)ethanol hydrobromide (LVTa79): 
  
 
 
 
 
 
 
 
Following method E using 2-(2-Imino-3-(2-(piperidin-1-yl)ethyl)-2,3-dihydro-1H-
benzo[d]imidazol-1-yl)-1-(4-(trifluoromethyl)phenyl)ethanone hydrobromide (LVTa77) 
(100 mg, 0.20 mmol, 1 eq.) as starting materials. The colourless solid LVTa79 (89.0 mg, 
0.17 mmol, 85%) required no purification.  
Data for LVTa79 
mp: 136–139 °C 
1H (300 MHz, CDCl3) δ 1.44–1.47 (2H, m, CH2(12)), 1.58–1.65 (4H, m, CH2(11)), 2.48–
2.50 (4H, m, CH2(10)), 2.59 (2H, t, J 6.8 Hz, CH2(9)), 3.87 (2H, t, J 6.8 Hz, CH2(8)), 4.15 
(2H, d, J 5.1 Hz, CH2(13)), 5.20 (1H, dd, J 5.1, 5.1 Hz, CH(14)), 6.62 (1H, d, J 7.1 Hz, 
ArCH), 6.86 (1H, d, J 8.7 Hz, ArCH), 6.91–7.00 (2H, m, ArCH), 7.55–7.61 (4H, m, 
ArCH(17,18)) 
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13C (75 MHz, D6-DMSO) δ 23.90 (s, CH2(12)), 25.55 (s, CH2(11)), 38.80 (s, CH2(8)), 49.28 
(s, CH2(13)), 54.30 (s, CH2(10)), 55.82 (s, CH2(9)), 70.78 (s, CH(14)), 106.30 (s, ArCH), 
106.66 (s, ArCH), 119.74 (s, ArCH), 119.85 (s, ArCH), 120.70 (q, 1JC-F 271 Hz, ArCF3(20)), 
124.74 (q, 3JC-F 7.4 Hz, ArCH(18)), 126.84 (s, ArCH(17)), 127.84 (q, 
2JC-F 31 Hz, ArC(19)), 
131.35 (s, ArC), 131.79 (s, ArC), 147.83 (s, ArC(16)), 153.95 (s, C=NH(7)) 
19F (376 MHz, D6-DMSO) δ −60.7 (s, Ar-CF3(20)) 
IR ʋ/ cm-1 1609 (C-O, s), 2809 (C-H, w), 3107 (Ar C-H, w), 3357 (O-H, br.) 
MS (ESI): 433 [M+H+]  
HRMS C23H28F3N4O [M+H-Br−]+ requires 433.2210, found 433.2210 (0.1 ppm error) 
 
Preparation of 2-(3-(2-(Diethylamino)ethyl)-2-imino-2,3-dihydro-1H-benzo[d]imidazol-1-
yl)-1-(4-(trifluoromethyl)phenyl)ethanol hydrobromide (LVTa80):  
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Following method E using 2-(3-(2-(Diethylamino)ethyl)-2-imino-2,3-dihydro-1H-
benzo[d]imidazol-1-yl)-1-(4-(trifluoromethyl)phenyl)ethanone hydrobromide (LVTa78) 
(100 mg, 0.20 mmol, 1 eq.) as starting materials. The clear glass LVTa80 (90.0 mg, 0.18 
mmol, 90%) required no purification.  
Data for LVTa80 
1H (300 MHz, CDCl3) δ 0.88 (6H, t, J 7.0 Hz, CH3(11)), 2.46 (4H, dq, J 7.0, 7.0 Hz, 
CH2(10)), 2.56 (2H, t, J 6.6 Hz, CH2(9)), 3.84 (2H, t, J 6.6 Hz, CH2(8)), 3.97–4.09 (2H, m, 
CH2(12)), 5.07 (1H, dd, J 5.7, 5.7 Hz, CH(13)), 6.80–6.92 (4H, m, ArCH(1,2,3,6)), 7.64 
(4H, s, ArCH(16,17)) 
13C (75 MHz, D6-DMSO) δ 11.86 (s, CH3(11)), 39.60 (s, CH2(8)), 46.65 (s, CH2(10)), 49.26 
(s, CH2(9)), 49.76 (s, CH2(12)), 70.84 (s, CH(13)), 106.23 (s, ArCH), 106.62 (s, ArCH), 
119.67 (s, ArCH), 119.83 (s, ArCH), 124.31 (q, 1JC-F 272 Hz, ArCF3(19)), 124.73 (q, 
3JC-F 
7.5 Hz, ArCH(17)), 126.84 (s, ArCH(16)), 127.62 (q, 2JC-F 31 Hz, ArC(18)), 131.45 (s, 
ArC), 131.79 (s, ArC), 147.83 (s, ArC(15)), 154.07 (s, C=NH(7)) 
19F (376 MHz, D6-DMSO) δ −60.7 (s, Ar-CF3(19)) 
IR ʋ/ cm-1 742 (C-F, s), 1608 (C-O, s), 2814 (C-H, w), 3066 (Ar C-H, w), 3319 (O-H, br.)  
MS (ESI): 421 [M+H+]  
HRMS C22H28F3ON4 [M+H-Br−]+ requires 421.2215, found 421.2215 (0.2 ppm error) 
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Preparation of 2-(2-Imino-3-(2-(piperidin-1-yl)ethyl)-2,3-dihydro-1H-benzo[d]imidazol-1-
yl)-1-(3-nitrophenyl)ethanone hydrobromide (LVTa81):  
 
 
 
 
 
 
 
Following method D using 1-(2-(Piperidin-1-yl)ethyl)-1H-benzo[d]imidazol-2-amine 
(LVTa49) (200 mg, 0.82 mmol, 1 eq.) and 2-bromo-3-nitroacetophenone (200 mg, 0.82 
mmol 1 eq.) as starting materials. The yellow solid LVTa81 (368 mg, 0.76 mmol, 93%) 
required no further purification.  
Data for LVTa81 
mp 210–213 ºC 
1H (300 MHz, CDCl3) δ 1.36–1.38 (2H, m, CH2(12)), 1.43–1.45 (4H, m, CH2(11)), 2.36–
2.38 (4H, m, CH2(10)), 2.68 (2H, t, J 7.1 Hz, CH2(9)), 4.35 (2H, t, J 7.1 Hz, CH2(8)), 6.07 
(2H, s, CH2(13)), 7.30 (1H, dd, J 7.7, 7.7 Hz, ArCH), 7.35 (1H, dd, J 7.7, 7.7 Hz, ArCH), 
7.65 (2H, m, ArCH), 7.97 (1H, dd, J 7.6, 7.6 Hz, ArCH(17)), 8.51 (1H, d, J 7.6 Hz, 
ArCH(18)), 8.62 (1H, d, J 7.6 Hz, ArCH(16)), 8.82 (1H, s, ArCH(20)) 
13C (75 MHz, D6-DMSO) δ 24.12 (CH2(12)), 26.01 (CH2(11)), 41.82 (CH2(8)), 50.67 
(CH2(13)), 54.54 (CH2(10)), 56.32 (CH2(9)), 110.97 (ArCH), 111.23 (ArCH), 123.26 
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(ArCH(20)), 123.96 (ArCH), 123.98 (ArCH), 128.81 (ArCH(16)), 130.59 (ArC), 130.61 
(ArC), 131.24 (ArCH(17)), 135.08 (ArCH(18)), 135.85 (ArC(19)), 148.48 (ArC(15)), 
151.38 (C=NH(7)), 190.66 (C=O(14)) 
IR ʋ/ cm-1 1350 (NO2, s), 1522 (NO2, s), 1699 (C=O, s), 2940 (C-H, w), 3159 (Ar C-H, w)  
MS (ESI): 408 [M+H+]  
HRMS C22H26N5O3 [M+H-Br−]+ requires 408.2036, found 408.2040 (0.9 ppm error) 
 
Preparation of 2-(3-(2-(Diethylamino)ethyl)-2-imino-2,3-dihydro-1H-benzo[d]imidazol-1-
yl)-1-(3-nitrophenyl)ethanone hydrobromide (LVTa82):  
 
 
 
 
 
 
 
Following method D using 1-(2-(Diethylamino)ethyl)-1H-benzo[d]imidazol-2-amine 
(LVTa47) (200 mg, 0.86 mmol, 1 eq.) and 2-bromo-3-nitroacetophenone (210 mg, 0.86 
mmol 1 eq.) as starting materials. The yellow solid LVTa82 (354 mg, 0.75 mmol, 87%) 
required no further purification.  
Data for LVTa82 
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mp 206–209 ºC 
1H (300 MHz, D6-DMSO) δ 0.83 (6H, t, J 6.5 Hz, CH3(11)), 2.45–2.51 (4H, m, CH2(10)), 
2.76 (2H, t, J 6.8 Hz, CH2(9)), 4.32 (2H, t, J 6.8 Hz, CH2(8)), 6.10 (2H, s, CH2(12)), 7.29 
(1H, dd, J 7.5, 7.5 Hz, ArCH), 7.37 (1H, dd, J 7.5, 7.5 Hz, ArCH), 7.65 (2H, d, J 7.8 Hz, 
ArCH), 7.97 (1H, dd, J 8.0, 8.0 Hz, ArCH(16)), 8.52 (1H, d, J 8.0 Hz, ArCH(17)), 8.60 (1H, 
d, J 8.0 Hz, ArCH(15)), 8.82 (1H, s, ArCH(19)) 
13C (75 MHz, D6-DMSO) δ 11.63 (CH3(11)), 41.98 (CH2(8)), 46.34 (CH2(10)), 50.19 
(CH2(12)), 110.44 (ArCH), 110.83 (ArCH), 122.76 (ArCH(19)), 123.41 (ArCH), 123.56 
(ArCH), 128.31 (ArCH(15)), 129.91 (ArC), 130.04 (ArC), 130.72 (ArCH(16)), 134.61 
(ArCH(17)), 135.29 (ArC(18)), 147.91 (ArC(14)), 150.68 (C=NH(7)), 190.13 (C=O(13)) 
IR ʋ/ cm-1 1346 (NO2, s), 1525 (NO2, s), 1660 (C=O, s), 1703 (C=N, s), 2963 (C-H, w), 3207 
(Ar C-H, w)  
MS (ESI): 396 [M+H+]  
HRMS C21H26N5O3 [M+H-Br−]+ requires 396.2036, found 396.2047 (0.9 ppm error) 
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Preparation of 2-(2-Imino-3-(2-(piperidin-1-yl)ethyl)-2,3-dihydro-1H-benzo[d]imidazol-1-
yl)-1-(3-nitrophenyl)ethanol hydrobromide (LVTa83): 
  
 
 
 
 
 
 
Following method E using 2-(2-Imino-3-(2-(piperidin-1-yl)ethyl)-2,3-dihydro-1H-
benzo[d]imidazol-1-yl)-1-(3-nitrophenyl)ethanone hydrobromide (LVTa81) (100 mg, 0.21 
mmol, 1 eq.) as starting materials. The yellow solid LVTa83 (92.0 mg, 0.19 mmol, 91%) 
required no purification.  
Data for LVTa83 
mp 80–83 °C 
1H (300 MHz, CDCl3) δ 1.44–1.47 (2H, m, CH2(12)), 1.59–1.66 (4H, m, CH2(11)), 2.49–
2.51 (4H, m, CH2(10)), 2.60 (2H, t, J 6.7 Hz, CH2(9)), 3.88 (2H, t, J 6.7 Hz, CH2(8)), 4.16–
4.30 (2H, m, CH2(13)), 5.29 (1H, dd, J 4.4, 4.4 Hz, CH(14)), 6.60 (1H, d, J 7.3 Hz, ArCH), 
6.85 (1H, d, J 8.6 Hz, ArCH), 6.89–7.00 (2H, m, ArCH), 7.47 (1H, dd, J 7.6, 7.6 Hz, 
ArCH(18)), 7.83 (1H, d, J 7.6 Hz, ArCH(19)), 8.06 (1H, d, J 7.6 Hz, ArCH(17)), 8.31 (1H, 
s, ArCH(21)) 
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13C (75 MHz, CDCl3) δ 24.10 (CH2(12)), 25.97 (CH2(11)), 40.69 (CH2(8)), 50.91 
(CH2(13)), 55.09 (CH2(10)), 56.66 (CH2(9)), 73.83 (CH(14)), 106.40 (ArCH), 106.92 
(ArCH), 121.13 (ArCH(21)), 121.34 (2C, ArCH), 122.49 (ArCH(17)), 129.31 (ArCH(18)), 
131.40 (2C, ArC), 132.19 (ArC(19)), 144.81 (ArC(20)), 148.22 (ArC(16)), 156.65 
(C=NH(7)) 
IR ʋ/ cm-1 1347 (NO2, s), 1494 (NO2, s), 1608 (C-O, s), 1622 (C=N, s), 2854 (C-H, w), 3061 
(Ar C-H, w), 3357 (O-H, br.)  
MS (ESI): 410 [M+H+] 
HRMS C22H28N5O3 [M+H-Br−]+ requires 410.2192, found 410.2199 (2.8 ppm error) 
 
Preparation of 2-(3-(2-(Diethylamino)ethyl)-2-imino-2,3-dihydro-1H-benzo[d]imidazol-1-
yl)-1-(3-nitrophenyl)ethanol hydrobromide (LVTa84):  
 
 
 
 
 
 
 
Following method E using 2-(3-(2-(Diethylamino)ethyl)-2-imino-2,3-dihydro-1H-
benzo[d]imidazol-1-yl)-1-(3-nitrophenyl)ethanone hydrobromide (LVTa82)  (100 mg, 0.21 
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mmol, 1 eq.) as starting materials. The orange glass LVTa84 (77.0 mg, 0.16 mmol, 76%) 
required no purification.  
Data for LVTa84 
1H (300 MHz, CDCl3) δ 1.03 (6H, t, J 7.1 Hz, CH3(12)), 2.60 (4H, dq, J 7.1, 7.1 Hz, 
CH2(10)), 2.70 (2H, t, J 6.6 Hz, CH2(9)), 3.82 (2H, t, J 6.6 Hz, CH2(8)), 4.15–4.29 (2H, m, 
CH2(12)), 5.26–5.28 (1H, m, CH(13)), 6.60 (1H, d, J 7.2 Hz, ArCH), 6.84 (1H, d, J 7.2 Hz, 
ArCH), 6.89–7.00 (2H, m, ArCH), 7.47 (1H, dd, J 7.9, 7.9 Hz, ArCH(17)), 7.82 (1H, d, J 
7.9 Hz, ArCH(18)), 8.06 (1H, d, J 7.9 Hz, ArCH(16)), 8.31 (1H, s, ArCH(20)) 
13C (75 MHz, CDCl3) δ 11.99 (CH2(11)), 41.81 (CH2(8)), 47.73 (CH2(10)), 50.93 (CH2(9)), 
51.11 (CH2(12)), 73.85 (CH(13)), 106.34 (ArCH), 106.87 (ArCH), 121.12 (ArCH(20)), 
121.18 (2C, ArCH), 122.46 (ArCH(16)), 129.30 (ArCH(17)), 131.42 (2C, ArC), 132.17 
(ArC(18)), 144.87 (ArC(19)), 148.22 (ArC(15)), 156.82 (C=NH(7)) 
IR ʋ/ cm-1 1346 (NO2, s), 1524 (NO2, s), 1608 (C-O, s), 1625 (C=N, s), 2810 (C-H, w), 3065 
(Ar C-H, w), 3269 (O-H, br.)  
MS (ESI): 398 [M+H+]  
HRMS C21H28N5O3 [M+H-Br−]+ requires 398.2187, found 398.2178 (2.2 ppm error) 
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Preparation of 2-(2-Imino-3-pentyl-2,3-dihydro-1H-benzo[d]imidazol-1-yl)-1-(4-
(trifluoromethyl)phenyl)ethanone hydrobromide (LVTa85):  
 
 
 
 
 
 
 
 
Following method D using 1-Pentyl-1H-benzo[d]imidazol-2-amine (LVTa55) (200 mg, 
0.98 mmol, 1 eq.) and 4-(trifluoromethyl)phenacyl bromide (262 mg, 0.98 mmol 1 eq.) as 
starting materials. The colourless solid LVTa85 (317 mg, 0.67 mmol, 68%) required no 
further purification.  
Data for LVTa85 
mp 238–241 ºC 
1H (300 MHz, D6-DMSO) δ 0.88 (3H, t, J 6.9 Hz, CH3(12)), 1.32–1.35 (4H, m, CH2(10,11)), 
1.73–1.75 (2H, m, CH2(9)), 4.25 (2H, t, J 6.5 Hz, CH2(8)), 6.04 (2H, s, CH2(13)), 7.30–7.38 
(2H, m, ArCH(1,2)), 7.68 (2H, d, J 7.0 Hz, ArCH(3,6)), 8.06 (2H, d, J 7.6 Hz, ArCH(17)), 
8.30 (2H, d, J 7.6 Hz, ArCH(16)) 
13C (75 MHz, D6-DMSO) δ 13.85 (s, CH3(12)), 21.84 (s, CH2(11)), 27.17 (s, CH2(9)), 27.84 
(s, CH2(10)), 42.61 (s, CH2(8)), 50.19 (s, CH2(13)), 110.50 (2C, s, ArCH), 123.57 (s, 
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ArCH), 123.68 (q, 1JC-F 273 Hz, ArCF3(19)), 123.77 (s, ArCH), 125.84 (q, 
3JC-F 4.8 Hz, 
ArCH(17)), 129.32 (s, ArCH(16)), 130.07 (2C, s, ArC), 132.88 (q, 2JC-F 31 Hz, ArC(18)), 
137.20 (s, ArC(15)), 149.98 (s, C=NH(7)), 190.90 (s, C=O(14)) 
19F (376 MHz, D6-DMSO) δ −61.5 (s, ArCF3(19)) 
IR ʋ/ cm-1 742 (C-F, s), 1661 (C=O, s), 1699 (C=N, s), 2855 (C-H, w), 3165 (Ar C-H, w)  
MS (ESI): 390 [M+H+]  
HRMS C21H23F3N3O [M+H-Br−]+ requires 390.1793, found 390.1814 (1.8 ppm error) 
 
Preparation of 2-(3-Hexyl-2-imino-2,3-dihydro-1H-benzo[d]imidazol-1-yl)-1-(4-
(trifluoromethyl)phenyl)ethanone hydrobromide (LVTa86):  
 
 
 
 
 
 
 
 
Following method D using 1-Hexyl-1H-benzo[d]imidazol-2-amine (LVTa56) (200 mg, 
0.92 mmol, 1 eq.) and 4-(trifluoromethyl)phenacyl bromide  (246 mg, 0.92 mmol 1 eq.) as 
 361 
 
starting materials. The colourless solid LVTa86 (297 mg, 0.61 mmol, 66%) required no 
further purification.  
Data for LVTa86 
mp 237–239 ºC 
1H (400 MHz, D6-DMSO) δ 0.87 (3H, t, J 6.5 Hz, CH3(13)), 0.97–1.37 (6H, m, 
CH2(10,11,12)), 1.74 (2H, t, J 6.5 Hz, CH2(9)), 4.22 (2H, t, J 6.5 Hz, CH2(8)), 6.00 (2H, s, 
CH2(13)), 7.31 (1H, dd, J 7.7, 7.7 Hz, ArCH), 7.37 (1H, dd, J 7.7, 7.7 Hz, ArCH), 7.66 (2H, 
d, J 7.3 Hz, ArCH), 8.06 (2H, d, J 8.3 Hz, ArCH(18)), 8.29 (2H, d, J 8.3 Hz, ArCH(17)), 
8.82 (1H, br. s, NH(21)) 
13C (100 MHz, D6-DMSO) δ 14.29 (s, CH3(13)), 22.45 (s, CH2(12)), 25.83 (s, CH2(11)), 
27.90 (s, CH2(9)), 31.31 (s, CH2(10)), 43.19 (s, CH2(8)), 50.06 (s, CH2(13)), 111.03 (s, 
ArCH), 111.09 (s, ArCH), 123.70 (q, 1JC-F 272 Hz, ArCF3(20)), 124.12 (s, ArCH), 124.33 
(s, ArCH), 126.30 (q, 3JC-F 7.0 Hz, ArCH(18)), 129.81 (s, ArCH(17)), 129.90 (s, ArC), 
130.59 (s, ArC), 133.88 (q, 2JC-F 31 Hz, ArC(19)), 137.73 (s, ArC(16)), 150.55 (s, 
C=NH(7)), 191.36 (s, C=O(15)) 
19F (376 MHz, D6-DMSO) δ −61.6 (s, ArCF3(20)) 
IR ʋ/ cm-1 743 (C-F, s), 1665 (C=O, s), 1698 (C=N, s), 2930 (C-H, w), 3190 (Ar C-H, w) 
MS (ESI): 404 [M+H+] 
HRMS C22H25F3N3O [M+H-Br−]+ requires 404.1950, found 404.1958 (3.2 ppm error) 
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Preparation of 2-(2-Imino-3-pentyl-2,3-dihydro-1H-benzo[d]imidazol-1-yl)-1-(4-
(trifluoromethyl)phenyl)ethanol hydrobromide (LVTa87): 
  
 
 
 
 
 
 
 
Following method E using 2-(2-Imino-3-pentyl-2,3-dihydro-1H-benzo[d]imidazol-1-yl)-1-
(4-(trifluoromethyl)phenyl)ethanone hydrobromide (LVTa85) (106 mg, 0.23 mmol, 1 eq.) 
as starting materials. The off-white solid LVTa87 (68.0 mg, 0.15 mmol, 65%) required no 
purification.  
Data for LVTa87 
mp: 104–107 °C 
1H (400 MHz, D6-DMSO) δ 0.85 (3H, t, J 6.8 Hz, CH3(12)), 1.23–1.33 (4H, m, CH2(10,11)), 
1.54–1.61 (2H, m, CH2(9)), 3.80 (2H, t, J 7.0 Hz, CH2(8)), 3.98–4.10 (2H, m, CH2(13)), 
5.09 (2H, t, J 6.1 Hz, CH(14)), 6.80–6.94 (4H, m, ArCH), 7.64 (4H, s, ArCH(17,18)) 
13C (100 MHz, D6-DMSO) δ 13.86 (s, CH3(12)), 21.90 (s, CH2(11)), 27.04 (s, CH2(9)), 
28.26 (s, CH2(10)), 40.50 (s, CH2(8)), 49.28 (s, CH2(13)), 70.83 (s, CH(14)), 106.12 (s, 
ArCH), 106.70 (s, ArCH), 119.73 (s, ArCH), 119.89 (s, ArCH), 124.30 (q, 1JC-F 272 Hz, 
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ArCF3(20)), 124.71 (q, 
3JC-F 3.7 Hz, ArCH(18)), 126.81 (s, ArCH(17)), 127.63 (q, 
2JC-F 31 
Hz, ArC(19)), 131.26 (s, ArC), 131.76 (s, ArC), 147.83 (s, ArC(16)), 153.94 (s, C=NH(7)) 
19F (376 MHz, D6-DMSO) δ −60.8 (s, ArC-F3(20)) 
IR ʋ/ cm-1 728 (C-F, s), 1609 (C-O, s), 2862 (C-H, w), 3339 (Ar C-H, w), 3455 (O-H, br.) 
MS (ESI): 392 [M+H+]  
HRMS C21H25F3N3O [M+H-Br−]+ requires 392.1950, found 392.1968 (1.5 ppm error) 
 
Preparation of 2-(3-Hexyl-2-imino-2,3-dihydro-1H-benzo[d]imidazol-1-yl)-1-(4-
(trifluoromethyl)phenyl)ethanol hydrobromide (LVTa88):  
 
 
 
 
 
 
 
Following method E using 2-(3-Hexyl-2-imino-2,3-dihydro-1H-benzo[d]imidazol-1-yl)-1-
(4-(trifluoromethyl)phenyl)ethanone hydrobromide (LVTa86) (100 mg, 0.21 mmol, 1 eq.) 
as starting materials. The colourless solid LVTa88 (69.0 mg, 0.14 mmol, 67%) required no 
purification.  
Data for LVTa88 
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mp: 107–109 °C 
1H (400 MHz, D6-DMSO) δ 0.84 (3H, t, J 6.8 Hz, CH3(13)), 1.23–1.30 (6H, m, 
CH2(10,11,12)), 1.53–1.58 (2H, m, CH2(9)), 3.79 (2H, t, J 7.1 Hz, CH2(8)), 3.99–4.06 (2H, 
m, CH2(14)), 5.08 (2H, t, J 6.5 Hz, CH(15)), 6.80–6.92 (4H, m, ArCH), 7.64 (4H, s, 
ArCH(18,19)) 
13C (100 MHz, D6-DMSO) δ 13.85 (s, CH3(13)), 22.01 (s, CH2(12)), 25.74 (s, CH2(11)), 
27.29 (s, CH2(10)), 30.98 (s, CH2(9)), 40.49 (s, CH2(8)), 49.28 (s, CH2(14)), 70.87 (s, 
CH(15)), 106.06 (s, ArCH), 106.62 (s, ArCH), 119.67 (s, ArCH), 119.83 (s, ArCH), 124.32 
(q, 1JC-F 272 Hz, ArCF3(21)), 124.76 (q, 
3JC-F 4.7 Hz, ArCH(19)), 126.81 (s, ArCH(18)), 
127.40 (q, 2JC-F 32 Hz, ArC(20)), 131.26 (s, ArC), 131.79 (s, ArC), 147.87 (s, ArC(17)), 
154.03 (s, C=NH(7)) 
19F (376 MHz, D6-DMSO) δ −60.8 (s, ArC-F3(21)) 
IR ʋ/ cm-1 728 (C-F, s), 1608 (C-O, s), 2859 (C-H, w), 2960 (Ar C-H, w), 3344 (O-H, br.) 
MS (ESI): 406 [M+H+]  
HRMS C22H27F3N3O [M+H-Br−]+ requires 406.2106, found 406.2115 (3.4 ppm error) 
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Preparation of 2-(2-Imino-3-pentyl-2,3-dihydro-1H-benzo[d]imidazol-1-yl)-1-(3-
nitrophenyl)ethanone hydrobromide (LVTa89):  
 
 
 
 
 
 
 
Following method D using 1-Pentyl-1H-benzo[d]imidazol-2-amine (LVTa55) (200 mg, 
0.98 mmol, 1 eq.) and 2-bromo-3-nitro acetophenone (240 mg, 0.98 mmol 1 eq.) as starting 
materials. The colourless solid LVTa89 (346 mg, 0.77 mmol, 79%) required no further 
purification.  
Data for LVTa89 
mp 240–242 ºC 
1H (300 MHz, D6-DMSO) δ 0.88 (3H, t, J 6.8 Hz, CH3(12)), 1.33–1.36 (4H, m, CH2(10,11)), 
1.70–1.76 (2H, m, CH2(9)), 4.25 (2H, t, J 7.1 Hz, CH2(8)), 6.11 (2H, m, CH2(13)), 7.29–
7.40 (2H, s, ArCH), 7.68 (2H, d, J 7.6 Hz, ArCH), 7.97 (1H, dd, J 8.0, 8.0 Hz, ArCH(17)), 
8.51 (1H, d, J 8.0 Hz, ArCH(18)), 8.61 (1H, d, J 8.0 Hz, ArCH(16)), 8.81 (1H, s, ArCH(20)), 
8.95 (1H, br. s, NH(21)) 
13C (75 MHz, D6-DMSO) δ 13.85 (CH3(12)), 21.84 (CH2(11)), 27.17 (CH2(9)), 27.84 
(CH2(10)), 42.64 (CH2(8)), 50.25 (CH2(13)), 110.52 (ArCH), 122.76 (ArCH(20)), 123.57 
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(ArCH), 123.79 (ArCH), 128.32 (ArCH(16)), 129.39 (ArC), 130.07 (ArC), 130.73 
(ArCH(17)), 134.63 (ArCH(18)), 135.27 (ArC(19)), 147.90 (ArC(15)), 149.99 (C=NH(7)), 
190.25 (C=O(14)) 
IR ʋ/ cm-1 1351 (NO2, s), 1524 (NO2, s), 1608 (C=O, s), 1698 (C=N, s), 2969 (C-H, w), 3162 
(Ar C-H, w) 
MS (ESI): 367 [M+H+]  
HRMS C20H23N4O3 [M+H-Br−]+ requires 367.1770, found 367.1774 (0.9 ppm error) 
 
Preparation of 2-(3-Hexyl-2-imino-2,3-dihydro-1H-benzo[d]imidazol-1-yl)-1-(3-
nitrophenyl)ethanone hydrobromide (LVTa90):  
 
 
 
 
 
 
 
Following method D using 1-Hexyl-1H-benzo[d]imidazol-2-amine (LVTa56) (200 mg, 
0.92 mmol, 1 eq.) and 2-bromo-3-nitro acetophenone (225 mg, 0.92 mmol 1 eq.) as starting 
materials. The colourless solid LVTa90 (331 mg, 0.72 mmol, 78%) required no further 
purification.  
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Data for LVTa90 
mp 239–241 ºC  
1H (400 MHz, D6-DMSO) δ 0.88 (3H, t, J 6.8 Hz, CH3(13)), 1.30–1.34 (4H, m, CH2(11,12)), 
1.36–1.39 (2H, m, CH2(10)), 1.72–1.76 (2H, m, CH2(9)), 4.23 (2H, t, J 7.1 Hz, CH2(8)), 
6.07 (2H, s, CH2(13)), 7.32 (1H, dd, J 7.4, 7.4 Hz, ArCH), 7.38 (1H, dd, J 7.4, 7.4 Hz, 
ArCH), 7.65 (2H, d, J 8.0 Hz, ArCH), 7.95 (1H, dd, J 8.0, 8.0 Hz, ArCH(18)), 8.50 (1H, d, 
J 8.0 Hz, ArCH(19)), 8.60 (1H, d, J 8.0 Hz, ArCH(17)), 8.82 (1H, s, ArCH(21)), 8.87 (1H, 
br. s, NH(22)) 
13C (75 MHz, D6-DMSO) δ 12.58 (CH3(13)), 20.90 (CH2(12)), 24.33 (CH2(11)), 26.35 
(CH2(9)), 29.77 (CH2(10)), 41.73 (CH2(8)), 49.14 (CH2(14)), 109.41 (ArCH), 109.51 
(ArCH), 121.74 (ArCH(21)), 122.52 (ArCH), 122.75 (ArCH), 127.21 (ArCH(17)), 128.39 
(ArC), 129.07 (ArC), 129.56 (ArCH(18)), 133.43 (ArC(20)), 134.30 (ArCH(19)), 146.98 
(ArC(16)), 149.03 (C=NH(7)), 189.09 (C=O(15)) 
IR ʋ/ cm-1 1353 (NO2, s), 1524 (NO2, s), 1664 (C=O, s), 1693 (C=N, s), 2861 (C-H, w), 3160 
(Ar C-H, w)  
MS (ESI): 381 [M+H+]  
HRMS C21H25N4O3 [M+H-Br−]+  requires 381.1927, found 381.1942 (1.3 ppm error) 
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Preparation of 2-(2-Imino-3-pentyl-2,3-dihydro-1H-benzo[d]imidazol-1-yl)-1-(3-
nitrophenyl)ethanol hydrobromide (LVTa91): 
  
 
 
 
 
 
 
Following method E using 2-(2-Imino-3-pentyl-2,3-dihydro-1H-benzo[d]imidazol-1-yl)-1-
(3-nitrophenyl)ethanone hydrobromide (LVTa89)  (100 mg, 0.22 mmol, 1 eq.) as starting 
materials. The dark orange glass LVTa91 (63.0 mg, 0.14 mmol, 64%) required no 
purification.  
Data for LVTa91 
1H (300 MHz, D6-DMSO) δ 0.84 (3H, t, J 6.9 Hz, CH3(12)), 1.18–1.33 (4H, m, CH2(10,11)), 
1.49–1.59 (2H, m, CH2(9)), 3.79 (2H, t, J 7.0 Hz, CH2(8)), 4.01–4.19 (2H, m, CH2(13)), 
5.15 (1H, dd, J 6.0 Hz, CH(14)), 6.81–6.93 (4H, m, ArCH), 7.56 (1H, dd, J 7.9, 7.9 Hz, 
ArCH(18)), 7.87 (1H, d, J 7.9 Hz, ArCH(19)), 8.05 (1H, d, J 7.9 Hz, ArCH(17)), 8.25 (1H, 
s, ArCH(21)) 
13C (75 MHz, CDCl3) δ 13.96 (CH3(12)), 22.41 (CH2(11)), 27.65 (CH2(9)), 29.09 
(CH2(10)), 41.92 (CH2(8)), 50.94 (CH2(13)), 74.05 (CH(14)), 106.20 (ArCH), 106.91 
(ArCH), 120.99 (ArCH(21)), 121.10 (2C, ArCH), 122.47 (ArCH(17)), 129.28 (ArCH(18)), 
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131.40 (ArC), 131.42 (ArC), 132.11 (ArCH(19)), 132.11 (ArCH(19)), 144.92 (ArC(20)), 
148.24 (ArC(16)), 156.68 (C=NH(7)) 
IR ʋ/ cm-1 1346 (NO2, s), 1525 (NO2, s), 1605 (C-O, s), 2860 (C-H, w), 3068 (Ar C-H, w), 
3372 (O-H, br.)  
MS (ESI): 369 [M+H+]  
HRMS C20H25N4O3 [M+H-Br−]+  requires 369.1927, found 369.1931 (2.7 ppm error) 
 
Preparation of 2-(3-Hexyl-2-imino-2,3-dihydro-1H-benzo[d]imidazol-1-yl)-1-(3-
nitrophenyl)ethanol hydrobromide (LVTa92):  
 
 
 
 
 
 
 
Following method E using 2-(3-Hexyl-2-imino-2,3-dihydro-1H-benzo[d]imidazol-1-yl)-1-
(3-nitrophenyl)ethanone hydrobromide (LVTa90)  (100 mg, 0.22 mmol, 1 eq.) as starting 
materials. The orange glass LVTa92 (66.0 mg, 0.14 mmol, 64%) required no purification.  
Data for LVTa92 
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1H (300 MHz, CDCl3) δ 0.89 (3H, t, J 7.0 Hz, CH3(13)), 1.25–1.40 (6H, m, CH2(10,11,12)), 
1.67–1.74 (2H, m, CH2(9)), 3.74 (2H, t, J 7.1 Hz, CH2(8)), 4.13–4.28 (2H, m, CH2(14)), 
5.26–5.28 (1H, m, CH(15)), 6.62 (1H, d, J 7.5 Hz, ArCH), 6.92 (1H, d, J 7.5 Hz, ArCH), 
6.92–6.99 (2H, m, ArCH), 7.47 (1H, dd, J 7.5, 7.5 Hz, ArCH(19)), 7.76 (1H, d, J 7.5 Hz, 
ArCH(20)), 8.07 (1H, d, J 7.5 Hz, ArCH(18)), 8.32 (1H, s, ArCH(22)) 
13C (75 MHz, CDCl3) δ 10.04 (CH3(13)), 22.51 (CH2(12)), 26.65 (CH2(11)), 27.88 
(CH2(9)), 31.44 (CH2(10)), 41.90 (CH2(8)), 50.91 (CH2(14)), 74.02 (CH(15)), 106.16 
(ArCH), 106.86 (ArCH), 120.95 (ArCH(22)), 121.07 (2C, ArCH), 122.45 (ArCH(18)), 
129.25 (ArCH(19)), 131.36 (ArC), 131.39 (ArC), 132.07 (ArCH(20)), 144.90 (ArC(21)), 
148.21 (ArC(17)), 156.67 (C=NH(7)) 
IR ʋ/ cm-1 1342 (NO2, s), 1526 (NO2, s), 1606 (C-O, s), 2857 (C-H, w) 3065 (Ar C-H, w), 
3370 (O-H, br.)  
MS (ESI): 383 [M+H+]  
HRMS C21H27N4O3 [M+H-Br−]+  requires 383.2083, found 383.2081 (1.0 ppm error) 
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Preparation of 1-(2,4-Dichlorophenyl)-2-(2-imino-3-pentyl-2,3-dihydro-1H-
benzo[d]imidazol-1-yl)ethanone hydrobromide (LVTa93):  
 
 
 
 
 
 
 
Following method D using 1-Pentyl-1H-benzo[d]imidazol-2-amine (LVTa55) (200 mg, 
0.98 mmol, 1 eq.) and 2-bromo-2,4-dichloro acetophenone (263 mg, 0.98 mmol 1 eq.) as 
starting materials. The colourless solid LVTa93 (339 mg, 0.72 mmol, 74%) required no 
further purification.  
Data for LVTa93 
mp 225–227 ºC 
1H (300 MHz, D6-DMSO) δ 0.87 (3H, t, J 6.9 Hz, CH3(12)), 1.31–1.35 (4H, m, CH2(10,11)), 
1.70–1.75 (2H, m, CH2(9)), 4.26 (2H, t, J 7.1 Hz, CH2(8)), 5.93 (2H, s, CH2(13)), 7.30–7.40 
(2H, m, ArCH(1,2)), 7.62–7.69 (2H, m, ArCH), 7.76 (1H, d, J 8.5 Hz, ArCH(17)), 7.89 (1H, 
s, ArCH(19)), 8.27 (1H, d, J 8.5 Hz, ArCH(16)), 9.06 (1H, s, NH(21)) 
13C (75 MHz, D6-DMSO) δ 13.84 (CH3(12)), 21.84 (CH2(11)), 27.18 (CH2(9)), 27.81 
(CH2(10)), 42.65 (CH2(8)), 51.79 (CH2(13)), 110.52 (2C, ArCH), 123.60 (ArCH), 123.79 
(ArCH), 127.59 (ArCH(16)), 129.40 (ArC), 129.93 (ArC), 130.80 (ArCH(19)), 132.24 
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(ArC(20)), 132.44 (ArCH(17)), 132.98 (ArC(18)), 137.91 (ArC(15)), 150.02 (C=NH(7)), 
191.04 (ArC(14)) 
IR ʋ/ cm-1 743 (C-Cl, s), 1663 (C=O, s), 1698 (C=N, s), 2898 (C-H, w), 3102 (Ar C-H, w)  
MS (ESI): 389/391/393 [M+H+] 
HRMS C20H22
35Cl2N3O [M+H-Br−]+  requires 390.1140, found 390.1145 (2.8 ppm error) 
 
Preparation of 1-(2,4-Dichlorophenyl)-2-(3-hexyl-2-imino-2,3-dihydro-1H-
benzo[d]imidazol-1-yl)ethanone hydrobromide (LVTa94):  
 
 
 
 
 
 
 
Following method D using 1-Hexyl-1H-benzo[d]imidazol-2-amine (LVTa56) (292 mg, 
1.34 mmol, 1 eq.) and 2-bromo-2,4-dichloro acetophenone (359 mg, 1.34 mmol 1 eq.) as 
starting materials. The colourless solid LVTa94 (456 mg, 0.94 mmol, 70%) required no 
further purification.  
Data for LVTa94 
mp 238–241 ºC 
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1H (300 MHz, D6-DMSO) δ 0.88 (3H, t, J 6.9 Hz, CH3(13)), 1.30–1.36 (4H, m, CH2(11,12)), 
1.37–1.39 (2H, m, CH2(10)), 1.72–1.77 (2H, m, CH2(9)), 4.22 (2H, t, J 7.1 Hz, CH2(8)), 
5.85 (2H, s, CH2(14)), 7.30–7.57 (2H, m, ArCH(1,2)), 7.59–7.61 (2H, m, ArCH), 7.79 (1H, 
d, J 8.5 Hz, ArCH(17)), 7.82 (1H, s, ArCH(20)), 8.19 (1H, d, J 8.5 Hz, ArCH(18)), 8.90 
(1H, s, NH(22)) 
13C (75 MHz, D6-DMSO) δ 12.55 (CH3(13)), 21.02 (CH2(12)), 24.47 (CH2(11)), 26.44 
(CH2(9)), 29.89 (CH2(10)), 41.88 (CH2(8)), 50.79 (CH2(14)), 109.47 (2C, ArCH), 122.66 
(ArCH), 122.86 (ArCH), 126.55 (ArCH(17)), 128.54 (2C, ArC), 129.06 (ArC(21)), 129.91 
(ArCH(21)), 131.34 (ArCH(18)), 132.23 (ArC(19)), 137.28 (ArC(16)), 149.23 (C=NH(7)), 
189.92 (ArC(15)) 
IR ʋ/ cm-1 747 (C-Cl, s), 1698 (C=O, s), 1701 (C=N, s), 2855 (C-H, w), 3162 (Ar C-H, w)  
MS (ESI): 403/405/407 [M+H+] 
HRMS C21H24
35Cl2N3O [M+H-Br−]+ requires 404.1296, found 404.1303 (3.0 ppm error) 
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Preparation of 1-(2,4-Dichlorophenyl)-2-(2-imino-3-pentyl-2,3-dihydro-1H-
benzo[d]imidazol-1-yl)ethanol hydrobromide (LVTa95): 
  
 
 
 
 
 
 
Following method E using 1-(2,4-Dichlorophenyl)-2-(2-imino-3-pentyl-2,3-dihydro-1H-
benzo[d]imidazol-1-yl)ethanone hydrobromide (LVTa93)  (100 mg, 0.21 mmol, 1 eq.) as 
starting materials. The colourless solid LVTa95 (67.0 mg, 0.14 mmol, 67%) required no 
purification.  
Data for LVTa95 
mp 145–148 °C 
1H (400 MHz, D6-DMSO) δ 0.85 (3H, t, J 7.1 Hz, CH3(12)), 1.20–1.32 (4H, m, CH2(10,11)), 
1.52–1.60 (2H, m, CH2(9)), 3.80 (2H, t, J 7.1 Hz, CH2(8)), 4.00–4.18 (2H, m, CH2(13)), 
5.24 (1H, t, J 6.0 Hz, CH(14)), 6.75 (1H, d, J 7.0 Hz, ArCH), 6.76–6.93 (2H, m, ArCH), 
6.94 (1H, d, J 7.0 Hz, ArCH), 7.40 (1H, d, J 7.9 Hz, ArCH(17)), 7.52 (1H, s, ArCH(20)), 
7.65 (1H, d, J 7.9 Hz, ArCH(18)) 
13C (100 MHz, D6-DMSO) δ 14.38 (CH3(12)), 22.41 (CH2(11)), 27.54 (CH2(9)), 28.78 
(CH2(10)), 41.12 (CH2(8)), 48.35 (CH2(13)), 68.84 (CH(14)), 106.74 (ArCH), 106.83 
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(ArCH), 120.40 (ArCH), 120.58 (ArCH), 127.84 (ArCH(17)), 128.71 (ArCH(20)), 130.29 
(ArCH(18)), 131.85 (ArC), 132.11 (ArC), 132.23 (ArC(21)), 132.93 (ArC(19)), 139.81 
(ArC(16)), 154.77 (C=NH(7)) 
IR ʋ/ cm-1 730 (C-Cl, s), 1621 (C-O, s), 2679 (C-H, w), 2929 (Ar C-H, w), 3357 (O-H, br.) 
MS (ESI): 391/393/395 [M+H+]  
HRMS C20H24
35Cl2N3O [M+H-Br−]+ requires 392.1296, found 392.1301 (2.8 ppm error) 
LVTa95_1 1H NMR (400 MHz, CDCl3) δ 0.91 (3H, t, J 6.8 Hz, CH3(12)), 1.34–1.39 (4H, 
m, CH2(10,11)), 1.68–1.75 (2H, m, CH2(9)), 3.73 (2H, t, J 7.1 Hz, CH2(8)), 4.18 (2H, dd, J 
15.1, 5.6 Hz, CH2(13)), 5.42 (1H, d, J 5.6 Hz, CH(14)), 6.80–6.83 (2H, m, ArCH), 6.94–
6.99 (2H, m, ArCH)), 7.19 (1H, d, J 8.4 Hz, ArCH(17)), 7.33 (1H, s ArCH(20)), 7.69 (1H, 
d, J 8.4 Hz, ArCH(18)) 
[α]D
25  +32.0 (c 1.0, MeOH) 
LVTa95_2 1H NMR (400 MHz, CDCl3) δ 0.91 (3H, t, J 6.8 Hz, CH3(12)), 1.34–1.37 (4H, 
m, CH2(10,11)), 1.68–1.75 (2H, m, CH2(9)), 3.72 (2H, t, J 7.2 Hz, CH2(8)), 4.18 (2H, dd, J 
14.1, 5.5 Hz, CH2(13)), 5.42 (1H, d, J 5.5 Hz, CH(14)), 6.79–6.83 (2H, m, ArCH), 6.93–
6.99 (2H, m, ArCH), 7.19 (1H, d, J 8.3 Hz, ArCH(17)), 7.33 (1H, s, ArCH(20)), 7.69 (1H, 
d, J 8.3 Hz, ArCH(18)) 
[α]D
25  –32.0 (c 1.0, MeOH) 
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Asymmetric Noyori transfer hydrogenation of LVTa93: Preparation of enantio-enriched 
LVTa95: 
A stock solution of the Noyori catalyst was first prepared. An oven-dried 25 mL round 
bottom flask was charged with 2-Propanol (1 mL) and triethylamine (0.2 mL) under a 
nitrogen atmosphere and the solution was sparged with a balloon of nitrogen. RuCl(p-
cymene)[(S,S)-Ts-DPEN] (100 mg, 0.16 mmol) was added via temporary removal of the 
septum. The orange mixture was then stirred at 80 °C for 1 hour under inert conditions until 
the solution turned dark red. The volatiles were removed and a 0.08 M stock solution in dry 
DMF (2 mL) was prepared. An oven-dried 25 mL round bottom flask was charged with 
LVTa93 (32 mg, 0.07 mmol, 1 eq.) and dry DMF (2 mL). A solution of formic 
acid/triethylamine (5:2, 0.2 mL) was added via needle and syringe and finally, the stock 
solution of (S,S)-Noyori catalyst (32 µL) was added. The reaction was stirred at 40 °C 
overnight. The orange mixture was transferred into a separating funnel and EtOAc (50 mL) 
and H2O (100 mL) were added. The organics were washed with saturated aqueous brine (15 
mL), dried over MgSO4 and filtered. The solvent was removed under reduced pressure to 
reveal a colourless solid amongst brown impurities. Cold EtOAc (10 mL) was added to the 
round bottom flask and the insoluble colourless solid LVTa95_NS (21 mg, 0.04 mmol, 63%) 
was collected via Büchner filtration using a sinter.  
LVTa95_NS 1H NMR (400 MHz, D6-DMSO) δ 0.87 (3H, t, J 6.7 Hz, CH3(12)), 1.30–1.34 
(4H, m, CH2(10,11)), 1.64–1.69 (2H, m, CH2(9)), 4.21 (2H, t, J 7.3 Hz, CH2(8)), 4.35 (1H, 
dd, J 14.9, 4.5 Hz, CH2(13a)), 4.45 (1H, dd, J 14.9, 8.1 Hz, CH2(13b)), 5.28 (1H, dd, J 8.1, 
4.5 Hz, CH(14)), 7.27–7.35 (3H, m, ArCH), 7.52 (1H, d, J 8.4 Hz, ArCH), 7.57–7.60 (2H, 
m, ArCH(20)), 7.84 (1H, d, J 8.4 Hz, ArCH(18)) 
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The above synthesis was repeated using activated RuCl(p-cymene)[(R,R)-Ts-DPEN] and 
LVTa93 (42 mg, 0.09 mmol) as starting materials to generate LVTa95_NR (22 mg, 0.05 
mmol, 56%).  
LVTa95_NR 1H NMR (400 MHz, D6-DMSO) δ 0.87 (3H, t, J 6.5 Hz, CH3(12)), 1.31–1.34 
(4H, m, CH2(10,11)), 1.65–1.70 (2H, m, CH2(9)), 4.21 (2H, t, J 7.5 Hz, CH2(8)), 4.35 (1H, 
dd, J 14.9, 4.5 Hz, CH2(13a)), 4.45 (1H, dd, J 14.9, 8.2 Hz, CH2(13b)), 5.28 (1H, dd, J 8.2, 
4.5 Hz, CH(14)), 7.27–7.35 (3H, m, ArCH), 7.52 (1H, d, J 8.2 Hz, ArCH), 7.57–7.60 (2H, 
m, ArCH(20)), 7.84 (1H, d, J 8.4 Hz, ArCH(18)) 
 
Preparation of 1-(2,4-Dichlorophenyl)-2-(3-hexyl-2-imino-2,3-dihydro-1H-
benzo[d]imidazol-1-yl)ethanol hydrobromide (LVTa96):  
 
 
 
 
 
 
Following method E using 1-(2,4-Dichlorophenyl)-2-(3-hexyl-2-imino-2,3-dihydro-1H-
benzo[d]imidazol-1-yl)ethanone hydrobromide (LVTa94)  (292 mg, 0.60 mmol, 1 eq.) as 
starting materials. The colourless solid LVTa92 (221 mg, 0.45 mmol, 75%) required no 
purification.  
Data for LVTa96 
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mp 116–118 °C 
1H (300 MHz, D6-DMSO) δ 0.85 (3H, t, J 7.1 Hz, CH3(13)), 1.22–1.30 (6H, m, 
CH2(10,11,12)), 1.52–1.58 (2H, m, CH2(9)), 3.79 (2H, t, J 6.8 Hz, CH2(8)), 3.99–4.04 (2H, 
m, CH2(14)), 5.24 (1H, t, J 6.6 Hz, CH(15)), 6.73–6.94 (4H, m, ArCH(1,2,3,6)), 7.40 (1H, 
d, J 7.5 Hz, ArCH(18)), 7.52 (1H, s, ArCH(21)), 7.65 (1H, d, J 7.5 Hz, ArCH(19)) 
13C (75 MHz, D6-DMSO) δ 13.88 (CH3(13)), 22.03 (CH2(12)), 25.76 (CH2(11)), 27.30 
(CH2(9)), 31.00 (CH2(10)), 40.55 (CH2(8)), 47.80 (CH2(14)), 68.34 (CH(15)), 106.11 
(ArCH), 106.24 (ArCH), 119.80 (ArCH), 119.97 (ArCH), 127.31 (ArCH(18)), 128.19 
(ArCH(21)), 129.74 (ArCH(19)), 131.32 (ArC), 131.59 (ArC), 131.67 (ArC(22)), 132.39 
(ArC(20)), 139.30 (ArC(17)), 154.28 (C=NH(7)) 
IR ʋ/ cm-1 731 (C-Cl, s), 1622 (C-O, s), 2858 (C-H, w), 3002 (Ar C-H, w), 3338 (O-H, br.) 
MS (ESI): 405/407/409 [M+H+] 
HRMS C21H26
35Cl2N3O [M+H-Br−]+ requires 406.1453, found 406.1458 (2.9 ppm error) 
LVTa96_1 1H NMR (400 MHz, CDCl3) δ 0.89 (3H, t, J 6.8 Hz, CH3(13)), 1.29–1.39 (4H, 
m, CH2(10,11,12)), 1.69–1.73 (2H, m, CH2(9)), 3.73 (2H, t, J 7.3 Hz, CH2(8)), 4.19 (2H, 
dd, J 14.8, 5.6 Hz, CH2(14)), 5.42 (1H, d, J 5.6 Hz, CH(15)), 6.80–6.83 (2H, m, ArCH), 
6.93–6.99 (2H, m, ArCH), 7.19 (1H, d, J 9.3 Hz, ArCH(18)), 7.34 (1H, s, ArCH(21)), 7.68 
(1H, d, J 9.3 Hz, ArCH(19)) 
[α]D
25  +42.0 (c 1.0, MeOH) 
LVTa96_2 1H NMR (400 MHz, CDCl3) δ 0.89 (3H, t, J 6.9 Hz, CH3(13)), 1.30–1.39 (4H, 
m, CH2(10,11,12)), 1.67–1.75 (2H, m, CH2(9)), 3.72 (2H, t, J 7.2 Hz, CH2(8)), 4.19 (2H, 
dd, J 14.9, 5.2 Hz, CH2(14)), 5.42 (1H, d, J 5.2 Hz, CH(15)), 6.79–6.83 (2H, m, ArCH), 
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6.93–6.99 (2H, m, ArCH), 7.19 (1H, d, J 8.3 Hz, ArCH(18)), 7.34 (1H, s, ArCH(21)), 7.67 
(1H, d, J 8.3 Hz, ArCH(19)) 
[α]D
25  –42.0 (c 1.0, MeOH) 
 
Asymmetric Noyori transfer hydrogenation of LVTa94: Preparation of enantio-enriched 
LVTa96: 
A stock solution of the Noyori catalyst was first prepared as shown in the preparation of 
enantio-enriched LVTa95. An oven-dried 25 mL round bottom flask was charged with 
LVTa94 (46 mg, 0.09 mmol, 1 eq.) and dry DMF (2 mL). A solution of formic 
acid/triethylamine (5:2, 0.2 mL) was added via needle and syringe and finally, the stock 
solution of (S,S)-Noyori catalyst (32 µL) was added. The reaction was stirred at 40 °C 
overnight. The mixture was transferred into a separating funnel and EtOAc (50 mL) and H2O 
(100 mL) were added. The organics were washed with saturated aqueous brine (15 mL), 
dried over MgSO4 and filtered. The solvent was removed under reduced pressure to reveal a 
colourless solid amongst brown impurities. Cold EtOAc (10 mL) was added to the round 
bottom flask and the insoluble colourless solid LVTa96_NS (20 mg, 0.04 mmol, 43%) was 
collected via Büchner filtration using a sinter.  
LVTa96_NS 1H NMR (400 MHz, CDCl3) δ 0.86 (3H, t, J 6.7 Hz, CH3(13)), 1.29–1.34 (4H, 
m, CH2(11,12)), 1.47–1.52 (2H, m, CH2(10)), 1.85–1.91 (2H, m, CH2(9)), 4.46 (2H, t, J 7.1 
Hz, CH2(8)), 4.54 (1H, dd, J 15.2, 3.6 Hz, CH2(14a)), 4.68 (1H, dd, J 15.2, 3.6 Hz, 
CH2(14b)), 5.60 (1H, t, J 3.6 Hz, CH(15)), 6.73 (1H, d, J 7.9 Hz, ArCH), 7.09 (1H, dd, J 
7.9, 7.2 Hz, ArCH), 7.16–7.25 (3H, m, ArCH), 7.32 (1H, s, ArCH), 7.77 (1H, d, J 8.4 Hz, 
ArCH) 
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The above synthesis was repeated using activated RuCl(p-cymene)[(R,R)-Ts-DPEN] and 
LVTa94 (32 mg, 0.09 mmol) as starting materials to generate LVTa96_NR (19 mg, 0.04 
mmol, 59%).  
LVTa96_NR 1H NMR (400 MHz, CDCl3) δ 0.86 (3H, t, J 6.9 Hz, CH3(13)), 1.28–1.35 (4H, 
m, CH2(11,12)), 1.46–1.53 (2H, m, CH2(10)), 1.84–1.91 (2H, m, CH2(9)), 4.43 (2H, t, J 7.5 
Hz, CH2(8)), 4.53 (1H, dd, J 15.2, 3.9 Hz, CH2(14a)), 4.66 (1H, dd, J 15.2, 3.9 Hz, 
CH2(14b)), 5.61 (1H, t, J 3.9 Hz, CH(15)), 6.73 (1H, d, J 8.1 Hz, ArCH), 7.09 (1H, dd, J 
7.4, 7.4 Hz, ArCH), 7.16–7.25 (3H, m, ArCH), 7.32 (1H, s, ArCH), 7.74 (1H, d, J 8.5 Hz, 
ArCH) 
 
Preparation of 1-(3-Chlorophenyl)-2-(2-imino-3-pentyl-2,3-dihydro-1H-benzo[d]imidazol-
1-yl)ethanone hydrobromide (LVTa97):  
 
 
 
 
 
 
 
Following method D using 1-Pentyl-1H-benzo[d]imidazol-2-amine (LVTa55) (200 mg, 
0.98 mmol, 1 eq.) and 3-chloro phenacylbromide (229 mg, 0.98 mmol 1 eq.) as starting 
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materials. The colourless solid LVTa97 (371 mg, 0.85 mmol, 87%) required no further 
purification.  
Data for LVTa97 
mp 239–241 ºC 
1H (300 MHz, CDCl3) δ 0.92 (3H, t, J 6.7 Hz, CH3(12)), 1.35–1.39 (4H, m, CH2(10,11)), 
1.72–1.77 (2H, m, CH2(9)), 3.76 (2H, t, J 7.2 Hz, CH2(8)), 5.27 (2H, s, CH2(13)), 6.69 (1H, 
d, J 7.2 Hz, ArCH), 6.85 (1H, d, J 7.2 Hz, ArCH), 6.91–7.02 (2H, m, ArCH(1,2)), 7.44 (1H, 
dd, J 7.8, 7.8 Hz, ArCH(17)), 7.58 (1H, d, J 7.8 Hz, ArCH(18)), 7.97 (1H, d, J 7.8 Hz, 
ArCH(16)), 8.07 (1H, s, NH(20)) 
13C (75 MHz, CDCl3) δ 13.99 (CH3(12)), 22.47 (CH2(11)), 27.69 (CH2(9)), 29.13 
(CH2(10)), 41.90 (CH2(8)), 48.13 (CH2(13)), 106.40 (ArCH), 106.52 (ArCH), 120.69 
(ArCH), 120.84 (ArCH)), 126.40 (ArCH(16)), 128.46 (ArCH(20)), 130.17 (ArCH(17)), 
131.53 (ArC), 131.60 (ArC), 133.79 (ArCH(18)), 135.17 (ArC(19)), 136.21 (ArC(15)), 
154.69 (C=NH(7)), 192.16 (ArC(14)) 
IR ʋ/ cm-1 743 (C-Cl, s), 1695 (C=O, s), 1697 (C=N, s), 2868 (C-H, w), 3162 (Ar C-H, w)  
MS (ESI): 355/357 [M+H+]  
HRMS C20H23
35ClN3O [M+H-Br−]+ requires 356.1530, found 356.1529 (2.01 ppm error) 
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Preparation of 1-(3-Chlorophenyl)-2-(3-hexyl-2-imino-2,3-dihydro-1H-benzo[d]imidazol-
1-yl)ethanone hydrobromide (LVTa98):  
 
 
 
 
 
 
 
Following method D using 1-Hexyl-1H-benzo[d]imidazol-2-amine (LVTa56) (200 mg, 
0.92 mmol, 1 eq.) and 3-chloro phenacylbromide (215 mg, 0.92 mmol 1 eq.) as starting 
materials. The colourless solid LVTa98 (456 mg, 0.94 mmol, 70%) required no further 
purification.  
Data for LVTa98 
mp 243–245 ºC 
1H (300 MHz, D6-DMSO) δ 0.87 (3H, t, J 7.1 Hz, CH3(13)), 1.27–1.38 (6H, m, 
CH2(10,11,12)), 1.68–1.74 (2H, m, CH2(9)), 4.24 (2H, t, J 6.9 Hz, CH2(8)), 6.00 (2H, s, 
CH2(14)), 7.31–7.38 (2H, m, ArCH), 7.65–7.72 (3H, m, ArCH(18)), 7.86 (1H, d, J 7.5 Hz, 
ArCH(19)), 8.04 (1H, d, J 7.5 Hz, ArCH(17)), 8.14 (1H, s, ArCH(21)), 8.89 (1H, s, NH(22)) 
13C (75 MHz, D6-DMSO) δ 12.82 (CH3(13)), 21.97 (CH2(12)), 25.32 (CH2(11)), 27.42 
(CH2(9)), 30.83 (CH2(10)), 42.64 (CH2(8)), 50.03 (CH2(14)), 110.54 (2C, ArCH), 123.57 
(ArCH), 123.75 (ArCH), 127.00 (ArCH(17)), 128.22 (ArCH(21)), 129.36 (ArC), 130.07 
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(ArC), 130.88 (ArCH(18)), 133.66 (ArC(20)), 135.83 (ArCH(19)), 149.98 (C=NH(7)), 
190.44 (ArC(15)) 
IR ʋ/ cm-1 745 (C-Cl, s), 1663 (C=O, s), 1697 (C=N, s), 2866 (C-H, w), 3165 (Ar C-H, w)  
MS (ESI): 370/372 [M+H+]  
HRMS C21H25
35ClN3O [M+H-Br−]+ requires 370.1686, found 370.1694 (3.6 ppm error) 
 
Preparation of 1-(3-Chlorophenyl)-2-(2-imino-3-pentyl-2,3-dihydro-1H-benzo[d]imidazol-
1-yl)ethanol hydrobromide (LVTa99): 
  
 
 
 
 
 
 
Following method E using 1-(3-Chlorophenyl)-2-(2-imino-3-pentyl-2,3-dihydro-1H-
benzo[d]imidazol-1-yl)ethanone hydrobromide (LVTa97)  (100 mg, 0.23 mmol, 1 eq.) as 
starting materials. The clear glass LVTa99 (89.0 mg, 0.20 mmol, 87%) required no 
purification.  
Data for LVTa99 
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1H (300 MHz, D6-DMSO) δ 0.86 (3H, t, J 6.9 Hz, CH3(12)), 1.25–1.33 (4H, m, CH2(10,11)), 
1.54–1.60 (2H, m, CH2(9)), 3.85 (2H, t, J 7.4 Hz, CH2(8)), 4.00–4.07 (2H, m, CH2(13)), 
4.98 (1H, t, J 7.1 Hz, CH(14)), 6.85–7.00 (4H, m, ArCH), 7.29 (1H, dd, J 6.8, 6.8 Hz, 
ArCH(18)), 7.33 (1H, d, J 6.8 Hz, ArCH(19)), 7.39 (1H, d, J 6.8 Hz, ArCH(17)), 7.48 (1H, 
s, ArCH(21)) 
13C (75 MHz, D6-DMSO) δ 14.36 (CH3(12)), 22.41 (CH2(11)), 27.57 (CH2(9)), 28.73 
(CH2(10)), 41.34 (CH2(8)), 49.81 (CH2(13)), 71.00 (CH(14)), 107.19 (ArCH), 107.90 
(ArCH), 120.77 (ArCH), 120.89 (ArCH), 125.28 (ArCH(19)), 126.49 (ArCH(21)), 126.57 
(ArCH(17)), 127.51 (ArCH(18)), 131.68 (ArC), 132.27 (ArC), 133.27 (ArC(20)), 145.97 
(ArC(16)), 153.94 (C=NH(7)) 
IR ʋ/ cm-1 731 (C-Cl, s), 1606 (C-O, s), 1622 (C=N, s), 2858 (C-H, w), 3059 (Ar C-H, w), 
3362 (O-H, br.)   
MS (ESI): 357/359 [M+H+]  
HRMS C20H25
35ClN3O [M+H-Br−]+ requires 358.1686, found 358.1690 (0.2 ppm error) 
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Preparation of 1-(3-Chlorophenyl)-2-(3-hexyl-2-imino-2,3-dihydro-1H-benzo[d]imidazol-
1-yl)ethanol hydrobromide (LVTa100):  
 
 
 
 
 
 
 
Following method E using 1-(3-Chlorophenyl)-2-(3-hexyl-2-imino-2,3-dihydro-1H-
benzo[d]imidazol-1-yl)ethanone hydrobromide (LVTa98)  (100 mg, 0.22 mmol, 1 eq.) as 
starting materials. The orange glass LVTa100 (85 mg, 0.19 mmol, 86%) required no 
purification.  
Data for LVTa100 
1H (400 MHz, D6-DMSO) δ 0.85 (3H, t, J 6.9 Hz, CH3(13)), 1.25–1.32 (6H, m, 
CH2(10,11,12)), 1.54–1.58 (2H, m, CH2(9)), 3.79 (2H, t, J 6.8 Hz, CH2(8)), 3.95–4.03 (2H, 
m, CH2(14)), 4.98 (1H, t, J 7.1 Hz, CH(15)), 6.81–6.91 (4H, m, ArCH), 7.26 (1H, dd, J 7.0, 
7.0 Hz, ArCH(19)), 7.35 (1H, d, J 7.0 Hz, ArCH(20)), 7.39 (1H, d, J 7.0 Hz, ArCH(18)), 
7.46 (1H, s, ArCH(22)) 
13C (100 MHz, D6-DMSO) δ 14.37 (CH3(13)), 22.52 (CH2(12)), 26.27 (CH2(11)), 27.81 
(CH2(9)), 31.50 (CH2(10)), 41.06 (CH2(8)), 49.82 (CH2(14)), 71.32 (CH(15)), 106.54 
(ArCH), 107.14 (ArCH), 120.21 (ArCH), 120.31 (ArCH), 125.20 (ArCH(20)), 126.41 
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(ArCH(22)), 126.45 (ArCH(18)), 127.40 (ArCH(19)), 132.12 (ArC), 132.37 (ArC), 133.24 
(ArC(21)), 146.25 (ArC(17)), 154.64 (C=NH(7)) 
IR ʋ/ cm-1 730 (C-Cl, s), 1606 (C-O, s), 1622 (C=N, s), 2856 (C-H, w), 3061 (Ar C-H, w), 
3341 (O-H, br.) 
MS (ESI): 371/373 [M+H+] 
HRMS C21H27
35ClN3O [M+H-Br−]+ requires 372.1843, found 372.1848 (0.13 ppm error) 
 
Preparation of 1-(3-Bromophenyl)-2-(2-imino-3-pentyl-2,3-dihydro-1H-benzo[d]imidazol-
1-yl)ethanone hydrobromide (LVTa101):  
  
 
 
 
 
 
Following method D using 1-Pentyl-1H-benzo[d]imidazol-2-amine (LVTa55) (200 mg, 
0.98 mmol, 1 eq.) and 3-bromo phenacylbromide (272 mg, 0.98 mmol 1 eq.) as starting 
materials. The colourless solid LVTa101 (391 mg, 0.81 mmol, 83%) required no further 
purification.  
Data for LVTa101 
mp 240–243 ºC 
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1H (400 MHz, D6-DMSO) δ 0.89 (3H, t, J 7.1 Hz, CH3(12)), 1.32–1.37 (4H, m, CH2(10,11)), 
1.72–1.77 (2H, m, CH2(9)), 4.22 (2H, t, J 6.9 Hz, CH2(8)), 5.97 (2H, s, CH2(13)), 7.32 (1H, 
d, J 7.5 Hz, ArCH), 7.37 (1H, d, J 7.5 Hz, ArCH), 7.60 (1H, dd, J 8.0, 8.0 Hz, ArCH(17)), 
7.96 (1H, d, J 8.0 Hz, ArCH(18)), 8.08 (1H, d, J 8.0 Hz, ArCH(16)), 8.28 (1H, s, ArCH(20)), 
8.89 (1H, s, NH(21)) 
13C (100 MHz, D6-DMSO) δ 12.56 (CH3(12)), 20.86 (CH2(11)), 26.16 (CH2(9)), 26.93 
(CH2(10)), 41.81 (CH2(8)), 49.00 (CH2(13)), 109.38 (ArCH), 109.49 (ArCH), 121.15 
(ArC(19)), 122.56 (ArCH), 122.76 (ArCH), 126.29 (ArCH(16)), 128.51 (ArCH(17)), 
129.10 (ArC), 129.94 (ArC), 130.15 (ArCH(20)), 135.16 (ArCH(18)), 135.74 (ArC(15)), 
149.20 (C=NH(7)), 189.33 (ArC(14)) 
IR ʋ/ cm-1 1690 (C=O, s), 1697 (C=N, s), 2952 (C-H, w), 3162 (Ar C-H, w)  
MS (ESI): 399/401 [M+H+]  
HRMS C20H23
79BrN3O [M+H-Br−]+ requires 400.1024, found 400.1029 (0.9 ppm error) 
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Preparation of 1-(3-Bromophenyl)-2-(3-hexyl-2-imino-2,3-dihydro-1H-benzo[d]imidazol-1-
yl)ethanone hydrobromide (LVTa102):  
 
 
 
 
 
 
Following method D using 1-Hexyl-1H-benzo[d]imidazol-2-amine (LVTa56) (200 mg, 
0.92 mmol, 1 eq.) and 3-bromo phenacylbromide (256 mg, 0.92 mmol 1 eq.) as starting 
materials. The colourless solid LVTa102 (333 mg, 0.67 mmol, 73%) required no further 
purification.  
Data for LVTa102 
mp 242–245 ºC 
1H (300 MHz, D6-DMSO) δ 0.87 (3H, t, J 7.1 Hz, CH3(13)), 1.27–1.35 (6H, m, 
CH2(10,11,12)), 1.69–1.74 (2H, m, CH2(9)), 4.25 (2H, t, J 7.0 Hz, CH2(8)), 6.01 (2H, s, 
CH2(14)), 7.30–7.39 (2H, m, ArCH), 7.65–7.68 (3H, m, ArCH(18)), 7.69 (1H, d, J 7.8 Hz, 
ArCH(19)), 8.06 (1H, d, J 7.8 Hz, ArCH(17)), 8.27 (1H, s, ArCH(21)), 8.90 (1H, s, NH(22)) 
13C (75 MHz, D6-DMSO) δ 13.82 (CH3(13)), 21.97 (CH2(12)), 25.31 (CH2(11)), 27.42 
(CH2(9)), 30.83 (CH2(10)), 42.65 (CH2(8)), 50.03 (CH2(14)), 110.55 (2C, ArCH(3,6)), 
122.07 (ArC(20)), 123.57 (ArCH), 123.75 (ArCH), 127.33 (ArCH(16)), 129.36 (ArC), 
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130.08 (ArC), 131.09 (ArCH(18,21)), 136.04 (ArC(16)), 136.75 (ArCH(19)), 149.98 
(C=NH(7)), 190.40 (ArC(15)) 
IR ʋ/ cm-1 1662 (C=O, s), 1698 (C=N, s), 2957 (C-H, w), 3157 (Ar C-H, w)  
MS (ESI): 413/415 [M+H+]  
HRMS C21H25
79BrN3O [M+H-Br−]+ requires 414.1181, found 414.1195 (2.4 ppm error) 
 
Preparation of 1-(3-Bromophenyl)-2-(2-imino-3-pentyl-2,3-dihydro-1H-benzo[d]imidazol-
1-yl)ethanol hydrobromide (LVTa103): 
  
 
 
 
 
 
 
Following method E using 1-(3-Bromophenyl)-2-(2-imino-3-pentyl-2,3-dihydro-1H-
benzo[d]imidazol-1-yl)ethanone hydrobromide (LVTa101)  (100 mg, 0.21 mmol, 1 eq.) as 
starting materials. The clear glass LVTa103 (84.0 mg, 0.17mmol, 81%) required no 
purification.  
Data for LVTa103 
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1H (300 MHz, CDCl3) δ 0.91 (3H, t, J 6.8 Hz, CH3(12)), 1.34–1.39 (4H, m, CH2(10,11)), 
1.70-1.75 (2H, m, CH2(9)), 3.23 (2H, t, J 7.2 Hz, CH2(8)), 4.12 (2H, d, J 4.5 Hz, CH2(13)), 
5.12 (1H, t, J 4.5 Hz, CH(14)), 6.68 (1H, d, J 6.7 Hz, ArCH), 6.83 (1H, d, J 6.7 Hz, ArCH), 
6.92–7.00 (2H, m, ArCH), 7.17 (1H, dd, J 7.7, 7.7 Hz, ArCH(18)), 7.33–7.36 (1H, m, 
ArCH(17,19)), 7.63 (1H, s, ArCH(21)) 
13C (75 MHz, CDCl3) δ 13.99 (CH3(12)), 22.45 (CH2(11)), 27.70 (CH2(9)), 29.11 
(CH2(10)), 41.86 (CH2(8)), 51.25 (CH2(13)), 74.37 (CH(14)), 106.35 (ArCH), 106.74 
(ArCH), 120.78 (ArCH), 120.99 (ArCH), 122.59 (ArC(20)), 125.52 (ArCH(17)), 129.10 
(ArCH(21)), 129.95 (ArCH(19)), 130.51 (ArCH(18)), 131.46 (ArC), 131.50 (ArC), 144.94 
(ArC(16)), 156.71 (C=NH(7)) 
IR ʋ/ cm-1 1606 (C-O, s), 1622 (C=N, s), 2859 (C-H, w), 3060 (Ar C-H, w), 3322 (O-H, br.)  
MS (ESI): 401/403 [M+H+]  
HRMS C20H25
79BrN3O [M+H-Br−]+ requires 402.1181, found 402.1192 (4.3 ppm error) 
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Preparation of 1-(3-Bromophenyl)-2-(3-hexyl-2-imino-2,3-dihydro-1H-benzo[d]imidazol-
1-yl)ethanol hydrobromide (LVTa104):  
 
 
 
 
 
 
 
Following method E using 1-(3-Bromophenyl)-2-(3-hexyl-2-imino-2,3-dihydro-1H-
benzo[d]imidazol-1-yl)ethanone hydrobromide (LVTa102)  (100 mg, 0.20 mmol, 1 eq.) as 
starting materials. The clear glass LVTa104 (86.0 mg, 0.17 mmol, 85%) required no 
purification.  
Data for LVTa104 
1H (300 MHz, D6-DMSO) δ 0.85 (3H, t, J 6.8 Hz, CH3(13)), 1.24–1.31 (6H, m, 
CH2(10,11,12)), 1.54–1.56 (2H, m, CH2(9)), 3.79 (2H, t, J 7.1 Hz, CH2(8)), 3.95–4.04 (2H, 
m, CH2(14)), 4.96 (1H, t, J 4.5 Hz, CH(15)), 6.81–6.92 (4H, m, ArCH), 7.20–7.29 (2H, m, 
ArCH(19,20)), 7.38–7.43 (2H, m, ArCH(18,22)), 7.61 (1H, s, NH(23)) 
13C (75 MHz, D6-DMSO) δ 13.89 (CH3(13)), 22.03 (CH2(12)), 25.76 (CH2(11)), 27.33 
(CH2(9)), 31.00 (CH2(10)), 40.55 (CH2(8)), 49.26 (CH2(14)), 70.65 (CH(15)), 106.12 
(ArCH), 106.76 (ArCH), 119.78 (ArCH), 119.80 (ArCH), 121.39 (ArC(21)), 127.03 
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(ArCH(18)), 127.91 (ArCH(20)), 128.79 (ArCH(22)), 131.19 (ArCH(19)), 131.77 (ArC), 
131.85 (ArC), 145.91 (ArC(17)), 153.93 (C=NH(7)) 
IR ʋ/ cm-1 1606 (C-O, s), 1622 (C=N, s), 2855 (C-H, w), 3060 (Ar C-H, w), 3347 (O-H, br.)  
MS (ESI): 416/418 [M+H+]  
HRMS C21H27
79BrN3O [M+H-Br−]+ requires 416.1338, found 416.1339 (1.8 ppm error) 
 
Preparation of 1-(3,4-Dichlorophenyl)-2-(2-imino-3-pentyl-2,3-dihydro-1H-
benzo[d]imidazol-1-yl)ethanone hydrobromide (LVTa105):  
 
  
 
 
 
 
 
Following method D using 1-Pentyl-1H-benzo[d]imidazol-2-amine (LVTa55) (200 mg, 
0.98 mmol, 1 eq.) and 2-bromo-3,4-dichloro acetophenone (263 mg, 0.98 mmol 1 eq.) as 
starting materials.  The colourless solid LVTa105 (340 mg, 0.72mmol, 74%) required no 
further purification.  
Data for LVTa105 
mp 240–243 ºC 
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1H (300 MHz, CDCl3) δ 0.91 (3H, t, J 7.1 Hz, CH3(12)), 1.32–1.40 (4H, m, CH2(10,11)), 
1.70–1.78 (2H, m, CH2(9)), 3.76 (2H, t, J 7.5 Hz, CH2(8)), 5.24 (2H, s, CH2(13)), 6.70 (2H, 
d, J 7.2 Hz, ArCH), 6.90 (2H, d, J 7.2 Hz, ArCH), 6.94–7.12 (2H, m, ArCH), 7.56 (1H, d, 
J 8.1 Hz, ArCH(17)), 7.93 (1H, d, J 8.1 Hz, ArCH(16)), 8.21 (1H, s, ArCH(20)) 
13C (75 MHz, CDCl3) δ 13.98 (CH3(12)), 22.47 (CH2(11)), 27.68 (CH2(9)), 29.12 
(CH2(10)), 41.94 (CH2(8)), 48.21 (CH2(13)), 106.48 (ArCH), 106.59 (ArCH), 120.80 
(ArCH), 120.97 (ArCH), 127.43 (ArCH(16)), 130.46 (ArCH(20)), 130.94 (ArCH(17)), 
131.37 (2C, ArC), 131.43 (ArC(19)), 133.55 (ArC(18)), 134.16 (ArC(15)), 154.49 
(C=NH(7)), 191.73 (ArC(14)) 
IR ʋ/ cm-1 829 (C-Cl, s), 1663 (C=O, s), 1698 (C=N, s), 2957 (C-H, w), 3159 (Ar C-H, w)  
MS (ESI): 389/391/393 [M+H+]  
HRMS C20H22
35Cl2N3O [M+H-Br−]+ requires 390.1140, found 390.1147 (1.9 ppm error) 
 
Preparation of 1-(3,4-Dichlorophenyl)-2-(3-hexyl-2-imino-2,3-dihydro-1H-
benzo[d]imidazol-1-yl)ethanone hydrobromide (LVTa106):  
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Following method D using 1-Hexyl-1H-benzo[d]imidazol-2-amine (LVTa56) (200 mg, 
0.92 mmol, 1 eq.) and 2-bromo-3,4-dichloro acetophenone (247 mg, 0.92 mmol 1 eq.) as 
starting materials. The colourless solid LVTa106 (370 mg, 0.77 mmol, 84%) required no 
further purification.  
Data for LVTa106 
mp 241–243 ºC 
1H (300 MHz, D6-DMSO) δ 0.86 (3H, t, J 7.1 Hz, CH3(13)), 1.27–1.35 (6H, m, 
CH2(10,11,12)), 1.68–1.74 (2H, m, CH2(9)), 4.23 (2H, t, J 6.8 Hz, CH2(8)), 5.98 (2H, s, 
CH2(14)), 7.30–7.38 (2H, m, ArCH(1,2)), 7.63–7.69 (2H, m, ArCH(3,6)), 7.96 (1H, d, J 7.9 
Hz, ArCH(18)), 8.03 (1H, d, J 7.9 Hz, ArCH(17)), 8.35 (1H, s, ArCH(21)), 8.87 (1H, s, 
NH(22)) 
13C (75 MHz, D6-DMSO) δ 13.81 (CH3(13)), 21.91 (CH2(12)), 25.33 (CH2(11)), 27.41 
(CH2(9)), 30.82 (CH2(10)), 42.65 (CH2(8)), 50.01 (CH2(14)), 110.52 (ArCH), 123.59 
(ArCH), 120.79 (ArCH), 128.34 (ArCH(17)), 130.02 (ArC), 130.43 (ArCH(21)), 131.24 
(ArCH(18)), 131.23 (ArCH(20)), 131.83 (ArC), 134.23 (ArC(19)), 136.92 (ArC(16)), 
149.94 (C=NH(7)), 189.83 (ArC(15)) 
IR ʋ/ cm-1 828 (C-Cl, s), 1662 (C=O, s), 1698 (C=N, s), 2954 (C-H, w), 3167 (Ar C-H, w)  
MS (ESI): 425/427/429 [M+H+]  
HRMS C21H24
35Cl2N3O [M+H-Br−]+ requires 426.1116, found 426.1122 (4.4 ppm error) 
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Preparation of 1-(3,4-Dichlorophenyl)-2-(2-imino-3-pentyl-2,3-dihydro-1H-
benzo[d]imidazol-1-yl)ethanol hydrobromide (LVTa107): 
  
 
 
 
 
 
 
Following method E using 1-(3,4-Dichlorophenyl)-2-(2-imino-3-pentyl-2,3-dihydro-1H-
benzo[d]imidazol-1-yl)ethanone hydrobromide (LVTa105) (100 mg, 0.21 mmol, 1 eq.) as 
starting materials. The colourless solid LVTa107 (89.0 mg, 0.19mmol, 91%) required no 
purification.  
Data for LVTa107 
mp 71–73 °C 
1H (300 MHz, D6-DMSO) δ 0.84 (3H, t, J 7.8 Hz, CH3(12)), 1.17–1.33 (4H, m, CH2(10,11)), 
1.52–1.60 (2H, m, CH2(9)), 3.78 (2H, t, J 7.1 Hz, CH2(8)), 3.95–4.11 (2H, m, CH2(13)), 
4.96 (1H, t, J 4.9 Hz, CH(14)), 6.80–6.93 (4H, m, ArCH), 7.36 (1H, d, J 8.0 Hz, ArCH(17)), 
7.53 (1H, d, J 8.0 Hz, ArCH(18)), 7.64 (1H, s, ArCH(21)) 
13C (75 MHz, D6-DMSO) δ 13.89 (CH3(12)), 21.92 (CH2(11)), 27.02 (CH2(9)), 28.24 
(CH2(10)), 40.48 (CH2(8)), 48.99 (CH2(13)), 70.22 (CH(14)), 106.13 (ArCH), 106.70 
(ArCH), 119.75 (ArCH), 119.92 (ArCH), 126.41 (ArCH(17)), 128.10 (ArCH(21)), 129.56 
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(ArC(20)), 130.04 (ArCH(18)), 130.57 (ArC(19)), 131.22 (ArC), 131.75 (ArC), 144.31 
(ArC(16)), 153.99 (C=NH(7)) 
IR ʋ/ cm-1 1585 (C-O, s), 2858 (C-H, w), 3064 (Ar C-H, w), 3257 (O-H, br.)  
MS (ESI): 391/393/395 [M+H+] 
HRMS C20H24
35Cl2N3O [M+H-Br−]+ requires 392.1291, found 392.1290 (0.2 ppm error) 
 
Preparation of 1-(3,4-Dichlorophenyl)-2-(2-imino-3-pentyl-2,3-dihydro-1H-
benzo[d]imidazol-1-yl)ethanol hydrobromide (LVTa108):  
 
 
 
 
 
 
 
Following method E using 1-(3,4-Dichlorophenyl)-2-(3-hexyl-2-imino-2,3-dihydro-1H-
benzo[d]imidazol-1-yl)ethanone hydrobromide (LVTa106)  (100 mg, 0.21 mmol, 1 eq.) as 
starting materials. The clear glass LVTa108 (87.0 mg, 0.18 mmol, 80%) required no 
purification.  
Data for LVTa108 
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1H (300 MHz, D6-DMSO) δ 0.85 (3H, t, J 7.6 Hz, CH3(13)), 1.20–1.28 (6H, m, 
CH2(10,11,12)), 1.52–1.59 (2H, m, CH2(9)), 3.78 (2H, t, J 6.9 Hz, CH2(8)), 3.95–4.05 (2H, 
m, CH2(14)), 5.00 (1H, t, J 4.5 Hz, CH(15)), 6.81–6.92 (4H, m, ArCH), 7.39 (1H, d, J 8.1 
Hz, ArCH(18)), 7.52 (1H, d, J 8.1 Hz, ArCH(19)), 7.63 (1H, s, ArCH(22)) 
13C (75 MHz, D6-DMSO) δ 14.36 (CH3(13)), 22.50 (CH2(12)), 26.24 (CH2(11)), 27.78 
(CH2(9)), 31.48 (CH2(10)), 41.07 (CH2(8)), 49.55 (CH2(14)), 70.74 (CH(15)), 106.67 
(ArCH), 107.23 (ArCH), 120.28 (ArCH), 120.46 (ArCH), 126.92 (ArCH(18)), 126.63 
(ArCH(22)), 130.54 (ArC(21)), 130.66 (ArCH(19)), 131.37 (2C, ArC), 132.28 (ArC(20)), 
144.81 (ArC(17)), 154.53 (C=NH(7)) 
IR ʋ/ cm-1 1606 (C-O, s), 2856 (C-H, w), 3062 (Ar C-H, w), 3256 (O-H, br.)  
MS (ESI): 405/407/409 [M+H+] 
HRMS C21H26
35Cl2N3O [M+H-Br−]+ requires 406.1453, found 406.1459 (2.9 ppm error) 
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